FINAL PROGRAM
The 26th International Congress of The Transplantation Society extends its appreciation to the following sponsors for their support:

**PREMIER SPONSOR**

![Astellas Transplant](image)

Advancing transplantation—Together

**PRINCIPAL SPONSOR**

![Roche](image)

**SPONSORS**

- neovii
- Novartis Pharmaceuticals
- One Lambda
  A Thermo Fisher Scientific Brand

**CONTRIBUTORS**

- Dr. F. Köhler Chemie
- JDRF
- Shire
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Using the Program</td>
<td>2</td>
</tr>
<tr>
<td>Web App and WiFi Information</td>
<td>3</td>
</tr>
<tr>
<td>Welcome Messages</td>
<td>4–6</td>
</tr>
<tr>
<td>Society Information</td>
<td>7–9</td>
</tr>
<tr>
<td>50th Anniversary of TTS</td>
<td>10</td>
</tr>
<tr>
<td>Congress Committees List</td>
<td>11–16</td>
</tr>
<tr>
<td>Invited Speakers</td>
<td>17–23</td>
</tr>
<tr>
<td>Session Chairs</td>
<td>24–28</td>
</tr>
<tr>
<td>Abstract Reviewers</td>
<td>29–35</td>
</tr>
<tr>
<td>Award Winners</td>
<td></td>
</tr>
<tr>
<td>Young Investigator Scientific Awards</td>
<td>36–38</td>
</tr>
<tr>
<td>Transplantation Science</td>
<td></td>
</tr>
<tr>
<td>Mentee-Mentor Awards</td>
<td>39–43</td>
</tr>
<tr>
<td>Congress Information</td>
<td></td>
</tr>
<tr>
<td>Venue and Floor Plans</td>
<td>45–51</td>
</tr>
<tr>
<td>Operating Hours</td>
<td>52–54</td>
</tr>
<tr>
<td>Program Schedule</td>
<td>55–56</td>
</tr>
<tr>
<td>Events Schedule</td>
<td>57</td>
</tr>
<tr>
<td>Use of Name Badge</td>
<td>58</td>
</tr>
<tr>
<td>Abstract Publication</td>
<td>59</td>
</tr>
<tr>
<td>Web Recordings and Live Broadcasting</td>
<td>59–61</td>
</tr>
<tr>
<td>Presenter Guidelines and Poster Sessions</td>
<td>62</td>
</tr>
<tr>
<td>CME Information</td>
<td>63–64</td>
</tr>
<tr>
<td>Onsite Services</td>
<td>65–69</td>
</tr>
<tr>
<td>Affiliate Events</td>
<td>69</td>
</tr>
<tr>
<td>Social Activities</td>
<td>70–73</td>
</tr>
<tr>
<td>Detailed Program</td>
<td></td>
</tr>
<tr>
<td>Day 1: Thursday, August 18</td>
<td>77–85</td>
</tr>
<tr>
<td>Day 2: Friday, August 19</td>
<td>89–103</td>
</tr>
<tr>
<td>Day 3: Saturday, August 20</td>
<td>107–160</td>
</tr>
<tr>
<td>Day 4: Sunday, August 21</td>
<td>163–214</td>
</tr>
<tr>
<td>Day 5: Monday, August 22</td>
<td>217–250</td>
</tr>
<tr>
<td>Day 6: Tuesday, August 23</td>
<td>253–272</td>
</tr>
<tr>
<td>Poster List</td>
<td>273–341</td>
</tr>
<tr>
<td>Sponsored Symposia</td>
<td>342–344</td>
</tr>
<tr>
<td>Exhibit Information</td>
<td></td>
</tr>
<tr>
<td>Exhibit Hours and Floor Plan</td>
<td>346–349</td>
</tr>
<tr>
<td>Sponsor Descriptions</td>
<td>350–353</td>
</tr>
<tr>
<td>Exhibitor Descriptions</td>
<td>354–366</td>
</tr>
<tr>
<td>Local Partners</td>
<td>367</td>
</tr>
<tr>
<td>Traveler Information</td>
<td>370–373</td>
</tr>
<tr>
<td>Presenter Index</td>
<td>378–395</td>
</tr>
</tbody>
</table>
As the scientific program for the Congress touches on a wide base of sub-programs, we have included the following icons for ease of knowledge on what topic(s) is covered during each Symposium, Oral, State-of-the-Art, and Poster Session.

In addition, in the detailed program section, each day of the Congress has been tabbed and printed with a Program-at-a-Glance for that specific day -- morning sessions on one side and afternoon sessions on the reverse -- and the subsequent pages color-coded.
SSID: TTS2016

How to connect in three simple steps:
Step 1: Connect to the TTS 2016 SSID
Step 2: Open your favorite browser
Step 3: When the Congress welcome page loads you are ready to surf the web

Troubleshooting:
- Ensure cookies are enabled on your device.
- Visit the Technology Area behind the TTS booth in Hall 5FG for help in connecting.

Congress WebApp

TTS will be using a new WebApp completely integrated into our management software.

To login, use the same password used to register for the Congress.

WebApp Highlights:
- view the program
- build your agenda
- take notes
- view sponsor/exhibitor information
- look up colleagues

No download is required, simply visit: http://tts.guide
n behalf of the TTS Council, I would like to welcome you all to the 26th Congress of The Transplantation Society. This Congress marks the 50th Anniversary of the Society, and it is only the second time that our Congress is being held in Asia. The program committee has been working hard to deliver you an exciting and innovative program. We have outstanding international experts at the highest level giving overviews of our understanding of modern biology and how it will impact transplantation. These include presentations on the microbiome, polyreactive alloantibodies, new outcomes for hepatitis C, our understanding of the molecular biology of aging, and mapping of the human immune system. In addition to excellent plenary talks, there are a wide range of state-of-the-art lectures on every facet of transplantation, as well as an excellent and extensive education program.

Finally, I would like to remind you of the 50th Anniversary celebrations for the Society. The highlight is a series of videos capturing key events and developments that defined the term of all available past presidents of the Society. This is an extraordinary retrospective of what we have achieved in the last 50 years. I urge you all to visit the Society’s booth in the Exhibit Area and view these presentations.

A warm welcome,

Philip J. O’Connell
TTS 2016 Congress Chair
President, The Transplantation Society
Dear Friends and Colleagues,

It is our tremendous pleasure and certainly an honor to extend to you a very warm welcome to the 26th International Congress and concurrent celebration of the 50th Anniversary of The Transplantation Society.

As the local host and one of the co-organizers together with the Thai Transplantation Society, we welcome you to Hong Kong, a special administrative region of China. Hong Kong, literally translated “Fragrant Harbor”, is one of the most significant global financial centers as well as one of the healthiest places in the world. However, with a deceased donor organ donation rate of only a fraction of that of most Western countries, organ transplantation here relies heavily on voluntary living organ donation. We hope this international event of the transplantation community not only provides transplant professionals with an instrumental and cozy arena for intellectual exchanges, but also serves as a cultural hub for generation of new ideas in the promotion of organ donation for the region and the world.

We believe you will enjoy the world-class educational activities carefully organized by the scientific committee. The Congress will offer plenty of networking opportunities for you to meet and interact with fellow researchers, clinicians, and friends. Time out from the Congress in the evenings will be particularly refreshing. We sincerely wish you a pleasant stay in this East-meets-West melting pot.

Thank you for coming to Hong Kong.

Dr. Wai Leung Chak
President, Hong Kong Society of Transplantation

Professor See Ching Chan
TTS 2016 Congress Vice-Chair
Dear colleagues, ladies, and gentlemen,

Welcome to the TTS 2016 Congress!

As co-host of the 26th International Congress of The Transplantation Society, we, the Thai Transplantation Society, would like to extend to you our warmest welcome to the TTS 2016 Congress in Hong Kong! This is also a special occasion for us to celebrate The Transplantation Society’s 50th Anniversary.

The Thai Transplantation Society has been working very hard in order to bring this important Congress to Asia. The Transplantation Society has supported this endeavor, and we are now brought together in Hong Kong.

We believe this Congress will provide an inspiring platform for transplant specialists to meet and communicate in the many forums to ensure that the TTS Congress remains at the cutting edge of our field. We shall all be very proud of the development of transplantation over the past 50 years, and excited about what is coming in the future.

We are certain that you will enjoy the Congress. Your interactions with your colleagues from many regions and countries will stimulate creative ideas and bring fresh perspectives. These will be your personal gain for attending the Congress.

The biennial TTS Congress has a long reputation of fostering friendships and new professional collaborations, and it provides an unprecedented occasion to network among transplant physicians, surgeons, and scientists in our related fields. We would like to encourage you to take part in a maximum of activities and maximize your benefits in joining the TTS 2016 Congress.

With warm wishes,

Kriengsak Vareesangthip MD, PhD, FACP
Associate Professor of Medicine
President, Thai Transplantation Society

Vasant Sumethkul MD, FRCP
Professor of Medicine
TTS 2016 Congress Vice-Chair
The mission of The Transplantation Society is to provide global leadership in the practice of human transplantation. The responsibility of The Transplantation Society is to establish guidelines of clinical practice, advance programs of education, and to promote ethical standards for clinical care and scientific investigation.

The Transplantation Society will provide the focus for global leadership in transplantation:

- Development of the science and clinical practice
- Scientific communication
- Continuing education
- Guidance on the ethical practice

FOR MORE INFORMATION, VISIT www.tts.org
The Hong Kong Society of Transplantation was incorporated in March 1995 and has been very active in the region. Its major objectives include:

- To promote for the public benefit the interests in and a better understanding of the advancement of science and knowledge in the transplantation and harvesting of organs and tissues
- To promote organ donation
- To promote research, education, training, and appreciation in the science and technology of transplantation, and to make available to the community up-to-date information on new developments in transplantation and organ/tissue harvesting for public benefit
- To promote academic and social exchange among local and overseas transplant community, and to organize activities/conferences in this respect

MORE INFORMATION AVAILABLE AT www.hkst.org
The Thai Transplantation Society has long been an ardent supporter of The Transplantation Society and is one of its affiliated societies. It has also worked with various international organizations, such as the World Health Organization, to improve transplantation practices in Thailand, which has a significant unfulfilled demand for transplantation treatments. To date, 330 patients in Thailand have received liver transplants from deceased donors, while a further 30 pediatric and adult patients have had liver transplants from living related donors. The total number of Thai patients who have received bone marrow and stem cell transplants now exceeds 1,000 transplantations.

Kidney transplants constitute the largest number of solid organ transplantations being performed in Thailand, with 4,202 patients to date having received kidney transplants from 23 Centres throughout the country. Fifty-five percent were kidney transplants from deceased donors and forty-five percent from living related donors. Currently, 400 kidney transplants are performed in Thailand each year. However, many more patients remain in need of transplantations.

MORE INFORMATION AVAILABLE AT www.transplantthai.org
The founding members of this Society developed many of the advances that have made transplantation the success it is today. TTS has at heart to carry on this legacy and to build on this foundation in science and clinical practice, where many challenges remain.

Under the direction of our our historian, Randall Morris, we will be marking our 50th Anniversary Congress by introducing two new historical projects:

**TTS Historical Mini-Theatre**: We have filmed our Past Presidents over the past two years and the interviews will be available for the first time in a special Mini-Theatre in the TTS booth.

**TTS Historical Timeline**: We have built an interactive multimedia timeline which will be on display next to TTS Historical Mini-Theatre.

Following the Congress, the videos and timeline will be available on [www.tts.org](http://www.tts.org).
## COMMITTEES

### Executive Committee

- Philip J. O’Connell, Westmead, Australia (Chair)
- See Ching Chan, Hong Kong SAR, P.R. of China (Vice-Chair)
- Vasant Sumethkul, Bangkok, Thailand (Vice-Chair)
- Nancy Ascher, San Francisco, CA, United States
- Jeremy R. Chapman, Westmead, Australia
- John J. Fung, Cleveland, OH, United States

### Finance Committee

- John J. Fung, Cleveland, OH, United States (Chair)
- (late) Josette M. Eris, Westmead, Australia
- William Lee, Hong Kong SAR, P.R. of China
- José María Morales, Madrid, Spain
- Elmi M. Muller, Cape Town, South Africa
- Philip J. O’Connell, Westmead, Australia
- Denise Rainville, Montreal, QC, Canada
- Kriengsak Vareesangthip, Bangkok, Thailand

### Host Country Liaison Committee (Hong Kong)

- Wai-Leung Chak (Chair)
- See Ching Chan
- Ka Foon Chau
- Kai Ming Chow
- Bo Ying Cindy Choy
- See Ming Simon Hou
- Jenny Koo
- William Lee
- Chung-Mau Lo
- Stanley HK Lo
- Nancy Kwan Man
- Maggie Kam Man Ma
- Matthew Kwok Lung Tong

### Scientific Program Committee

- Jeremy R. Chapman, Westmead, Australia (Chair)
- Nancy Ascher, San Francisco, CA, United States
- Yingyos Avihingsanon, Bangkok, Thailand
- Marcelo Cantarovich, Montreal, QC, Canada
- Wai-Leung Chak, Hong Kong SAR, P.R. of China
- Josep Grinyo, Barcelona, Spain
- Philip J. O’Connell, Westmead, Australia
- Vasant Sumethkul, Bangkok, Thailand
- Megan Sykes, New York, NY, United States
- Shiro Takahara, Osaka, Japan
- Stefan G. Tullius, Boston, MA, United States
**Program Subcommittees**

**Postgraduate Course**
Marcelo Cantarovich, Canada (Co-Chair)
Vivekanand Jha, India (Co-Chair)
Nancy Kwan Man, Hong Kong SAR, P.R. of China (Co-Chair)
David Rothstein, United States (Co-Chair)

**Basic Sciences and Translational Sciences**
Carla Baan, The Netherlands (Co-Chair)
Anita Chong, United States (Co-Chair)
Curie Ahn, Korea
Shane T. Grey, Australia
Fadi G. Lakkis, United States
Xian C. Li, United States
Giovanna Lombardi, United Kingdom
Minnie M. Sarwal, United States
Birgit S. Sawitzki, Germany
Qizhi Tang, United States

**Cell Transplantation/ Bone Marrow/ HSC**
Anil Dhawan, United Kingdom (Co-Chair)
Maria Koulmanda, United States (Co-Chair)
Jeffrey Szer, Australia

**Complications**
Steve J. Chadban, Australia (Co-Chair)
Angela Webster, Australia (Co-Chair)
Alan G. Jardine, United Kingdom
Michael A. Nalesnik, United States
Shigeru Satoh, Japan
Claire M. Vajdic, Australia

**Composite Tissue**
Linda C. Cendales, United States (Co-Chair)
Emmanuel Morelon, France (Co-Chair)
Palmina Petruzzo, France (Co-Chair)

**Declaration of Istanbul**
Gabriel Danovitch, United States (Co-Chair)
Francis L. Delmonico, United States (Co-Chair)
Beatriz Dominguez-Gil, Spain (Co-Chair)
PROGRAM SubCommittees

- Donation and Procurement
  Marti Manyalich, Spain (Co-Chair)
  Kimberly Young, Canada (Co-Chair)
  Stephen D. Beed, Canada
  John S. Gill, Canada
  Jongwon Ha, Korea
  Thomas A. Nakagawa, United States
  Dorry Segev, United States
  Gregory I. Snell, Australia

- Ethics, Community and Economics
  Beatriz Dominguez-Gil, Spain (Co-Chair)
  Dominique E. Martin, Australia (Co-Chair)

- Heart
  Peter S. MacDonald, Australia (Co-Chair)
  Joseph Rogers, United States (Co-Chair)

- Histocompatibilty
  Frans H.J. Claas, Netherlands (Co-Chair)
  Peter William Nickerson, Canada (Co-Chair)
  Susan V. Fuggle, United Kingdom
  Howie M. Gebel, United States
  Maria Gerbase-DeLima, Brazil
  Rhonda Holdsworth, Australia
  Anat R. Tambur, United States

- Infections Diseases
  Deborah Marriott, Australia (Co-Chair)
  Michele I. Morris, United States (Co-Chair)

- Intestine & Multivisceral
  Douglas G. Farmer, United States (Co-Chair)
  Debra L. Sudan, United States (Co-Chair)
**Kidney**

Dirk Kuypers, Belgium (Co-Chair)  
Peter Stock, United States (Co-Chair)  
Daniel C. Brennan, United States  
Klemens Budde, Germany  
Robert B. Colvin, United States  
Anthony Dorling, United Kingdom  
(late) Josette M. Eris, Australia  
Paolo Ferrari, Australia  
Mark Haas, United States  
Philip F. Halloran, Canada  
Stuart Knechtle, United States  
Alan B. Leichtman, United States  
Henri G.D. Leuvenink, The Netherlands  
Valeria Mas, United States  
Robert M. Merion, United States  
Robert A. Montgomery, United States  
Brian J. Nankivell, Australia  
Milagros Samaniego, United States  
Kazunari Tanabe, Japan  
Chris J. E. Watson, United Kingdom  
Germaine Wong, Australia  
Andrea A. Zachary, United States

**Kidney Immunosuppression**

Lionel Rostaing, France (Co-Chair)  
Flavio Vincenti, United States (Co-Chair)  
Stephan Busque, United States  
Josep M. Campistol, Spain  
Sandy Feng, United States  
Stuart M. Flechner, United States  
Edward K. Geissler, Germany  
Joseph Leventhal, United States  
Helio Tedesco-Silva Jr., Brazil  
Teun Van Gelder, The Netherlands
PROGRAM Subcommittees

- Liver
  Elizabeth A. Pomfret, United States (Co-Chair)
  Chung-Mau Lo, Hong Kong SAR, P.R. of China (Co-Chair)
  Marina Berenguer, Spain
  Patrizia Burra, Italy
  Pierre Alain Clavien, Switzerland
  Sandy Feng, United States
  Peter Friend, United Kingdom
  Julie K. Heimbach, United States
  John R. Klinck, United Kingdom
  Jan P. Lerut, Belgium
  Claus Niemann, United States
  Gabriel C. Oniscu, United Kingdom
  Andreas Pascher, Germany
  Johann Pratschke, Germany
  Saigal Sanjiv, India
  Abraham Shaked, United States

- Lung
  Allan R. Glanville, Australia (Chair)

- Paediatrics
  Anne I. Dipchand, Canada (Co-Chair)
  Ron Shapiro, United States (Co-Chair)
  David Briscoe, United States
  Helen M. Evans, New Zealand

- Pancreas and Islet
  Thierry P.S. Berney, Switzerland (Co-Chair)
  Mitsukazu Gotoh, Japan (Co-Chair)
  Raja Kandaswamy, United States (Co-Chair)
  Jon Odorico, United States (Co-Chair)

- Registries
  Bertram L. Kasiskie, United States (Co-Chair)
  Adisorn Lumpaopong, Thailand (Co-Chair)
Surgical Techniques
George W. Burke, United States (Co-Chair)
Henry Pleass, Australia (Co-Chair)

Transplantation in Developing Countries
Curie Ahn, Korea (Co-Chair)
Elmi M. Muller, South Africa (Co-Chair)

Transplantation Nursing
Kathy Kable, Australia (Co-Chair)
Patrice Pfeiffenberger, United States (Co-Chair)
Cynthia Russell, United States (Co-Chair)

Xenotransplantation
Agnes Azimzadeh, United States (Co-Chair)
Peter Cowan, Australia (Co-Chair)

Women in Transplantation
(late) Josette M. Eris, Australia (Co-Chair)
Lori J. West, Canada (Co-Chair)
## Post-Graduate Courses

<table>
<thead>
<tr>
<th>Name</th>
<th>City and Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roberta J. Al Housani-Blakely</td>
<td>Abu Dhabi, United Arab Emirates</td>
</tr>
<tr>
<td>Carla Baan</td>
<td>Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>Markus Barten</td>
<td>Hamburg, Germany</td>
</tr>
<tr>
<td>Christian Benden</td>
<td>Zurich, Switzerland</td>
</tr>
<tr>
<td>Jonathan S. Bromberg</td>
<td>Baltimore, MD, United States</td>
</tr>
<tr>
<td>Steve J. Chadban</td>
<td>Camperdown, Australia</td>
</tr>
<tr>
<td>Wai Ming Chan</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>Ka Foon Chau</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>Jingyu Chen</td>
<td>Jiangsu, People’s Republic of China</td>
</tr>
<tr>
<td>Menna R. Clatworthy</td>
<td>Cambridge, United Kingdom</td>
</tr>
<tr>
<td>Jonathan Craig</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>Zhenhua Dai</td>
<td>Guangzhou, People’s Republic of China</td>
</tr>
<tr>
<td>Emanuele de Rinaldis</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Anne I. Dipchand</td>
<td>Toronto, ON, Canada</td>
</tr>
<tr>
<td>Thu Thi Ngoc Du</td>
<td>Ho Chi Minh, Viet Nam</td>
</tr>
<tr>
<td>Magnus Fontes</td>
<td>Paris, France</td>
</tr>
<tr>
<td>John S. Gill</td>
<td>Vancouver, BC, Canada</td>
</tr>
<tr>
<td>Shane T. Grey</td>
<td>Darlinghurst, Australia</td>
</tr>
<tr>
<td>Paul C. Grimm MD</td>
<td>Stanford, CA, United States</td>
</tr>
<tr>
<td>Susan Gunderson</td>
<td>Minneapolis, MN, United States</td>
</tr>
<tr>
<td>Yanhong Guo</td>
<td>Beijing, People’s Republic of China</td>
</tr>
<tr>
<td>Jongwon Ha</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>Philip F. Halloran</td>
<td>Edmonton, AB, Canada</td>
</tr>
<tr>
<td>Paul Harden</td>
<td>Oxford, United Kingdom</td>
</tr>
<tr>
<td>Xiaoshun He</td>
<td>Guangzhou, People’s Republic of China</td>
</tr>
<tr>
<td>Hallvard Holdaas</td>
<td>Oslo, Norway</td>
</tr>
<tr>
<td>Jiefu Huang</td>
<td>Beijing, People’s Republic of China</td>
</tr>
<tr>
<td>Kathy Kable</td>
<td>Westmead, Australia</td>
</tr>
<tr>
<td>John W. Kao</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>Daniel Kreisel</td>
<td>St. Louis, MO, United States</td>
</tr>
<tr>
<td>Dirk Kuypers</td>
<td>Leuven, Belgium</td>
</tr>
<tr>
<td>Janette Kwok</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>Christophe Michel Legendre</td>
<td>Paris, France</td>
</tr>
<tr>
<td>Bronwyn J. Levvey</td>
<td>Melbourne, Australia</td>
</tr>
<tr>
<td>Xian C. Li</td>
<td>Houston, TX, United States</td>
</tr>
<tr>
<td>Qizhou Lian</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>Andreas Linkermann</td>
<td>Kiel, Germany</td>
</tr>
<tr>
<td>Chun-Jen Liu</td>
<td>Taipei City, Taiwan</td>
</tr>
</tbody>
</table>
INVITED Speakers

Post-Graduate Courses (cont.)

Chung-Mau Lo, Hong Kong SAR, P.R. of China
Alexandre Loupy, Paris, France
Marti Manyalich, Barcelona, Spain
Valeria Mas, Charlottesville, VA, United States
George V. Mazariegos, Pittsburgh, PA, United States
Michael Mengel, Edmonton, AB, Canada
Robert A. Montgomery, New York, NY, United States
Adrian E. Morelli, Pittsburgh, PA, United States
Randall E. Morris, Carmel, CA, United States
Elmi M. Muller, Cape Town, South Africa
Brian J. Nankivell, Westmead, Australia
Anwar Naqvi, Karachi, Pakistan
Howard M. Nathan, Philadelphia, PA, United States
Aurora Navarro, Barcelona, Spain
Kenneth A. Newell, Atlanta, GA, United States
Peter William Nickerson, Winnipeg, MB, Canada
José Ramón Núñez Peña, Geneva, Switzerland
Philip J. O’Connell, Westmead, Australia
Martin Oberbarnscheidt, Pittsburgh, PA, United States
Giuseppe Orlando, Winston Salem, NC, United States
Benita Padilla, San Juan City, Philippines
Lars Pape, Hannover, Germany
Mir M. Rahman, Chittagong, Bangladesh
Elaine F. Reed, Los Angeles, CA, United States
Paul Robertson, Westmead, Australia
Eduardo Rocha, Rio de Janeiro, Brazil
David Rothstein, Pittsburgh, PA, United States
Alberto Sanchez-Fueyo, London, United Kingdom
Liz Schick, Anzè re, Switzerland
Dorry Segev, Baltimore, MD, United States
Faissal Shaheen, Riyadh, Saudi Arabia
Abraham Shaked, Philadelphia, PA, United States
Diana Shellmer, Pittsburgh, PA, United States
Bingyi Shi, Beijing, People’s Republic of China
Dibya Singh, Kathmandu, Nepal
Xuyong Sun, Beijing, People’s Republic of China
Htar Kyi Swe, Mandalay, Myanmar
Ban Hock Tan, Singapore, Singapore
Kazunari Tanabe, Tokyo, Japan
Qizhi Tang, San Francisco, CA, United States
Olivier Thaunat, Lyon, France
INVITED Speakers

Post-Graduate Courses (cont.)

Chris Thomas, Chatswood, Australia
Kathryn Tinckam, Toronto, ON, Canada
Burkhard Tönshoff, Heidelberg, Germany
Hung Fat Tse, Hong Kong SAR, P.R. of China
Marcel R.M. van den Brink, New York, NY, United States
Teun Van Gelder, Rotterdam, The Netherlands
Haibo Wang, Hong Kong SAR, P.R. of China
Angela Webster, Sydney, Australia
Piotr Witkowski, Chicago, IL, United States
Germaine Wong, Westmead, Australia
Aimin Xu, Hong Kong SAR, P.R. of China
Qifa Ye, Wuhan, People’s Republic of China
Kimberly Young, Edmonton, AB, Canada
Mirza Naqi Zafar, Karachi, Pakistan
Nicolas Zavazava, Iowa City, IA, United States
Yuan Zhai, Los Angeles, CA, United States
Shusen Zheng, Hangzhou, People’s Republic of China
Zhe Zheng, Beijing, People’s Republic of China
INVITED Speakers

TTS 2016 Congress

Robert J. Al Housani-Blakely, Abu Dhabi, United Arab Emirates
Matthew L. Albert, San Francisco, CA, United States
Monal Afukhaimi, Dubai, United Arab Emirates
Dany Anglicheau, Paris, France
Nancy Ascher, San Francisco, CA, United States
Medhat Z. Askar, Dallas, TX, United States
Agnes Azimzadeh, Baltimore, MD, United States
Carla Baan, Rotterdam, The Netherlands
Byambadorji Batsuuri, Ulaanbaatar, Mongolia
Pierre Y. Benhamou, Grenoble, France
Marina Berenguer, Valencia, Spain
Thierry P.S. Berney, Geneva, Switzerland
Sandra Burchett, Boston, MA, United States
George W. Burke, Miami, FL, United States
Alexander M. Capron, Los Angeles, CA, United States
Linda C. Cendales, Durham, NC, United States
Daniel T.M. Chan, Hong Kong SAR, P.R. of China
See Ching Chan, Hong Kong SAR, P.R. of China
Wai Ming Chan, Hong Kong SAR, P.R. of China
Sindhu Chandran, San Francisco, CA, United States
Jeremy R. Chapman, Westmead, Australia
Chao-Long Chen, Taiwain
Sharon Chen, Westmead, Australia
Jacqueline J. Chin, Singapore
Frans H.J. Claas, Leiden, Netherlands
Menna R. Clatworthy, Cambridge, United Kingdom
Peter Cowan, Melbourne, Australia
Antonia Cronin, London, United Kingdom
Dolly Daniel, Vellore, India
Francis L. Delmonico, Waltham, MA, United States
Anil Dhawan, London, United Kingdom
Kumud K. Dhital, Darlinghurst, Australia
Fritz Diekman, Barcelona, Spain
Anne I. Dipchand, Toronto, ON, Canada
Beatriz Dominguez-Gil, Madrid, Spain
Duska Dragun, Berlin, Germany
Joel T. Dudley, New York, NY, United States
Gregory T. Everson, Aurora, CO, United States
Donna L. Farber, New York, NY, United States
Douglas G. Farmer, Los Angeles, CA, United States
Alton "Brad" Farris III, Atlanta, GA, United States
INVITED Speakers

TTS 2016 Congress (cont.)

Sandy Feng, San Francisco, CA, United States
Paolo Ferrari, Sydney, Australia
Constantino Fondevila, Barcelona, Spain
James Fung, Hong Kong SAR, P.R. of China
Rudolf A. Garcia-Gallont, Guatemala City, Guatemala
Edward K. Geissler, Regensburg, Germany
Sommer E. Gentry, Baltimore, MD, United States
John S. Gill, Vancouver, BC, Canada
Allan R. Glanville, Sydney, Australia
Gabriel E. Gondolesi, Buenos Aires, Argentina
Shane T. Grey, Darlinghurst, Australia
Faikah Gueler, Hannover, Germany
Duck-Jong Han, Seoul, Korea
Wayne W. Hancock, Philadelphia, PA, United States
Wayne J. Hawthorne, Westmead, Australia
Margaret Hay, Clayton, Australia
Wayne C. Hodgson, Clayton, Australia
Hallvard Holdaas, Oslo, Norway
Martin J. Hoogduijn, Rotterdam, The Netherlands
Kirsten Howard, Sydney, Australia
Jiefu Huang, Beijing, People’s Republic of China
Suzanne T. Ildstad, Louisville, KY, United States
Trond Jenssen, Oslo, Norway
Paul R. V. Johnson, Oxford, United Kingdom
Raja Kandaswamy, Minneapolis, MN, United States
Bertram L. Kasiske, Minneapolis, MN, United States
Dixon B. Kaufman, Madison, WI, United States
Brian K. Kennedy, Novato, CA, United States
Gregory Alan Knoll, Ottawa, ON, Canada
Wing-Man Ko, Hong Kong SAR, P.R. of China
Jenny Koo, Hong Kong SAR, P.R. of China
Maria Koulmanda, Boston, MA, United States
Christophe Michel Legendre, Paris, France
Megan Levings, Vancouver, BC, Canada
Bronwyn J. Levvey, Melbourne, Australia
Chung-Mau Lo, Hong Kong SAR, P.R. of China
Marta López Fraga, Strasbourg, France
Peter S. MacDonald, Sydney, Australia
Clarisse Machado, São Paulo, Brazil
Beatriz B. Mahillo, Madrid, Spain
Marti Manyalich, Barcelona, Spain
TTS 2016 Congress (cont.)

Dominique E. Martin, Geelong, Australia
Olivia M. Martinez, Stanford, CA, United States
Tereza Martinu, Toronto, ON, Canada
Philip Masson, Edinburgh, United Kingdom
George V. Mazariegos, Pittsburgh, PA, United States
Sue McDiarmid, Los Angeles, CA, United States
Stephen McDonald, Adelaide, Australia
Raphael Meier, Geneva, Switzerland
Philip Meissner, Munich, Germany
Simon J. Messer, Cambridge, United Kingdom
Muhammad M. Mohiuddin, Bethesda, MD, United States
Robert A. Montgomery, New York, NY, United States
José María Morales, Madrid, Spain
Emmanuel Morelon, Lyon, France
Michele I. Morris, Miami, FL, United States
David W. Mudge, Brisbane, Australia
Elmi M. Muller, Cape Town, South Africa
Brian J. Nankivell, Westmead, Australia
Kenneth A. Newell, Atlanta, GA, United States
Michael L. Nicholson, Cambridge, United Kingdom
Peter William Nickerson, Winnipeg, MB, Canada
Claus Niemann, San Francisco, CA, United States
José Ramón Núñez Peña, Geneva, Switzerland
Philip J. O’Connell, Westmead, Australia
Rudolf Oehler, Vienna, Austria
Giuseppe Orlando, Winston Salem, NC, United States
Lars Pape, Hannover, Germany
Chung-Gyu Park, Seoul, Korea
Myoung Hee Park, Seoul, Korea
François Pattou, Lille, France
Julie Pavlovic, Heidelberg, Australia
Martin F. Pera, Parkville, Australia
Palmina Petruzzo, Lyon, France
Helen Pilmore, Auckland, New Zealand
Klara M. Posfay-Barbe, Geneva, Switzerland
Andrew Posselt, San Francisco, CA, United States
Elaine F. Reed, Los Angeles, CA, United States
Petra Reinke, Berlin, Germany
Mohamed Rela, Chennai, India
Adibul Hasan Rizvi, Karachi, Pakistan
Franklin L. Rosenfeldt, Melbourne, Australia
TTS 2016 Congress (cont.)

Alexander Rudensky, New York, NY, United States
Alberto Sanchez-Fueyo, London, United Kingdom
Minnie M. Sarwal, San Francisco, CA, United States
Stefan Schaub, Basel, Switzerland
Carrie A. Schinstock, Rochester, MN, United States
Hanne Scholz, Oslo, Norway
Christian Schuetz, Boston, MA, United States
Dorry Segev, Baltimore, MD, United States
Marina Sirota, San Francisco, CA, United States
Yuji Soejima, Fukuoka, Japan
Peter Stock, San Francisco, CA, United States
Simone I. Strasser, Camperdown, Australia
Kyung-Suk Suh, Seoul, Korea
Vasant Sumethkul, Bangkok, Thailand
Caner Süsal, Heidelberg, Germany
Megan Sykes, New York, NY, United States
Anat R. Tambur, Chicago, IL, United States
Ban Hock Tan, Singapore, Singapore
Kazunari Tanabe, Tokyo, Japan
Qizhi Tang, San Francisco, CA, United States
Cara Tannenbaum, Montreal, QC, Canada
Alfred Joseph Tector, Birmingham, AL, United States
Olivier Thaunat, Lyon, France
Mirjam Tielen, Rotterdam, The Netherlands
Kathryn Tinckam, Toronto, ON, Canada
Yaman Tokat, Istanbul, Turkey
Allison Tong, Sydney, Australia
Hung Fat Tse, Hong Kong SAR, P.R. of China
Stefan G. Tullius, Boston, MA, United States
Flavio Vincenti, San Francisco, CA, United States
Angela Webster, Sydney, Australia
Chris J. Wiebe, Winnipeg, MB, Canada
Colin Wilson, Newcastle-upon-Tyne, United Kingdom
Michael Wolf, Chicago, IL, United States
Germaine Wong, Westmead, Australia
Kathryn J. Wood, Oxford, United Kingdom
Di Yu, Clayton, Australia
Mirza Naqi Zafar, Karachi, Pakistan
Emmanuel Zorn, New York, NY, United States
SESSION Chairs

Curie Ahn, Seoul, Korea
Roberta J. Al Housani-Blakely, Abu Dhabi, United Arab Emirates
Richard D.M. Allen, Sydney, Australia
Mona Alrukhaimi, Dubai, United Arab Emirates
Dany Anglicheau, Paris, France
Rebecca Arroyo Hornero, Oxford, United Kingdom
Nancy Ascher, San Francisco, CA, United States
Medhat Z. Askar, Dallas, TX, United States
Yingyos Avihingsanon, Bangkok, Thailand
Agnes Azimzadeh, Baltimore, MD, United States
Carla Baan, Rotterdam, Netherlands
Marina Berenguer, Valencia, Spain
Thierry P.S. Berney, Geneva, Switzerland
Jonathan S. Bromberg, Baltimore, MD, United States
Klemens Budde, Berlin, Germany
Leo Buhler, Geneva, Switzerland
George W. Burke, Miami, FL, United States
Roy Calne, Cambridge, United Kingdom
Marcelo Cantarovich, Montreal, QC, Canada
Alexander M. Capron, Los Angeles, CA, United States
Linda C. Cendales, Durham, NC, United States
Steve J. Chadban, Camperdown, Australia
Wai-Leung Chak, Hong Kong SAR, P.R. of China
Albert Chan, Hong Kong SAR, P.R. of China
See Ching Chan, Hong Kong SAR, P.R. of China
Sindhu Chandran, San Francisco, CA, United States
Li Chao, Hangzhou, People’s Republic of China
Jeremy R. Chapman, Westmead, Australia
Ka Foon Chau, Hong Kong SAR, P.R. of China
Sharon Chen, Westmead, Australia
Ignatius Kum-Po Cheng, Hong Kong SAR, P.R. of China
Chi Yuen Simon Cheung, Hong Kong SAR, P.R. of China
Kenneth Siu Ho Chok, Hong Kong SAR, P.R. of China
Bo Ying Cindy Choy, Hong Kong SAR, P.R. of China
Frans H.J. Claas, Leiden, Netherlands
Menna R. Clatworthy, Cambridge, United Kingdom
Peter Cowan, Melbourne, Australia
Jonathan Craig, Sydney, Australia
Francis L. Delmonico, Waltham, MA, United States
Anil Dhawan, London, United Kingdom
Visist Dhitavat, Bangkok, Thailand
Fritz Diekman, Barcelona, Spain
Anne I. Dipchand, Toronto, ON, Canada
Beatriz Dominguez-Gil, Madrid, Spain
Duska Dragun, Berlin, Germany
Karen Dwyer, Victoria, Australia
SESSION Chairs

Hiroto Egawa, Tokyo, Japan
Howard Eisen, Philadelphia, PA, United States
Katherine Fan, Hong Kong SAR, P.R. of China
Douglas G. Farmer, Los Angeles, CA, United States
Sandy Feng, San Francisco, CA, United States
Paolo Ferrari, Sydney, Australia
Peter Friend, Oxford, United Kingdom
James Fung, Hong Kong SAR, P.R. of China
John J. Fung, Cleveland, OH, United States
Rudolf A. Garcia-Gallont, Guatemala City, Guatemala
Edward K. Geissler, Regensburg, Germany
John S. Gill, Vancouver, BC, Canada
Allan R. Glanville, Sydney, Australia
Gabriel E. Gondolesi, Buenos Aires, Argentina
Mitsukazu Gotoh, Osaka, Japan
Shane T. Grey, Darlinghurst, Australia
Josep Grinyo, Barcelona, Spain
Carole Guillonneau, Nantes, France
Susan Gunderson, Minneapolis, MN, United States
Jongwon Ha, Seoul, Korea
Mehmet Haberal, Ankara, Turkey
Philip F. Halloran, Edmonton, AB, Canada
Duck-Jong Han, Seoul, Korea
Wayne W. Hancock, Philadelphia, PA, United States
Paul Harden, Oxford, United Kingdom
Wayne J. Hawthorne, Westmead, Australia
Maria Hernandez-Fuentes, London, United Kingdom
Kelvin Kai-Leung Ho, Hong Kong SAR, P.R. of China
Hallvard Holdaas, Oslo, Norway
Rhonda Holdsworth, Melbourne, Australia
Martin J. Hoogduijn, Rotterdam, Netherlands
See Ming Simon Hou, Hong Kong SAR, P.R. of China
Feng Huo, Guangzhou, People's Republic of China
Fadi Issa, Oxford, United Kingdom
Vivekanand Jha, Chandigarh, India
Paul R. V. Johnson, Oxford, United Kingdom
Kathy Kable, Westmead, Australia
Raja Kandaswamy, Minneapolis, MN, United States
Bertram L. Kasiske, Minneapolis, MN, United States
Dixon B. Kaufman, Madison, WI, United States
Thomas Kay, Victoria, Australia
Gregory Alan Knoll, Ottawa, ON, Canada
Takaaki Kobayashi, Nagoya, Japan
Jenny Koo, Hong Kong SAR, P.R. of China
Maria Koulmanda, Boston, MA, United States
Daniel Kreisel, St. Louis, MO, United States
SESSION Chairs

Dirk Kuypers, Leuven, Belgium
Janette Kwok, Hong Kong SAR, P.R. of China
Man Fai Lam, Hong Kong SAR, P.R. of China
William Lee, Hong Kong SAR, P.R. of China
Christophe Michel Legendre, Paris, France
Jan Lerut, Louvain-la-Neuve, Belgium
Henri G.D. Leuvenink, Groningen, The Netherlands
Megan Levings, Vancouver, BC, Canada
Bronwyn J. Levvey, Melbourne, Australia
Chun Sang Li, Hong Kong SAR, P.R. of China
Xian C. Li, Houston, TX, United States
Kieron Lim, Singapore, Singapore
Andreas Linkermann, Kiel, Germany
Chung-Mau Lo, Hong Kong SAR, P.R. of China
Stanley HK Lo, Hong Kong SAR, P.R. of China
Jayme E. Locke, Birmingham, AL, United States
Marta López Fraga, Strasbourg, France
Alexandre Loupy, Paris, France
Siu Fai Lui, Hong Kong, SAR, P.R. of China
Adisorn Lumpaopong, Bangkok, Thailand
Xunrong Luo, Chicago, IL, United States
Maggie Kam Man Ma, Hong Kong SAR, P.R. of China
Peter S. MacDonald, Sydney, Australia
Nancy Kwan Man, Hong Kong SAR, P.R. of China
Marti Manyalich, Barcelona, Spain
Deborah Marriott, Sydney, Australia
Dominique E. Martin, Geelong, Australia
Olivia M. Martinez, Stanford, CA, United States
Tereza Martinu, Toronto, ON, Canada
Valeria Mas, Charlottesville, VA, United State
Philip Masson, Edinburgh, United Kingdom
George V. Mazariegos, Pittsburgh, PA, United States
Sue McDiarmid, Los Angeles, CA, United States
Stephen McDonald, Adelaide, Australia
Michael Mengel, Edmonton, AB, Canada
J. Michael Millis, Chicago, IL, United States
Anthony Peter Monaco, Boston, MA, United States (not confirmed)
Robert A. Montgomery, New York, NY, United States
José Maria Morales, Madrid, Spain
Luis E. Morales-Buenrostro, Mexico City, Mexico
Emmanuel Morelon, Lyon, France
Michele I. Morris, Miami, FL, United States
Peter J. Morris, London, United Kingdom
Randall E. Morris, Carmel, CA, United States
Elmi M. Muller, Cape Town, South Africa
Thomas A. Nakagawa, St. Petersburg, FL, United States
SESSION Chairs

Brian J. Nankivell, Westmead, Australia
Anwar Naqvi, Karachi, Pakistan
Howard M. Nathan, Philadelphia, PA, United States
Kenneth A. Newell, Atlanta, GA, United States
Peter William Nickerson, Winnipeg, MB, Canada
Claus Niemann, San Francisco, CA, United States
Alejandro Nino-Murcia, Bogota, Colombia
José Ramón Núñez Peña, Geneva, Switzerland
Philip J. O’Connell, Westmead, Australia
Martin Oberbarnscheidt, Pittsburgh, PA, United States
Jon Odorico, Madison, WI, United States
Rudolf Oehler, Vienna, Austria
Gerhard Opelz, Heidelberg, Germany
Benita Padilla, San Juan City, Philippines
Chung-Gyu Park, Seoul, Korea
Myoung Hee Park, Seoul, Korea
Julie Pavlovic, Heidelberg, Australia
Palmina Petruzzo, Lyon, France
Patrice Pfeiffenberger, Chicago, IL, United States
Helen Plimore, Auckland, New Zealand
Henry Pleass, Hunters Hill, Australia
Mei Lan May Pong, Hong Kong SAR, P.R. of China
Andrew Possett, San Francisco, CA, United States
Elaine F. Reed, Los Angeles, CA, United States
Petra Reinke, Berlin, Germany
Mohamed Rela, Chennai, India
Adibul Hasan Rizvi, Karachi, Pakistan
Paul Robertson, Westmead, Australia
Eduardo Rocha, Rio de Janeiro, Brazil
Lionel Rostaing, Toulouse, France
David Rothstein, Pittsburgh, PA, United States
Graeme Russ, Adelaide, Australia
Alberto Sanchez-Fueyo, London, United Kingdom
Minnie M. Sarwal, San Francisco, CA, United States
Stefan Schaub, Basel, Switzerland
Carrie A. Schinstock, Rochester, MN, United States
Stefan Schneeberger, Innsbruck, Austria
Dorry Segev, Baltimore, MD, United States
Midas Seyda, Boston, MA, United States
Faissal Shaheen, Riyadh, Saudi Arabia
Abraham Shaked, Philadelphia, PA, United States
Ron Shapiro, New York, PA, United States
William Sharr, Hong Kong SAR, P.R. of China
Diana Shellmer, Pittsburgh, PA, United States
Pui Yin Jocelyn Sim, Hong Kong SAR, P.R. of China
Gursharam Singh, Coibatore, India
SESSION Chairs

Andrew L. Singer, Phoenix, AZ, United States
Sanju Sobnach, Cape Town, South Africa
Yuji Soejima, Fukuoka, Japan
Jean-Paul P. Soulilou, Nantes, France
Peter Stock, San Francisco, CA, United States
Simone I. Strasser, Camperdown, Australia
Debra L. Sudan, Durham, NC, United States
Kyung-Suk Suh, Seoul, Korea
Vasant Sumethkul, Bangkok, Thailand
Caner Süsal, Heidelberg, Germany
Megan Sykes, New York, NY, United States
Shiro Takahara, Osaka, Japan
Ban Hock Tan, Singapore, Singapore
Kazunari Tanabe, Tokyo, Japan
Qizhi Tang, San Francisco, CA, United States
Olivier Thaunat, Lyon, France
Chris Thomas, Chatswood, Australia
Kathryn Tinckam, Toronto, ON, Canada
Allison Tong, Sydney, Australia
Matthew Kwok Lung Tong, Hong Kong SAR, P.R. of China
Burkhard Tönshoff, Heidelberg, Germany
Joyce A. Trompeta, San Francisco, CA, United States
Stefan G. Tullius, Boston, MA, United States
Ifeoma Ulasi, Enugu, Nigeria
Marcel R.M. van den Brink, New York, NY, United States
Teun Van Gelder, Rotterdam, Netherlands
Anantharaman Vathsala, Singapore, Singapore
Flavio Vincenti, San Francisco, CA, United States
Haibo Wang, Hong Kong SAR, P.R. of China
Angela Webster, Sydney, Australia
Johannes Wedel, Boston, MA, United States
Lori J. West, Edmonton, AB, Canada
Chi Fong Wong, Hong Kong SAR, P.R. of China
Germaine Wong, Westmead, Australia
Kazuhiko Yamada, New York, NY, United States
Hui Kim Yap, Singapore, Singapore
Ming Kwong Yu, Hong Kong SAR, P.R. of China
Kimberly Young, Edmonton, AB, Canada
Mirza Naqi Zafar, Karachi, Pakistan
Ali Zarrinpar, Los Angeles, CA, United States
Yuan Zhai, Los Angeles, CA, United States
Tianshu Zhang, Baltimore, MD, United States
Emmanuel Zorn, New York, NY, United States
ABSTRACT

Reviewers

Reza Abdi
Andrew B. Adams
Deborah Adey
Joel Adler
Dwomoa Adu
Vatche Agopian
Curie Ahn
Enver Akalin
S. Fazal Akhtar
Sanjeev Akkina
Khalid Al-Meshari
Nada Alachkar
Josefina Alberu
Maria-Luisa Alegre
Rodolfo Alejandro
Mario Alessiani
Stephen Alexander
Simi Ali
Richard D.M. Allen
Hala Alshayeb
Frederike Ambagsheer
Leo Amodu
David Andresen
Dany Anglicheau
M. Javeed Ansari
Samantha Anthony
Suheyla Apaydin
Helmut Arbogast
Nancy Ascher
Folkert Asselbergs
Sadaf Atarod
Meredith J. Aull
Yingyos Avihingsanon
Agnès Azimzadeh
Jamil Azzi
Carla Baan
John W. Baddley
Stephen Badylak
Jessamyn Bagley
Seema J. Baid- Agrawal
Zunaid Ahmed Barday
Adam Barlow
Benoit Barrou
Rashad S. Barsoum
Markus Barten
Ibrahim Batal
Bryan Becker
Stephen D. Beed
Melena Bellin
Marina Berenguer
Gabriela A. Berlakovich

Thierry P.S. Berney
Federico Bertuzzi
Chandra Bhati
Kelly Birdwell
G. Alex Bishop
Gilles Blancho
Christopher Blosser
Emily A. Blumberg
Georg Böhmig
Ilka Boin
Eleanor Bolton
Geoff Bond
Ann Bonner
Michael Adrian Bos
Katrina Bramstedt
Gerald Brandacher
William E. Braun
Robert Bray
Kenneth L. Brayman
Daniel C. Brennan
Todd Brennan
David Briscoe
Jonathan S. Bromberg
Klemens Budde
Leo Buhler
George W. Burke
Patrizia Burra
Zeeshan Butt
Riccardo Calafiore
Chris Callaghan
Scott Campbell
Josep M. Campistol
Jeffrey Campsen
Guillaume Canaud
Diego Cantarovich
Felix Cantarovich
Marcelo Cantarovich
Tobias Cantz
Domingo D. Casadei
John Casey
Aimee Catalan Cunningham
Linda C. Cendales
Laurens Ceulemans
Wai-Leung Chak
Laurence Chan
See Ching Chan
Jeremy R. Chapman
Bernard Charpentier
Ka Foon Chau
Yu Fan Cheng
Aravind Cherukuri
ABSTRACT

Reviewers

Srinath Chinnakotla
Kenneth Siu Ho Chok
Anita Chong
Kai Ming Chow
Bo Ying Cindy Choy
Dale Christiansen
Eduardo Chuluyan
Frans H.J. Claas
Menna R. Clatworthy
Edward Herman Cole
Robert Cole
Michael Collins
Robert B. Colvin
Patrizia Comoli
Jennifer Conway
David K. C. Cooper
Matthew Cooper
Lisa A. Coscia
Lionel Couzi
Peter Cowan
Emmanuelle Cozzi
Paolo Cravedi
Marta Crespo Barrio
Gonzalo Crespo
David Cronin
John Crosson
Joseph Cruzado
Darshana Dadhania
Dag Olav Dahl
Gabriel Danovitch
Lara Danziger-Isakov
John Dark
Leonardo de Castro
Hanneke de Kort
Sacha De Serres
Nicolas Degauque
Mary DeKlerk
Göran Dellgren
Francis L. Delmonico
Christian Denecke
Mary Amanda Dew
Anil Dhawan
Esme Dijke
Anne I. Dipchand
Ian D. Dittmer
Fabienne Dobbels
Beatriz Dominguez-Gil
Jose-Maria Dominguez-Roldan
Frank J.M.F. Dor
Anthony Dorling
Karen Elizabeth Doucette
Alden Doyle
Cynthia B. Drachenberg
Francois Durand
Magdalena Durlak
Antoine Durrbach
Karen Dwyer
Hirotoshi Egawa
Bijan Eghtesad
Susumu Eguchi
Burcin Ekser
Christine Ellis
Matt Ellis
Sukru Emre
Amir Entezazjoo
Karen English
Carlos O. Esquivel
Helen M. Evans
Matthew J. Everly
Gregory T. Everson
Mohamed Ezzelarab
Robert L. Fairchild
Katherine Fan
Douglas G. Farmer
Alton Farris
Richard Fatica
Jonathan Fawcett
Sandy Feng
Mario Fernández-Ruiz
Luis Fernandez
Paolo Ferrari
Kevin Ferreri
Charles Ferro
Nowell M. Fine
Erik Finger
Roy First
Robert A. Fisher
Stuart M. Flechner
Constantino Fondevila
Mandy Ford
John L.R. Forsythe
Marie-Chantal Fortin
Bethany Foster
Ira J. Fox
Ross S. Francis
Ulrich Frei
Peter Friend
Susan V. Fuggle
Valentin Fuhrmann
James Fung
John J. Fung
Abstract

Reviewers

Brian J. Gallay
Lorenzo Gallon
Rainer Ganschow
Luís García Covarrubias
Rudolf A. García-Gallont
Juan Carlos García-Valdecasas
Jordan Gauthier
Howie M. Gebel
Maria Gerbase-DeLima
Undine Gerlach
Nasrollah Ghahramani
Mark Ghobrial
Pierre Gianello
Edoardo G. Giannini
John S. Gill
Richard Gilroy
Matthias Girndt
Allan R. Glanville
Jonathan Gleadle
Denis Glotz
Gabriel E. Gondolesi
Stevan Gonzalez
David J. Goodman
Simin Goral
Vijay Gorantla
Masafumi Goto
Mitsukazu Gotoh
Daniel Gotthardt
David Gottlieb
Amit Govil
David M. Gracey
Darla K. Granger
Dale L. Greiner
Shane T. Grey
Matthew Griffin
Paul C. Grimm
Josep Grinyo
H. Albin Gritsch
Paolo A. Grossi
Rainer W.G. Gruessner
Christina Guerra
Lluis Guirado Perich
Sandep Guleria
Susan Gunderson
Sanjeev Gupta
Jongwon Ha
Mark Haas
Bernadette Haase-Kromwijk
Mehmet Haberal
Wayne W. Hancock
Douglas W. Hanto
Mark A. Hardy
Abdolreza Haririan
William E. Harmon
Tomonori Hasegawa
Koji Hashimoto
Wayne J. Hawthorne
Ilkka Helanterä
Roberto Hernandez-Alejandro
Maria Hernandez-Fuentes
J. Ignacio Herrero
Dennis Hesslink
Luis G. Hidalgo
Jonathan Hind
Hallvard Holdaas
Rhonda Holdsworth
Christer Holmberg
Mark Holmes
Johnny C. Hong
Simon Horslien
See Ming Simon Hou
Jean-Michel Hougardy
Dieter Hoyer
Michael Hsin
Luis Ibanez
Hirohito Ichii
Naotsugu Ichimaru
Francesco Ierino
Suzanne Ildstad
Ashley Bruce Irish
Hideki Ishida
Michael Ison
Fadi Issa
Naim Issa
Neal Iwakoshi
Daiki Iwami
Annette Jackson
Nichon N.E. Jansen
Alan G. Jardine
Emilia Jaskula
Vivekanand Jha
Hao Feng Ji
Ina Jochmans
Sven Jonas
Dong Jin Joo
Stanley C. Jordan
Michelle Josephson
Kusum Joshi
Annemarie Kaan
Joseph Kåhwa
Fady Kaldas
ABSTRACT

Reviewers

Igal Kam
Nassim Kamar
Raja Kandaswamy
John Kanellis
Mureo Kasahara
Bertram L. Kasiske
Christina Kaufman
Dixon B. Kaufman
Lori M. Kautzman
Tatsuo Kawai
Liise Kayler
Brendan Keating
Andrew P. Keaveny
Takashi Kenmochi
Sean Kennedy
Ronald Kerman
Jesper Kers
Vijay Kher
Kirian Khush
Bryce Alan Kiberd
Richard Kirk
Günter Kirste
John R. Klinck
Richard J. Knight
Simon Knight
Gregory Alan Knoll
Takaaki Kobayashi
Martina Koch
Jenny Koo
Wouter Kopp
Beverly Kosmach-Park
Katja Kotsch
Srdaha Kotwal
Maria Koulimanda
Tomasz Kozlowski
Bernhard Krämer
Sheri Krams
Edward S. Kraus
Daniel Kreisel
Aleksandra Kukla
Deepali Kumar
Vineeta Kumar
Martin Kumng
Vivek Kute
Dirk Kuypers
Janette Kwok
Choon Huyuck David Kwon
Keren Ladin
Jennifer C. Lai
John Lake
Fadi G. Lakiss
David Landsberg
Ali Asghar A. Lanewala
Audrey Lau
Irmeli Lautenschlager
Yvon Lebranchu
Nicolae Leca
John Lee
Seung Duk Lee
SungGyu Lee
Mary S. Leffell
Debra Lefkowitz
Leslie Lehmann
Alan B. Leichtman
Maria Crespo Leiro
Phillippe Lemaître
Francine Lemos
Karl Lemstrom
Henri G.D. Leuvenink
Joseph Leventhal
Eric Levesque
David Levi
Megan Levings
Gary Levy
Marlon F. Levy
Xian C. Li
Kieron Lim
Wai Lim
Per Ljungman
Marc Llordella Martinez
Stanley H.K. Lo
Jayme E. Locke
Giovanna Lombardi
Marcos Lopez-Hoyos
Lina Lu
Adisorn Lumpaopong
Xunrong Luo
Grant Luxton
Stephen V. Lynch
Maggie Kam Man Ma
Peter S. MacDonald
Clarisse Machado
Iain MacPhee
Joren C. Madsen
John C. Magee
Mitra Mahdavi-Mazdeh
Jacques F.I.R. Malaise
Jonathan Maltzman
Daniel G. Maluf
Nizam Mamode
Alex Manara
Martin Mangino
ABSTRACT

Reviewers

Roslyn B. Mannon
Oriol Manuel
Marti Manyalich
Hannah Maple
Pierre Marquet
Dominique E. Martin
Olivia M. Martinez
Jaume Martorell
Valeria Mas
Marco Masetti
Allan Massie
Steven Masson
David W. Mathes
Cal Matsumoto
Shinichi Matsumoto
George V. Mazariegos
Lisa McElroy
Dianne McKay
Jose Medina Pestana
Bruno Meiser
Eduardo Melilli
Solomon Menahem
Michael Mengel
Robert M. Merion
J. Michael Millis
Shuji Miyagawa
Pranjal Modi
Cyril Moers
Martina Mogl
Saeed Mohammad
Sumit Mohan
Thalachallour Mohanakumar
Muhammad M. Mohiuddin
Ernesto Molmenti
Eduard Montanya
Edna Montero
Carolina Moore
Deonna Moore
Luis E. Morales-Buenrostro
José María Morales
Adrian E. Morelli
Francisco Moreso Mateos
Michele I. Morris
Peter J. Morris
Paul Morrissey
Sherif Mossad
Ash Moudgil
Istvan Mucsi
Thomas F. Mueller
Elmi M. Muller
William R. Mulley
David C. Mulligan
Gerhard Mundinger
Thangamani Muthukumar
Silvio Nadalin
Satish N. Nadig
Maarten Naessens
Abhijit Naik
Nader Najafian
Thomas A. Nakagawa
Atsunori Nakao
Michael A. Nalesnik
Brian J. Nankivell
Björn Nashan
Howard M. Nathan
Kyla Naylor
James Neuberger
Thomas Nevins
Volker Nickeleit
Peter William Nickerson
Claus Niemann
Heiner Niemann
Gertrude Nieuwenhuijs
Johan Nilsson
Alejandro Nino-Murcia
Marina Noris
Douglas J. Norman
Grzegorz Nowak
Patrick Gerald O’Callaghan
Philip J. O’Connell
Kevin J. O’Connor
John O’Grady
Jacqueline G. O’Leary
Jordi Cano Ochando
Jon Odorico
Hideki Ohdan
Mihai Oltean
Nicholas Onaca
Gabriel C. Oniscu
Helen Opdam
Gerhard Opelz
Federico Oppenheimer
Babak Orandi
Giuseppe Orlando
Susan Orloff
Klearchos K. Papas
Lars Pape
Chung-Gyu Park
Julio Pascual
Julie Pavlovic
Thamara Perera
Norberto Perico
ABSTRACT

Reviewers

Dana Perry
Todd Pesavento
Henrik Petrowsky
Palmina Petruzzo
Patrice Pfeifferberger
Ligia Pierrotti
Richard N. Pierson
Helen Pilmoro
Sean Pinney
Loris Pironi
John D. Pirsch
Henry Pleass
Rutger J. Ploeg
Andrew Posselt
Luciano Potena
Raaj K. Praseedom
Jutta Krista Preiskaitis
Jeffrey D. Punch
Luis F. Quintana
Cristiano Quintini
Marion Rabant
Hamid Rabb
Lorraine Racusen
Axel Rahmel
Angelique Ralph
Gurch Randhawa
Parmjeet Singh Randhawa
Gopi Rangan
Pandu Rao
Nathanael Raschzok
Kadiyala Ravindra
William D. Rawlinson
Gina R. Rayat
Raymund Razonable
Kunam S. Reddy
Elaine F. Reed
Michael A. Rees
Heinz Regele
Tomas Reischig
Giuseppe Remuzzi
John Renz
Alejandro Restrepo
Jorge Reyes
Mike Rickels
Camillo Ricordi
Robert Rieben
Leonardo Riella
Adele Rike-Shields
Paul Viktor Ritschl
Thomas Ritter
Adibul Hasan Rizvi
Paul Robertson
Simon C. Robson
Eduardo Rocha
Bruno Roche
Emilio Rodrigo
James R. Rodrigue
Christin Rogers
Joseph Rogers
Darling Rojas-Canales
Alvaro Rojas-Peña
Charles B. Rosen
Ana Rossi
Lionel Rostaing
Ajda Rowshani
Prajey Ruangkanchanasetr
Phillip Ruiz
David Nicholas Rush
Tapani Ruutu
David Sachs
Behnam Sadeghi
Kourosh Saeb-Parsy
Junichiro Sageshima
Faouzi Saliba
Mauro S. Sandrin
Saigal Sanjiv
Alfonso Santos
Ruth Sapir-Pichhadze
Minnie M. Sarwal
Shigeru Satoh
rantisek Saudek
Deirdre Sawinski
John D. Scandling
Janet Scheel
Peter Schemmer
Francesco Paolo Schena
Thomas Schiano
Stefan Schneeberger
Constanze Schoenemann
Jesse Schold
Bernd SchroeppeI
Henk Jan Schuurman
Antonio Secchi
Daniel Seelhofer
Dorry Segev
Joana Sellares Roig
Markus Selzner
Nazia Selzner
Daniel Seron
Martina Sester
Faissal Sester
Michael F.E. Shapiro

34
26th International Congress of The Transplantation Society
Reviewers

Ron Shapiro
Fuad Shihab
Rebecca Shilling
Tsuyoshi Shimamura
Sunil Shroff
Mary Ann Simpson
Rakesh Sindhi
Ashwani Singal
Jon Snyder
Avinder Soin
Mario Solarí
Hans W. Sollinger
Marijn Speekkaert
Carlo Sposito
Jean-Paul Squifflet
Titte R. Srinivas
Jürg Steiger
Peter Stock
Simone I. Strasser
Robert J. Stratta
Samuel Strober
Kamal Sud
Debra L. Sudan
Yasuhiro Sugawara
Vasant Sumethkul
Suchitra Sumiran-Holgersson
Caner Süssal
Stuart Sweet
Megan Sykes
Jeffrey Szer
David Taber
Brian Duncan Tait
Shiro Takahara
Anat R. Tambur
Ban Hock Tan
Carmela D. Tan
Kazunari Tanabe
Timucin Taner
Bekir Tanrıöver
Helen Te
Nicole Theodoropoulos
Julie A. Thompson
Angus W. Thomson
Raphael Thuillier
Lee Anne Tibbles
Kathryn Tinckam
Allison Tong
Matthew Kwok Lung Tong
Burkhard Tönshoff
Juan Ambros Torras
Armando Torres
Christian Toso
Chutwichai Tovikkai
Roberto Troisi
Richard Trompeter
Christoph Troppmann
Pavel Trunecka
Donald Tsai
Ray Tsai
Bernard E. Tuch
Gunnar Tufveson
Stefan G. Tullius
Nicole Turgeon
Heth Turnquist
Andreas G. Tzakis
Ifeoma Ulasi
Simon Urschel
Parsia A. Vajefí
Claire M. Vajdic
Anna Valujskikh
Kristof Van Assche
Marcel R.M. van den Brink
J. A. Van der Vliet
H. van Goor
Bernard van Hove
Cees van Kooten
Steven Van Laecke
Dirk van Raemdonck
Robert Venick
Stijn Verleden
Richard Viebahn
Denis Viglietti
Ondrej Viklický
Flavio Vincenti
Robin Vos
Rowan G. Walker
Haibo Wang
Wei Wang
Andreas Wannhoff
Angela Webster
Lori J. West
Chi Fong Wong
Kazuhiko Yamada
Alvin Lerrmann Young
Kimberly Young
Mirza Naqi Zafar
TTS Young Investigator Scientific Awards

The Transplantation Society is pleased to announce the recipients of the 2016 Young Investigator Scientific Awards. The awards will be presented in conjunction with the President’s Plenary on Monday, August 22, from 10:30 to 12:30. Look for the in the program, which identifies the award winners.

Penelope Allen, Australia
550.3 THE IMPACT OF RECURRENT GLOMERULONEPHRITIS AFTER KIDNEY TRANSPLANTATION IN THE ERA OF CONTEMPORARY MAINTENANCE IMMUNOSUPPRESSION

Vaishnavi Calisa, Australia
453.1 THE RELATIVE COSTS AND HEALTH BENEFITS OF AN AGE-MATCHED DECEASED DONOR ALLOCATION ALGORITHM COMPARED TO CURRENT PRACTICE

Aravind Cherukuri, United States
358.2 EARLY DE NOVO DSA WITH T CELL MEDIATED REJECTION (TCMR) IS ASSOCIATED WITH ALLOGRAFT DYSFUNCTION WITH CHRONIC INJURY

Jason Davis, United States
329.8 CHANGES IN LIVER ALLOGRAFT STEATOSIS AND ITS IMPACT ON EARLY GRAFT FUNCTION AND LONG TERM SURVIVAL

Denis Efimov, Belarus
355.2 DAMP-ASSOCIATED PRESERVATION INJURY AND COMPLICATIONS AFTER LIVER TRANSPLANTATION: PROOF OF CONCEPT

Shaimaa Elkholy, Egypt
425.6 PREDICTORS OF MORTALITY IN LIVING DONOR LIVER TRANSPLANTATION

Jianing Fu, United States
451.5 GENERATION OF NAÏVE DONOR-DERIVED LYMPHOCYTES FROM GRAFT-RESIDENT LYMPHOID PROGENITORS AFTER HUMAN INTESTINAL TRANSPLANTATION
BARBARA KERN, AUSTRIA
329.13 NONALCOHOLIC STEATOHEPATITIS AS INDICATION FOR LIVER TRANSPLANTATION IN EUROPE. CLINICAL ANALYSIS OF OVER 37,000 PATIENTS.

QIANG LIU, UNITED STATES
322.1 TRIGLYCERIDE EXPORTATION IN THE PRESERVATION OF DISCARDED STEATOTIC HUMAN LIVERS USING 24 HOURS EX-VIVO NORMOTHERMIC MACHINE PERFUSION

DAVID NASRALLA, UNITED KINGDOM
355.1 A MULTICENTRE RANDOMISED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF NORMOTHERMIC MACHINE PERFUSION WITH STATIC COLD STORAGE IN HUMAN LIVER TRANSPLANTATION: EARLY OUTCOMES

KEVIN TAK-PAN NG, HONG KONG SAR, P.R. OF CHINA
625.2 UP-REGULATION OF GSTA2 AT EARLY-PHASE AFTER LIVER TRANSPLANTATION INCREASES THE RISK OF LATE-PHASE HEPATOCELLULAR CARCINOMA RECURRENCE

THOMAS SCHACHTNER, GERMANY
424.1 KINETICS OF CMV-SPECIFIC T-CELLS FROM PRE-TO-POSTTRANSPLANTATION PREDICT OUTCOMES IN CMV-SERONEGATIVE KIDNEY TRANSPLANT RECIPIENTS

OSCAR SERRANO, UNITED STATES
422.1 DEFINING THE TIPPING POINT IN SURGICAL PERFORMANCE IN LAPAROSCOPIC DONOR NEPHRECTOMY DURING ABDOMINAL TRANSPLANT SURGERY FELLOWSHIP: A LEARNING CURVE ANALYSIS

RASHMI SHINGDE, AUSTRALIA
550.4 TROJAN KIDNEYS: UNEXPECTED DONOR-DERIVED VIRAL TRANSMISSION IN KIDNEY TRANSPLANT RECIPIENTS – A SYSTEMATIC REVIEW

UMANG THAKKAR, INDIA
456.9 STEM CELL THERAPY AS AN EMERGING MODALITY FOR POST-TRAUMATIC PARAPLEGIA AND FOR RENAL PARENCHYMAL DISEASES
Mirjam Tielen, The Netherlands
626.3 IMPORTANCE OF EARLY MEDICATION ADHERENCE FOR LONG-TERM GRAFT SURVIVAL: A PROSPECTIVE, SINGLE-CENTRE COHORT STUDY

Thomas Vanhove, Belgium
556.2 TUBULOINTERSTITIAL EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR IN RENAL ALLOGRAFT PROTOCOL BIOPSIES AT 3 MONTHS PREDICTS INTERSTITIAL FIBROSIS AT 5 YEARS

Georgios Vrakas, United Kingdom
451.6 DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AFTER COMBINED INTESTINAL AND VASCULARIZED COMPOSITE ALLOTRANSPLANTATION

Johannes Wedel, United States
427.2 DEPTOR MODULATES ALLOIMMUNITY BY INCREASING REGULATORY T CELL FUNCTION AND STABILIZING FOXP3 EXPRESSION

Cheng Yang, People's Republic of China
428.3 CYCLIC HELIX B PEPTIDE INHIBITS ISCHEMIA REPERFUSION-INDUCED RENAL FIBROSIS VIA THE PI3K/AKT/FOXO3A PATHWAY

Wai Ho Oscar Yeung, Hong Kong SAR, P.R. of China
625.1 DYSREGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR III INDUCES TUMOR PROMOTING MACROPHAGES VIA COMPLEMENT C3A IN HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
AWARDS Winners

2016 International Transplantation Science Mentee-Mentor Awards

The Transplantation Society (TTS) along with the collaboration of its Affiliated Societies celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Awards by recognizing the efforts of basic scientists who have advanced our understanding of transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

The Awards will be given on Sunday, August 21, during the International Transplantation Science Mentee-Mentor Networking Event to be held from 18:30 to 19:30 in the Convention Hall A - Level 1 (attendance by invitation only).

TTS-CST AWARD

This award was made possible with the contribution of the Canadian Society of Transplantation (CST).

Minal Borkar, Canada – Mentee
Lori J. West – Mentor

550.1 PROSPECTIVE TREATMENT AND NOVEL BIOMARKERS OF BK POLYOMAVIRUS ASSOCIATED NEPHROPATHY

TTS-DTG AWARDS

These awards were made possible with the contribution of the Deutsche Transplantationsgesellschaft (DTG).

Midas Seyda, Germany – Mentee
Stefan G. Tullius – Mentor

357.1 CELL-FREE MITOCHONDRIAL DNA ACTIVATES DCS IN AN AGE-DEPENDENT FASHION AND COMPROMISES THE SURVIVAL OF OLDER GRAFTS

Markus Quante, United States – Mentee
Stefan G. Tullius – Mentor

427.7 METABOLITES ASSOCIATED WITH BARIATRIC SURGERY REVERSE ACCELERATED REJECTION AND AUGMENTED ALLOIMMUNITY IN OBESE ALLOGRAFT RECIPIENTS
These awards were made possible with the contribution of the Indian Society of Organ Transplantation (ISOT).

Vivek Kute, India – Mentee
Pankaj R. Shah – Mentor
422.10 IMPACT OF SINGLE CENTRE KIDNEY PAIRED DONATION TRANSPLANTATION TO INCREASE DONOR POOL IN INDIA

Brijesh Yadav, India – Mentee
Narayan Prasad – Mentor
427.1 IMBALANCE OF T HELPER 17 CELLS AND T REGULATORY CELLS IS ASSOCIATED WITH CHRONIC ACTIVE ANTIBODY MEDIATED REJECTION IN RENAL ALLOGRAFT RECIPIENTS

Sailaja Kesiraju, India – Mentee
Sahariah Sarbeshwar – Mentor
556.8 PERIPHERAL NK-CELL REPERTOIRE DISTRIBUTION IN CHRONIC ALLOGRAFT DYSFUNCTION AFTER RENAL TRANSPLANTATION

Shailesh Raval, India – Mentee
Vijay Gorantla – Mentor
624.2 ULTRA-HIGH RESOLUTION NON-CONTRAST IMAGING FOR CHRONIC REJECTION MONITORING AND PROCEDURAL PLANNING IN RECONSTRUCTIVE TRANSPLANTATION

Sonia Mehotra, India – Mentee
RajKumar Sharma – Mentor
P.1053 DEVELOPMENT OF DE-NOVO DONOR SPECIFIC ANTIBODY (DSA) AND VITAMIN D STATUS AFTER RENAL TRANSPLANTATION
AWARDS Winners

TTS-JST AWARDS

These awards were made possible with the contribution of the Japan Society for Transplantation (JST).

Kazuhiro Taguchi, Japan - Mentee
Takashi Onoe – Mentor

451.2 CLINICAL AND IMMUNOLOGICAL SIGNIFICANCE OF CONTROLLING PORTAL VEIN PRESSURE IN LIVING DONOR LIVER TRANSPLANTATION

Songjie Cai, Japan - Mentee
Shiro Takahara – Mentor

457.2 SYSTEMIC THERAPY OF REGULATORY DENDRITIC CELLS DERIVED FORM INDUCED PLURIPOTENT STEM CELLS ALLOWS ALLOGENEIC CARDIAC GRAFTS ACCEPTANCE

Hiroshi Sakai, Japan - Mentee
Yuka Tanaka – Mentor

628.3 VARIOUS PATHOGENIC MICROBES INDUCE CNI-RESISTANCE IN B-CELLS RESPONDING TO BLOOD GROUP ANTIGENS THROUGH TLR–MYD88 PATHWAY

TTS-NTV AWARD

This award was made possible with the contribution of the Nederlandse Transplantatie Vereniging (NTV).

Gretchen de Graav, Netherlands - Mentee
Carla Baan – Mentor

427.6 BELATACEPT FAILS TO INHIBIT DONOR-REACTIVE TFH-B CELL INTERACTION, BUT FAVORS A REGULATORY TRANSITIONAL B CELL PROFILE OVER TACROLIMUS

TTS-SFT AWARD

This award was made possible with the contribution of the Société Française de Transplantation (SFT).

Séverine Bézie, France - Mentee
Carole Guillonneau – Mentor

356.3 INTERLEUKIN-34 IS A TREG-SPECIFIC CYTOKINE AND MEDIATES TRANSPLANT TOLERANCE
AWARDS Winners

TTS-SMT AWARD
This award was made possible with the contribution of the Sociedad Mexicana de Trasplantes (SMT).

José Manuel Arreola Guerra, Mexico - Mentee
Luis Eduardo Morales Buenrostro – Mentor

323.2 PRE-TRANSPLANT AT1RABS ARE ASSOCIATED WITH ACUTE REJECTION IN 2-HAPLOTYPES KIDNEY TRANSPLANT RECIPIENTS

TTS-TSANZ AWARDS
These awards were made possible with the contribution of the Transplantation Society of Australia and New Zealand (TSANZ).

Sebastian Olivier Stead, Australia - Mentee
Patrick Coates – Mentor

428.8 DENDRITIC CELL PHENOTYPE AND FUNCTION MODIFICATION WITH TARGETED POROUS SILICON NANO PARTICLES

Anjan Bongoni, Australia - Mentee
Peter Cowan – Mentor

429.9 SURFACE MODIFICATION OF PORCINE AORTIC ENDOTHELIAL CELLS WITH CORLINE HEPARIN CONJUGATE (CHC) PROTECTS AGAINST XENOGENEIC THROMBOSIS AND INFLAMMATION

Imogen Thomson, Australia - Mentee
Angela C. Webster – Mentor

552.9 RISKY ORGANS: TRENDS IN COMORBIDITIES AMONG POTENTIAL AND ACTUAL AUSTRALIAN ORGAN DONORS IN NEW SOUTH WALES

Moumita Paul-Heng, Australia - Mentee
Alexandra Sharland – Mentor

628.6 DISRUPTION OF CD8-CORECEPTOR BINDING ABROGATES TOLERANCE INDUCTION VIA LIVER-DIRECTED EXPRESSION OF DONOR MHC CLASS I
These awards were made possible with the contribution of The Transplantation Society (TTS).

Jiang Liu, Hong Kong - Mentee
Chung Mau Lo – Mentor
357.8 AMP-ACTIVATED PROTEIN KINASE ATTENUATED MARGINAL LIVER GRAFT INJURY VIA PROMOTING MITOCHONDRIAL BIOGENESIS AND RESPIRATORY FUNCTION

Rebeca Arroyo Hornero, United Kingdom - Mentee
Kathryn Wood – Mentor
456.2 CD45RA IDENTIFIES TSDR DEMETHYLATED REGULATORY T CELLS WITH A STABLE PHENOTYPE AND SUPPRESSIVE CYTOKINE PROFILE

Sai Vineela Bontha, United States - Mentee
Valeria Mas – Mentor
556.3 EFFECT OF EPIGENETIC MODIFICATIONS IN GRAFT KIDNEYS PROGRESSING TO CHRONIC ALLOGRAFT DYSFUNCTION

Xiang Qi, Hong Kong - Mentee
Nancy Kwan Man – Mentor
625.4 THE CLINICAL SIGNIFICANCE AND POTENTIAL THERAPEUTIC ROLE OF GPX3 IN TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION

Chien-Chia Chen, France - Mentee
Olivier Thaunat – Mentor
628.5 VASCULAR SEQUESTRATION OF DONOR-SPECIFIC ANTIBODIES PROTECTS ALLOGENEIC ISLETS FROM HUMORAL REJECTION

Joshua Chan, United States - Mentee
Muhammad Mohiuddin – Mentor
629.8 HUMAN ANTI THROMBOTIC GENES DO NOT OBVIATE THE NEED FOR ANTICOAGULATION IN AIDING LONG TERM XENOGRAFT SURVIVAL
THE ISN-TTS SISTER TRANSPLANT CENTER PROGRAM is a new joint partnership between the International Society of Nephrology (ISN) and The Transplantation Society (TTS) to create new kidney transplant centers and develop existing kidney transplant programs in emerging countries. This initiative encourages transplant centers to work together to increase opportunities for kidney transplant patients in developing countries. An experienced transplant center in the developed world lends its support to an emerging transplant center to facilitate vital multidisciplinary training and encourage both centers to exchange their knowledge and expertise. 

www.theisn.org/programs/sister-transplant-centers-program

Guide to the quality and safety of organs for transplantation

6th edition

Free download

State-of-the-art guidance for professionals involved in donation and transplantation of human organs.

Helping to ensure the successful and safe clinical application of human organs.

go.edqm.eu/dl
Framed by Hong Kong’s stunning skyline, the Hong Kong Convention and Exhibition Centre (HKCEC) is a magnificent multi-purpose venue located right in the heart of Hong Kong on Victoria Harbour.

The brilliant glass structure, which extends into the harbour, is designed to resemble a bird soaring into flight. The HKCEC is one of the largest multi-use venues in Asia and continues to be a globally recognised landmark complimenting Hong Kong’s cityscape. Not only does the harbour location provide a spectacular backdrop to the proceedings, but it also means Hong Kong’s Central Business District, along with the best of this vibrant, colourful city, is at the Centre’s doorstep. The HKCEC is also connected to two world-class hotels, and within walking distance to nearly 6,000 hotel rooms.
• Post-Graduate Course Rooms
• Session Rooms:
  Theatre 1 & 2
  Convention Hall A/B/C

• Main Entrance
CONGRESS Information

• Session Room S221
• Speaker Ready Room
• Meeting Rooms
• Offices

This level not in use during the TTS 2016 Congress
• Registration
• Plenary Room: Hall 5BC
• Session Rooms: Hall 5D Hall 5E1/5E2/5E3
• Exhibit Area
  Campfires & Poster Sessions
All TTS 2016 events will take place in the Hong Kong Convention and Exhibition Centre (HKCEC) unless otherwise noted.

### Operating Hours - Services

#### REGISTRATION (LEVEL 1 & 5)

Registration for the Post-Graduate Course (PGC) will be located on Level 1 and registration for the Congress on Level 5 at the following opening hours.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, Aug 17</td>
<td>15:00-19:00</td>
<td>Conv. Foyer - L1 (PGC)</td>
</tr>
<tr>
<td>Thursday, Aug 18</td>
<td>07:00-17:00</td>
<td>Conv. Foyer - L1 (PGC)</td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>07:30-17:30</td>
<td>Conv. Foyer - L1 (PGC)</td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>07:30-19:00</td>
<td>Hall 5FG - L5 (Congress)</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>06:30-18:00</td>
<td>Hall 5FG - L5</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>06:30-18:00</td>
<td>Hall 5FG - L5</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>06:30-18:00</td>
<td>Hall 5FG - L5</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>06:30-13:30</td>
<td>Hall 5E S. Concourse - L5</td>
</tr>
</tbody>
</table>

#### DELEGATE SERVICES AREA (LEVEL 5)

Housing, Information Desk, Media Accreditation, and Airline Boarding Pass Self-Printing Station on August 22-23 (Hall 5E South Concourse - Level 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>12:00-19:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>10:00*-18:00</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>10:00*-18:00</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>10:00*-19:00</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>06:30**-13:30</td>
</tr>
</tbody>
</table>

*Media desk will open at 08:00

**Housing desk will open at 08:30
# SPEAKER READY ROOM (ROOM S223 - LEVEL 2)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, Aug 17</td>
<td>15:00-19:00</td>
</tr>
<tr>
<td>Thursday, Aug 18</td>
<td>07:00-17:00</td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>07:30-19:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>06:00-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>06:30-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>06:30-18:00</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>06:30-13:30</td>
</tr>
</tbody>
</table>

# EXHIBIT HALL (HALL SFG - LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>18:30-20:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>09:30-19:00</td>
</tr>
</tbody>
</table>

# TECHNOLOGY CENTRE (HALL SFG - LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>18:30-20:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>09:30-19:00</td>
</tr>
</tbody>
</table>

# YOUNG INVESTIGATORS’ LOUNGE (HALL SFG - LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>18:30-20:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>09:30-19:00</td>
</tr>
</tbody>
</table>
# Mobile Food Concession (Hall 5FG - Level 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>09:30-15:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>09:30-15:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>09:30-15:30</td>
</tr>
</tbody>
</table>

# Coat Check (Room V104 – Level 1)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, Aug 18</td>
<td>07:30-17:30</td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>07:30-20:30</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>06:30-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>06:30-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>06:30-19:30</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>06:30-14:00</td>
</tr>
</tbody>
</table>

# Press Room (G112 – Level 1)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>15:00-19:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>08:00-18:00</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>08:00-18:00</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>08:00-18:00</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>08:00-13:30</td>
</tr>
</tbody>
</table>
## Program Schedule

### POST-GRADUATE COURSES
Please refer to the Detailed Program for room locations - Level 1

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, Aug 18</td>
<td>08:30-17:30</td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>08:30-17:30</td>
</tr>
</tbody>
</table>

### OPENING CEREMONY (HALL 5BC - LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>17:30-18:30</td>
</tr>
</tbody>
</table>

### PLENARY SESSIONS

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>08:30-10:00</td>
<td>Hall 5BC – Level 5</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>08:30-10:00</td>
<td>Hall 5BC – Level 5</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>08:30-10:00</td>
<td>Hall 5BC – Level 5</td>
</tr>
<tr>
<td></td>
<td>10:30-12:30</td>
<td>Hall 5BC – Level 5</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>08:30-10:00</td>
<td>Hall 5E3 – Level 5</td>
</tr>
</tbody>
</table>

### EARLY MORNING SYMPOSIA

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>07:00-08:15</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>07:00-08:15</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>07:00-08:15</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>07:00-08:15</td>
</tr>
</tbody>
</table>

Please refer to the Detailed Program for room locations.
## ORAL AND MINI-ORAL SESSIONS

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>10:30-12:30</td>
</tr>
<tr>
<td></td>
<td>15:30-17:00</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>10:30-12:30</td>
</tr>
<tr>
<td></td>
<td>15:30-17:00</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>15:30-17:00</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>10:30-12:00</td>
</tr>
</tbody>
</table>

Please refer to the Detailed Program for room locations.

## INDUSTRY SYMPOSIA (HALL 5E3- LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>12:30-13:30</td>
</tr>
<tr>
<td></td>
<td>17:30-19:00</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>12:30-13:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>12:30-13:30</td>
</tr>
</tbody>
</table>

## CAMPFIRES & POSTER SESSIONS (HALL 5FG - LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>17:00-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>17:00-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>18:00-19:00</td>
</tr>
</tbody>
</table>

## CLOSING CEREMONY (HALL 5E3 - LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, Aug 23</td>
<td>13:00-13:30</td>
</tr>
<tr>
<td>Events Schedule</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td><strong>WELCOME RECEPTION (HALL 5FG - LEVEL 5)</strong></td>
<td></td>
</tr>
<tr>
<td><em>Open to all Congress registrants</em></td>
<td></td>
</tr>
<tr>
<td><strong>Date</strong></td>
<td><strong>Time</strong></td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>18:30-20:00</td>
</tr>
<tr>
<td><strong>WIT NETWORKING EVENT (THEATRE 2 – LEVEL 1)</strong></td>
<td></td>
</tr>
<tr>
<td><em>Open to all Congress registrants - by pre-registration</em></td>
<td></td>
</tr>
<tr>
<td><strong>Date</strong></td>
<td><strong>Time</strong></td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>17:00-19:00</td>
</tr>
<tr>
<td><strong>YOUNG INVESTIGATORS' NETWORKING EVENT</strong></td>
<td></td>
</tr>
<tr>
<td><em>Ticket required</em></td>
<td></td>
</tr>
<tr>
<td><strong>OFFSITE:</strong> The Pawn, 62 Johnston Road Wan Chai, Hong Kong</td>
<td></td>
</tr>
<tr>
<td><strong>Date</strong></td>
<td><strong>Time</strong></td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>19:30-21:30</td>
</tr>
<tr>
<td><strong>INTERNATIONAL TRANSPLANTATION SCIENCE MENTEE-MENTOR AWARDS NETWORKING EVENT</strong></td>
<td></td>
</tr>
<tr>
<td><em>By invitation - see page 72 for details</em></td>
<td></td>
</tr>
<tr>
<td><strong>Date</strong></td>
<td><strong>Time</strong></td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>18:30-19:30</td>
</tr>
<tr>
<td><strong>CONGRESS NETWORKING EVENING</strong></td>
<td></td>
</tr>
<tr>
<td><em>Ticket required</em></td>
<td></td>
</tr>
<tr>
<td><strong>OFFSITE:</strong> Jumbo Kingdom Floating Restaurant</td>
<td></td>
</tr>
<tr>
<td><strong>Date</strong></td>
<td><strong>Time</strong></td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>19:00-22:00</td>
</tr>
<tr>
<td><em>(Coaches depart @ 18:30 from HKCEC)</em></td>
<td></td>
</tr>
</tbody>
</table>
Use of Name Badge

For security and regulation purposes, all attendees are required to wear their name badge at all times during the Congress in order to participate in the Scientific Sessions, Social Events, and Exhibit Area.

Badge swapping is strictly prohibited.

BADGE COLOUR IDENTIFICATION

DELEGATE MEMBER & DELEGATE

ORGANIZING COMMITTEE

TTS: EXECUTIVE / COUNCILLOR

INVITED SPEAKER & CHAIR

STAFF & VOLUNTEER

POST-GRADUATE COURSE DELEGATE, SPEAKER & CHAIR

SPONSOR

EXHIBITOR

GUEST

ACCOMPANYING PERSON

MEDIA

LOST BADGES

In the event of a lost or forgotten badge, an administrative fee of $25 USD will be charged for the reprinting of the badge after verification of identification (passport, driving license, or other recognised identification paper).
Abstracts Publication

All abstract presentations (oral, mini-oral, campfire and poster) listed in the program have been assigned consecutive program numbers. This number corresponds to the number of the abstract that can be viewed online on the Congress Web App and in the online supplement of the Transplantation Journal published in July 2016.

The free online version of Transplantation can be accessed at the following url:

journals.lww.com/transplantjournal/toc/2016/07001

(click on the FREE-PDF), or via the publishers’ homepage at www.transplantjournal.com.

Web Recordings and Live Broadcasting

All registered attendees will have the chance to view the Congress Session recordings online through the TTS website for up to a year after the Congress.

Only presentations for which we received pre-authorization from the presenter will be available online for viewing.
Free Access to Congress Delegates and TTS Members

We anticipate the majority of the presentations from TTS 2016 will be available to view from any device.

Access available at:
http://tts.guide • Congress Delegates
www.tts.org • TTS Members

Available as of September 1!
Calling all transplant professionals!

Our Free Plenaries Livecast

Sponsored by Roche

Tell your colleagues!

- Livecasts are open to all transplant professionals.
- Chat with other online attendees and submit questions to the session chairs.
  - Missed a session? Watch recordings of the livecast with “On-Air Rewind”.
- While online visit the “Roche Virtual Booth”.

Sign up today
http://onair.tts.org

TTS 2016
26th International Congress of The Transplantation Society
Hong Kong | August 18-23
**Presenter Guidelines**

**Post-Graduate Course, Plenary, Early Morning Symposium, SOTA, Oral, Mini-Oral, and Campfire presentations:**

The Speaker Ready Room is located on Level 2 of the Hong Kong Convention and Exhibition Centre (Room S-223). Presenters **MUST** review their presentation in the Speaker Ready Room at least 3 hours prior to their scheduled presentation. The Room will be staffed with technicians who can assist with any compatibility or formatting issues. Presenters with video **MUST** come the day before in order to run through the media file with a technician.

**HOURS OF OPERATION (S-223):**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, Aug 17</td>
<td>15:00-19:00</td>
</tr>
<tr>
<td>Thursday, Aug 18</td>
<td>07:00-17:00</td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>07:30-19:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>06:00-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>06:30-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>06:30-18:00</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>06:30-13:30</td>
</tr>
</tbody>
</table>

All downloads and changes to your presentations will need to be done in advance at the Speaker Ready Room. The meeting rooms will not be equipped with the app to submit a presentation at the podium. Therefore, no laptop or USB device will be accepted in the meeting rooms.

**Poster Sessions**

Posters will be available for attendees to view during the day from August 20 at 12:30 until August 22 at 19:00 in the Exhibit Area, Hall SFG-Level 5.

The poster presenters are required to be available for questions only during the three Poster Sessions noted below.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>17:00-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>17:00-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>18:00-19:00</td>
</tr>
</tbody>
</table>
Continuing Medical Education (ACCME)

ACCREDITATION STATEMENT

The Transplantation Society (TTS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

TTS designates this live activity for a maximum of 41.50 AMA PRA Category 1 Credit(s)™ (14 hours for the Post-Graduate Course and 27.50 hours for the Congress). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All social events, industry symposia, poster sessions, campfire sessions, opening ceremony, President’s plenary, and closing ceremony do not qualify for CME accreditation.

TO CLAIM YOUR CME CERTIFICATE…

Simply go to the www.tts.cmecertificateonline.com, click on the “26th International Congress of TTS” and complete the evaluation. A certificate will be made available after the evaluation. Do not forget to print your certificate at the end of the process.

IMPORTANT!

The online certificate site will only be available until October 28, 2016. After that date, the site will be removed and certificates will no longer be available. If you need a CME certificate, you must complete the evaluation and certification process prior to this date, otherwise you will forfeit your credit for the Congress.

DISCLOSURE OF CONFLICT OF INTEREST

The disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content of CME disclosed to The Transplantation Society. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1—6.2, 6.5). See the registration desk for the complete list of disclosures.
Continuing Medical Education in Hong Kong (CME-CNE)

CME FOR DOCTORS

Doctors from Hong Kong can be accredited by CME points from the medical colleges. Details are posted on the TTS 2016 Congress Website under the program section.

If Hong Kong delegates wish to obtain CME points, please signify your attendance DAILY at the designated area of the Registration Desk.

CNE FOR NURSES

CNE points would be accredited by The Hong Kong Society of Transplantation (HKST). HKST is accredited as a provider of CNE points by the Nursing Council of Hong Kong. Details are posted on the TTS 2016 Congress Website.

If Hong Kong nurses wish to obtain CNE points, they must complete the Evaluation Form provided at the designated Registration Desk and return it to the same Registration Desk by August 23.

A Certificate of Attendance will be emailed to the nurses by HKST after the Congress.

Congress Evaluation

A Congress evaluation form will be distributed during the Plenary Sessions on Monday, August 22. Please complete and return the form to the Registration Desk at the end of that day or at the very latest by the Closing Ceremony on August 23.

An electronic version will be available on-site. The address will be listed in the sessions’ opening slides.

Please note that all attendees will also receive a follow-up questionnaire this fall and that your feedback would be greatly appreciated.
On-site Services

DELEGATE SERVICES AREA

Located on the Hall 5E South Concourse, the Delegate Services Area will be dedicated to ensuring TTS 2016 Congress participants fully enjoy their experience in Hong Kong. The Delegate Services Area features three dedicated counters:

- **General Information:** touristic information on Hong Kong, transportation, local attractions
- **Media:** press accreditation and communications
- **Housing:** ICC, TTS Official Housing Bureau, will be available on-site throughout the TTS 2016 Congress to assist participants with their hotel booking. A full map of the official hotels can be found on the back, inside cover of this program.

A self-printing station to print your airline boarding pass will be made available on August 22 and 23.

The Delegate Services Area opening hours:

<table>
<thead>
<tr>
<th>Date, Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
</tr>
</tbody>
</table>

*Media desk will open at 08:00
** Housing desk will open at 08:30

Cell Phones and Cameras

No cameras or video cameras are allowed at any event during the 26th International Congress of The Transplantation Society without proper authorizations from the meeting organizers. Continued use of any type of camera may result in your removal from the meeting venue. As a courtesy to fellow attendees, please silence cell phones during educational sessions.

Furthermore, exhibitors, their representatives, and participants will not perform or video capture any media-related interviews with any participants (delegates, staff, or exhibitors) of the Congress during the event, without written consent from the organizers. Request for permission to conduct media-related interviews may be obtained on-site at the Media Counter, located on Level 5 of the HKCEC, at the Delegate Services Area (Hall 5E South Concourse).
**Business Centre**

Please note that there is no business centre per se at the HKCEC. Alternatively, photocopy and printing services are available at the HKCEC Information Counter at a small charge. The Information Counter is located on the Ground Floor of the HKCEC, next to the Harbour Road Café near the entrance of the facility.

**Meals & Snacks, Coffee Breaks**

Coffee breaks (coffee and tea only) will be served in the Exhibit Area (Hall 5FG - Level 5) at the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td></td>
<td>15:00-15:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td></td>
<td>15:00-15:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td></td>
<td>15:00-15:30</td>
</tr>
<tr>
<td>Tuesday, Aug 23</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td></td>
<td>15:00-15:30</td>
</tr>
</tbody>
</table>

Coffee will also be served for the Early Morning Symposia on August 20, 21, 22, and 23 in the Convention Foyer on Level 1.

The coffee break on Tuesday, August 23 will be served from 10:00-10:30 in the Hall 5E South Concourse.

The coffee breaks for the Post Graduate Courses will be served in the Convention Foyer, Level 1, at the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, Aug 18</td>
<td>10:30-11:00</td>
</tr>
<tr>
<td></td>
<td>15:30-16:00</td>
</tr>
<tr>
<td>Friday, Aug 19</td>
<td>10:30-11:00</td>
</tr>
<tr>
<td></td>
<td>15:30-16:00</td>
</tr>
</tbody>
</table>

**MOBILE FOOD CONCESSION**

Note that no food will be served during the Congress. The TTS 2016 Congress is happy to offer its participants the option to conveniently purchase food items, such as snacks, pastries and sandwiches, within the Exhibit Area (Hall 5FG - Level 5). Enjoy a snack or your lunch while mingling with our exhibitors and sponsors, or catch up with colleagues, old and new, over a coffee.

**RESTAURANTS**

Hong Kong is a renowned culinary destination. Restaurants offering cuisine from all over the world and coffee shops are easily accessible outside of the HKCEC, within a 5-minute walk. The Information Desk located in the Delegate Services Area on Level 5 will have a list of restaurants and “Locals’ picks” for your convenience.
**Multi Faith Prayer Rooms**

The TTS 2016 Congress has dedicated spaces for delegates to use for contemplation or prayer. These quiet spaces are available for any religious or spiritual practice, and are separated by gender. Located on the Hall 5E South Concourse, these rooms are accessible throughout the duration of the Congress.

**Lost and Found**

All lost and found property will be handed by the Registration Desk, located on Level 5 of the HKCEC.

**Young Investigators’ Lounge**

Proudly supported by Roche, the Young Investigators’ Lounge is located within the Exhibit Area (Hall 5FG – Level 5). It provides a quiet area for our younger attendees to mingle, take a break or even blow off some steam in a friendly foosball match. A board will be made available for institutions to post career opportunities.
WiFi

The 26th International Congress of The Transplantation Society is pleased to offer complimentary WiFi access to all its delegates. Kindly select the network called “TTS2016” to enjoy wireless internet access throughout the venue.

WEB APP

The Transplantation Society is pleased to introduce its very own web app, developed especially for The 26th International Congress in Hong Kong. Featuring all the various sessions, complete with descriptions and speakers’ biographies, the web app allows the Congress delegates to customize the Congress to their needs and schedule.

To have full functionality of the app, delegates must be logged in. Log-in details (user and password) were sent out to all registrants in a logistics email.

For further assistance visit the Technology Centre in the Exhibit Area, Hall 5FG – Level 5 of the HKCEC

Access the web app now! Go to tts.guide
TECHNOLOGY HELP DESK

Our friendly and tech-savvy staff members will be happy to help Congress participants with technology-related questions and issues, including those concerning WiFi Access, the web app, or the online program. The Technology Help Desk is located in the Technology Centre in the Exhibit Area, Hall SFG – Level 5 of the HKCEC.

TECHNOLOGY CENTRE

Built around the Technology Help Desk, this lounge area will be equipped with charging stations and working desks for Congress delegates’ use. The Technology Centre will also be the place to come and get information and assistance with the TTS 2016 Congress web app!

■ Affiliate Events

The following meetings are closed meetings, by invitation only.

■ Meeting of the Hong Kong Transplantation Societies: “Presentation of Best Abstracts from HK”

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>07:00-8:15</td>
<td>S-228, Level 2</td>
</tr>
</tbody>
</table>

■ SONG-Tx Consensus Workshop

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>12:00-14:00</td>
<td>S-228, Level 2</td>
</tr>
</tbody>
</table>

■ Living Donor Organ Transplantation in Asia (5th Vitallink International Workshop)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>18:00-21:00</td>
<td>S-226, Level 2</td>
</tr>
</tbody>
</table>

■ Joint meeting of the Thai, Japanese, and Korean Transplantation Societies: “WHO Registry for Organ Coding & Traceability”

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, Aug 21</td>
<td>07:00-8:30</td>
<td>S-228, Level 2</td>
</tr>
</tbody>
</table>
## SOCIAL Activities

### PLENARY: OPENING CEREMONY

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>17:30-18:30</td>
<td>Hall 5BC-Level 5</td>
</tr>
</tbody>
</table>

**OPEN TO ALL REGISTERED ATTENDEES**

### NETWORKING EVENT: WELCOME RECEPTION

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>18:30-20:00</td>
<td>Hall 5FG-Level 5</td>
</tr>
</tbody>
</table>

**OPEN TO ALL REGISTERED ATTENDEES**

Our local hosts from the Hong Kong Society of Transplantation and the Thai Transplantation Society will join our President, Dr. Philip O’Connell, and a Government official from the Hong Kong Special Administration Region, in order to officially welcome you to Hong Kong.

All participants are invited to attend the Opening Ceremony and enjoy traditional Hong Kong cultural performances; subsequently, please join the Welcome Reception in the Exhibit Hall to enjoy great food and drinks while networking with long-standing colleagues and new friends.
**SOCIAL Activities**

**WOMEN IN TRANSPLANTATION NETWORKING EVENT**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>17:00-19:00</td>
<td>Theatre 2-Level 1</td>
</tr>
</tbody>
</table>

**BY PRE-REGISTRATION ONLY**

Join members of the Women in Transplantation initiative of TTS and other leaders in the field for a discussion about issues affecting women in the field of medicine as well as topics related to leadership development. This two-hour session will provide you with insight and tips from some of transplantation's top female leaders and researchers. A full program of lectures for this event will be updated in the coming weeks. The session will be followed by an opportunity to network with your peers during a light cocktail.

**YOUNG INVESTIGATORS NETWORKING EVENT**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>19:30-21:30</td>
<td>Offsite - The Pawn&lt;br&gt;62 Johnston Road&lt;br&gt;Wan Chai, Hong Kong</td>
</tr>
</tbody>
</table>

**BY PRE-REGISTRATION ONLY - Ticketed Event ($)**

Students, Fellows and Trainees are welcome to an evening of networking, delicious food, drinks, music and good vibes. Proudly sponsored by Bridge to Life, this event will be held at The Pawn, a communal social venue for arts, design and innovative dining, located only a short walk away from the HKCEC. Don’t miss your chance to mingle and learn from younger faculty who have begun successful careers, as well as a special presentation by a guest of honour which will be given over the course of the evening.
INTERNATIONAL TRANSPLANTATION SCIENCE MENTEE-MENTOR AWARDS NETWORKING EVENT

Date       Time       Location
Sunday, Aug 21  18:30-19:30  Convention Hall A-Level 1

BY INVITATION ONLY

The Transplantation Society, along with the collaboration of National and International Societies, celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Travel Awards by recognizing the efforts of basic scientists, who have advanced our understanding of transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

CONGRESS NETWORKING EVENING

Date       Time       Location
Monday, Aug 22  19:00-22:00  Offsite - Jumbo Kingdom Floating Restaurant
                Shum Wan Pier Dr., Aberdeen, Hong Kong

BY PRE-REGISTRATION ONLY - Ticketed Event ($)

*We will sell tickets at the Registration Desk until Saturday, August 20 at 10:00.

TTS and the members of the Host Country Liaison Committee invite the participants of the 26th International Congress of The Transplantation Society to a unique evening under the theme ‘Asian Market Place’. This will be held at the Jumbo Kingdom, an internationally renowned tourist attraction, ornated like an ancient Chinese palace.

Come and wander around in a Night Asian Market, the perfect place to network with colleagues from around the world, while enjoying food stalls and activities from different Asian countries! See why Hong Kong is called “the gateway to Asia” and get a taste of delicacies from our 2 host countries (Hong Kong and Thailand) as well as other Asian countries.

Note: Coach transportation will be provided and will depart between 18:30 and 19:00 from the Harbour Road entrance on the Ground Floor of the HKCEC.
CONGRESS CLOSING CEREMONY

Date       Time       Location
Tuesday, Aug 23 13:00-13:30 Hall SE3-Level 5

OPEN TO ALL REGISTERED ATTENDEES

Closing Addresses will be given by Past-President Philip J. O’Connell from Australia, and by the new TTS President, Nancy Ascher from the United States. The Congress will close by a presentation of the TTS 2018 Congress in Madrid, Spain by the Congress Vice-Chair, José María Morales.
**MORNING SESSIONS**

**THURSDAY • AUGUST 18**

**08:30**
- **PGC** HLA and Antibodies (Clinical Science)

**10:30**
- **Coffee Break**

**11:00**
- **PGC** Immunosuppression (Clinical Science)
- **PGC** The Beginning: Innate Immune System in Allorecognition (Basic Science)

**13:00**
- **Lunch Break**
### Afternoon Sessions

**Thursday • August 18**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Satellite Meeting (08:30 to 18:00)</td>
</tr>
<tr>
<td>14:00</td>
<td>PGC The New Era of Organ Tx in China</td>
</tr>
<tr>
<td>15:30</td>
<td>PGC The Brand-New Model in China</td>
</tr>
<tr>
<td>16:00</td>
<td>PGC The Adaptive Immune System: B Cells (Basic Science)</td>
</tr>
<tr>
<td></td>
<td>PGC Regulation of the Immune Response (Clinical Science)</td>
</tr>
<tr>
<td></td>
<td>PGC Clinical Trials Design Part I</td>
</tr>
<tr>
<td></td>
<td>PGC Clinical Trials Design Part II</td>
</tr>
<tr>
<td></td>
<td>PGC Pathology (Clinical Science)</td>
</tr>
<tr>
<td></td>
<td>PGC “Brave New World” (Clinical Science)</td>
</tr>
</tbody>
</table>

**Satellite Meeting**

- **Time:** 08:30 to 18:00
- **Details:** Not included in the TTS 2016 Congress or Post-Graduate Course
Post-Graduate Courses (PGC) are scheduled on August 18 and 19, 2016 at the Hong Kong Convention and Exhibition Centre (HKCEC) on Level 1.

The Post-Graduate Courses program is designed specifically for medical professionals in training or for those in the early stages of their careers and is an excellent opportunity to obtain in-depth exposure to transplantation medicine. This year’s PGC program offers sessions in both Clinical and Basic Science topics, in addition to specialty sessions on Clinical Trials, Organ Procurement in China, Pediatrics, Organ Donation, Transplant Nursing, Computational Immunology and a session by the World Transplant Games Federation.

Registration for the Post-Graduate Courses is required. These two-day courses are not included in the TTS 2016 Congress registration fees. On-site registration will be possible at the PGC Registration Desk located on Level 1 on August 17, 18, and 19.
MORNING SESSIONS

08:30 - 10:30
THEATRE 1-LEVEL 1
CLINICAL SCIENCE

HLA and Antibodies

Chairs: Vivekanand Jha, Chandigarh, India
       Marcelo Cantarovich, Montreal, QC, Canada

100.1 TISSUE TYPING TECHNOLOGIES:
       WHAT SHOULD A CLINICIAN AND
       TRANSLATIONAL RESEARCHER KNOW?

Janette Kwok
Hong Kong SAR, P.R. of China

100.2 HOW CAN A SENSITIZED RECIPIENT GET
       AN ORGAN?

Kathryn Tinckam
Toronto, ON, Canada

100.3 WHAT TO DO IN PATIENTS WITH POST-
       TRANSPLANT DSA?

Robert A. Montgomery
New York, NY, United States

100.4 HOW TO DEAL WITH NON-HLA AB IN SOLID
       ORGAN TX RECIPIENTS

Elaine F. Reed
Los Angeles, CA, United States

08:30 - 10:30
CONVENTION HALL B-LEVEL 1
BASIC SCIENCE

The Beginning:
Innate Immune System in Allorecognition

Chairs: David Rothstein, Pittsburgh, PA, United States
       Nancy Kwan Man, Hong Kong SAR, P.R. of China

101.1 INFLAMMATORY TRIGGERS OF ALLOGRAFT
       REJECTION THROUGH ACTIVATION OF THE
       INNATE IMMUNE SYSTEM BY DAMPS AND TLRS

Daniel Kreisel
St. Louis, MO, United States

101.2 ISCHEMIA REPERFUSION INJURY AS AN
       INFLAMMATORY TRIGGER

Yuan Zhai
Los Angeles, CA, United States
101.3  REGULATED CELL DEATH PATHWAYS AND ALLOGRAFT REJECTION
Andreas Linkermann
Kiel, Germany

101.4  SPECIFIC ALLORECOGNITION BY THE INNATE IMMUNE SYSTEM
Martin Oberbarnscheidt
Pittsburgh, PA, United States

10:30 - 11:00
COFFEE BREAK
CONVENTION FOYER-LEVEL 1

11:00 - 13:00
THEATRE 1-LEVEL 1
CLINICAL SCIENCE

Immunosuppression
Chairs: Philip F. Halloran, Edmonton, AB, Canada
Brian J. Nankivell, Westmead, Australia

110.1  MECHANISM OF ACTION OF IMMUNOSUPPRESSIVE MEDICATIONS: WHAT DOES IT MEAN IN TERMS OF EFFICACY AND SIDE-EFFECTS?
Christophe Michel Legendre
Paris, France

110.2  TDM AND PHARMACOGENETICS IN TRANSPLANTATION: WHAT DOES THE EVIDENCE SAY?
Teun Van Gelder
Rotterdam, Netherlands

110.3  IMMUNOSUPPRESSION IN THE HIGHLY SENSITIZED PATIENTS
Kazunari Tanabe
Tokyo, Japan

110.4  BIOSIMILARS AND GENERICS: DO THEY HELP OR HARM?
Dirk Kuypers
Leuven, Belgium
11:00 - 13:00
CONVENTION HALL B-LEVEL 1
BASIC SCIENCE

The Adaptive Immune System: T Cells

Chairs: Martin Oberbarnscheidt, Pittsburgh, PA, United States
       Daniel Kreisel, St. Louis, MO, United States

111.1 ALLORECOGNITION BY THE ADAPTIVE IMMUNE SYSTEM: DIRECT, INDIRECT, AND SEMIDIRECT
Adrian E Morelli
Pittsburgh, PA, United States

111.2 HOW THE MICROBIOTA SHAPE THE ALLORESPONSE
Jonathan S. Bromberg
Baltimore, MD, United States

111.3 UPDATE ON CD4 EFFECTOR T CELLS: ACTIVATION, COSTIMULATION, TH REPERTOIRE, AND (FINALLY) EXHAUSTION!
Xian C. Li
Houston, TX, United States

111.4 AG PRESENTATION IN THE ALLOGRAFT FOR TEFF HOMING AND FUNCTION
Martin Oberbarnscheidt
Pittsburgh, PA, United States

13:00 - 14:00
LUNCH BREAK

AFTERNOON SESSIONS

13:30 - 15:30
CONVENTION HALL A-LEVEL 1
NOT A CME SESSION

China OPO Program - The New Era of Organ Transplantation in China

Chairs: Jeremy R. Chapman, Westmead, Australia
       Nancy Ascher, San Francisco, CA, United States

In collaboration with

China Organ Transplantation Development Foundation
China Organ Transplant Response System
120.1 OPENING SPEECH
Philip J. O’Connell
Westmead, Australia

120.2 CHINA’S ORGAN TRANSPLANTATION REFORM: A MAJOR FIRST STEP ON A LONG JOURNEY
Jiefu Huang
Beijing, People’s Republic of China

120.3 THE OVERVIEW OF ORGAN DONATION AND TRANSPLANTATION IN CHINA IN THE NEW ERA
Haibo Wang
Hong Kong SAR, P.R. of China

120.4 LIVER TRANSPLANTATION IN CHINA IN THE NEW ERA
Shusen Zheng
Hangzhou, People’s Republic of China

120.5 KIDNEY TRANSPLANTATION IN CHINA IN THE NEW ERA
Bingyi Shi
Beijing, People’s Republic of China

120.6 HEART TRANSPLANTATION IN CHINA IN THE NEW ERA
Zhe Zheng
Beijing, People’s Republic of China

120.7 LUNG TRANSPLANTATION IN CHINA IN THE NEW ERA
Jingyu Chen
Wuxi, People’s Republic of China

14:00 - 15:30
THEATRE 1-LEVEL 1
CLINICAL SCIENCE

Pathology

Chairs: Kazunari Tanabe, Tokyo, Japan
Christophe M. Legendre, Paris, France

121.1 HISTOLOGICAL DIAGNOSIS OF IMMUNOLOGICAL INJURY IN SOLID ORGAN TRANSPLANTATION
Michael Mengel
Edmonton, AB, Canada
121.2 NON-HISTOLOGICAL DIAGNOSIS OF ALLOGRAFT INJURY - STATE OF THE ART
Philip F. Halloran
Edmonton, AB, Canada

121.3 NON-IMMUNE INJURY TO THE ALLOGRAFT
Brian J. Nankivell
Westmead, Australia

14:00 - 15:30
CONVENTION HALL B-LEVEL 1
BASIC SCIENCE
The Adaptive Immune System: B Cells
Chairs: Yuan Zhai, Los Angeles, CA, United States
Andreas Linkermann, Kiel, Germany

122.1 UPDATE ON B CELL ACTIVATION, MEMORY AND ANTIBODY SECRETING CELLS
Olivier Thaunat
Lyon, France

122.2 NON-ANTIBODY MEDIATED ROLES OF B CELLS IN REJECTION
Shane T. Grey
Darlinghurst, Australia

122.3 TARGETING B CELLS AND AB-PRODUCING CELLS
Menna R. Clatworthy
Cambridge, United Kingdom

14:00 - 15:30
THEATRE 2-LEVEL 1
Clinical Trials Design Part 1
Chairs: Dirk Kuypers, Leuven, Belgium
Randall E. Morris, Carmel, CA, United States

An Initiative of
INTRODUCTION

123.2 UNMET MEDICAL NEEDS IN TRANSPLANTATION AND PAST CLINICAL TRIAL (FAILURE)

John S. Gill
Vancouver, BC, Canada

123.3 REPORT ON THE FDA MEETING ON SURROGATE ENDPOINTS

Dirk Kuypers
Leuven, Belgium

123.4 REPORT ON THE DC MEETING ON CLINICAL TRIAL DESIGN

Randall E. Morris
Carmel, CA, United States

15:30 - 16:00
COFFEE BREAK
CONVENTION FOYER-LEVEL 1

16:00 - 17:30
THEATRE 1-LEVEL 1
CLINICAL SCIENCE
Ready for Prime Time? Or “Brave New World”

Chairs: Kathryn Tinckam, Toronto, ON, Canada
Michael Mengel, Edmonton, AB, Canada

130.1 ARE STEM CELLS KEY TO TRANSPLANT TOLERANCE?

Hung Fat Tse
Hong Kong SAR, P.R. of China

130.2 WILL MANIPULATION OF MICROBIOME PLAY A ROLE IN MANAGEMENT OF TRANSPLANT RECIPIENT?

Marcel R.M. van den Brink
New York, NY, United States

130.3 HOW FAR ARE WE FROM PRINTING A SOLID ORGAN FOR TRANSPLANTATION?

Giuseppe Orlando
Winston Salem, NC, United States
16:00 - 17:30  
CONVENTION HALL B-LEVEL 1  
**BASIC SCIENCE**

**Regulation of the Immune Response**

*Chairs: Shane T. Grey, Darlinghurst, Australia  
Menna R. Clatworthy, Cambridge, United Kingdom*

131.1 **UPDATE ON TREGS: FROM MICE TO CLINICAL TRIALS**

*Qizhi Tang*  
San Francisco, CA, United States

131.2 **BREGS SHAPE THE ALLORESPONSE IN MICE AND HUMANS**

*David Rothstein*  
Pittsburgh, PA, United States

131.4 **CD8+ TREGS**

*Zhenhua Dai*  
Guangzhou, People's Republic of China

---

16:00 - 17:30  
THEATRE 2-LEVEL 1  
**Clinical Trials Design Part 2**

*Chairs: Dirk Kuypers, Leuven, Belgium  
Randall E. Morris, Carmel, CA, United States*

**An Initiative of**

*AUGUST 18*
China OPO Program - The Brand-New Organ Donation and Procurement Model in China

Chairs: Francis L. Delmonico, Waltham, MA, United States  
J. Michael Millis, Chicago, IL, United States

In collaboration with

133.1 THE GREEN PASSAGE SYSTEM FOR ORGAN TRANSPORTATION IN CHINA

Yanhong Guo
Beijing, People’s Republic of China

133.2 DEVELOPING AN OPO NETWORK TO INCREASE DONATION RATE AND ORGAN UTILIZATION

Qifa Ye
Changsha, People’s Republic of China

133.3 MULTI-CENTRE EXPERIENCE: THE OPO ALLIANCE MODEL

Xiaoshun He
Guangzhou, People’s Republic of China

133.4 SINGLE CENTRE EXPERIENCE: HOSPITAL-BASED OPO MODEL

Xuyong Sun
Nanning, People’s Republic of China

133.5 CLOSING REMARKS

José Ramón Núñez Peña
Geneva, Switzerland
MORNING SESSIONS  FRIDAY • AUGUST 19

08:30
PGC Focused Session on Presentation and Writing Skills

10:30
Coffee Break

11:00
PGC Interactive Sessions: Case Presentation (Clinical Science)

13:00
Lunch Break

In Collaboration with
PGC Organ Donation Organization

In Collaboration with
PGC Organ Donation Strategies

In Collaboration with
PGC New Techniques and Platform for Organ Tx (Basic Science)

In Collaboration with
PGC Can We Apply OMICS to the Clinic Yet? (Basic Science)

www.focisnet.org®

In Collaboration with
Organ Donation Strategies

In Collaboration with
Organ Donation Organization

In Collaboration with
PGC Computational Immunology 1 Course (FOCiS)

In Collaboration with
PGC Computational Immunology 2 Course (FOCiS)

In Collaboration with
PGC Focused Session on Presentation and Writing Skills

In Collaboration with
PGC New Techniques and Platform for Organ Tx (Basic Science)

In Collaboration with
PGC Can We Apply OMICS to the Clinic Yet? (Basic Science)
### AFTERNOON SESSIONS

**FRIDAY • AUGUST 19**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PGC*  
- Listing Children for Solid Organ Tx. and Donor Selection

*PGC*  
- Focused on Epidemiology and Statistics

*PGC*  
- Organ Donation Management

*PGC*  
- Can We Apply Biomarkers...? (Basic Science)

*PGC*  
- Strategies in Personalizing Immunosupp.

<table>
<thead>
<tr>
<th>15:30</th>
<th>Coffee Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td></td>
</tr>
</tbody>
</table>

*PGC*  
- Specific Aspects of Post-Transplant Care...

*PGC*  
- Sports in Transplantation (WTGF)

*PGC*  
- Issues in Deceased Organ Donation in Asia

*PGC*  
- Strategies in Personalizing Immunosupp.

| 17:30 | In Collaboration with

- International Pediatric Transplant Association
- World Transplant Games Federation
- International Society for Organ Creativity and Innovation

| 18:30 | TTS 2016 Opening Ceremony (Hall 5BC - L5)  
Networking Event: Welcome Reception (Hall 5FG - L5) |
All participants are invited to attend the Opening Ceremony and enjoy traditional Hong Kong cultural performances; subsequently, please join the Welcome Reception in the Exhibit Hall to enjoy great food and drinks while networking with long-standing colleagues and new friends.

HALLS SBC & SFG - LEVEL 5
MORNING SESSIONS

08:30 - 10:30
THEATRE 1-LEVEL 1

Focused Session:
Presentation and Writing Skills

Chairs: Vivekanand Jha, Chandigarh, India
       Marcelo Cantarovich, Montreal, QC, Canada

200.1 ELEMENTS OF A SUCCESSFUL GRANT APPLICATION
Aimin Xu
Hong Kong SAR, P.R. of China

200.2 THE ART OF MAKING A GREAT PRESENTATION
John W. Kao
Hong Kong SAR, P.R. of China

200.3 HOW TO PUBLISH MY PAPER
Jonathan S. Bromberg
Baltimore, MD, United States

08:30 - 10:30
CONVENTION HALL B-LEVEL 1
BASIC SCIENCE

New Techniques and Platforms for Organ Transplantation

Chairs: David Rothstein, Pittsburgh, PA, United States
        Nancy Kwan Man, Hong Kong SAR, P.R. of China

201.1 APPLICATION OF GENE-SPECIFIC NUCLEASES
       (MEGANUCLEASES, ZFNs, TALEN, CRISPR) IN
       TRANSGENIC ANIMALS AND IN VITRO MODELS OF
       TRANSPLANT IMMUNOLOGY
TBA

201.2 XENOTRANSPLANTATION
Kefeng Dou
Xi’an, People’s Republic of China

201.3 PLURIPOTENT STEM CELL-DERIVED
       MESENCHYMAL STEM CELLS: FROM ANIMAL
       MODELS TO CLINICAL PERSPECTIVES
Qizhou Lian
Hong Kong SAR, P.R. of China
201.4 STEM CELLS: HUMAN IPS CELL-DERIVED PANCREATIC \( \beta \)-CELLS CORRECT HYPERGLYCEMIA IN DIABETIC MICE

Nicolas Zavazava
Iowa City, IA, United States

08:30 - 10:30
THEATRE 2-LEVEL 1

Computational Data Analysis in Immunology: Transforming Big Data into Smart Data - Part 1

Chair: Megan Sykes, New York, NY, United States

In collaboration with

202.1 INTRODUCTION TO BIOINFORMATICS AND GENOMICS

202.2 BIOINFORMATICS APPROACHES IN IMMUNE AND TRANSLATIONAL RESEARCH

Emanuele de Rinaldis
London, United Kingdom

08:30 - 10:30
CONVENTION HALL A-LEVEL 1

Organ Donation Strategies

Chairs: Kimberly Young, Edmonton, AB, Canada
       Faissal Shaheen, Riyadh, Saudi Arabia

In collaboration with

International Society For Organ Donation and Procurement

203.1 STRATEGIES TO IMPROVE DECEASED ORGAN DONATION

Wai Ming Chan
Hong Kong SAR, P.R. of China
203.2 LIVING ORGAN DONATION: HOW TO COMMUNICATE RISK TO DONORS?

Dorry Segev
Baltimore, MD, United States

203.3 CROSS-BORDER COLLABORATION TO COMBAT ORGAN TRAFFICKING AND PROTECT THE VULNERABLE

Elmi M. Muller
Cape Town, South Africa

203.4 PRE-TRANSPLANT MALIGNANCIES: WHEN CAN THE PATIENT BE LISTED FOR TRANSPLANTATION?

Germaine Wong
Westmead, Australia

10:30 - 11:00
COFFEE BREAK
CONVENTION FOYER-LEVEL 1

11:00 - 13:00
THEATRE 1-LEVEL 1
CLINICAL SCIENCE

Interactive Clinical Cases in Transplant Recipients

Chairs: Helen Pilmore, Auckland, New Zealand
Hallvard Holdaas, Oslo, Norway

210.1 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH INFECTIONS (HBV AND HCV)

Chun-Jen Liu
Taipei City, Taiwan

210.2 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH INFECTIONS (BACTERIAL, FUNGAL AND PARASITIC)

Ban Hock Tan
Singapore, Singapore

210.3 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH CARDIOVASCULAR COMPLICATIONS

Hallvard Holdaas
Oslo, Norway
210.4 INTERACTIVE CLINICAL CASES IN TRANSPLANT RECIPIENTS WITH MALIGNANCIES

Chung-Mau Lo
Hong Kong SAR, P.R. of China

11:00 - 13:00
CONVENTION HALL B-LEVEL 1
BASIC SCIENCE

Translational Science 1: Can We Apply Omics to the Clinic Yet?

Chairs: Peter William Nickerson, Winnipeg, MB, Canada
         Alexandre Loupy, Paris, France

211.1 THE GENOMICS OF ALLOGRAFT FIBROSIS AND REJECTION

Valeria Mas
Charlottesville, VA, United States

211.2 ASSESSMENT OF THE ALLOIMMUNE RESPONSE BY MOLECULAR ANALYSIS OF RENAL ALLOGRAFTS

Michael Mengel
Edmonton, AB, Canada

211.3 TOLERANCE: DO DIFFERENT PROFILES EXIST AND HOW CAN THEY BE USED? LIVER

Alberto Sanchez-Fueyo
London, United Kingdom

211.4 TOLERANCE: DO DIFFERENT PROFILES EXIST AND HOW CAN THEY BE USED? KIDNEY

Kenneth A. Newell
Atlanta, GA, United States
11:00 - 13:00
THEATRE 2-LEVEL 1

Computational Data Analysis in Immunology: Transforming Big Data into Smart Data - Part 2

Chair: Megan Sykes, New York, NY, United States

In collaboration with

212.1 BIG DATA DRIVEN RESEARCH

212.2 PRESENTATION OF A SCIENTIFIC SCENARIO

Magnus Fontes
Paris, France

11:00 - 13:00
CONVENTION HALL A-LEVEL 1

Organ Donation Organization

Chairs: Howard M. Nathan, Philadelphia, PA, United States
Jongwon Ha, Seoul, Korea

In collaboration with

International Society For Organ Donation and Procurement

213.1 LEADERSHIP

Susan Gunderson
Minneapolis, MN, United States

213.2 NATIONAL PROGRAM MANAGEMENT

Kimberly Young
Edmonton, AB, Canada

213.3 OPO ORGANIZATION

Howard M. Nathan
Philadelphia, PA, United States

213.4 HOW TO DEVELOP ORGAN DONATION IN ASIA

Jongwon Ha
Seoul, Korea
Afternoon Sessions

14:00 - 15:30
Theatre 1-Level 1

Listing Children for Solid Organ Transplantation and Donor Selection

Chair: Ron Shapiro, New York, NY, United States

In collaboration with
International Pediatric Transplant Association

220.1 Welcome Remarks
Burkhard Tönshoff
Heidelberg, Germany
Christian Benden
Zurich, Switzerland

220.2 Specific Issues of Listing Children for Kidney Transplantation
Paul C. Grimm
Stanford, CA, United States

220.3 Specific Issues of Listing Children for Thoracic Transplantation
Anne I. Dipchand
Toronto, ON, Canada

220.4 Specific Issues of Listing Children for Liver Transplantation
George V. Mazariegos
Pittsburgh, PA, United States
14:00 - 15:30
CONVENTION HALL B-LEVEL 1
BASIC SCIENCE

Translational Science 2: Can We Apply Biomarkers to the Clinic Yet?

Chairs: Alberto Sanchez-Fueyo, London, United Kingdom
       Kenneth A. Newell, Atlanta, GA, USA

221.1 BIOMARKERS FOR RENAL ALLOGRAFT SURVIVAL

Peter William Nickerson
Winnipeg, MB, Canada

221.2 ROLE OF PROTOCOL BIOPSIES FOR GUIDING THERAPY AND PROGNOSIS IN RENAL ALLOGRAFT PATIENTS

Alexandre Loupy
Paris, France

221.3 BIOMARKERS IN LIVER TRANSPLANTATION

Valeria Mas
Charlottesville, VA, United States

14:00 - 15:30
THEATRE 2-LEVEL 1

Focused Session on Epidemiology and Statistics

Chairs: Gregory Alan Knoll, Ottawa, ON, Canada
       Philip Masson, Edinburgh, United Kingdom

222.1 HOW TO DESIGN AND IMPLEMENT A CLINICAL TRIAL

John S. Gill
Vancouver, BC, Canada

222.2 HOW TO PERFORM AND INTERPRET A SYSTEMATIC REVIEW

Angela Webster
Sydney, Australia

222.3 META-ANALYSIS AND NETWORK META-ANALYSIS: WHAT AND HOW

Jonathan Craig
Sydney, Australia
14:00 - 15:30
CONVENTION HALL A-LEVEL 1

Organ Donation Management

Chairs: Susan Gunderson, Minneapolis, MN, United States
       Eduardo Rocha, Rio de Janeiro, RJ, Brazil

In collaboration with

International Society For Organ Donation and Procurement

223.1 REGIONAL ORGANIZATION FOR ORGAN AND TISSUE DONATION
Paul Robertson
Westmead, Australia

223.2 HOW TO DEVELOP ORGAN DONATION IN MIDDLE EAST
Faissal Shaheen
Riyadh, Saudi Arabia

223.3 COST OF DONATION AND HOW TO GET THE BUDGET
Eduardo Rocha
Rio de Janeiro, RJ, Brazil

223.4 ICU ROLE IN ORGAN DONATION
Marti Manyalich
Barcelona, Spain

223.5 WORLD HEALTH ORGANIZATION IN ASIA
José Ramón Núñez Peña
Geneva, Switzerland
14:00 - 15:30
CONVENTION HALL C-LEVEL 1

Strategies in Personalizing Immunosuppression Management

Chair: Kathy Kable, Westmead, Australia

In collaboration with

224.1 CLINICAL AND BIOMARKER GUIDED APPROACH TO PERSONALIZE IMMUNOSUPPRESSION

Abraham Shaked
Philadelphia, PA, United States

224.2 PANCREATIC ISLET TRANSPLANTATION AS A BETA CELL REPLACEMENT THERAPY

Piotr Witkowski
Chicago, IL, United States

224.3 T FOLLICULAR HELPER CELLS IN TRANSPLANTATION: THE TARGET TO ATTENUATE ANTIBODY MEDIATED RESPONSES

Carla Baan
Rotterdam, The Netherlands

15:30 - 16:00
COFFEE BREAK
CONVENTION FOYER-LEVEL 1
Specific Aspects of Post-Transplant Care in Children

Chairs: Hui Kim Yap, Singapore, Singapore
Patrice Pfeiffenberger, Chicago, IL, United States

In collaboration with

International Pediatric Transplant Association

230.1 DONOR-SPECIFIC ANTIBODIES IN PAEDIATRIC SOLID ORGAN TRANSPLANT RECIPIENTS
Lars Pape
Hannover, Germany

230.2 PSYCHOSOCIAL ASPECTS OF CHILDREN UNDERGOING SOLID ORGAN TRANSPLANTATION
Diana Shellmer
Pittsburgh, PA, United States

230.3 TRANSITION FROM PAEDIATRIC TO ADULT CARE
Christian Benden
Zurich, Switzerland

230.4 CLOSING REMARKS
Burkhard Tönshoff
Heidelberg, Germany
16:00 - 17:30
CONVENTION HALL A-LEVEL 1

Issues in Deceased Organ Donation in Asia

Chairs: Marti Manyalich, Barcelona, Spain
       Francis L. Delmonico, Waltham, MA, United States

In collaboration with

International Society For Organ Donation and Procurement

231.1 PHILIPPINES
Benita Padilla
San Juan City, Philippines

231.2 VIETNAM
Thu Thi Ngoc Du
Ho Chi Minh, Viet Nam

231.3 NEPAL
Dibya Singh Shah
Kathmandu, Nepal

231.4 MYANMAR
Htar Kyi Swe
Mandalay, Myanmar

231.5 BANGLADESH
Mir M. Rahman
Chittagong, Bangladesh

231.6 PAKISTAN
Mirza Naqi Zafar
Karachi, Pakistan

231.7 OVERVIEW OF ASIAN DONATION AND TRANSPLANTATION ACTIVITIES (CAST)
Anwar Naqvi
Karachi, Pakistan
16:00 - 17:30
CONVENTION HALL C-LEVEL 1
Maximizing Transplant Resources for Better Outcomes

Chairs: Joyce A Trompeta, San Francisco, CA, United States
       Patrice Pfeiffenberger, Chicago, IL, United States

In collaboration with

232.1 RAPID ACCESS CLINIC TRANSFORMING TRANSPLANT CARE
Kathy Kable
Westmead, Australia

232.2 CHALLENGES OF STARTING A COUNTRY’S FIRST TRANSPLANT PROGRAM
Roberta J. Al Housani-Blakely
Abu Dhabi, United Arab Emirates

232.3 MAXIMIZING THE USE OF DONOR LUNGS THROUGH INNOVATION, EVOLUTION AND TRANSLATION
Bronwyn J. Levvey
Melbourne, Australia
16:00 - 17:30
THEATRE 2-LEVEL 1

Sports in Transplantation
(World Transplant Games Federation)

Chair: Chris Thomas, Chatswood, Australia

Organized by the
World Transplant Games Federation

233.1 THE WORLD TRANSPLANT GAMES FEDERATION: HELPING RECIPIENTS ADJUST TO A LIFE-LONG COMMITMENT TO SPORT AND PHYSICAL ACTIVITY

Chris Thomas
Chatswood, Australia

233.2 THE ROLE OF SPORT AND PHYSICAL ACTIVITY IN THE LONG-TERM MANAGEMENT OF TRANSPLANTATION: STAYING HEALTHY AROUND A TRANSPLANTED GRAFT

Paul Harden
Oxford, United Kingdom

233.3 INSPIRING NEW RECIPIENTS TO EMBRACE A LIFE OF PHYSICAL ACTIVITY AND WELLNESS

Liz Schick
Anzère, Switzerland

233.4 WORLD UPDATES ON TRANSPLANTATION AND SPORT

Ka Foon Chau
Hong Kong SAR, P.R. of China

233.5 WORLD UPDATES ON TRANSPLANTATION AND SPORT

Markus J. Barten
Hamburg, Germany

233.6 IS THERE A LIMIT ON THE AMOUNT OF PHYSICAL ACTIVITY AND EXERCISE FOR TRANSPLANTED ORGANS?

Panel Discussions

MUSICAL PRESENTATION BY HONG KONG TRANSPLANT RECIPIENTS

Organized by the
World Transplant Games Federation

AUGUST 19
16:00 - 17:00
CONVENTION HALL B-LEVEL 1

TTS 2016 Chairs Briefing
Chair: Jeremy R. Chapman, Westmead, Australia

NOTE: All Session Chairs are requested to attend

17:30 - 18:30
HALL 5BC-LEVEL 5
NOT A CME SESSION

Plenary Session: Opening Ceremony

240.1 WELCOME FROM CONGRESS CHAIR AND TTS PRESIDENT
Philip J. O’Connell
Australia

240.2 WELCOME ADDRESS FROM THE HONG KONG SAR GOVERNMENT
Wing-Man Ko
Hong Kong

240.3 WELCOME FROM THE HONG KONG TOURISM BOARD
Anthony Lau
Hong Kong

240.4 WELCOME FROM THE HONG KONG SOCIETY OF TRANSPLANTATION
See Ching Chan
Hong Kong

240.5 WELCOME FROM THE THAI SOCIETY OF TRANSPLANTATION
Vasant Sumethkul
Thailand

18:30 - 20:00
HALL 5FG-LEVEL 5

Welcome Reception
# Afternoon Sessions

**Saturday • August 20**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Hall 5BC</td>
<td>SOTA Renal Allograft Dysfunction</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Beta Cell Replacement</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Increased Deceased Donation in Asia</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Cellular Therapies in Kidney Tx.</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Are Tx. Registries Relevant or Irrelevant?</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Liver Allocation</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Transplantomics in Motion</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Tx. &amp; Tx. Tourism in the Tropics</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>Advance Nursing Practice</td>
</tr>
<tr>
<td></td>
<td>SOTA</td>
<td>10th Ann. of DOI Policy &amp; Guidance</td>
</tr>
<tr>
<td>15:00</td>
<td>SOTA</td>
<td>Liver Allocation</td>
</tr>
<tr>
<td>15:30</td>
<td>OS</td>
<td>Novel Agents</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Experimental Islet Tx.: Engraftment</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Increasing the Organ’s Pool DCD &amp; Beyond</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Acute Injury</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Making Lung Transplant Work</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Ischaemia Reperfusion / Preservation</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Regulatory Mechanisms 1</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Exploring Cellular Interactions in Tissue Injury</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>Histocompatibility</td>
</tr>
<tr>
<td></td>
<td>OS</td>
<td>...Barriers in Paediatric Solid Organ Tx.</td>
</tr>
<tr>
<td>17:00</td>
<td>Campfire</td>
<td>&amp; Poster Sessions (Hall SFG - L5)</td>
</tr>
<tr>
<td></td>
<td>Unraveling Alloreactivity 1 / Kidney 1 / Deceased Donation / Liver / Developing Tx. Programs</td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>TTS</td>
<td>Young Investigators Networking Event</td>
</tr>
</tbody>
</table>

**Supported by**

![Bridge Life](image-url)
Join members of the Women in Transplantation initiative of TTS and other leaders in the field for a discussion about issues affecting women in the field of medicine as well as topics related to leadership development. This two hour session will provide you with insight and tips from some of transplantation’s top female leaders and researchers. A full program of lectures for this event will be updated in the coming weeks. The lecture will be followed by an opportunity to network with your peers over cocktails and canapés.

THEATRE 2 - LEVEL 1
Students, Fellows and Trainees are welcome to an evening of networking, delicious food, drinks, music and good vibes. Proudly supported by Bridge to Life, this event will be held at The Pawn, a communal social venue for arts, design and innovative dining, located only a short walk away from the HKCEC. Don’t miss your chance to mingle and learn from younger faculty who have begun successful careers, as well as a special presentation by Dr. Peter Stock.

THE PAWN, 62 Johnston Rd., Wan Chai
07:00 - 08:15
S-221-LEVEL 2

Early Morning Symposia:
Starting a Career in Transplantation: Hurdles, Obstacles and Successes

Chairs:  
Elmi M. Muller, Cape Town, South Africa
Jayme E. Locke, Birmingham, AL, United States
Sanju Sobnach, Cape Town, South Africa

300.1 TURNING FAILURE INTO SUCCESS
Dorry Segev
Baltimore, MD, United States

300.2 HOW I BUILT MY CAREER AND MADE CHOICES
Beatriz Dominguez-Gil
Madrid, Spain

300.3 HOW TO HAVE A LIFE OUTSIDE OF THE OR AS A TRANSPLANT SURGEON
Peter Stock
San Francisco, CA, United States

300.4 WOULD I CHOOSE TRANSPLANTATION AGAIN IF I COULD GO BACK IN TIME?
Nancy Ascher
San Francisco, CA, United States

300.5 HOW DID I BALANCE MY CAREER WITH MY FAMILY - TIPS AND TRICKS
Michele I. Morris
Miami, FL, United States

07:00 - 08:15
THEATRE 1-LEVEL 1

Early Morning Symposia:
Personalized Medicine in Transplantation: Time to Translate for Improving Long-term

Chairs:  
Christophe Michel Legendre, Paris, France
Klemens Budde, Berlin, Germany

301.1 CURRENT CHALLENGES IN KIDNEY TRANSPLANTATION
Brian J. Nankivell
Westmead, Australia
IMMUNOLOGICAL RISKS OF MINIMIZATION STRATEGIES: SUCCESSES AND UNMET NEEDS

Christophe Michel Legendre
Paris, France

NOVEL DIAGNOSTICS: BIOMARKERS AND CLINICAL TRIALS, A DESPERATE NEED

Flavio Vincenti
San Francisco, CA, United States

07:00 - 08:15
THEATRE 2-LEVEL 1

Early Morning Symposia:
Nursing Workshop: Health Literacy and Transplant Adherence

Chairs: Kathy Kable, Westmead, Australia
Patrice Pfeiffenberger, Chicago, IL, United States

INTERVENTIONS TO IMPROVE HEALTH LITERACY IN TRANSPLANT RECIPIENTS

Angela Webster
Sydney, Australia

PROMOTING ADHERENCE AND SELF-MANAGEMENT IN CLINICAL PRACTICE AMONG KIDNEY TRANSPLANT PATIENTS

Mirjam Tielen
Rotterdam, Netherlands

HEALTH LITERACY AND ITS IMPLICATIONS IN TRANSPLANT RECIPIENT MEDICATION ADHERENCE

Michael Wolf
Chicago, IL, United States
07:00 - 08:15
CONVENTION HALL A-LEVEL 1

Early Morning Symposia:
Establishing Immunogenetics & Transplantation Laboratories & Implementing Newer Technologies

Chairs: Medhat Z. Askar, Dallas, TX, United States
Rhonda Holdsworth, Melbourne, Australia

303.1 CHALLENGES IN ESTABLISHING TRANSPLANT IMMUNOLOGY SERVICES IN A LOW RESOURCE COUNTRY
Mirza Naqi Zafar
Karachi, Pakistan

303.2 CHALLENGES DRIVE INNOVATION AND NOVEL STRATEGIES: THE STORY OF A TRANSPLANT IMMUNOLOGY LABORATORY IN INDIA
Dolly Daniel
Vellore, India

303.3 ESTABLISHING AN ORGAN PROCUREMENT ORGANIZATION LABORATORY IN KOREA
Myoung Hee Park
Seoul, Korea

07:00 - 08:15
CONVENTION HALL B-LEVEL 1

Early Morning Symposia:
Deceased Organ Donation Research

Chairs: Kimberly Young, Edmonton, AB, Canada
Li Chao, Hangzhou, People’s Republic of China

304.1 CRITICAL PATHWAY ANALYSIS PRACTICES IN HONG KONG
Jenny Koo
Hong Kong SAR, P.R. of China

304.2 ORGAN DONATION RESEARCH IN ICU
Claus Niemann
San Francisco, CA, United States

304.3 LIVING DONOR QUALITY SAFETY AND TRANSPARENCY
Fritz Diekman
Barcelona, Spain
07:00 - 08:15
CONVENTION HALL C-LEVEL 1

Early Morning Symposia: Towards a Uniform Definition of Beta Cell Graft Failure-Levelling the Playing Field

Chairs: Jon Odorico, Madison, WI, United States
       Paul R. V. Johnson, Oxford, United Kingdom

305.1 WHY WE NEED A BETTER DEFINITION OF PANCREAS ALLOGRAFT FAILURE
       Raja Kandaswamy
       Minneapolis, MN, United States

305.2 THE CASE FOR HYPOGLYCEMIA CORRECTION AS DEFINITION OF GRAFT SUCCESS IN ISLET TRANSPLANTATION
       Paul R. V. Johnson
       Oxford, United Kingdom

305.3 THE CASE FOR INSULIN-INDEPENDENCE AS DEFINITION OF GRAFT SUCCESS IN ISLET TRANSPLANTATION
       François Pattou
       Lille, France

07:00 - 08:15
S-228-LEVEL 2
BY INVITATION ONLY - NOT A CME SESSION

Meeting of the Hong Kong Society of Transplantation: Presentation of Best Abstracts from Hong Kong
08:30 - 10:00
HALL 5BC-LEVEL 5

Plenary: Basic and Translational Sciences

Chairs: Megan Sykes, New York, NY, United States
        Stefan G. Tullius, Boston, MA, United States

310.1 HOW THE MICROBIOME SHAPES THE IMMUNE SYSTEM
   Alexander Rudensky
   New York, NY, United States

310.2 INSIGHTS FROM LARGE-SCALE HUMAN IMMUNE PROFILING
   Matthew Albert
   South San Francisco, CA, United States

310.3 MAPPING HUMAN IMMUNE SYSTEM
   Donna L. Farber
   New York, NY, United States

10:00 - 10:30
COFFEE BREAK
HALL 5FG-LEVEL 5

10:30 - 12:30
HALL 5BC-LEVEL 5

Orals and Mini-Orals Session: Living Donor Transplant / ABOi Tx

Chairs: Andrew Posselt, San Francisco, CA, United States
        Adibul Hasan Rizvi, Karachi, Pakistan

320.1 POTENTIAL KIDNEY DONORS WITH ASYMPOTOMATIC MICROSCOPIC HEMATURIA: HISTOPATHOLOGICAL FINDINGS & OUTCOMES
   Ehab A. Hammad
   Riyadh, Saudi Arabia

320.2 COMPARISON OF THE RATE OF DECLINE OF GFR AND 1.5 AND 10 YEAR OUTCOMES OF LIVE KIDNEY DONORS – UK COHORT STUDY
   Nithya Krishnan
   Coventry, United Kingdom
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>320.3</td>
<td>ACUTE OPERATIVE COMPLICATIONS AND 1, 5, &amp; 10 YEAR OUTCOMES IN LIVING DONORS BY TYPE OF LIVE DONOR NEPHRECTOMY</td>
<td>Nithya Krishnan</td>
<td>Coventry, United Kingdom</td>
</tr>
<tr>
<td>320.4</td>
<td>THE PERCENTAGE OF CD19 POSITIVE CELLS IN LYMPHOCYTES CAN PREDICT ACUTE ANTIBODY-MEDIATED REJECTION AFTER ADMINISTRATION OF RITUXIMAB IN ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION</td>
<td>Takayuki Hirose</td>
<td>Sapporo, Japan</td>
</tr>
<tr>
<td>320.5</td>
<td>ABO INCOMPATIBLE RENAL TRANSPLANTATION WITHOUT SPLENECTOMY OR ANTI-CD20 TREATMENT: COMPARISON WITH ABO COMPATIBLE RENAL TRANSPLANT</td>
<td>Amit Sharma</td>
<td>Mohali, Punjab, India</td>
</tr>
<tr>
<td>320.6</td>
<td>HLA IDENTICAL RENAL TRANSPLANTS. IMMUNOLOGICALLY PRIVILEGED WHY DO THEY FAIL?</td>
<td>Adibul Hasan Rizvi</td>
<td>Karachi, Pakistan</td>
</tr>
<tr>
<td>320.7</td>
<td>RETROPERITONEAL VERSUS INTRAPERITONEAL HAND ASSISTED LAPAROSCOPIC DONOR NEPHRECTOMY: A CASE MATCHED STUDY</td>
<td>Zubir Ahmed</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>320.8</td>
<td>DIFFERENT SENSITIVITY OF RITUXIMAB-TREATMENT TO B-CELLS BETWEEN ABO-INCOMPATIBLE KIDNEY AND LIVER TRANSPLANTATION</td>
<td>Asuka Tanaka</td>
<td>Hiroshima, Japan</td>
</tr>
<tr>
<td>320.9</td>
<td>IMMUNOSUPPRESSIVE MYELOID CELLS IN PATIENTS GIVEN COMBINED KIDNEY AND HEMATOPOIETIC CELL TRANSPLANTS IN A TOLERANCE PROTOCOL WITH TLI AND ATG CONDITIONING</td>
<td>Samuel Strober</td>
<td>Stanford, CA, United States</td>
</tr>
</tbody>
</table>
MINI-ORALS

320.10 TREATMENT OF LARGE PLASMA VOLUMES USING SPECIFIC IMMUNOADSORPTION TO DESENSITIZE ABO-INCOMPATIBLE KIDNEY-TRANSPLANT CANDIDATES

Lionel Rostaing
Toulouse, France

320.11 "PAIRED KIDNEY EXCHANGE" PROGRAM – SINGLE CZECH INSTITUTION EXPERIENCE WITH 50 PAIRED TRANSPLANTS SINCE 2011

Tomas Marada
Prague, Czech Republic

320.12 MANAGEMENT OF PLASMA CELLS RICH ACUTE REJECTIONS- ROLE OF PROTEASOME INHIBITORS

Khawar Abbas
Karachi, Pakistan

320.13 THE IMPORTANCE OF RENAL BIOPSY IN CANDIDATE LIVING DONORS WITH PROTEINURIA

Handan Özdemir
Ankara, Turkey

10:30 - 12:30
HALL 5D-LEVEL 5

Orals and Mini-Orals Session: Outcomes of Pancreas Tx

Chairs: Angela Webster, Sydney, Australia
   Peter J. Morris, London, United Kingdom

321.1 RISK OF ACUTE CARDIOVASCULAR COMPLICATIONS FOLLOWING PANCREAS TRANSPLANTATION

Jim Kim
New York, NY, United States

321.2 POSTOPERATIVE MONITORING AND DIAGNOSIS OF COMMON SURGICAL COMPLICATIONS FOLLOWING PANCREAS TRANSPLANTATION BY MICRODIALYSIS CATHETERS

Gisle Kjøsen
Oslo, Norway
321.3  LONGITUDINAL ASSESSMENT OF ORAL GLUCOSE TOLERANCE TEST PARAMETERS FOR THE PREDICTION OF PANCREAS TRANSPLANT DYSFUNCTION

Emmanuel Morelon
Lyon, France

321.4  PANCREAS TRANSPLANTATION RESULTS ARE NOT MORE PROGRESSING AND REQUIRE SIGNIFICANT INNOVATIONS

Diego Cantarovich
Nantes, France

321.5  RECIPIENT AND PANCREAS GRAFT SURVIVAL AFTER KIDNEY-PANCREAS TRANSPLANTATION IN AUSTRALIA AND NEW ZEALAND: A COHORT STUDY 1984-2014 USING ANZIPTR

Angela Webster
Sydney, Australia

321.6  PANCREAS-AFTER-ISLET TRANSPLANTATION: A PATH FOR LONG TERM INSULIN INDEPENDENCE

Steven A. Wisel
San Francisco, CA, United States

321.7  CLINICAL PANCREAS TRANSPLANTATION FROM DECEASED DONOR IN JAPAN

Takashi Kenmochi
Toyoake, Aichi, Japan

321.8  THE PREDICTION OF THE ENDOCRINE FUNCTION OF THE GRAFT USING CONTRAST-ENHANCED ULTRASONOGRAPHY IN CLINICAL PANCREAS TRANSPLANTATION

Naohiro Aida
Toyoake, Japan

321.9  SUPERIOR LONG-TERM OUTCOME OF PANCREAS TRANSPLANTATION ALONE WITH PORTAL VENOUS DRAINAGE VS. SYSTEMIC VENOUS DRAINAGE

Stephen T. Bartlett
Baltimore, MD, United States
MINI-ORALS

321.10 EN BLOC DUAL KIDNEY-PANCREAS TRANSPLANTATION INTO AN ADULT RECIPIENT UTILIZING VERY SMALL PEDIATRIC DONOR: NO CONFLICT WITH LIVER TRANSPLANTATION CONCERNING ANATOMICAL DIVISION IN RESPECT TO DIVIDING ARTERIES - ALL ORGANS CAN BE USED

Johan A Nordström
Stockholm, Sweden

321.11 LONG TERM RESULTS IN PANCREAS RE TRANSPLANTATION DEPENDING ON THE CAUSE OF PRIMARY GRAFT FAILURE

Lilia Martinez de la Maza
Barcelona, Spain

321.12 THE OPTIMAL RANGE OF NATIVE KIDNEY FUNCTION BEFORE PANCREAS TRANSPLANT ALONE MINIMIZING THE RISK OF END-STAGE RENAL DISEASE

Sung Shin
Seoul, Korea

321.13 HYPERINSULINEMIA AFTER PANCREAS TRANSPLANTATION: A RISK FOR EXCESSIVE WEIGHT GAIN, METABOLIC SYNDROME, AND FATTY LIVER DISEASE

Richard J. Knight
Houston, TX, United States

10:30 - 12:30
HALL 5E1-LEVEL 5

Orals and Mini-Orals Session: Future of Organ Preservation/Perfusion

Chairs: Jongwon Ha, Seoul, Korea
Elmi M. Muller, Cape Town, South Africa

322.1 TRIGLYCERIDE EXPORTATION IN THE PRESERVATION OF DISCARDED STEATOTIC HUMAN LIVERS USING 24 HOURS EX-VIVO NORMOTHERMIC MACHINE PERFUSION

Qiang Liu
Cleveland, OH, United States
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>322.2</td>
<td>A COMPARISON OF LIVER TRANSPLANT BILIARY COMPLICATIONS FOR DECEASED DONOR DRAFTS PRESERVED WITH HISTIDINE-TRYPTOPHAN-KETOGLUTARATE AND UNIVERSITY OF WISCONSIN SOLUTIONS</td>
<td>Richard S. Mangus</td>
<td>Indianapolis, IL, United States</td>
</tr>
<tr>
<td>322.3</td>
<td>SURGICAL EXPERIENCE OF NORMOTHERMIC MACHINE PERFUSION IN HUMAN LIVER TRANSPANTATION</td>
<td>David Nasralla</td>
<td>Oxford, United Kingdom</td>
</tr>
<tr>
<td>322.4</td>
<td>EFFECT OF MACHINE PERFUSION AND UROKINASE ON THE KIDNEY TRANSPLANTS WITH GLOMERULAR THROMBOSIS</td>
<td>Xiaopeng Yuan</td>
<td>Guangzhou, People’s Republic of China</td>
</tr>
<tr>
<td>322.5</td>
<td>A NOVEL METHOD OF SPLIT LIVER EX VIVO PERFUSION</td>
<td>Viola Huang</td>
<td>Cambridge, MA, United States</td>
</tr>
<tr>
<td>322.6</td>
<td>EX VIVO PERFUSION OF HUMAN LIVERS INDUCES LEUKOCYTE MOBILISATION</td>
<td>William R. Critchley</td>
<td>Manchester, United Kingdom</td>
</tr>
<tr>
<td>322.7</td>
<td>HARMONIC SCALPEL IN THE RAPID PROCUREMENT OF THE PANCREAS FOR TRANSPLANTATION: RECIPIENT OUTCOMES</td>
<td>Ahmer Hameed</td>
<td>Eastwood, Australia</td>
</tr>
<tr>
<td>322.8</td>
<td>HYPOTHERMIC MACHINE PERFUSION OF EN BLOC KIDNEYS FROM INFANT AND NEONATAL DONORS</td>
<td>Imeshi Wijetunga</td>
<td>Leeds, United Kingdom</td>
</tr>
<tr>
<td>322.9</td>
<td>PERFUSION CHARACTERISTICS DURING CONTROLLED OXYGENATED REWARMING AND SUBNORMOTHERMIC MACHINE PERFUSION OF STEATOTIC HUMAN LIVERS</td>
<td>Dieter Hoyer</td>
<td>Essen, Germany</td>
</tr>
</tbody>
</table>
MINI-ORALS

322.10 PERI-OPERATIVE ORGAN PERFUSION WITH ATG-FRESENIUS RESULTS IN IMPROVED GRAFT FUNCTION IN CLINICAL LIVER AND KIDNEY TRANSPLANTATION
Paul Viktor Ritschl
Berlin, Germany

322.11 WHAT SHOULD BE MOVED, GRAFT OR MACHINE? TRAVEL STRATEGY IN AN EXPANDED CRITERIA DONOR PROGRAM. ORGAN PROCUREMENT AND TRANSPLANT ORGANIZATIONS (OPO) PERSPECTIVE
Francisco Javier Burgos Revilla
Madrid, Spain

322.12 HYPERBRANCHED POLYGLYCEROL-BASED ORGAN PRESERVATION SOLUTION: ADVANTAGES FOR COLD KIDNEY PERFUSION
Caigan Du
Vancouver, BC, Canada

322.13 EX VIVO NORMOTHERMIC PERFUSION REDUCES KIDNEY IMMUNOGENICITY PRIOR TO TRANSPLANTATION VIA REMOVAL OF PASSENGER LEUKOCYTES
John P. Stone
Manchester, United Kingdom

10:30 - 12:30
HALL 5E2-LEVEL 5
Orals and Mini-Orals Session: Antibody Mediated Injury

Chairs: Pui Yin Jocelyn Sim, Hong Kong SAR, P.R. of China
TBA

323.1 CORRELATION BETWEEN C3D-FIXING DONOR SPECIFIC HLA ANTIBODY AND LUMINEX MFI
Lionel Rostaing
Toulouse, France

323.2 PRETRANSPLANT AT1RABS ARE ASSOCIATED WITH ACUTE REJECTION IN 2-HAPLOTYPES KIDNEY TRANSPLANT RECIPIENTS
Jose Manuel Arreola
Aguascalientes, Mexico
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>323.3</td>
<td>THE LEVELS OF DE NOVO HLA ANTIBODIES ARE DETERMINED BY SOLUBLE B CELL-</td>
<td>Junchao Cai</td>
</tr>
<tr>
<td></td>
<td>ACTIVATING FACTOR BELONGING TO THE TNF FAMILY (BAFF) POST TRANSPLANTATION</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>323.4</td>
<td>PREFORMED C1Q-BINDING DSA ARE MORE CLEARLY ASSOCIATED WITH ADVERSE</td>
<td>Jorge Malheiro</td>
</tr>
<tr>
<td></td>
<td>OUTCOMES AFTER HLA-INCOMPATIBLE KIDNEY TRANSPLANTATION THAN DSA STRENGTH</td>
<td>Porto, Portugal</td>
</tr>
<tr>
<td>323.5</td>
<td>ABO INCOMPATIBILITY MIGHT PROTECT AGAINST CHRONIC ANTIBODY MEDIATED</td>
<td>Manabu Okada</td>
</tr>
<tr>
<td></td>
<td>REJECTION CAUSED BY DE NOVO DSA AFTER RENAL TRANSPLANTATION</td>
<td>Nagoya, Japan</td>
</tr>
<tr>
<td>323.6</td>
<td>DE NOVO DONOR SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANTATION - A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
<td>Ankit Sharma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Westmead, Australia</td>
</tr>
<tr>
<td>323.7</td>
<td>DO WE KNOW HOW TO TREAT RESISTANT ANTIBODY-MEDIATED REJECTION</td>
<td>Janka Slatinska</td>
</tr>
<tr>
<td></td>
<td>EFFECTIVELY? A SINGLE CENTRE EXPERIENCE</td>
<td>Prague, Czech Republic</td>
</tr>
<tr>
<td>323.8</td>
<td>EARLY ACUTE HUMORAL REJECTION IN THE ABSENCE OF ANTI-HLA ANTIBODIES:</td>
<td>Marianne Delville</td>
</tr>
<tr>
<td></td>
<td>CLINICO-PATHOLOGICAL DESCRIPTION FROM A FRENCH NATION-WIDE STUDY</td>
<td>Paris, France</td>
</tr>
<tr>
<td>323.9</td>
<td>POST-TRANSPLANT MONITORING OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES AND</td>
<td>Alexandre Loupy</td>
</tr>
<tr>
<td></td>
<td>THEIR CHARACTERISTICS IMPROVES RISK STRATIFICATION OF KIDNEY ALLOGRAFT LOSS</td>
<td>Paris, France</td>
</tr>
</tbody>
</table>
MINI-ORALS

323.10 COMPLEMENT-BINDING DONOR-SPECIFIC ANTI-HLA ANTIBODIES ARE ASSOCIATED WITH SEVERE KIDNEY ALLOGRAFT ARTERIOSCLEROSIS
Alexandre Loupy
Paris, France

323.11 THE NATURAL HISTORY OF DONOR SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS AND ASSOCIATED CLINICAL OUTCOMES
Susan S. Wan
Ultimo, Australia

323.12 NON-VALIDATION OF PRE-TRANSPLANT SENSITIZATION AGAINST ANGIOTENSIN II TYPE1 RECEPTOR AS RISK FACTOR OF GRAFT AND PATIENTS OUTCOMES IN KIDNEY TRANSPLANTATION
Magali Giral
Nantes, France

323.13 URINE IP-10 AS THE BIOMARKER FOR ABMR IN KIDNEY TRANSPLANT RECIPIENT WITH DGF
Natavudh Townamchai
Bangkok, Thailand

10:30 - 12:30
S-221-LEVEL 2
Orals and Mini-Orals Session: Clinical Outcomes: Heart transplants and VADs

Chairs: Howard Eisen, Philadelphia, PA, United States
Katherine Fan, Hong Kong SAR, P.R. of China

324.1 COMBINED EN-BLOC HEART-LIVER TRANSPLANTATION FOR PATIENTS WITH CONGENITAL HEART DISEASE COMPLICATED BY CIRRHOSIS
Jacqueline I. Lee
Palo Alto, CA, United States

324.2 EFFECTS OF ACUTE AND CHRONIC AMIODARONE USE IN PATIENTS BEFORE HEART TRANSPLANTATION ON POST-TRANSPLANT OUTCOMES
Rasmus Rivinius
Heidelberg, Germany
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>324.3</td>
<td>TERLIPRESSIN INCREASES BLOOD PRESSURE AND FACILITATES WEANING FROM CARDIOPULMONARY BYPASS IN HEART TRANSPLANT RECIPIENTS WITH REFRACTORY HYPOTENSION</td>
<td>Pinar Zeyneloglu</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>324.4</td>
<td>PRE-ORTHOTOPIC HEART TRANSPLANT (OHT) ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) PREDICTS POST-OHT MORTALITY AND RENAL OUTCOMES</td>
<td>Hani Wadei</td>
<td>Jacksonville, FL, United States</td>
</tr>
<tr>
<td>324.5</td>
<td>RELATIONSHIP BETWEEN BRACHIAL ARTERY FLOW-MEDIATED DILATION AND CLINICAL CHARACTERISTICS IN HEART TRANSPLANT RECIPIENTS</td>
<td>Takuya Watanabe</td>
<td>Osaka, Japan</td>
</tr>
<tr>
<td>324.6</td>
<td>EFFECTS OF EXERCISE TRAINING ON CARDIAC RESERVE AND AUTONOMIC ACTIVITY IN POST HEART TRANSPLANT PATIENTS AND PATIENTS RECEIVING LEFT VENTRICULAR ASSIST DEVICES SUPPORT BY ASSESSMENT OF HEART RATE PROFILE</td>
<td>Katherine Fan</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>324.7</td>
<td>PHYSICAL FUNCTION AND SELF-REPORTED HEALTH STATUS IN PRE-TRANSPLANT PATIENTS WITH LEFT VENTRICULAR ASSISTED DEVICE - LOCAL EXPERIENCE OF OUT-PATIENT CARDIAC REHABILITATION PROGRAM IN HONG KONG</td>
<td>Jenny Y.Y. Ng</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>324.8</td>
<td>IS PERFECT LONG-TERM RESULT OF CONTINUOUS-FLOW LVAD FOR BRIDGE TO TRANSPLANTATION POSSIBLE?</td>
<td>Minoru Ono</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td>324.9</td>
<td>MEDICAL UTILIZATION AND COSTS OF HERPES ZOSTER HOSPITALIZATIONS FOLLOWING HEART TRANSPLANTATION IN TAIWAN</td>
<td>Yi-Chang Lin</td>
<td>Taipei, Taiwan</td>
</tr>
</tbody>
</table>
MINI-ORALS

324.10 METABOLIC PROFILE OF DONATION AFTER CIRCULATORY DEATH HEARTS DURING RECONDITIONING

Hong Chee Chew
Kingsgrove, Australia

324.11 LOW MOLECULAR WEIGHT HEPARINE AS ALTERNATIVE ANTICOAGULATION THERAPY IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES

Bahadir Gültekin
Ankara, Turkey

324.12 HOSPITAL READMISSIONS AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION

Christian Heim
Erlangen, Germany

324.13 PRIOR CLOTTING EVENTS AS PREDICTOR OF POST LVAD MORBIDITY AND MORTALITY

Justin H. Johannesen
Philadelphia, PA, United States

10:30 - 12:30
THEATRE 1-LEVEL 1

Orals and Mini-Orals Session: Liver Technical Complications

Chairs: Kyung-Suk Suh, Seoul, Korea
Peter Friend, Oxford, United Kingdom

325.1 OUTFLOW RECONSTRUCTION USING THE HOMOLOGOUS VENOUS GRAFTS IN LIVING DONOR LIVER TRANSPLANTATION: EXPERIENCE AT THE UNIVERSITY OF TOKYO HOSPITAL

Nobuhisa Akamatsu
Tokyo, Japan

325.2 OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION USING RIGHT LIVER ALLOGRAFTS WITH MULTIPLE ARTERIAL SUPPLY

Kyo Won Lee
Seoul, Korea
325.3 THE EFFECT OF ANHEPATIC PHASE EXTENDED BY TEMPORARY PORTOCALVAL SHUNT ON ANESTHETIC SENSITIVITY TO DESFLURANE ADMINISTERED AT A CONSTANT AGE-ADJUSTED MINIMUM ALVEOLAR CONCENTRATION AND POSTOPERATIVE COGNITIVE FUNCTION IN PATIENTS UNDERGOING LIVING DONOR LIVER TRANSPLANTATION

Jong Hae Kim
Daegu, Korea

325.4 DOMINO LIVER TRANSPLANTATION: TECHNIQUE AND OUTCOME

Neslihan Celik
Pittsburgh, PA, United States

325.5 OUTCOME OF PARTIAL RECONSTRUCTION OF MULTIPLE HEPATIC ARTERIES IN PEDIATRIC LIVING DONOR LIVER TRANSPLANTATION USING LEFT LATERAL SECTION GRAFTS

Seounghyun Kim
Seoul, Korea

325.6 THE NOVEL USE BIODEGRADABLE SX-ELLA BILIARY STENT PLACED BY PERCUTANEOUS TRANSHEPATIC APPROACH FOR THE TREATMENT OF BILIARY STENOSIS AFTER LIVER TRANSPLANTATION

Cristina Dopazo
Barcelona, Spain

325.7 V5/V8 HEPATIC VEIN THROMBUS AFTER LEFT LOBE DONATION SURGERY

Kaori Kuramitsu
Kobe, Japan

325.8 AUXILIARY PARTIAL ORTHOTOPIC LIVER TRANSPLANTATION (APOLT): A SAFE & EFFECTIVE ALTERNATIVE TO ORTHOTOPIC LIVER TRANSPLANTATION FOR PATIENTS WITH ACUTE LIVER FAILURE AND NON-CIRRHOTIC METABOLIC LIVER DISEASE

Mettu Srinivas Reddy
Chennai, India

325.9 REDUCING NON-ANASTOMOTIC BILIARY STRICTURES AFTER DONATION AFTER CIRCULATORY DEATH LIVER TRANSPLANTATION, A MATTER OF TIME?

Nicholas Gilbo
Leuven, Belgium
MINI-ORALS

**325.10** LIVER STIFFNESS MEASUREMENT USING ACOUSTIC RADIATION FORCE IMPULS (ARFI) IN LIVING AND DECEASED DONOR ORTHOTOPIC LIVER TRANSPLANTATION PATIENTS

*Murat Haberal*
Ankara, Turkey

**325.11** EFFICACY OF ACOUSTIC RADIATION FORCE IMPULSE (ARFI) ELASTOGRAPHY FOR PREDICTING POST-TRANSPLANT CLINICAL OUTCOMES IN LIVING DONOR LIVER TRANSPLANTATION

*Koji Natsuda*
Nagasaki, Japan

**325.12** EARLY ENTERAL FEEDING AFTER LIVING DONOR LIVER TRANSPLANTATION PREVENTS INFECTIOUS COMPLICATIONS: A PROSPECTIVE PILOT STUDY

*Jong Man Kim*
Seoul, Korea

**325.13** AUXILIARY PARTIAL ORTHOTOPIC LIVER TRANSPLANTATION VERSUS HETEROTOPIC AUXILIARY PARTIAL LIVER TRANSPLANTATION – SINGLE CENTER EXPERIENCE

*Kohei Miura*
Niigata City, Japan

---

10:30 - 12:30
THEATRE 2-LEVEL 1

Orals and Mini-Orals Session: Ethics on Donation in Transplantation

*Chairs: Vivekanand Jha, Chandigarh, India
Alexander M. Capron, Los Angeles, CA, United States*

**326.1** WHAT KEEPS TTS MEMBERS UP AT NIGHT? PRELIMINARY RESULTS OF AN INTERNATIONAL ETHICS SURVEY

*Dominique E. Martin*
Geelong, Australia
326.2 GPS-ENABLED SMARTPHONE INTEGRATION INTO DIGITALDONOR ELECTRONIC DONOR RECORD PRODUCES DOUBLE-DIGIT INCREASE IN DONATION BY ENSURING RAPID RESPONSE TO ASSIST DONOR FAMILIES AND PHYSICIANS

**Thomas D. Mone**  
Los Angeles, CA, United States

326.3 LIVING LIVER DONORS MAY UNDER-REPORT MENTAL HEALTH COMORBIDITIES

**Hillary J. Braun**  
San Francisco, CA, United States

326.4 KIDNEY TRANSPLANT PATIENT PREFERENCES AND TRADE-OFFS FOR OUTCOMES AFTER TRANSPLANTATION

**Martin Howell**  
Westmead, Australia

326.5a INTERVIEWS WITH PATIENTS WHO TRAVELLED FROM MACEDONIA, KOSOVO, THE NETHERLANDS AND SWEDEN FOR PAID KIDNEY TRANSPLANTATIONS (abst. P.1727 in the Transplantation Journal)

**Willem Weimar**  
Rotterdam, The Netherlands

326.6 MOBILE APPS TO IMPROVE ORGAN DONATION RATE

**Sujatha Suriyamoorthi**  
Chennai, India


**Riadh A.S. Fadhil**  
Doha, Qatar

326.8 A QUALITATIVE STUDY INTO THE MODUS OPERANDI, INVESTIGATION AND PROSECUTION OF ORGAN TRAFFICKING NETWORKS IN SOUTH AFRICA, ISRAEL AND KOSOVO

**Frederike Ambagsheer**  
Rotterdam, The Netherlands
326.9  REPORTING ORGAN TRAFFICKING NETWORKS: A SURVEY-BASED PLEA TO BREACH THE SECRECY OATH

Frederike Ambagtsheer
Rotterdam, The Netherlands

MINI-ORALS

326.10  A SYSTEMATIC REVIEW ON THE PREVALENCE OF PATIENTS WHO PURCHASE ORGAN TRANSPLANTS ABROAD

Frederike Ambagtsheer
Rotterdam, The Netherlands

326.11  A KIDNEY PAIRED DONATION STANDARD ACQUISITION CHARGE PILOT PROGRAM

Michael A. Rees
Cleveland, OH, United States

326.12  RESEARCH PRIORITY SETTING IN SOLID ORGAN TRANSPLANTATION: A SYSTEMATIC REVIEW

Claudia L. Harper
Sydney, Australia

326.13  HEALTH-RELATED QUALITY OF LIFE IMPROVES FURTHER AFTER LIVER TRANSPLANTATION AND IS INFLUENCED BY LENGTH OF STAY

Louis G. Onghena
Ghent, Belgium

10:30 - 12:30
CONVENTION HALL A-LEVEL 1

Orals and Mini-Orals Session: Experimental Islet Tx: Immunologic Aspects

Chairs:  Kenneth A. Newell, Atlanta, GA, United States
         Thomas Kay, Victoria, Australia

327.1  CD4+CD25+FOXP3+ TREG CELLS ARE CRITICAL TO TOLERANCE INDUCTION BY SA-FASL-ENGINEERED PORCINE ISLETS TRANSPLANTED INTO MICE

Kyle Woodward
Louisville, KY, United States
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>327.2</td>
<td>DUAL PHASES AND MECHANISTIC BASIS OF TOLERANCE INDUCED BY ALLOGENEIC PANCREATIC ISLETS ENGINEERED WITH SA-FASL PROTEIN</td>
<td>Kyle Woodward</td>
<td>Louisville, KY, United States</td>
</tr>
<tr>
<td>327.3</td>
<td>THE INFLUENCE OF DISSOCIATION ENZYMES ON ISOLATED ISLETS DURING PANCREATIC ISLET ISOLATION PROCEDURES</td>
<td>Yuki Miyazaki</td>
<td>Sendai, Japan</td>
</tr>
<tr>
<td>327.4</td>
<td>PRETREATMENT OF DONOR ISLETS WITH PAPAIN IMPROVES ALLOGRAFT SURVIVAL WITHOUT SYSTEMIC IMMUNOSUPPRESSION IN MICE</td>
<td>Kenjiro Kumano</td>
<td>Fukuoka, Japan</td>
</tr>
<tr>
<td>327.5</td>
<td>SUSTAINED EUGLYCEMIA AFTER ISLET XENOTRANSPLANTATION IN DIABETIC NOD MICE USING NOVEL PURIFICATION AND ENCAPSULATION TECHNOLOGIES</td>
<td>Jonathan Lakey</td>
<td>Orange, CA, United States</td>
</tr>
<tr>
<td>327.6</td>
<td>COTRANSPLANTATION OF PREACTIVATED MESENCHYMAL STEM CELLS INHIBITS LIVER NATURAL KILLER CELL–INDUCED ISLET GRAFT INJURY DURING INSTANT BLOOD–MEDIATED INFLAMMATORY REACTION AFTER SYNGENEIC INTRAPORTAL ISLET TRANSPLANTATION</td>
<td>Ishida Nobuki</td>
<td>Hiroshima, Japan</td>
</tr>
<tr>
<td>327.7</td>
<td>SA-FASL-ENGINEERED PORCINE ISLETS INDUCE TOLERANCE IN MICE FOLLOWING INTRAPORTAL TRANSPLANTATION</td>
<td>Haval Shirwan</td>
<td>Louisville, KY, United States</td>
</tr>
<tr>
<td>327.8</td>
<td>ANTI-INFLAMMATORY CD169+ TIM-4+ ISLET RESIDENT MACROPHAGES INDUCE TREGS AND PROLONG ALLOGRAFT SURVIVAL</td>
<td>Periklis P. Kyriazis</td>
<td>Chestnut Hill, MA, United States</td>
</tr>
</tbody>
</table>
327.9  ENDOSCOPIC BIOPSY OF ISLET TRANSPLANTS IN THE GASTRIC SUBMUCOSAL SPACE PROVIDES EVIDENCE OF ISLET GRAFT REJECTION IN DIABETIC PIGS

Hidetaka Hara
Pittsburgh, PA, United States

MINI-ORALS

327.10  SPHINGOLIPIDS REGULATE THE PODOCYTE INSULIN SIGNALING IN DIABETIC KIDNEY DISEASE

George W. Burke
Miami, FL, United States

327.11  SPHINGOSINE-1-PHOSPHATE PROMOTES THE MIGRATION OF INTRAISLET VASCULAR CELLS: IMPLICATIONS FOR POST-TRANSPLANT ISLET FUNCTION

Darling Rojas-Canales
Adelaide, Australia

327.12  HYPOTHERMIC MACHINE PERFUSION PRESERVATION OF NON-HEART-BEATING DONOR PANCREAS FOR ISLET TRANSPLANTATION

Naotake Akutsu
Chiba, Japan

327.13  ANALYSIS OF POST-TRANSPLANT ISLET BY ORGAN TRANSPARENCY AND MACRO THREE-DIMENSIONAL IMAGE

Koya Shinohara
Tokyo, Japan

10:30 - 12:30

CONVENTION HALL B-LEVEL 1

Orals and Mini-Orals Session: A Fresh Look at Tolerance and Rejection

Chairs:  Marcel R.M. van den Brink, New York, NY, United States Karen Dwyer, Victoria, Australia

328.1  MAINTENANCE OF LONG-TERM TOLERANCE BY T REGULATORY CELLS IN A MOUSE MODEL OF HEART TRANSPLANTATION

Junjie Xia
Xiamen, People’s Republic of China
328.2 NEONATAL TOLERANCE IN A MOUSE MODEL OF ABO-INCOMPATIBLE HEART TRANSPLANTATION

Lori J. West
Edmonton, AB, Canada

328.3 INTERLEUKIN-5 THERAPY PREVENTS CHRONIC ALLOGRAFT REJECTION BY INDUCTION OF ANTIGEN SPECIFIC CD4+CD25+ T REGULATORY CELLS

Suzanne J. Hodkinson
Sydney, Australia

328.4 CONTRASTING EFFECTS OF TACROLIMUS AND EVEROLIMUS ON REGULATORY T CELL ACTIVATION AND MIXED HEMATOPOIETIC CHIMERISM INDUCED BY NATURAL KILLER T CELL STIMULATION

Toshihito Hirai
Tokyo, Japan

328.5 IFN-GAMMA/B7-H1 SIGNALING PATHWAYS IN GRAFT MESNECHYMAL CELLS MEDIATE LIVER TRANSPLANT TOLERANCE

John J. Fung
Cleveland, OH, United States

328.6 LIVER REGENERATION WAS ATTENUATED BY DELETION OF CXCL10 OR ITS RECEPTOR CXCR3 VIA YAP1 SIGNALING

Yuen Yuen Ma
Hong Kong SAR, P.R. of China

328.7 HEPARIN-GELATIN MIXTURE IMPROVES VASCULAR RECONSTRUCTION EFFICIENCY AND HEPATIC FUNCTION IN BIOENGINEERED LIVER

Kamal Hany Hussein
Chuncheon-si, Korea

328.8 SUPERCHARGING MESENCHYMAL STEM CELLS WITH INTERLEUKIN-17A: AN ALTERNATIVE TO INTERFERON-GAMMA ENHANCEMENT OF MESENCHYMAL STEM CELL IMMUNOMODULATION

Kisha Nandini Sivanathan
Adelaide, Australia

328.9 AN INCREASE IN CD8+ EFFECTOR MEMORY T CELLS PRECEDES REJECTION IN A PRIMATE CARDIAC TRANSPLANT MODEL

Natalie A. O’Neill
Baltimore, MD, United States
MINI-ORALS

328.10 DONOR-SPECIFIC CELL-FREE DNA AS A NON-INVASIVE MARKER OF ORGAN REJECTION AFTER LIVER TRANSPLANTATION: A PILOT STUDY

Su Kah Goh
Heidelberg, Australia

328.11 INFLAMMASOME EXACERBATED FATTY GRAFT INJURY WITH ACCUMULATION OF MYELOID-DERIVED SUPPRESSOR CELLS AFTER LIVING DONOR LIVER TRANSPLANTATION

Hui Liu
Hong Kong SAR, P.R. of China

328.12 OPTIMIZING IMMUNOMODULATORY PROPERTIES AND IMMUNOGENICITY OF MSC FOR IMMUNOTHERAPY FOLLOWING ORGAN TRANSPLANTATION

Samantha F.H. de Witte
Rotterdam, The Netherlands

328.13 EFFECT OF ADIPOSE-DERIVED MESENCHYMYAL STEM CELLS IN A RAT MODEL OF CHRONIC RENAL ALLOGRAFT REJECTION

Irene Noronha Sr.
Sao Paulo, Brazil

10:30 - 12:30
CONVENTION HALL C-LEVEL 1

Orals and Mini-Orals Session: Allocation/Donor Variables

Chairs: Claus Niemann, San Francisco, CA, United States Kenneth Siu Ho Chok, Hong Kong SAR, P.R. of China

329.1 TRANSPLANTATION OF GRAFT FROM OLDER DONORS: DOES AGE STILL MATTER?

Nicholas Gilbo
Leuven, Belgium

329.2 DYNAMIC LIVER COMPLIANCE- A NEW RADIOLOGICAL METRIC TO PREDICT PERI-OPERATIVE COURSE OF DONOR HEPATECTOMY

Mettu Srinivas Reddy
Chennai, India
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>329.3</td>
<td>POST-OPERATIVE THROMBOCYTOPENIA DETERMINES THE FATE OF ADULT-TO-ADULT LIVING DONOR PARTIAL LIVER TRANSPLANTATION; PROPOSAL OF “THROMBOTIC MICROANGIOPATHY (LTX-TMA) SCORE”</td>
<td>Koichiro Hata</td>
<td>Kyoto, Japan</td>
</tr>
<tr>
<td>329.4</td>
<td>IMPACT OF THE SHARE 35 LIVER ALLOCATION POLICY ON CANDIDATES WITH MELD EXCEPTION SCORES</td>
<td>Elaine Y. Cheng</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>329.5</td>
<td>LIVE DONOR CHAMPION PROGRAM FOR LIVER TRANSPLANTATION: TIME TO REDEFINE THE STRATEGY</td>
<td>Daniel G. Maluf</td>
<td>Charlottesville, VA, United States</td>
</tr>
<tr>
<td>329.6</td>
<td>FACTORS ASSOCIATED WITH WORSE OUTCOME IN KOREAN SPLIT-LIVER TRANSPLANTATION: ANALYSIS OF THE 10-YEAR KOREAN NETWORK FOR ORGAN SHARING DATA BASE</td>
<td>Nam-Joon Yi</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>329.7</td>
<td>PRINCIPLES FROM HIGH VOLUME LIVING DONOR LIVER TRANSPLANTATION CENTRE DOUBLES THE DONOR POOL IN DECEASED DONOR LIVER TRANSPLANTATION</td>
<td>Shishir Pareek</td>
<td>Gurgaon, India</td>
</tr>
<tr>
<td>329.8</td>
<td>CHANGES IN LIVER ALLOGRAFT STEATOSIS AND ITS IMPACT ON EARLY GRAFT FUNCTION AND LONG TERM SURVIVAL</td>
<td>Jason Davis</td>
<td>Indianapolis, IN, United States</td>
</tr>
<tr>
<td>329.9</td>
<td>EVALUATION OF THE POTENTIAL IMPACT OF INTER-REGIONAL SHARING FOR HIGH MELD PATIENTS WAITING FOR LIVER TRANSPLANTATION</td>
<td>Michael Fink</td>
<td>Heidelberg, Australia</td>
</tr>
</tbody>
</table>
### MINI-ORALS

**329.10** HISTOLOGIC CHANGE AFTER BODY WEIGHT REDUCTION OF POTENTIAL LIVING LIVER DONORS WITH FATTY LIVER  
*YoungRok Choi*  
Seoul, Korea

**329.11** PREDICTION OF NONALCOHOLIC FATTY LIVER IN APPARENTLY HEALTHY LIVING LIVER DONORS: A LARGE HISTOLOGY BASED COMPARISON TO NORMAL CONTROLS  
*Saigal Sanjiv*  
Gurgaon, India

**329.12** SIGNIFICANCE OF LIVING DOMINO DONOR LIVER TRANSPLANTATION IN THE CONTEXT OF LIMITED NUMBER OF DECEASED ORGAN DONORS IN JAPAN -A SINGLE CENTER EXPERIENCE-  
*Shintaro Hayashida*  
Kumamoto, Japan

**329.13** NONALCOHOLIC STEATOHEPATITIS AS INDICATION FOR LIVER TRANSPLANTATION IN EUROPE. CLINICAL ANALYSIS OF OVER 37,000 PATIENTS  
*Barbara Kern*  
Innsbruck, Austria

---

**12:00 - 14:00**  
**S-228-LEVEL 2**  
**BY INVITATION ONLY - NOT A CME SESSION**  
**SONG-Tx Consensus Workshop**

**12:30 - 13:30**  
**LUNCH BREAK**
12:30 - 13:30  
HALL 5E3-LEVEL 5  
NOT A CME SESSION  

Industry Symposium:  
Optimizing Immunosuppression: A Key for Improving Long-term Outcomes

Organized by

Please refer to page 342 for details.

13:30 - 15:00  
HALL 5BC-LEVEL 5

State-of-the-Art Session:  
Renal Allograft Dysfunction: Balancing Between Patient Care and Graft Survival

Chairs: Peter Stock, San Francisco, CA, United States  
       Daniel T.M. Chan, Hong Kong SAR, P.R. of China

340.1 CLINICAL-PATHOLOGICAL FINDINGS IN LATE INDICATION BIOPSIES: WHAT, HOW AND WHEN TO TREAT?  
Brian J. Nankivell  
Westmead, Australia

340.2 TREATING CHRONIC KIDNEY DISEASE OF THE RENAL ALLOGRAFT (CKDT): SHOULDN’T WE DO THINGS BETTER OR SHOULD WE DO DIFFERENT FROM CKD?  
Bertram L. Kasiske  
Minneapolis, MN, United States

Daniel T.M. Chan  
Hong Kong SAR, P.R. of China
13:30 - 15:00
HALL 5D-LEVEL 5

State-of-the-Art Session:
Beta Cell Replacement:
Recent Clinical Trials

Chairs: Thierry P.S. Berney, Geneva, Switzerland
        Jon Odorico, Madison, WI, United States

341.1 OUTCOMES OF THE COLLABORATIVE ISLET
       TRANSPLANT NIH TRIAL
       Dixon B. Kaufman
       Madison, WI, United States

341.2 TRIMECO STUDY RESULTS: ITA VS. IAK VS.
       MEDICAL THERAPY
       Pierre Y. Benhamou
       Grenoble, France

341.3 PRELIMINARY RESULTS OF THE NIH CTOT-15
       SPK TRANSPLANTATION TRIAL
       Kenneth A. Newell
       Atlanta, GA, United States

13:30 - 15:00
HALL 5E1-LEVEL 5

State-of-the-Art Session:
Increased Deceased Donation –
Focus on Asia

Chairs: Kimberly Young, Edmonton, AB, Canada
        Wai-Leung Chak, Hong Kong SAR, P.R. of China

342.1 THE ICU SPECIALIST ROLE IN ORGAN
       DONATION
       Wai Ming Chan
       Hong Kong SAR, P.R. of China

342.2 ASIAN PRACTICES FOR DECEASED DONATION
       Vasant Sumethkul
       Bangkok, Thailand

342.3 INTERNATIONAL PRACTICES IN DONATION
       AFTER CIRCULATORY DEATH
       Marti Manyalich
       Barcelona, Spain
13:30 - 15:00
HALL 5E2-LEVEL 5

State-of-the-Art Session: Cellular Therapies in Kidney Transplantation

Chairs: Christophe Michel Legendre, Paris, France
        Wayne W. Hancock, Philadelphia, PA, United States

343.1 MANY HORSES IN THE RACE: WHAT ARE THE FAVORITES?
Kathryn J. Wood
Oxford, United Kingdom

343.2 UPDATE FROM THE ONE STUDY: ARE CELLULAR THERAPIES SAFE?
Edward K. Geissler
Regensburg, Germany

343.3 INNOVATIVE TRIAL DESIGNS IN TOLERANCE STUDIES: HOW WILL EFFICACY BE DEMONSTRATED?
Sindhu Chandran
San Francisco, CA, United States

13:30 - 15:00
S-221-LEVEL 2

State-of-the-Art Session: Are Transplantation Registries Relevant or Irrelevant?

Chairs: Stephen McDonald, Adelaide, Australia
        Bo Ying Cindy Choy, Hong Kong SAR, P.R. of China

344.1 WHAT IS THE FUTURE OF INTERNATIONAL REGISTRIES? CARDIAC EXEMPLARS?
Anne I. Dipchand
Toronto, ON, Canada

344.2 TOWARDS A GLOBAL TRANSPLANT REGISTRY
Beatriz B. Mahillo
Madrid, Spain

344.3 HOW LINKING TRANSPLANT REGISTRIES TO OTHER DATABASES CAN ENHANCE THE VALUE OF REGISTRIES
Germaine Wong
Westmead, Australia
13:30 - 15:00
THEATRE 1-LEVEL 1

State-of-the-Art Session: Liver Allocation

Chairs: Abraham Shaked, Philadelphia, PA, United States
Jan Lerut, Louvain-la-Neuve, Belgium

345.1 OUT OF TIME: SHOULD LIVING DONOR TRANSPLANTATION BE THE PREFERRED OPTION FOR FULMINANT AND ACUTE ON CHRONIC LIVER FAILURE? THE PERSPECTIVE FROM TURKEY

Yaman Tokat
Istanbul, Turkey

345.2 WHAT ARE THE BARRIERS TO DECEASED DONOR LIVER TRANSPLANTATION IN INDIA, AND HOW THIS IMPACTED RECIPIENT SELECTION?

Mohamed Rela
Chennai, India

345.3 LIVER TRANSPLANTATION IN SOUTH KOREA: THE BEST OF BOTH WORLDS? THE IMPACT OF GROWTH OF DECEASED DONOR ORGAN TRANSPLANTATION IN A REGION WITH A VERY HIGH VOLUME LDLT PRACTICE

Kyung-Suk Suh
Seoul, Korea

13:30 - 15:00
THEATRE 2-LEVEL 1

State-of-the-Art Session: Transplantomics in Motion

Chairs: Elaine F. Reed, Los Angeles, CA, United States
Jonathan S. Bromberg, Baltimore, MD, United States

346.1 REDUCING COMPLEXITY IN TRANSPLANTOMICS

Marina Sirota
San Francisco, CA, United States

346.2 GENOME/PROTEOME VARIATIONS IN TRANSPLANT INJURY

Minnie M. Sarwal
San Francisco, CA, United States

346.3 APPLICATIONS OF HTS TO UNDERSTANDING INNATE AND ALLOIMMUNITY

Joel T. Dudley
New York, NY, United States
13:30 - 15:00
CONVENTION HALL A-LEVEL 1

State-of-the-Art Session:
Caveat Emptor: Transplantation & Transplant Tourism in the Tropics

Chairs: Michele I. Morris, Miami, FL, United States
Ka Foon Chau, Hong Kong SAR, P.R. of China

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>347.1</td>
<td>PERILS OF VIRAL INFECTION TRANSMISSIONS FROM ORGAN DONORS</td>
<td>Ban Hock Tan</td>
<td>Singapore, Singapore</td>
</tr>
<tr>
<td>347.2</td>
<td>PERILS OF FUNGAL AND BACTERIAL INFECTIONS RISKS OF TRANSPLANT TOURISM</td>
<td>Sharon Chen</td>
<td>Westmead, Australia</td>
</tr>
<tr>
<td>347.3</td>
<td>TRANSPLANTATION IN LATIN AMERICA</td>
<td>Clarisse Machado</td>
<td>Sao Paulo, Brazil</td>
</tr>
</tbody>
</table>

13:30 - 15:00
CONVENTION HALL B-LEVEL 1

State-of-the-Art Session:
Advance Nursing Practice and its Contribution to Excellence in Transplant Management

Chairs: Kathy Kable, Westmead, Australia
Patrice Pfeiffenberger, Chicago, IL, United States

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>348.1</td>
<td>LUNG TRANSPLANT ADVANCE PRACTICE NURSE</td>
<td>Bronwyn J. Levvey</td>
<td>Melbourne, Australia</td>
</tr>
<tr>
<td>348.2</td>
<td>ADVANCED PRACTICE NURSES AND THEIR ROLE IN TRANSPLANTATION</td>
<td>Roberta J. Al Housani-Blakely</td>
<td>Abu Dhabi, United Arab Emirates</td>
</tr>
<tr>
<td>348.3</td>
<td>LIVER TRANSPLANT ADVANCE PRACTICE</td>
<td>Julie Pavlovic</td>
<td>Heidelberg, Australia</td>
</tr>
</tbody>
</table>
State-of-the-Art Session: Towards the 10th Anniversary of the Declaration of Istanbul – Policy and Guidance

Chairs: Beatriz Dominguez-Gil, Madrid, Spain, TBA

349.1 THE COUNCIL OF EUROPE CONVENTION AGAINST TRAFFICKING IN HUMAN ORGANS: PRESENT AND FUTURE
Marta López Fraga
Strasbourg, France

349.2 DEFINING PROPER TRAVEL FOR TRANSPLANTATION VERSUS TRANSPLANT TOURISM
Elmi M. Muller
Cape Town, South Africa

349.3 DECLARATION OF ISTANBUL: SUCCESSES AND FAILURES
Francis L. Delmonico
Waltham, MA, United States

15:00 - 15:30
COFFEE BREAK
HALL 5FG-LEVEL 5
15:30 - 17:00
HALL 5BC-LEVEL 5

Orals Session: Novel Agents

Chairs: Lionel Rostaing, Toulouse, France
       Flavio Vincenti, San Francisco, CA, United States

350.1 UTILIZATION AND CLINICAL OUTCOMES OF BELATACEPT-BASED IMMUNOSUPPRESSION IN U.S. RENAL TRANSPLANT RECIPIENTS

Karl L. Womer
Gainesville, FL, United States

350.2 OUTCOMES OF DE NOVO BELATACEPT VERSUS TACROLIMUS IN KIDNEY RECIPIENTS OF HIGH RISK DONORS

Giselle Guerra
Miami, FL, United States

350.3 BELATACEPT RESCUE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS WITH SEVERELY IMPAIRED RENAL FUNCTION

Klemens Budde
Berlin, Germany

350.4 PATTERNS OF IMPROVEMENT IN KIDNEY FUNCTION AMONG PATIENTS CONVERTED TO BELATACEPT FROM CALCINEURIN INHIBITORS FOR KIDNEY ALLOGRAFT DYSFUNCTION

Dhiren Kumar
Richmond, VA, United States

350.5 EARLY CONVERSION TO BELATACEPT IN PATIENTS WITH POOR OR DELAYED GRAFT FUNCTION

Ron Shapiro
New York, NY, United States

350.6 TOFACITINIB IN RENAL ALLOGRAFT RECIPIENTS: LONG-TERM EFFICACY AND SAFETY IN AN ACTIVE-COMPARATOR-CONTROLLED EXTENSION TRIAL

Philip J. O’Connell
Westmead, Australia
350.7 EFFICACY OF A CHIMERIC ANTI-HUMAN ICAM-1 MONOCLONAL ANTIBODY, MD-3, FOR KIDNEY TRANSPLANTATION IN RHESUS MONKEYS

Minji Cho
Seoul, Korea

350.8 A NOVEL NON-INVASIVE BLOOD TRANSCRIPTIONAL ASSAY, KSORT, MONITORS ALLOIMMUNE RESPONSE IN THE SAILOR RANDOMIZED MULTICENTER EU TRIAL

Minnie M. Sarwal
San Francisco, CA, United States

350.9 IMMUNOLOGIC BASIS FOR A NOVEL ORGAN-SPECIFIC THERAPY: IMMUNOCLOAKING

Lauren Brasile
Watervliet, NY, United States

15:30 - 17:00
HALL 5D-LEVEL 5
Orals Session: Experimental Islet Tx: Engraftment

Chairs: Maria Koulmanda, Boston, MA, United States
Paul R. V. Johnson, Oxford, United Kingdom

351.1 COMPOSITE PANCREATIC ISLET GRAFTS WITH ADIPOSE TISSUE-DERIVED STEM CELLS ENHANCE THE SURVIVAL AND INSULIN FUNCTION OF ISLET GRAFTS IN DIABETIC MICE

Masahiro Tanemura
Osaka, Japan

351.2 WHAT ARE FACTORS AFFECTING INSULIN INDEPENDENCE IN PATIENTS AFTER TOTAL PANCREATECTOMY AND ISLET AUTOTRANSPLANTATION (TPIAT)?

Julia Solomina
Chicago, IL, United States

351.3 CYANIDIN-3-O-GLUCOSIDE (C3G) IMPROVES THE CELL VIABILITY OF HUMAN ISLETS TREATED WITH HUMAN AMYLIN OR ABETA1-42 IN VITRO

Josue Rodrigues Silva
Edmonton, AB, Canada
351.4 THE PROTECTIVE EFFECT OF DIMETHYL FUMARATE ON HUMAN PANCREATIC ISLETS
Hirohito Ichii
Orange, CA, United States

351.5 OPTIMIZATION OF PRE-VASCULARIZATION PROCEDURES FOR IMPROVING ISLET ENGRAFTMENT UNDER THE SKIN
Satomi Suzuki Uematsu
Sendai, Japan

351.6 Y1 RECEPTOR ANTAGONISM ENHANCES INSULIN SECRETION AND IMPROVES ISLET TRANSPLANTATION EFFICIENCY
Stacey N. Walters
Darlinghurst, Australia

351.7 HUMAN MESENCHYMAL STROMAL CELLS IMPROVE SURVIVAL AND FUNCTION OF PANCREATIC ISLETS BY CELL-TO-CELL CONTACT THROUGH N-CADHERIN
Raphael Meier
Geneva, Switzerland

351.8 PROTECTION OF STEM-CELL-DERIVED INSULIN-PRODUCING CELLS FROM ISCHEMIC INJURY
Gaetano Faleo
San Francisco, CA, United States

351.9 SPROUTING OF INTRA-ISLET ENDOTHELIAL CELLS TO FORM PERI-ISLET VESSELS IN HUMAN ISLETS
Balamurugan N. Appakalai
Louisville, KY, United States

15:30 - 17:00
HALL 5E1-LEVEL 5
Orals Session: Increasing the Organs Pool DCD and Beyond

Chairs: Marti Manyalich, Barcelona, Spain
Haibo Wang, Hong Kong SAR, P.R. of China

352.1 KIDNEY TRANSPLANTATION FROM UNCONTROLLED DONORS AFTER CIRCULATORY DEATH: THE SPANISH EXPERIENCE
Beatriz Domínguez-Gil
Madrid, Spain
352.2 LARGEST US OPO DCD EXPERIENCE: 1014 DCD DONORS OVER TWO DECADES
Howard M. Nathan
Philadelphia, PA, United States

352.3 EXPERIENCE WITH DONATION AFTER CIRCULATORY DEATH (DCD) IN DONORS AGED 56-65: A PRELIMINARY REPORT ON KIDNEY UTILIZATION AND INITIAL OUTCOMES
Jeffrey P. Orlowski
Oklahoma City, OK, United States

352.4 WORLD FIRST REPORT OF LIVER TRANSPLANTATION FROM AN HIV-POSITIVE DONOR TO AN HIV-POSITIVE RECIPIENT
Christian van Delden
Geneva, Switzerland

352.5 INITIAL EXPERIENCE OF EN-BLOC KIDNEY TRANSPLANTATION FROM DONORS LESS THAN TWO MONTHS OF AGE IN THE UNITED KINGDOM: A POTENTIAL NEW DONOR POOL
Imeshi U. Wijetunga
Leeds, United Kingdom

352.6 ORGAN DONATION AFTER EUTHANASIA LEADS TO GOOD TRANSPLANT RESULTS
Jan Bollen
Maastricht, The Netherlands

352.7 SAVING LIVES ONE ORGAN AT A TIME: ONE OPO’S EXPERIENCE IN A SERVICE AREA WITH A HIGH INCIDENCE OF CEREBROVASCULAR ACCIDENTS
Vernon L Langley
Norcross, GA, United States

352.8 IDENTIFYING NEONATAL POTENTIAL FOR SOLID ORGAN AND TISSUE DONATION IN THE NEWCASTLE UPON TYNE HOSPITALS (UK)
Aranzazu Quiralte Baglietto
Newcastle, United Kingdom

352.9 EVALUATE QUALITY OF KIDNEYS FROM DCD/ECD DONORS BY PARAMETERS OF MACHINE PERFUSION
Guodong Chen
Guangzhou, People’s Republic of China
15:30 - 17:00
HALL 5E2-LEVEL 5

Orals Session: Acute Injury

Chairs: Teun Van Gelder, Rotterdam, Netherlands
Fritz Diekman, Barcelona, Spain

353.1 STEM CELL-MEDIATED REGENERATION OF ISCHEMICALLY DAMAGED HUMAN RENAL ALLOGRAFTS DURING EX VIVO WARM PERFUSION

Lauren Brasile
Watervliet, NY, United States

353.2 PROPERDIN DEFICIENCY AGGRAVATES THE RENAL INJURY OF ISCHEMIA REPERFUSION

Bin Yang
Leicester, United Kingdom

353.3 FRACTIONAL EXCRETION OF NGAL INSTEAD OF 99MTCMAG3 RENOGRAPHY TO MONITOR RESOLUTION OF DELAYED GRAFT FUNCTION

J. R. Bank
Leiden, The Netherlands

353.4 HYPOTHERMIC PULSATILE PRESERVATION OF KIDNEYS FROM UNCONTROLLED DECEASED DONORS AFTER CARDIAL ARREST

Palmina Petruzzo
Lyon, France

353.5 ECULIZUMAB FOR PREVENTION AND TREATMENT OF THE KIDNEY GRAFT REPERFUSION INJURY

Michael M. Kaabak
Moscow, Russian Federation

353.6 IMPACT OF PRE-EXISTING DIABETES MELLITUS ON THE IMMUNOLOGIC OUTCOME AFTER KIDNEY TRANSPLANTATION

Dmytro Khadzynov
Berlin, Germany

353.7 IS PROLONGED COLD ISCHEMIA A CONTRAINDICATION TO USING KIDNEYS FROM ACUTE KIDNEY INJURY DONORS?

Giuseppe Orlando
Winston Salem, NC, United States
353.8 RETROSPECTIVE STUDY OF POST RENAL TRANSPLANT DELAYED GRAFT FUNCTION - ANALYSIS OF MULTIPLE DEFINITIONS AND RESPECTIVE PROGNOSTIC CAPACITY

Samantha M. Bateman
Fitzroy North, Australia

353.9 INTERIM ANALYSIS TO DETERMINE WHETHER PREOPERATIVE INTRAVENOUS FLUIDS RESULT IN A DECREASE IN DONOR SUBCLINICAL ACUTE KIDNEY INJURY

Ryan Ghita
Glasgow, United Kingdom

15:30 - 17:00
S-221-LEVEL 2

Orals Session: Making Lung Transplant Work

Chairs: Bronwyn J Levvey, Melbourne, Australia
Allan R. Glanville, Sydney, Australia

354.1 EXTRACORPOREAL MEMBRANE OXYGENATION PRACTICES CHANGES AS BRIDGE TO LUNG TRANSPLANTATION: AN INSTITUTIONAL EXPERIENCE AND LITERATURE REVIEW

Daniel Oscar Absi
Buenos Aires, Argentina

354.2 DONOR CCR2+ CARDIAC MACROPHAGES MEDIATE NEUTROPHIL EXTRAVASATION AFTER HEART TRANSPLANTATION THROUGH MYD88-DEPENDENT PRODUCTION OF CHEMOTRACTANTS

Wenjun Li
St Louis, MO, United States

354.3 TERTIARY LYMPHOID ORGANS WITHIN PULMONARY ALLOGRAFTS PROMOTE TOLERANCE

Wenjun Li
St Louis, MO, United States

354.4 EFFECTS OF BRAIN DEATH (BD) OR CARDIAC DEATH (DCD) ON ALLOGENEIC LUNG GRAFT SURVIVAL IN PRECLINICAL MHC-INBRED CLAWN MINIATURE SWINE

Yuichi Ariyoshi
Kagoshima, Japan
354.5 INTRAOPERATIVE VASOPRESSIN USE AS A FAVORABLE PROGNOSTIC FACTOR FOR EARLY SURVIVAL AFTER LUNG TRANSPLANTATION

Kyoung Shik Narm
Seoul, Korea

354.6 THE IMMUNOSUPPRESSIVE EFFECT VIA HGF-CMET PATHWAY OF AUTOLOGOUS ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN A RAT LUNG TRANSPLANTATION MODEL

Hironosuke Watanabe
Nagasaki, Japan

354.7 OUTCOMES OF ACUTE KIDNEY INJURY OCCURRING IMMEDIATELY POST LUNG TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTRE AUDIT

Solomon Menahem
Melbourne, Australia

354.8 RENAL OUTCOMES IN LUNG TRANSPLANT RECIPIENTS TREATED WITH THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) INHIBITOR EVEROLIMUS

Timothy E. Coughlan
Mount Waverly, Australia

15:30 - 17:00 THEATRE 1-LEVEL 1

Orals Session: Ischaemia Reperfusion/Preservation

Chairs: William Sharr, Hong Kong SAR, P.R. of China
Mehmet Haberal, Ankara, Turkey

355.1 A MULTICENTRE RANDOMISED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF NORMOTHERMIC MACHINE PERFUSION WITH STATIC COLD STORAGE IN HUMAN LIVER TRANSPLANTATION: EARLY OUTCOMES

David Nasralla
Oxford, United Kingdom

355.2 DAMP-ASSOCIATED PRESERVATION INJURY AND COMPLICATIONS AFTER LIVER TRANSPLANTATION: PROOF OF CONCEPT

Denis Efimov
Minsk, Belarus
355.3 BILIARY EPITHELIAL DAMAGE, REGENERATIVE CAPACITY AND LOCAL IMMUNE RESPONSE AFTER COLD STORAGE OF DBD LIVERS DETERMINE BILIARY COMPLICATIONS AFTER LIVER TRANSPLANTATION

Hans J. Schlitt
Regensburg, Germany

355.4 IMPORTANCE OF DNA METHYLATION PATTERNS AND ASSOCIATION WITH GRAFT INJURY SEVERITY AFTER LIVER TRANSPLANTATION

Daniel G. Maluf
Charlottesville, VA, United States

355.5 EXOGENOUS MELATONIN PROMOTES GRAFT REGENERATION IN SMALL-FOR-SIZE LIVER TRANSPLANTATION

Zhuolun Song
Zurich, Switzerland

355.6 REPERFUSION FIBRINOLYSIS SHUTDOWN AFTER LIVER TRANSPLANTATION: RATIONALE FOR PERMISSIVE HYPOCOAGULABILITY IN THE POST-OPERATIVE SETTING

Hunter B. Moore
Aurora, CO, United States

355.7 THE EFFECT OF NAFAMOSTAT MESILATE TO MINIMIZE ISCHEMIC-REPERFUSION INJURY OF THE LIVER FOLLOWING LIVER TRANSPLANTATION: A SINGLE ARM PILOT STUDY

Young-Dong Yu
Seoul, Korea

355.8 IMPACT OF A NEWLY DEVELOPED SOLUTION CONTAINING ARTIFICIAL OXYGEN CARRIER HEMOGLOBIN VESICLES UNDER SUBNORMOTHERMIC CONDITIONS WITH MACHINE PERFUSION PRESERVATION FOR DCD LIVER GRAFTS IN PIGS

Naoto Matsuno
Asahikawa, Japan

355.9 THE COMPARISON WITH DONATION AFTER CARDIAC DEATH LIVER GRAFTS BY OXYGENATED SUBNORMOTHERMIC WITHREWARMING MACHINE PERFUSION IN PIGS

Naoto Matsuno
Asahikawa, Japan
15:30 - 17:00
THEATRE 2-LEVEL 1
Orals Session:
Regulatory Mechanisms 1

Chair: Andreas Linkermann, Kiel, Germany
Kazuhiko Yamada, New York, NY, United States

356.1 DONOR DCs IN CHIMERIC VASCULARIZED THYMIC GRAFTS, BUT NOT ANTIGEN-PRESENTING HOST DCs, PLAY AN ESSENTIAL ROLE IN THE INDUCTION OF TOLERANCE OF SOLID ORGANS IN A PRECLINICAL LARGE ANIMAL MODEL
Kazuhiko Yamada
New York, NY, United States

356.2 THE COMBINED EFFECT OF STEM CELL FACTOR AND GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ADMINISTRATION AFTER 90% PARTIAL HEPATECTOMY IN RATS
Hyerim Byeon
Goyang-si, Korea

356.3 INTERLEUKIN-34 IS A TREG-SPECIFIC CYTOKINE AND MEDIATES TRANSPLANT TOLERANCE
Séverine Bézie
Nantes, France

356.4 IL-10 EXPRESSION OF IN VITRO ACTIVATED B CELLS AS A BIOMARKER FOR B CELL TOLERANCE
Kiyohiko Hotta
Boston, MA, United States

356.5 IMMUNE TOLERANCE MONITORING IN RENAL ALLOGRAFT TOLERANCE INDUCED BY TRANSIENT MIXED CHIMERISM IN NONHUMAN PRIMATES AND HUMANS
Kiyohiko Hotta
Boston, MA, United States

356.6 RECENTLY ALLOACTIVATED CD4+CD8-CD25+TREG EXPRESS CD8 AND ARE THE ANTIGEN-SPECIFIC TREG
Bruce M. Hall
Sydney, Australia
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>356.7</td>
<td>THE UK ONE STUDY TRIAL: SAFETY AND FEASIBILITY OF REGULATORY T (TREG) CELL THERAPY IN RENAL TRANSPLANTATION</td>
<td>Paul Harden</td>
<td>Oxford, United Kingdom</td>
</tr>
<tr>
<td>356.8</td>
<td>COMBINATION OF VETO CELL TRANSFER AND INKT CELL THERAPY ESTABLISHES COMPLETE HEMATOPOIETIC CHIMERISM IN NON-MYELOABLATIVE BMT RECIPIENTS</td>
<td>Toshihito Hirai</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td>356.9</td>
<td>NATURAL KILLER CELLS DEMONSTRATE FUNCTIONAL AND RECEPTOR DIVERSITY IN RESPONSE TO ALLOANTIGEN</td>
<td>Sheri Krams</td>
<td>Stanford, CA, United States</td>
</tr>
</tbody>
</table>

**15:30 - 17:00**

**CONVENTION HALL A-LEVEL 1**

**Orals Session:** Exploring Cellular Interactions in Tissue Injury

**Chairs:** Olivia M. Martinez, Stanford, CA, United States
Midas Seyda, Boston, MA, United States

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>357.1</td>
<td>CELL-FREE MITOCHONDRIAL DNA ACTIVATES DCs IN AN AGE-DEPENDENT FASHION AND COMPROMISES THE SURVIVAL OF OLDER GRAFTS</td>
<td>Midas Seyda</td>
<td>Boston, MA, United States</td>
</tr>
<tr>
<td>357.2</td>
<td>DONOR BRAIN DEATH INFLUENCES EARLY NK CELL MIGRATION IN MURINE HEART AND KIDNEY TRANSPLANTATION</td>
<td>Paul Viktor Ritschl</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>357.3</td>
<td>EVOLUTION OF INNATE AND ADAPTIVE CYTOKINE RESPONSES IN ISCHEMIA REPERFUSION INJURY IN ORTHOTOPIC LIVER TRANSPLANTATION</td>
<td>Ali Zarrinpar</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>Session 357</td>
<td>Title</td>
<td>Author(s)</td>
<td>Institution/Location</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>357.4</td>
<td>BRUTON’S TYROSINE KINASE INHIBITION ATTENUATES MOUSE LIVER DAMAGE DUE TO ISCHEMIA AND REPERFUSION</td>
<td>Ali Zarrinpar</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>357.5</td>
<td>PRE-TREATMENT OF HEART ALLOGRAFTS WITH THE CYTOTOPIC ANTI-THROMBIN INHIBITOR THROMBALEXIN PROLONGS TRANSPLANT SURVIVAL AND AUGMENTS THE THERAPEUTIC EFFICACY OF ADOPTIVELY TRANSFERRED REGULATORY T CELLS</td>
<td>Qi Peng</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>357.6</td>
<td>REPRESSOR AND ACTIVATOR PROTEIN ACCELERATES HEPATIC ISCHEMIA REPERFUSION INJURY BY PROMOTING NEUTROPHIL INFLAMMATORY RESPONSE</td>
<td>Chang Xian Li</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>357.7</td>
<td>EXPRESSION OF HUMAN CD55 AND CD59 REDUCES COMPLEMENT DEPOSITION AND PRESERVES RENAL FUNCTION IN A MOUSE MODEL OF RENAL ISCHEMIA REPERFUSION INJURY</td>
<td>David Bo Lu</td>
<td>Hoppers Crossing, Australia</td>
</tr>
<tr>
<td>357.8</td>
<td>AMP-ACTIVATED PROTEIN KINASE ATTENUATED MARGINAL LIVER GRAFT INJURY VIA PROMOTING MITOCHONDRIAL BIOGENESIS AND RESPIRATORY FUNCTION</td>
<td>Jiang Liu</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>357.9</td>
<td>CHANGES IN ACTIVIN LEVELS AND THE IMPACT OF FOLLISTATIN TREATMENT IN RENAL ISCHEMIA-REPERFUSION INJURY IN MICE</td>
<td>Peter Cowan</td>
<td>Melbourne, Australia</td>
</tr>
</tbody>
</table>
15:30 - 17:00
CONVENTION HALL B-LEVEL 1

Orals Session: Histocompatibility

**Chairs:** Caner Süsal, Heidelberg, Germany  
Frans H.J. Claas, Leiden, The Netherlands

358.1 **TIME-SERIES VARIATIONS IN CALCULATED PANEL REACTIVE ANTIBODY AMONG KIDNEY TRANSPLANT CANDIDATES**

**Clarence E. Foster III**  
Irvine, CA, United States

358.2 **EARLY DE NOVO DSA WITH T CELL MEDIATED REJECTION (TCMR) IS ASSOCIATED WITH ALLOGRAFT DYSFUNCTION WITH CHRONIC INJURY**

**Aravind Cherukuri**  
Pittsburgh, PA, United States

358.3 **THE NEW OPTN KIDNEY ALLOCATION SYSTEM: A LOOK AT THE ONE YEAR TRANSPLANT TREND IN THE HIGHLY SENSITIZED PATIENT COHORT**

**Taba Kheradmand**  
Ann Arbor, MI, United States

358.4 **ASSOCIATION OF KIR3DL1/3DS1 ALLELES WITH RENAL ALLOGRAFT REJECTION**

**Swayam Prakash**  
Lucknow, India

358.5 **C1Q-FIXING ANTIBODIES AGAINST DENATURED HLA AND MICA ANTIGENS ARE ASSOCIATED WITH ANTIBODY MEDIATED REJECTION**

**Junchao Cai**  
Los Angeles, CA, United States

358.6 **AGREEMENT BETWEEN NUMBER OF DONOR / RECIPIENT EPLET MISMATCHES CALCULATED USING TWO-DIGIT SEROLOGICAL VERSUS FOUR-DIGIT MOLECULAR HUMAN LEUCOCYTE ANTIGEN (HLA)-TYPING**

**Samantha J. Fidler**  
Perth, Australia
358.7 CAREFUL DESELECTION OF LOW RISK UNACCEPTABLE ANTIGENS CAN FACILITATE RENAL TRANSPLANTATION IN HIGHLY SENSITISED PATIENTS WITH EXCESSIVE TIME ON THE WAITING LIST

Stuart J. Falconer
Glasgow, United Kingdom

358.8 C1Q/C3D SINGLE ANTIGEN BEAD ASSAY ONLY DETECTS HIGH TITER/AVIDITY CLASS-I ANTI-HLA ANTIBODIES DETECTED BY SINGLE ANTIGEN BEADS

Manish Gandhi
Rochester, MN, United States

358.9 REGULATION OF MICRORNA HSA-MIR-663A BY HLA CLASS I ANTIBODIES IN ENDOTHELIAL CELLS

Omar Moussa
Charleston, SC, United States

15:30 - 17:00
CONVENTION HALL C-LEVEL 1

Orals Session: Overcoming Medical, Surgical and Immunologic Barriers in Paediatric Solid Organ Transplantation

Chairs: George V. Mazariegos, Pittsburgh, PA, United States
       Minnie M. Sarwal, San Francisco, CA, United States

359.1 MASS CYTOMETRY REVEALS NK CELL AND T CELL SUBSETS IN PEDIATRIC LIVER TRANSPLANT PATIENTS WITH ACUTE REJECTION

Sheri Krams
Stanford, CA, United States

359.2 PEDIATRIC LIVER TRANSPLANTATION USING SEGMENTAL GRAFTS IN JAPAN: A SINGLE-CENTER EXPERIENCE WITH 270 PATIENTS

Koichi Mizuta
Tochigi, Japan

359.3 SINGLE KIDNEY TRANSPLANTATION FROM PEDIATRIC DONORS YOUNGER THAN 3 YEARS TO ADULT RECIPIENTS

Lan Zhu
Wuhan, People’s Republic of China
359.4 OVERCOMING BARRIERS IN COMPLEX PAEDIATRIC RENAL TRANSPLANTATION

Pankaj Chandak
London, United Kingdom

359.5 BARRIERS TO PREEMPTIVE RENAL TRANSPLANTATION IN NEW ZEALAND CHILDREN

Tonya Kara
Auckland, New Zealand

359.6 ASSOCIATION OF C1Q FIXING DONOR-SPECIFIC HLA ANTIBODIES WITH LATE GRAFT FAILURE IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS

Burkhard Tönshoff
Heidelberg, Germany

359.7 ACCEPTABLE POST-HEART TRANSPLANTATION OUTCOMES OF CHILDREN LISTED IN TOTAL RENAL FAILURE

Nassiba Alami Laroussi
Edmonton, AB, Canada

359.8 CONTRIBUTING FACTORS TO TRANSPLANT MEDICATION ERRORS IN PEDIATRIC PATIENTS

Yew Weng Perry Lau
Singapore, Singapore

359.9 CYTOKINE PROFILES IN CHILDREN AFTER PEDIATRIC KIDNEY TRANSPLANTATION WITH ACUTE CELLULAR COMPARED TO CHRONIC HUMORAL REJECTION AND STABILE PATIENTS

Nadja Borsum
Hannover, Germany
### ISN-TTS Sister Transplantation Center Program

360. PRESENTATION OF ISN-TTS SISTER TRANSPLANTATION CENTER PROGRAM
   **Randall Lou Meda**  
   Guatemala, Guatemala
   **Abdullah El-Kishawi**  
   Gaza City, Palestine

### Campfire Presentations: Kidney I - Campfire Table 1

**Chairs:** José Ramón Núñez Peña, Geneva, Switzerland  
Robert A. Montgomery, New York, NY, United States

370.1 CLINICAL IMPACT OF GRAFT VOLUME CHANGE AFTER BODY WEIGHT MISMATCHED KIDNEY TRANSPLANTATION: BASED ON DATA OF POSTOPERATIVE MAGNETIC RESONANCE VOLUMETRY
   **Kyungjai Ko**  
   Seoul, Korea

370.2 LONG TERM, SINGLE CENTRE EXPERIENCE WITH SIMULTANEOUS AORTOILIAC ALLOGENIC RECONSTRUCTION AND KIDNEY TRANSPLANTATION
   **Tomas Marada**  
   Prague, Czech Republic

370.3 LAPAROSCOPIC DONOR NEPHRECTOMY: A COMPARISON OF RETROPERITONEOSCOPIC VERSUS TRANSPERITONEOSCOPIC APPROACH
   **Zi Qin Ng**  
   Perth, Australia
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>370.4</td>
<td>THE UPPER URINARY TRACT UROTHELIAL CARCINOMA BEHAVIORS AFTER KIDNEY TRANSPLANTATION IN TAIWAN</td>
<td>Chia-Shen Chien</td>
<td>Kaohsiung, Taiwan</td>
</tr>
<tr>
<td>370.5</td>
<td>COMPARISON OF BASELINE CO-MORBIDITY AND MORTALITY IN LIVING DONORS – 10 YEAR UK COHORT STUDY</td>
<td>Nithya Krishnan</td>
<td>Coventry, United Kingdom</td>
</tr>
<tr>
<td>370.6</td>
<td>EFFECTIVENESS OF THREE-DIMENSIONAL IMAGE ANALYSIS FOR SURGICAL SIMULATION OF LIVING DONOR KIDNEY TRANSPLANTATION WITH MULTIPLE RENAL ARtery GRAFTING</td>
<td>Koichi Tomita</td>
<td>Tokyo, Japan</td>
</tr>
</tbody>
</table>

**17:00 - 18:00**  
**HALL 5FG-LEVEL 5**  
**NOT A CME SESSION**

**Campfire Presentations:**  
Liver - Campfire Table 2  

*Chairs: Kieron Lim, Singapore, Singapore  
Gursharam Singh, Coimbatore, India*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>371.1</td>
<td>WHICH IS THE PREDICTABLE VALUES OF POST-TRANSPLANT HCC RECURRENCE IN PATIENTS RECEIVED DOWN STAGING THERAPY OR BRIDGING THERAPY?</td>
<td>Jae Geun Lee</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>371.2</td>
<td>ISCHEMIC CHOLANGIOPATHY IS THE ONLY BILIARY COMPLICATION THAT IMPACTS OUTCOME FOLLOWING DONATION AFTER CARDIAC DEATH LIVER TRANSPLANTATION</td>
<td>Shiva Kumar</td>
<td>Abu Dhabi, United Arab Emirates</td>
</tr>
<tr>
<td>371.3</td>
<td>IMPACT OF DONATION AFTER CARDIAC DEATH ALLOGRAFTS ON OUTCOME FOLLOWING SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION</td>
<td>Shiva Kumar</td>
<td>Abu Dhabi, United Arab Emirates</td>
</tr>
</tbody>
</table>
### 371.4 EX VIVO SUBNORMOTHERMIC OXYGENATED LIVER PERFUSION JUST BEFORE LIVER TRANSPLANTATION FROM NON-HEART-BEATING DONORS MIGHT IMPROVE GRAFT VIABILITY, IN PIG MODEL

*Yuta Kakizaki*
Sendai, Japan

### 371.5 ABO INCOMPATIBLE DUAL GRAFT LIVING DONOR LIVER TRANSPLANTATION

*Jae Hyun Kwon*
Seoul, Korea

### 371.6 INFLAMMATION-BASED PROGNOSTIC SCORE IN LIVING DONOR LIVER TRANSPLANTATION FOR HEPATOCgLLEAR CARCINOMA

*Norifumi Harimoto*
Fukuoka, Japan

---

### 17:00 - 18:00

**HALL 5FG-LEVEL 5**

**NOT A CME SESSION**

**Campfire Presentations:**
**Deceased Donation - Campfire Table 3**

**Chairs:** Howard M. Nathan, Philadelphia, PA, United States
Mei Lan May Pong, Hong Kong SAR, P.R. of China

### 372.1 SIGNIFICANT CHANGES IN THE ORGAN DONOR POOL OVER THE LAST 10 YEARS: DONORS FROM ANOXIC CAUSE OF DEATH (COD) MORE THAN DOUBLE WHICH INCLUDES A 300% INCREASE IN DONORS WITH A DRUG OVERDOSE

*Howard M. Nathan*
Philadelphia, PA, United States

### 372.2 CAN KNOWLEDGE AND ATTITUDES OF CRITICAL CARE PROFESSIONALS INFLUENCE ORGAN DONATION? - A MALAYSIAN PERSPECTIVE

*James W. Foong*
Serdang, Malaysia

### 372.3 EYE DONATION IN HONG KONG: ATTITUDES OF FAMILY MEMBERS OF DECEASED PATIENTS

*Chor Kwan Amanda Luk*
Hong Kong SAR, P.R. of China
372.4 KNOWLEDGE AND ATTITUDES REGARDING BRAIN DEATH AND ORGAN DONATION AMONG YOUNG MALES IN THE NORTHEASTERN THAILAND

Jongruk Pongskul
Bangkok, Thailand

372.5 THE DEVELOPMENT AND MANAGEMENT OF CHINA ORGAN PROCUREMENT ORGANIZATION ALLIANCE

Xiaoli Fan
Wuhan, People’s Republic of China

372.6 OUTCOMES OF KIDNEY TRANSPLANTATION USING KIDNEYS FROM EXPANDED CRITERIA DONORS AND DONORS WITH ACUTE KIDNEY INJURY IN THAILAND

North Techawathanawanna
Bangkok, Thailand

17:00 - 18:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

Campfire Presentations:
Unraveling Alloreactivity: Innovative Approaches (I) - Campfire Table 4

Chairs: Nancy Kwan Man, Hong Kong SAR, P.R. of China
Rebeca Arroyo Hornero, Oxford, United Kingdom

373.1 EXPRESSION OF THREE ALLOGENEIC MHC CLASS I IN RECIPIENT LIVER SIGNIFICANTLY PROLONGS SURVIVAL OF FULLY-ALLOGENEIC VASCULARISED CARDIAC ALLOGRAFTS

Mamdoh Moawadh
Sydney, Australia

373.2 HEIGHTENED EXPRESSION OF HLA-DQB2 AND HLA-DPB1 GENES IN PRE-IMPLANTATION KIDNEY BIOPSIES IS ASSOCIATED WITH POOR GRAFT FUNCTION

Maria Gerbase-DeLima
Sao Paulo, Brazil
LONG-TERM SURVIVAL OF HUMAN STEM CELL-DERIVED INSULIN PRODUCING CELLS (SCIPCs) TRANSPLANTED TO THE SUBCUTANEOUS SPACE IN A DIABETIC MURINE MODEL

Steven A. Wisel
San Francisco, CA, United States

SECRETORY LEUKOCYTE PROTEINASE INHIBITOR: A BIOMARKER FOR ACUTE KIDNEY INJURY HAS A PROTECTIVE ROLE IN KIDNEY TRANSPLANTATION

Eduardo Chuluyan
Buenos Aires, Argentina

EXPRESSION OF CXCR3 BY ISLET-INFILTRATING MEMORY T CELLS IN THE PANCREAS TRANSPLANT WITH RECURRENT TYPE 1

George W. Burke
Miami, FL, United States

17:00 - 18:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

Campfire Presentations:
Developing Transplant Programmes Across the World - Campfire Table 5

Chairs: Jongwon Ha, Seoul, Korea
Curie Ahn, Seoul, Korea

KNOWLEDGE AND ATTITUDE OF PEOPLE TOWARDS END-STAGE KIDNEY DISEASE, KIDNEY TRANSPLANTATION AND KIDNEY DONATION: OPINION FROM A DEVELOPING COUNTRY

Palash Mitra
Dhaka, Bangladesh

DEVELOPMENT OF A DECEASED DONOR PROGRAM IN NEW CALEDONIA THROUGH AN INTERNATIONAL HYBRID MODEL

Nicolas Quirin
Noumea, New Caledonia

SUCCESS TRANSFORMATION OF ORGAN DONATION SYSTEM BRINGS POSITIVE FEEDBACK TO DONATION MANNER OF MEDICAL FRONTIERS IN CHINA

Nga-Lei Tam
Shenzhen, People’s Republic of China
374.4 ORGAN DONATION AND TRANSPLANTATION IN MONTENEGRIN POPULATION

Marina Ratkovic
Podgorica, Montenegro

374.5a POST TRANSPLANT INFECTIONS: A SINGLE CENTRE EXPERIENCE
(abst. P.1267 in the Transplantation Journal)

Tahir Aziz
Karachi, Pakistan

374.6 THE TRINIDAD AND TOBAGO EXPERIENCE: A SUCCESSFUL MODEL TO DEVELOP A DONATION SYSTEM USING SEUSA PROGRAM
(abst. P.1633 in the Transplantation Journal)

Gloria Páez
Barcelona, Spain

17:00 - 18:30
HALL 5FG-LEVEL 5

NOT A CME SESSION

Poster Sessions
Detailed list of all the posters available on page 273

17:00 - 19:00
THEATRE 2-LEVEL 1

NOT A CME SESSION

Women in Transplantation Workshop and Networking Event

17:30 - 19:00
HALL 5E3-LEVEL 5

NOT A CME SESSION

Industry Symposium: Donor Specific Antibody Monitoring

Organized by

ONE LAMBDA
A Thermo Fisher Scientific Brand

Please refer to page 343 for details.
18:00 - 21:00
S-226-LEVEL 2
BY INVITATION ONLY - NOT A CME SESSION
Living Donor Organ Transplantation in Asia (5th Vitallink International Workshop)

19:30 - 21:30
OFFSITE - THE PAWN
62 JOHNSTON RD., WAN CHAI
TICKETED EVENT $ - NOT A CME SESSION
TTS Young Investigators Networking Event

With the Kind Support from Bridge to Life

382. LESSONS LEARNED IN MY CAREER

Peter Stock
San Francisco, CA, United States
**Plenary: Antibody Mediated Injury (Hall 5BC - L5)**

- Current Status of Alloantibody Measurement & Management in Tx. - Dr. Peter W. Nickerson
- Polyreactive Alloantibodies - Dr. Emmanuel Zorn
- Impact of Complement Binding & Non-Binding Antibodies... - Prof. Christophe M. Legendre

**Coffee Break and Poster Viewing (Hall 5FG - L5)**

**MORNING SESSIONS**

**SUNDAY • AUGUST 21**
The Transplantation Society celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Travel Awards. These awards recognize the efforts of basic scientists who have advanced our understanding of transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

CONVENTION HALL A - LEVEL 1

See the names of this year’s awardees on page 39
Early Morning Symposia: KDIGO Kidney Transplant Guidelines

Chairs: Steven J. Chadban, Camperdown, Australia
       Bertram L. Kasiske, Minneapolis, MN, United States

400.1 PREDICTING INDIVIDUALIZED LIFETIME RISK OF END-STAGE RENAL DISEASE IN KIDNEY DONOR CANDIDATES

Bertram L. Kasiske
Minneapolis, MN, United States

400.2 STRATEGIES FOR OPTIMIZING EFFICIENCY IN LIVING KIDNEY DONOR EVALUATION AND FOLLOW-UP

Dorry Segev
Baltimore, MD, United States

400.3 EVALUATION AND SELECTION OF CANDIDATES FOR KIDNEY TRANSPLANTATION

Gregory Alan Knoll
Ottawa, ON, Canada

Early Morning Symposia: Women in Transplantation

Chairs: Nancy Ascher, San Francisco, CA, United States
        Lori J. West, Edmonton, AB, Canada

401.1 ARE WOMEN IN TRANSPLANT LEADERSHIP ROLES JUDGED MORE HARSHLY THAN THEIR MALE COLLEAGUES?

Nithya Krishnan
Coventry, United Kingdom

401.2 WHY SEX AND GENDER MATTER IN TRANSPLANTATION RESEARCH

Cara Tannenbaum
Montreal, QC, Canada
07:00 - 08:15
CONVENTION HALL A-LEVEL 1

Early Morning Symposia: HLA Antibody Assessment for Clinicians

Chairs: Myoung Hee Park, Seoul, Korea
        Rhonda Holdsworth, Melbourne, Australia

402.1 OVERVIEW OF ADVANCES IN HLA DIAGNOSTICS
Anat R. Tambur
Chicago, IL, United States

402.2 INTERPRETING HLA DIAGNOSTICS FOR THE CLINICIAN
Kathryn Tinckam
Toronto, ON, Canada

402.3 CLINICAL RELEVANCE OF HLA ANTIBODY
Stefan Schaub
Basel, Switzerland

07:00 - 08:15
CONVENTION HALL B-LEVEL 1

Early Morning Symposia: The Ethics of Choice in Donation and Transplantation

Chairs: Beatriz Dominguez-Gil, Madrid, Spain
        Dominique E. Martin, Geelong, Australia

403.1 HOW MUCH INFORMATION IS ENOUGH FOR CONSENT TO TRANSPLANTATION OF DECEASED DONOR ORGANS?
Antonia Cronin
London, United Kingdom

403.2 DECISION MAKING IN TRANSPLANTATION: WHO DECIDES? PATIENTS, CLINICIANS, POLICY MAKERS
Kirsten Howard
Sydney, Australia

403.3 WHAT THE PUBLIC NEEDS OR WANTS TO KNOW WHEN DECIDING WHETHER TO BECOME AN ORGAN DONOR
Alexander M. Capron
Los Angeles, CA, United States
07:00 - 08:15
CONVENTION HALL C-LEVEL 1

Early Morning Symposia:
Publishing in Transplantation

*Chairs:* Jonathan S. Bromberg, Baltimore, MD, United States
Edward K. Geissler, Regensburg, Germany

404.1 PANEL DISCUSSIONS

Jeremy R. Chapman
Westmead, Australia

404.2 Carla Baan
Rotterdam, The Netherlands

404.3 Stefan G. Tullius
Boston, MA, United States

404.4 Thierry P.S. Berney
Geneva, Switzerland

07:00 - 08:30
S-228-LEVEL 2

BY INVITATION ONLY - NOT A CME SESSION

Joint Meeting of the Thai, Japanese, and Korean Transplantation Societies: WHO Registry for Organ Coding & Traceability
08:30 - 10:00
HALL 5BC-LEVEL 5

Plenary: Antibody Mediated Injury

Chairs: Dirk Kuypers, Leuven, Belgium
        Vasant Sumethkul, Bangkok, Thailand

410.1 CURRENT STATUS OF ALLOANTIBODY MEASUREMENT AND MANAGEMENT IN TRANSPLANTATION

   Peter William Nickerson
   Winnipeg, MB, Canada

410.2 POLYREACTIVE ALLOANTIBODIES

   Emmanuel Zorn
   New York, NY, United States

410.3 IMPACT OF COMPLEMENT BINDING AND NON-BINDING ANTIBODIES ON REJECTION

   Christophe Michel Legendre
   Paris, France

10:00 - 10:30
COFFEE BREAK
HALL 5FG-LEVEL 5

10:30 - 12:30
HALL 5BC-LEVEL 5

Orals and Mini-Orals Session: Immunosuppression Adherence

Chairs: Steve J. Chadban, Camperdown, Australia
        Matthew Kwok Lung Tong, Hong Kong SAR, P.R. of China

420.1 THE IMPACT OF RITONAVIR-BOOSTED PROTEASE INHIBITORS AND NON-DEPLETING ANTIBODY INDUCTION ON OUTCOMES IN HIV-INFECTED KIDNEY TRANSPLANT RECIPIENTS

   Ron Shapiro
   New York, NY, United States
TRENDS IN IMMUNOSUPPRESSIVE MEDICATION USE AMONG HEMODIALYSIS PATIENTS WITH FAILED KIDNEY TRANSPLANTS IN EUROPE, AUSTRALIA, NEW ZEALAND AND NORTH AMERICA: RESULTS FROM THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY

Alan B. Leichtman
Ann Arbor, MI, United States

CONVERSION FROM TWICE-DAILY PROGRAF TO ONCE-DAILY ADVAGRAF IN MULTI-ETHNIC ASIAN ADULT RENAL TRANSPLANT RECIPIENTS WITH OR WITHOUT CONCOMITANT USE OF DILTIAZEM – IMPACT OF CYP3A5 GENETIC POLYMORPHISM ON TACROLIMUS PHARMACOKINETICS

Wai-Ping Yau
Singapore, Singapore

USE OF MOBILE INTERNET APPLICATION TO IMPROVE ADHERENCE TO IMMUNOSUPPRESSIVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS: PRELIMINARY RESULTS OF THE PRIMA (IMPROVING ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY BY MOBILE INTERNET APPLICATION) STUDY

Minji Cho
Seoul, Korea

CHARACTERIZATION OF GENETIC VARIATION INFLUENCING PHARMACOKINETICS OF ONCE-DAILY TACROLIMUS FORMULATION BY NEXT GENERATION SEQUENCING TECHNOLOGIES IN KOREAN

Minji Cho
Seoul, Korea

ADVERSE EVENTS OF MAINTENANCE IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION REPORTED IN RANDOMIZED CONTROLLED TRIALS: A SYSTEMATIC REVIEW

Martin Howell
Westmead, Australia
420.7 A HIGH INTRA-PATIENT VARIABILITY IN TACROLIMUS EXPOSURE IS ASSOCIATED WITH POOR LONG-TERM OUTCOME OF KIDNEY TRANSPLANTATION

Teun Van Gelder
Rotterdam, The Netherlands

420.8 DOES POST-TRANSPLANT ADHERENCE COME AT A COST?

Kunal Yadav
Minneapolis, MN, United States

420.9 LOW PREVALENCE OF POST POST-TRANSPLANT ANTI-HLA CLASS 2 ANTIBODIES IN LIVING DONOR RENAL TRANSPLANT RECIPIENTS TREATED WITH ATG INDUCTION THERAPY – A SINGLE CENTRE EXPERIENCE

Ninoslav Ivanovski
Skopje, The Former Yugoslav Republic of Macedonia

MINI-ORALS

420.10 SIMULTANEOUS LIMITED BLOOD SAMPLING MODELS FOR TACROLIMUS AND MYCOPHENOLIC ACID PROVIDE AN ACCURATE AREA UNDER THE CURVE PREDICTION FOR KIDNEY TRANSPLANT RECIPIENTS

Kouhei Nishikawa
Tsu, Mie, Japan

420.11 A COMPARATIVE STUDY BETWEEN LOW DOSE ANTI-THYMOCYTE GLOBULIN VERSUS BASILIXIMAB AS INDUCTION THERAPY FOR STANDARD IMMUNOLOGIC RISK KIDNEY TRANSPLANT PATIENTS

Paolo Miguel A. David
Quezon City, Philippines

420.12 DEPRESSION OF COMPLEMENT REGULATORY FACTORS IN RAT AND HUMAN RENAL GRAFTS IS ASSOCIATED WITH THE PROGRESS OF ACUTE T-CELL MEDIATED REJECTION

Kazuaki Yamanaka
Suita, Japan

420.13 EFFECT OF ABCB1 DIPLOTYPE ON TACROLIMUS DISPOSITION IN RENAL RECIPIENTS DEPENDS ON CYP3A5 AND CYP3A4 GENOTYPE

Thomas Vanhove
Leuven, Belgium
Orals and Mini-Orals Session: Complications

Chairs: Sindhu Chandran, San Francisco, CA, United States
William Lee, Hong Kong SAR, P.R. of China

421.1 OUTCOMES OF RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS POST KIDNEY TRANSPLANTATION
Anna Francis
Nundah, Australia

421.2 AGE-INDEPENDENT INFLUENCE OF PRE-TRANSPLANT CORONARY ARTERY DISEASE AND DIABETES MELLITUS ON PATIENT SURVIVAL AFTER KIDNEY TRANSPLANTATION
Fabian Halleck
Berlin, Germany

421.3 FRAILTY IN KIDNEY TRANSPLANT RECIPIENTS
Mara A. McAdams-DeMarco
Baltimore, MD, United States

421.4 BK VIRUS INFECTION IS A HIGH RISK FACTOR FOR UROTHELIAL CARCINOMA IN RENAL TRANSPLANT RECIPIENTS
Masashi Takenaka
Aichi, Japan

421.5 INTRAVOXEL INCOHERENT MOTION IMAGING IS AN EFFECTIVE WAY TO MONITOR CHRONIC ALLOGRAFT DYSFUNCTION IN RAT MODELS
Qiang Zhang
Beijing, People's Republic of China

421.6 THE EFFICACY OF SONOELASTOGRAPHY METHOD FOR THE DIAGNOSIS OF FIBROSIS IN RENAL TRANSPLANT PATIENTS
Funda Ulu Ozturk
Ankara, Turkey

421.7 PREVALENCE AND CHARACTERISTICS OF DUODENAL VILLOUS ATROPHY IN RENAL TRANSPLANT PATIENTS PRESENTING WITH PERSISTENT DIARRHEA
Farina Hanif
Karachi, Pakistan
421.8 DIFFERENT PATTERNS OF RISK FACTORS FOR LATE GRAFT LOSS ACCORDING RECIPIENT AGE AFTER RENAL TRANSPLANTATION IN THE REAL MEDICINE. AN OBSERVATIONAL, MULTICENTER AND PROSPECTIVE STUDY AT TEN YEARS
José María Morales
Madrid, Spain

421.9 AGE ADAPTED IMMUNOSUPPRESSION FOR ELDERLY KIDNEY ALLOGRAFT RECIPIENTS: BALANCING RISKS FOR CANCER VERSUS REJECTION
Francesca Jackson-Spence
Birmingham, United Kingdom

MINI-ORALS

421.10 CANCER-RELATED OUTCOMES IN KIDNEY ALLOGRAFT RECIPIENTS IN ENGLAND VERSUS NEW YORK STATE: A COMPARATIVE POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013
Francesca Jackson-Spence
Birmingham, United Kingdom

421.11 EFFECT OF URETERAL STENTS ON BK VIRUS ACTIVATION IN KIDNEY TRANSPLANT RECIPIENTS
Rachid Akiki
Watertown, MA, United States

421.12 CLINICAL PROFILE AND MESSENGER RNA TRANSCRIPTOME SEQUENCING OF KIDNEY ALLOGRAFT RECIPIENTS WITH PLASMA CELL RICH ACUTE REJECTION (PCAR)
Thangamani Muthukumar
New York, NY, United States

421.13 TREATMENTS AGAINST RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM COULD INFLUENCE FGF23 AND KLOTHO LEVELS IN RENAL TRANSPLANT RECIPIENTS
Turan Colak
Ankara, Turkey
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>422.1</td>
<td>DEFINING THE TIPPING POINT IN SURGICAL PERFORMANCE IN LAPAROSCOPIC DONOR NEPHRECTOMY DURING ABDOMINAL TRANSPLANT SURGERY FELLOWSHIP: A LEARNING CURVE ANALYSIS</td>
<td>Oscar K. Serrano</td>
<td>Minneapolis, MN, United States</td>
</tr>
<tr>
<td>422.2</td>
<td>A PREDICTION MODEL FOR LONG-TERM RISK OF ESRD IN LIVING KIDNEY DONORS BASED ON INDIVIDUAL CHARACTERISTICS</td>
<td>Allan Massie</td>
<td>Baltimore, MD, United States</td>
</tr>
<tr>
<td>422.3</td>
<td>WHERE DO LIVING DONORS COME FROM? A COMPARISON OF POTENTIAL LIVING LIVER AND KIDNEY DONORS AT A HIGH-VOLUME U.S. CENTER</td>
<td>Hillary J. Braun</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td>422.4</td>
<td>PSYCHOSOCIAL EVALUATION OF LIVING ORGAN DONORS (PELOD): AN INTERNATIONAL PROFESSIONAL SURVEY OF CURRENT PRACTICES</td>
<td>Lucinda Wynter</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>422.5</td>
<td>LIVING KIDNEY DONOR PRIORITIES FOR OUTCOMES: A NOMINAL GROUP TECHNIQUE STUDY</td>
<td>Camilla S. Hanson</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>422.6</td>
<td>PERI-OPERATIVE EVENTS AND COMPLICATIONS IN MINIMALLY-INVASIVE LIVE DONOR NEPHRECTOMY: WHAT SHOULD WE TELL POTENTIAL DONORS? A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
<td>Kirsten Kortram</td>
<td>Rotterdam, The Netherlands</td>
</tr>
</tbody>
</table>
422.7 EVOLUTION OF LIVING DONOR NEPHRECTOMY AT A SINGLE CENTER: LONG-TERM OUTCOMES WITH 4 DIFFERENT TECHNIQUES IN > 4,000 DONORS FOR OVER HALF-CENTURY

Raja Kandaswamy
Minneapolis, MN, United States

422.8 PSYCHOSOCIAL LONG IMPACT OF LIVING KIDNEY DONATION: EVALUATION OF DONORS SATISFACTION

Ana T. Menjivar
Barcelona, Spain

422.9 A 5-YEAR ANALYSIS AFTER LIVE DONOR NEPHRECTOMY WITHIN THE ERA OF EXTENDED CRITERIA DONORS – IDENTIFYING FACTORS FOR DECLINE OF KIDNEY FUNCTION

Khe Tran
Rotterdam, The Netherlands

MINI-ORALS

422.10 IMPACT OF SINGLE CENTER KIDNEY PAIRED DONATION TRANSPLANTATION TO INCREASE DONOR POOL IN INDIA

Vivek Kute
Ahmedabad, India

422.11 WORLD RECORD: 77 KIDNEY PAIRED DONATION TRANSPLANTATION IN YEAR 2015 AT ONE TRANSPLANT CENTER IN INDIA: A MODEL FOR THE DEVELOPING WORLD TO PREVENT COMMERCIAL TRANSPLANTATION

Vivek Kute
Ahmedabad, India

422.12 SIMULATION OF INTERNATIONAL KIDNEY EXCHANGE BETWEEN SAUDI ARABIA AND THE UNITED STATES USING ACTUAL INCOMPATIBLE PAIR DATA

Abdulnaser M. Alabadi
Dammam, Saudi Arabia

422.13 INCREASING DECEASED DONOR TRANSPLANT ACTIVITY IN INDIA: THE RAJASTHAN STORY

Christopher Taylor Barry
Jaipur, India
Orals and Mini-Orals Session: Access and Allocation

Chairs: Roberta J. Al Housani-Blakely, Abu Dhabi, United Arab Emirates
Bertram L. Kasiske, Minneapolis, MN, United States

423.1 EFFICIENT PRA MONITORING STRATEGY FOR COST REDUCTION AND IMPROVED WAITLIST MANAGEMENT
Hirohito Ichii
Orange, CA, United States

423.2 FINANCIAL IMPLICATIONS OF PERITONEAL DIALYSIS CATHETER REMOVAL AT THE TIME OF KIDNEY TRANSPLANTATION
Meredith Barrett
Ann Arbor, MI, United States

423.3 LOW ACCESS OF HIGHLY-SENSITIZED PATIENTS TO KIDNEY TRANSPLANTATION ASSOCIATED WITH VIRTUAL CROSSMATCH USING STANDARD MFI THRESHOLD: DATA FROM NORTHERN PORTUGAL
Jorge Malheiro
Porto, Portugal

423.4 THE NEW KIDNEY ALLOCATION SYSTEM: EARLY IMPACT AT ONE OF THE MOST ACTIVE TRANSPLANT CENTERS IN THE US
Franco H. Cabeza
Miami, FL, United States

423.5 A SIMPLIFIED METHOD OF CALCULATING cPRA FOR KIDNEY ALLOCATION APPLICATION IN HONG KONG
Janette Kwok
Hong Kong SAR, P.R. of China

423.6 COMPARISON OF HONG KONG cPRA RESULTS WITH RESULTS OBTAINED FROM OPTN AND EUROTRANSPLANT PRA ONLINE CALCULATORS
Janette Kwok
Hong Kong SAR, P.R. of China
423.7 ACCESS TO KIDNEY TRANSPLANTATION AMONG HIV-INFECTED WAITLIST CANDIDATES

Jayme E. Locke
Birmingham, AL, United States

423.8 PRIORITISING RENAL TRANSPLANTATION BASED ON CLINICAL NEED: THE ROLE OF AN "URGENT" KIDNEY WAITING LIST

Emma L. Aitken
Glasgow, United Kingdom

423.9 EFFICIENCY SAVINGS THROUGH REDUCTION OF RED BLOOD CELL CROSS-MATCH AND TRANSFUSION IN RENAL TRANSPLANTATION

Sarah-Jayne Edmondson
London, United Kingdom

MINI-ORALS

423.10 KIDNEY TRANSPLANTATION IN THE ELDERLY: EVALUATION OF EFFECTS OF DONOR AGE ON SHORT- AND LONG-TERM CLINICAL OUTCOME

Martin Ronaghi
Solna, Sweden

423.11 AVOIDING UNNECESSARY HEALTHCARE UTILIZATION: THE ADVANTAGES OF PREEMPTIVE KIDNEY TRANSPLANTATION

Patrick G. Dean
Rochester, MN, United States

423.12 THE END OF THE EXPANDED CRITERIA DONOR ERA: LESSONS LEARNED

Giuseppe Orlando
Winston Salem, NC, United States

423.13 FINANCIAL COST OF COLD ISCHEMIA TIME IN KIDNEY TRANSPLANTATION

Erik Finger
Minneapolis, MN, United States
**Orals and Mini-Orals Session: Infections**

*Chairs: Sharon Chen, Westmead, Australia  
James Fung, Hong Kong SAR, P.R. of China*

**424.1 KINETICS OF CMV-SPECIFIC T-CELLS FROM PRE-TO-POSTTRANSPLANTATION PREDICT OUTCOMES IN CMV-SERONEGATIVE KIDNEY TRANSPLANT RECIPIENTS**

*Thomas Schachtner  
Berlin, Germany*

**424.2 TREATMENT OF CARBAPENEM RESISTANT ENTEROBACTERIACEAE WITH REDUCED SUSCEPTIBILITY TO POLYMYXIN AMONG KIDNEY TRANSPLANT RECIPIENTS EXPERIENCE DURING AN OUTBREAK PERIOD**

*Maristela Pinheiro Freire  
São Paulo, Brazil*

**424.3 VZV-SPECIFIC T-CELL MEMORY RESPONSES AFTER REACTIVATION IN TRANSPLANT RECIPIENTS AND AFTER VACCINATION IN TRANSPLANT CANDIDATES**

*Marcia M.L. Kho  
Rotterdam, The Netherlands*

**424.4 STILL AN EQUAL B-CELL RESPONSE TO A VZV-BOOSTER IN BOTH RENAL TRANSPLANT RECIPIENTS AND HEALTHY INDIVIDUALS AT ONE YEAR POST VACCINATION**

*Marcia M.L. Kho  
Rotterdam, The Netherlands*

**424.5 DIAGNOSTIC POTENTIAL OF INTERFERON GAMMA RELEASE ASSAY TO DETECT LATENT TUBERCULOSIS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS IN ENDEMIC AREA**

*Hassan A. Aleid  
Riyadh, Saudi Arabia*

**424.6 EARLY BLOODSTREAM INFECTIONS AMONG SOLID ORGAN TRANSPLANT RECIPIENTS**

*Hande Arslan  
Ankara, Turkey*
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>424.7</td>
<td>EFFICACY OF INH PROPHYLAXIS IN RENAL TRANSPLANT RECIPIENTS: A FOLLOW UP OF 5 YEARS</td>
<td>Anwar Naqvi</td>
<td>Karachi, Pakistan</td>
</tr>
<tr>
<td>424.8</td>
<td>EPIDEMIOLOGY OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN INTESTINAL TRANSPLANT (IT) RECIPIENTS</td>
<td>Luis F. Guzman Vinasco</td>
<td>Omaha, NE, United States</td>
</tr>
<tr>
<td>424.9</td>
<td>INCIDENCE AND OUTCOME OF PARASITIC INFECTION AFTER KIDNEY TRANSPLANTATION IN THAILAND</td>
<td>Sirion Watcharananan</td>
<td>Bangkok, Thailand</td>
</tr>
<tr>
<td></td>
<td><strong>MINI-ORALS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>424.10</td>
<td>PATHOGENESIS OF POLYOMAVIRUS-ASSOCIATED NEPHROPATHY: INSIGHTS FROM A MOUSE MODEL</td>
<td>Gang Huang</td>
<td>Guangzhou, People's Republic of China</td>
</tr>
<tr>
<td>424.11</td>
<td>PNEUMOCYSTIS PNEUMONIA CLUSTER OUTBREAK AT A SCOTTISH RENAL TRANSPLANT CENTRE</td>
<td>Andrew WJ McClarey</td>
<td>Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>424.12</td>
<td>NEUTROPHIL FUNCTION ASSAY IN RENAL TRANSPLANT RECIPIENTS WITH BACTERIAL AND FUNGAL INFECTIONS</td>
<td>Sabiha Anis</td>
<td>Karachi, Pakistan</td>
</tr>
<tr>
<td>424.13</td>
<td>FACTORS ASSOCIATED WITH CLOSTRIDIUM DIFFICILE INFECTION AFTER HEART AND HEART-LUNG TRANSPLANTATION</td>
<td>Jackrapong Bruminhent</td>
<td>Bangkok, Thailand</td>
</tr>
</tbody>
</table>
Orals and Mini-Orals Session: Recipient Variables

Chairs: Nancy Ascher, San Francisco, CA, United States
       Julie Pavlovic, Heidelberg, Australia

425.9 PRE TRANSPLANT RECIPIENT FRAILTY COMBINED WITH DISEASE SEVERITY PREDICTS POST LIVER TRANSPLANT (OLT) MORTALITY

John J. Fung
Cleveland, OH, United States

425.1 LIVER TRANSPLANTATION IN THE ELDERLY: AN INCREASING AND APPROPRIATE INDICATION

Gabriel E. Gondolesi
Buenos Aires, Argentina

425.2 LONG TERM OUTCOME RESULTS USING PREDICTIVE SCORES IN LIVER RE-TRANSPLANTATION

Gabriel E. Gondolesi
Buenos Aires, Argentina

425.3 PATIENTS ON THE LIVER TRANSPLANT WAITING LIST AT RISK FOR DEVELOPING NEW ONSET PORTAL VEIN THROMBOSIS

Martin Montenovo
Seattle, WA, United States

425.4 DETERMINATION OF ALCOHOL ABSTINENCE IN TRANSPLANT CANDIDATES BY ETHYL GLUCURONIDE HAIR ANALYSIS

Brigitta K.M. Globke
Berlin, Germany

425.5 INFLUENCING FACTORS OF FATIGUE IN LIVER TRANSPLANT RECIPIENTS

Hongxia Liu
Beijing, People’s Republic of China

425.6 PREDICTORS OF MORTALITY IN LIVING DONOR LIVER TRANSPLANTATION

Shaimaa Elkholy
Cairo, Egypt
425.7 LIVER TRANSPLANTATION IN ELDERLY RECIPIENTS: WHEN IS OLD TOO OLD?
Nicholas Gilbo
Leuven, Belgium

425.8 EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT FOR CRITICALLY ILL LIVER TRANSPLANTATION RECIPIENT
KyeongSik Kim
Seoul, Korea

MINI-ORALS

425.10 A NATIONWIDE ANALYSIS OF REOPERATION AFTER LIVER TRANSPLANT
Giselle Guerra
Miami, FL, United States

425.11 EFFECT OF GRAFT WEIGHT TO RECIPIENT BODY WEIGHT RATIO ON HEMODYNAMIC AND METABOLIC PARAMETERS IN PEDIATRIC LIVER TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
Zeynep Ersoy
Ankara, Turkey

425.12 THE ROLE OF CURATIVE INTENT SURGICAL RESECTION FOR THE RECURRENT HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
Sukyung Kwon
Seoul, Korea

425.13 INTRAOPERATIVE BLOOD LOSS IS AN INDEPENDENT PROMOTER OF TUMOR RECURRENCE IN LIVER TRANSPLANT PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Arno Kornberg
Munich, Germany
Orals and Mini-Orals Session: Pregnancy/Metabolic and Surgical Complications

Chairs: Paolo Ferrari, Sydney, Australia  
Ming Kwong Yiu, Hong Kong SAR, P.R. of China

426.1 BIOINTACT FGF-23 NORMALIZES FASTER AND CORRELATES BETTER WITH INORGANIC PHOSPHORUS AS COMPARED TO INTACT PTH IN LIVING DONOR RENAL ALLOGRAFT RECIPIENTS

Narayan Prasad  
Lucknow, India

426.2 ARE THERE RISKS TO FATHERING PREGNANCIES AFTER SOLID ORGAN TRANSPLANTATION?

Serban Constantinescu  
Philadelphia, PA, United States

426.3 IMPACT OF INDUCTION THERAPY ON INCIDENT CARDIOVASCULAR EVENTS IN KIDNEY TRANSPLANT RECIPIENTS

Shaifali Sandal  
Montreal, QC, Canada

426.4 PARICALCITOL VERSUS PLACEBO FOR REDUCTION OF PROTEINURIA IN KIDNEY TRANSPLANT RECIPIENTS: A DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL

Miha Arnol  
Ljubljana, Slovenia

426.5 EFFECT OF THE RANKL INHIBITOR DENOSUMAB ON EARLY LOSS OF BONE MINERAL DENSITY AND SKELETAL MICROSTRUCTURE IN FIRST-YEAR KIDNEY TRANSPLANT RECIPIENTS

Rudolf P. Wuthrich  
Zurich, Switzerland

426.6 ARTERIOVENOUS FISTULA (AVF) MATURATION AMONG PREVALENT HEMODIALYSIS PATIENTS WITH FAILED KIDNEY TRANSPLANTS: RESULTS FROM THE UNITED STATES RENAL DATA SYSTEM (USRDS)

Kenneth J. Woodside  
Ann Arbor, MI, United States
426.7  A NATIONWIDE ANALYSIS OF REOPERATION AFTER KIDNEY TRANSPLANT  
Linda J. Chen  
Miami, FL, United States

426.8  EFFICACY OF USING FLOSEAL TO PREVENT POST RENAL TRANSPLANTATION LYMPHOCELE FORMATION  
Yiu Chung Lam  
Hong Kong SAR, P.R. of China

426.9  EXTERNAL URETERAL STENTING IN KIDNEY TRANSPLANTATION; DOES THE TYPE OF STENT MATTER?  
Robert Minnee  
Rotterdam, The Netherlands

MINI-ORALS

426.10  STANDARDIZED INTRAOPERATIVE APPLICATION OF HAEMOCER™ MAY REDUCE THE INCIDENCE OF LYMPHOCELE AFTER KIDNEY TRANSPLANTATION  
Christopher K. Burghuber  
Vienna, Austria

426.11  PREGNANCY AFTER RENAL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE  
Toyofumi Abe  
Suita, Japan

426.12  A MULTIDISCIPLINARY APPROACH TO REVIEWING PATIENT CARE IN ABDOMINAL TRANSPLANTATION  
Ron Shapiro  
New York, NY, United States

426.13  THE IMPACT OF RENAL FUNCTION ON POST-OPERATIVE RESPIRATORY COMPLICATIONS IN BARIATRIC SURGERY  
Hirohito Ichii  
Orange, CA, United States
**10:30 - 12:30**  
**CONVENTION HALL A-LEVEL 1**  
Orals and Mini-Orals Session  
T-Regs and B-Regs

*Chairs: Johannes Wedel, Boston, MA, United States  
Petra Reinke, Berlin, Germany*

427.1 IMBALANCE OF T HELPER 17 CELLS AND T REGULATORY CELLS IS ASSOCIATED WITH CHRONIC ACTIVE ANTIBODY MEDIATED REJECTION IN RENAL ALLOGRAFT RECIPIENTS

*Brijesh Yadav*  
Lucknow, India

427.2 DEPTOR MODULATES ALLOIMMUNITY BY INCREASING REGULATORY T CELL FUNCTION AND STABILIZING FOXP3 EXPRESSION

*Johannes Wedel*  
Boston, MA, United States

427.3 ROLE OF BONE MARROW MATURITY, INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) AND FORKHEAD BOX PROTEIN N1 (FOXN1) IN THYMIC INVOLUTION AND REJUVENATION IN A PRECLINICAL LARGE ANIMAL MODEL

*Masayuki Tasaki*  
Niigata, Japan

427.4 RAPAMYCIN PROMOTES ALLOGRAFT SURVIVAL IN ELDERLY TRANSPLANT RECIPIENTS LINKED TO AN ACCUMULATION OF IL-10+ CD4+ T CELLS AND CD4+CD25+FOXP3+ T-REGS

*Stefan G. Tullius*  
Boston, MA, United States

427.5 NAD+ ALTERS CD4+ T CELL DIFFERENTIATION AND PROMOTES ALLOGRAFT SURVIVAL INDEPENDENTLY OF CD4+CD25+FOXP3+ REGULATORY T CELLS

*Stefan G. Tullius*  
Boston, MA, United States

427.6 BELATACEPT FAILS TO INHIBIT DONOR-REACTIVE TFH-B CELL INTERACTION, BUT FAVORS A REGULATORY TRANSITIONAL B CELL PROFILE OVER TACROLIMUS

*Gretchen N. de Graav*  
Rotterdam, The Netherlands
427.7 METABOLITES ASSOCIATED WITH BARIATRIC SURGERY REVERSE ACCELERATED REJECTION AND AUGMENTED ALLOIMMUNITY IN OBESE ALLOGRAFT RECIPIENTS
Markus Quante
Boston, MA, United States

427.8 IS TH17 ASSOCIATED WITH CHRONIC CALCINEURIN INHIBITOR TOXICITY IN RENAL ALLOGRAFT RECIPIENTS?
Narayan Prasad
Lucknow, India

427.9 LYMPHOTOXIN ON HUMAN AND MOUSE TREG PROMOTES MIGRATION ACROSS LYMPHATIC ENDOTHELIUM
Jonathan S. Bromberg
Baltimore, MD, United States

MINI-ORALS

427.10 T-BET REGULATES nTREG HOMING INTO DRAINING LYMPH NODES TO SUPPRESS ALLOIMMUNE RESPONSES
Jonathan S. Bromberg
Baltimore, MD, United States

427.11 MONOCYTE-DERIVED DENDRITIC CELLS PROMOTE TH POLARIZATION, WHEREAS CONVENTIONAL DENDRITIC CELLS PROMOTE TH PROLIFERATION
Kevin Chow
Parkville, Australia

427.12 URINARY LEVELS OF CHEMOKINES AND GROWTH FACTORS IN RENAL TRANSPLANT PATIENTS
Ayisha Abid
Karachi, Pakistan

427.13 POSITIVE ASSOCIATION OF T CELL HYPORESPONSIVENESS AND AGE OF KIDNEY TRANSPLANT IN PATIENTS ATTENDING INKOSI ALBERT LUTHULI CENTRAL HOSPITAL (DURBAN, SOUTH AFRICA)
Alain G. Assounga
Durban, South Africa
10:30 - 12:30
CONVENTION HALL B-LEVEL 1

Orals and Mini-Orals Session: Immunology of IRI

**Chairs:** Xian C. Li, Houston, TX, United States  
Ali Zarrinpar, Los Angeles, CA, United States

**428.1 DEVELOPMENT OF NOVEL FERROPTOSIS INHIBITORS FOR THE TREATMENT OF ISCHEMIA/REPERFUSION INJURIES**

*Betina Proneth*
Neuherberg, Germany

**428.2 PROTEOME ANALYSIS OF RENOPROTECTION MEDIATED BY A NOVEL CYCLIC HELIX B PEPTIDE IN KIDNEY ISCHEMIA REPERFUSION INJURY**

*Cheng Yang*
Shanghai, People's Republic of China

**428.3 CYCLIC HELIX B PEPTIDE INHIBITS ISCHEMIA REPERFUSION-INDUCED RENAL FIBROSIS VIA THE PI3K/AKT/FOXO3A PATHWAY**

*Cheng Yang*
Shanghai, People's Republic of China

**428.4 OUTCOMES AFTER DCD HEART NORMOTHERMIC MACHINE PERFUSION USING BANKED BLOOD IN A PORCINE MODEL**

*Hong Chee Chew*
Kingsgrove, Australia

**428.5 TREATMENT WITH TETRAHYDROBIOPTERIN PROTECTS FROM TRANSPLANT VASCULOPATHY VIA PREVENTION OF eNOS UNCOUPLING**

*Rupert Oberhuber*
Innsbruck, Austria

**428.6 ATG5/ATG7-INDEPENDENT MACROAUTOPHagy MEDIATES HEPATIC SINUSOIDAL ENDOTHELIAL CELLS’ RESPONSE TO ISCHEMIA-REPERFUSION INJURY**

*Xiaobing Liu*
Hong Kong SAR, P.R. of China

**428.7 DONOR LIVER TRANSPLANT REJUVENATION: FROM BENCH-TO-BEDSIDE**

*Ali Zarrinpar*
Los Angeles, CA, United States
428.8 DENDRITIC CELL PHENOTYPE AND FUNCTION MODIFICATION WITH TARGETED POROUS SILICON NANOPARTICLES

Sebastian O. Stead
Adelaide, Australia

428.9 FOLLISTATIN MODULATES ISCHEMIA-REPERFUSION-INDUCED RENAL FIBROSIS IN MICE

Peter Cowan
Melbourne, Australia

MINI-ORALS

428.10 LIVER SPECIFIC ACTIVATING TRANSCRIPTION FACTOR 5 (ATF5) REGULATES LIVER ISCHEMIA/REPERFUSION INJURY

John J. Fung
Cleveland, OH, United States

428.11 LOW EXPRESSION IN PREIMPLANTATION BIOPSIES OF FABP3, A GENE THAT CODES FOR FATTY ACID BINDING PROTEIN, IS A MARKER FOR DELAYED KIDNEY GRAFT FUNCTION

Maria Gerbase-DeLima
Sao Paulo, Brazil

428.12 USING INTRAVOXEL INCOHERENT MOTION MR IMAGING AND BLOOD OXYGEN LEVEL-DEPENDENT MR IMAGING TO EVALUATE RAT ACUTE ALLOGRAFT REJECTION MODEL

Song Zeng
Beijing, People’s Republic of China

428.13 IMMUNE-MODIFYING NANOPARTICLE THERAPY REDUCES KIDNEY ISCHEMIA REPERFUSION INJURY

Huiling Wu
Sydney, Australia
**10:30 - 12:30**
**CONVENTION HALL C-LEVEL 1**

**Orals and Mini-Orals Session: Preventing Immune and Inflammatory Injury**

*Chairs: Takaaki Kobayashi, Nagoya, Japan  
Leo Buhler, Geneva, Switzerland*

---

**429.1** KNOCK-IN OF ANTI-CD2 AND HUMAN THROMBOMODULIN TRANSGENES INTO PIG GGTA1 USING CRISPR/CAS9

*Peter Cowan*  
Melbourne, Australia

---

**429.2** CD39 PLAYS AN IMPORTANT ROLE IN THE SUPPRESSIVE CAPACITY OF XENOANTIGEN STIMULATED AND EXPANDED NON-HUMAN PRIMATE REGULATORY T CELLS

*Dandan Huang*  
Sydney, Australia

---

**429.3** LONG-TERM ISLET XENOGRAFT SURVIVAL REQUIRES EFFECTIVE EARLY CONTROL OF XENOGENEIC IL-17 RESPONSE BUT LATE CONTROL OF XENOGENEIC IFN-γ RESPONSE

*Xunrong Luo*  
Chicago, IL, United States

---

**429.4** HUMAN REGULATORY MACROPHAGES ARE MORE POTENT IN SUPPRESSION OF THE XENO- THAN THE ALLO-RESPONSE

*Fei Guo*  
Changsha, People’s Republic of China

---

**429.5** SCR-4 IS REQUIRED FOR CD55-INDUCED SUPPRESSION ON MACROPHAGE-MEDIATED CYTOTOXICITY

*Rieko Sakai*  
Suita, Japan

---

**429.6** PRETREATMENT OF TRANSGENIC PORCINE ENDOTHELUM EXPRESSING HUMAN ENDOTHELIAL PROTEIN C RECEPTOR WITH ACTIVATED PROTEIN C ATTENUATES ENDOTHELIAL DAMAGE AND THROMBOSIS DURING HUMAN BLOOD PERFUSION

*Christopher T. Laird*  
Baltimore, MD, United States
429.7 REDUCING THE INFLAMMATORY RESPONSE BY EXPRESSING HUMAN THROMBOMODULIN IN PIGS

Hidetaka Hara
Pittsburgh, PA, United States

429.8 GROWTH HORMONE RECEPTOR KNOCKOUT ON PORCINE ENDOTHELIAL CELLS: EFFECT ON COMPLEMENT AND COAGULATION

Riccardo Sfriso
Bern, Switzerland

429.9 SURFACE MODIFICATION OF PORCINE AORTIC ENDOTHELIAL CELLS WITH CORLINE HEPARIN CONJUGATE (CHC) PROTECTS AGAINST XENOGENEIC THROMBOSIS AND INFLAMMATION

Anjan K. Bongoni
Fitzroy, Melbourne, Australia

MINI-ORALS

429.10 INHIBITION OF XENOGENEIC PLATELET ACTIVATION AND AGGREGATION BY SURFACE CONJUGATION OF APYRASE TO PORCINE AORTIC ENDOTHELIAL CELLS

Anjan K. Bongoni
Fitzroy, Melbourne, Australia

429.11 FOXP3+ REGULATORY T CELLS ARE ESSENTIAL FOR THE INDUCTION AND MAINTENANCE OF TOLERANCE TO NEONATAL PORCINE ISLET CELL CLUSTER XENOGRAFTS INDUCED BY CO-STIMULATORY BLOCKADE

Min Hu
Westmead, Australia

429.12 COMPARISON OF POST TRANSPLANT INFLAMMATORY RESPONSE FROM 6-GENE VS. 3-GENE DONOR PIGS IN HETEROTOPIC CARDIAC XENOTRANSPLANTATION

Muhammad M. Mohiuddin
Bethesda, MD, United States

429.13 HUMAN CD200 SUPPRESSES THE M0 MACROPHAGE-MEDIATED CYTOTOXICITY IN XENOTRANSPLANTATION

Akira Maeda
Suita, Japan
12:30 - 13:30
LUNCH BREAK

12:30 - 13:30
HALL 5E3-LEVEL 5
NOT A CME SESSION

Industry Symposium:
Modern Approaches of Immunosuppressive Therapies for Renal Transplant Patients

Organized by
NOVARTIS PHARMACEUTICALS

Please refer to page 343 for details.

13:30 - 15:00
HALL 5BC-LEVEL 5

State-of-the-Art Session:
Live Kidney Donation – Donor Selection and Outcomes

Chairs: Dorry Segev, Baltimore, MD, United States
Andrew L. Singer, Phoenix, AZ, United States

440.1 RISK OF END-STAGE RENAL DISEASE FOLLOWING LIVE KIDNEY DONATION
Adibul Hasan Rizvi
Karachi, Pakistan

440.2 ASSESSMENT OF LIVE KIDNEY DONORS: ARE CURRENT PROTOCOLS ADEQUATE TO ENSURE DONOR SAFETY?
Duck-Jong Han
Seoul, Korea

440.3 DONATION FROM OLD LIVING DONORS: HOW SAFE IS IT?
Hallvard Holdaas
Oslo, Norway
13:30 - 15:00  
HALL 5D-LEVEL 5

State-of-the-Art Session:  
What’s New and Hot in Intestinal Transplantation?

Chairs:  Debra L. Sudan, Durham, NC, United States  
         Douglas G. Farmer, Los Angeles, CA, United States

441.1 ANTI-HLA ANTIBODIES AND OUTCOME WITH INTESTINAL TRANSPLANTATION  

George V. Mazariegos  
Pittsburgh, PA, United States

441.2 WHEN GASTRIC BYPASS GOES BAD  

Douglas G. Farmer  
Los Angeles, CA, United States

441.3 BEST ABSTRACTS FROM THE 2015 INTERNATIONAL SMALL BOWEL TRANSPLANT SYMPOSIUM  

Gabriel E. Gondolesi  
Buenos Aires, Argentina

13:30 - 15:00  
HALL 5E1-LEVEL 5

State-of-the-Art Session:  
Importance of Non-HLA Antibodies in Chronic Rejection

Chairs:  Medhat Z. Askar, Dallas, TX, United States  
         Rhonda Holdsworth, Melbourne, Australia

442.1 NON-HLA TARGET ANTIGENS IN KIDNEY TRANSPLANTATION  

Rudolf Oehler  
Vienna, Austria

442.2 ANTIBODIES AGAINST G-PROTEIN COUPLED RECEPTORS  

Duska Dragun  
Berlin, Germany

442.3 ANTI-VIMENTIN ANTIBODIES AFTER KIDNEY TRANSPLANTATION  

Caner Süsal  
Heidelberg, Germany
13:30 - 15:00  
**HALL 5E2-LEVEL 5**

**State-of-the-Art Session: Repurposing Drugs for Transplant Indications**

*Chairs: Kazunari Tanabe, Tokyo, Japan  
Josep Grinyo, Barcelona, Spain*

**443.1 CD28-TARGETING ANTAGONIST OF T CELL ACTIVATION**

*Agnes Azimzadeh*  
Baltimore, MD, United States

**443.2 TOCILIZUMAB**

*Robert A. Montgomery*  
New York, NY, United States

**443.3 INFLIZUMAB**

*Petra Reinke*  
Berlin, Germany

**443.4 EFALIZUMAB**

*Andrew Posselt*  
San Francisco, CA, United States

13:30 - 15:00  
**S-221-LEVEL 2**

**State-of-the-Art Session: Gender Effect on Transplantation Access and Outcomes**

*Chairs: Germaine Wong, Westmead, Australia  
Benita Padilla, San Juan City, Philippines*

**444.1 GENDER RELATED VARIABLES AFFECTING DECEASED DONOR LISTING AND ALLOCATION ALGORITHMS**

*Sommer E. Gentry*  
Baltimore, MD, United States

**444.2 GEOGRAPHICAL DISPARITIES IN GENDER ACCESS TO TRANSPLANTATION ESP LIVING DONATION - DONORS VS RECIPIENT; LISTING OF GENDERS ACROSS DIFFERENT GLOBAL REGIONS**

*Mona Alrukhaimi*  
Dubai, United Arab Emirates
444.3 BIOLOGIC IMPACT OF GENDER/SEX ON OUTCOMES OF TRANSPLANTATION AND LIVING DONATION
Kathryn Tinckam
Toronto, ON, Canada

13:30 - 15:00
THEATRE 1-LEVEL 1
State-of-the-Art Session: Tolerance in Liver Transplantation

Chairs: Nancy Kwan Man, Hong Kong SAR, P.R. of China
John J. Fung, Cleveland, OH, United States

445.1 WITHDRAWAL VERSUS INDUCTION IN ADULT AND PEDIATRIC LIVER TRANSPLANT RECIPIENTS: WHERE DO WE STAND?
Sandy Feng
San Francisco, CA, United States

445.2 TOLERANCE: CAN WE PREDICT OR INDUCE IT? ARE ANY APPROACHED READY FOR PRIME TIME?
Alberto Sanchez-Fueyo
London, United Kingdom

445.3 A CLINICAL TRIAL OF CELL THERAPY-BASED TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION: LONG-TERM FOLLOW-UP RESULTS
Kenichiro Yamashita
Sapporo, Japan

445.4 DONOR-SPECIFIC ANTI-HLA ANTIBODY MEDIATED REJECTION IN LIVER TRANSPLANT RECIPIENTS
Tomasz Dziodzio
Berlin, Germany
13:30 - 15:00
THEATRE 2-LEVEL 1

State-of-the-Art Session: Cell Transplantation

Chairs: Shane T. Grey, Darlinghurst, Australia
        Roy Calne, Cambridge, United Kingdom

446.1 HEPATOCYTE, A CELL SOURCE FOR LIVER
       REPOPULATION AND ORGANOGENESIS
       Anil Dhawan
       London, United Kingdom

446.2 CLINICAL TRIALS FOR STEM-BASED
       REGENERATIVE MEDICINE
       Martin F. Pera
       Parkville, Australia

446.3 THE ROLE OF INFLAMMATION IN CELL
       TRANSPLANTATION
       Maria Koulmanda
       Boston, MA, United States

13:30 - 15:00
CONVENTION HALL A-LEVEL 1

State-of-the-Art Session: Emerging Technologies in
Bioengineering, Regeneration and Repair

Chairs: Lori J. West, Edmonton, AB, Canada
        Curie Ahn, Seoul, Korea

447.1 REGENERATIVE MEDICINE TECHNOLOGIES
       APPLIED TO ORGAN TRANSPLANTATION
       Giuseppe Orlando
       Winston Salem, NC, United States

447.2 KIDNEY TRANSPLANT REGENERATION
       THROUGH DELIVERY OF MESENCHYMAL
       STEM CELLS
       Martin J. Hoogduijn
       Rotterdam, The Netherlands

447.3 CARDIAC REGENERATION USING
       PLURIPOTENT STEM CELLS
       Hung Fat Tse
       Hong Kong SAR, P.R. of China
13:30 - 15:00
CONVENTION HALL B-LEVEL 1

State-of-the-Art Session: Pulmonary AMR: The Way Ahead

Chairs: Chi Fong Wong, Hong Kong SAR, P.R. of China
        Gerhard Opelz, Heidelberg, Germany

448.1 B-CELLS AND PULMONARY AMR: FRIEND OR FOE?

Tereza Martinu
Toronto, ON, Canada

448.2 PULMONARY AMR CONSENSUS OR NOT?

Allan R. Glanville
Sydney, Australia

448.3 CHRONIC PULMONARY AMR AND NON HLA ANTIBODIES: EVIDENCE AND OUTCOMES

Elaine F. Reed
Los Angeles, CA, United States

13:30 - 15:00
CONVENTION HALL C-LEVEL 1

State-of-the-Art Session: Vaccination Strategies/Viral Infections

Chairs: Burkhard Tönshoff, Heidelberg, Germany
        Ron Shapiro, New York, NY, United States

449.1 USE OF LIVE VIRUS VACCINES POST-TRANSPLANTATION: CLINICAL EXPERIENCE

Klara M. Posfay-Barbe
Geneva, Switzerland

449.2 OPTIMAL TIMING AND LONG-TERM IMMUNE MONITORS OF VACCINATION IN CHILDREN

Sandra Burchett
Boston, MA, United States

449.3 THE ROLE OF VIRUS SPECIFIC T CELLS IN CHILDREN WITH VIRAL INFECTIONS AFTER TRANSPLANTATION

Lars Pape
Hannover, Germany

15:00 - 15:30
COFFEE BREAK
HALL 5FG-LEVEL 5
15:30 - 17:00
HALL 5BC-LEVEL 5
Orals Session: Tolerance and Regimens to Improve Outcome

Chairs: Jayme E. Locke, Birmingham, AL, United States
       Edward K. Geissler, Regensburg, Germany

450.1 SEVEN YEAR FOLLOW-UP OF A PHASE 2 CLINICAL TRIAL TO INDUCE TOLERANCE IN LIVING DONOR RENAL TRANSPLANT RECIPIENTS

Suzanne T. Ildstad
Louisville, KY, United States

450.2 RELATIONSHIP BETWEEN MIXED CHIMERISM AND CLINICAL TOLERANCE AFTER COMBINED KIDNEY AND HEMATOPOIETIC CELL TRANSPLANTATION USING TOTAL LYMPHOID IRRADIATION AND ANTITHYMOCYTE GLOBULIN CONDITIONING

John D. Scandling
Stanford, CA, United States

450.3 A RANDOMIZED-CONTROLLED TRIAL COMPARING THE EFFICACY OF CYP3A5 GENOTYPE-BASED WITH BODYWEIGHT-BASED TACROLIMUS DOSING AFTER LIVING DONOR KIDNEY TRANSPLANTATION

Dennis Hesselink
Rotterdam, The Netherlands

450.4 IMPACT OF INDUCTION AND MAINTENANCE IMMUNOSUPPRESSION ON PRE-TRANSPLANT IgM DSA TO POST-TRANSPLANT IgG DSA CONVERSION

Matthew J. Everly
Los Angeles, CA, United States

450.5 T-REGULATORY CELLS SUPPORT STEM CELLS IN SAFE MINIMIZATION OF IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION

Aruna Vanikar
Ahmedabad, India

450.6 TOLERANCE INDUCTION IN RENAL TRANSPLANTATION USING STEM CELL THERAPY: LESSONS LEARNED

Aruna Vanikar
Ahmedabad, India
450.7 MALIGNANCIES CONTRIBUTE TO PRESENSITIZATION WITH ALLOREACTIVE T-CELLS IN KIDNEY TRANSPLANT RECIPIENTS
Thomas Schachtner
Berlin, Germany

450.8 THE EFFECT OF EVEROLIMUS AND TACROLIMUS EXPOSURE LEVELS ON RENAL HISTOLOGY PARAMETERS 6 MONTHS POST-TRANSPLANTATION
Flavio Vincenti
San Francisco, CA, United States

450.9 EVEROLIMUS PLUS REDUCED-EXPOSURE CYCLOSPORIN VERSUS MYCOPHENOLIC ACID PLUS CYCLOSPORIN: LONG-TERM FOLLOW-UP OF AUSTRALIA AND NEW ZEALAND KIDNEY TRANSPLANT RECIPIENTS IN THE A2309 RANDOMISED CONTROLLED TRIAL
Wai Lim
Perth, Australia

15:30 - 17:00
HALL 5D-LEVEL 5
Orals Session:
Liver and Intestine Transplantation

Chairs: Gabriel E. Gondolesi, Buenos Aires, Argentina
Douglas G. Farmer, Los Angeles, CA, United States

451.1 BROAD ASSESSMENT OF THE CLINICAL IMPACT OF PORTAL VEIN THROMBOSIS IN THE WAITLIST FOR LIVER TRANSPLANTATION
Martin Montenovo
Seattle, WA, United States

451.2 CLINICAL AND IMMUNOLOGICAL SIGNIFICANCE OF CONTROLLING PORTAL VEIN PRESSURE IN LIVING DONOR LIVER TRANSPLANTATION
Kazuhiro Taguchi
Hiroshima, Japan
451.3 IMPACT OF HEPATORENAL SYNDROME ON OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE IN 357 PATIENTS

Yusuke Okamura
Kyoto, Japan

451.4 RISK FACTORS FOR PRIMARY SCLEROSING CHOLANGITIS RECURRENCE AFTER OTHOTOPIC LIVER TRANSPLANTATION

Pavel Drastich
Praha, Czech Republic

451.5 GENERATION OF NAÏVE DONOR-DERIVED LYMPHOCYTES FROM GRAFT-RESIDENT LYMPHOID PROGENITORS AFTER HUMAN INTESTINAL TRANSPLANTATION

Jianing Fu
Fort Lee, NJ, United States

451.6 DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AFTER COMBINED INTESTINAL AND VASCULARIZED COMPOSITE ALLOTRANSPLANTATION

Georgios Vrakas
Oxford, United Kingdom

451.7 INTESTINAL RETRANSPANTATION IN CHILDREN: SINGLE CENTER EXPERIENCE

Neslihan Celik
Pittsburgh, PA, United States

451.8 SKIN GVHD IN PAEDIATRIC INTESTINAL TRANSPLANT RECIPIENTS – EXPERIENCE FROM A NATIONAL UK CENTRE

Suzan S Y Warner
Birmingham, United Kingdom

451.9 DONOR-SPECIFIC ANTIBODIES ARE ASSOCIATED WITH REJECTION AFTER INTESTINAL TRANSPLANT IN PEDIATRIC PATIENTS

Jacqueline I. Lee
Palo Alto, CA, United States
### Orals Session: Malignancy and Cardio-Vascular Complications

**Chairs:** Klemens Budde, Berlin, Germany  
Siu Fai Lui, Hong Kong SAR, P.R. of China

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
</table>
| 452.1   | 15:30 - 17:00 | MICRORNAS IN EBV+ B CELL LYMPHOMAS AND SECRETED EXOSOMES | Sheri Krams  
Stanford, CA, United States |
| 452.2   | INHIBITION OF THE CONSTITUTIVELY ACTIVE PI3K/ AKT/MTOR SIGNALING PATHWAY IN EPSTEIN-BARR VIRUS B CELL LYMPHOMAS DEMONSTRATE BOTH ANTITUMOR AND ANTIREJECTION PROPERTIES | Olivia M. Martinez  
Stanford, CA, United States |
| 452.3   | LYMPHOPROLIFERATIVE DISORDERS AFTER RENAL TRANSPLANTATION ALONG TWO DECADES: A LARGE LONGITUDINAL STUDY OF 21,546 RECIPIENTS | Antonio Franco  
Alicante, Spain |
| 452.4   | STEM CELL LIKE MEMORY B CELLS ATTENUATE HEPATITIS B VIRUS RELAPSE IN HEPATOCELLULAR CARCINOMA PATIENTS POST LIVER TRANSPLANTATION | Yin Fan Lynn Lam  
Hong Kong SAR, P.R. of China |
| 452.5   | SEQUENTIAL THERAPY AND RISK-STRATIFICATION IN PTLD: POOLED ANALYSIS OF 222 PATIENTS TREATED IN THE PROSPECTIVE, INTERNATIONAL, MULTICENTRIC PTLD-1 TRIALS | Ralf Ulrich Trappe  
Bremen, Germany |
| 452.6   | CANCER-RELATED INCIDENCE AND PROGRESSION TO MORTALITY AMONG KIDNEY ALLOGRAFT RECIPIENTS IN ENGLAND: A POPULATION-COHORT ANALYSIS BETWEEN 2003 AND 2013 | Francesca Jackson-Spence  
Birmingham, United Kingdom |
452.7 IMPACT OF PULSE PRESSURE ON PATIENT AND GRAFT SURVIVAL IN RENAL TRANSPLANT RECIPIENTS: RESULTS FROM THE COLLABORATIVE TRANSPLANT STUDY
Bernd Krüger
Mannheim, Germany

452.8 CARDIAC BIOMARKERS CORRELATE WITH CHANGES IN LEFT VENTRICULAR MASS INDEX AND DIASTOLIC DYSFUNCTION FOLLOWING RENAL TRANSPLANTATION
Amy A. Crosthwaite
Eaglemont, Australia

452.9 INTEGRATIVE, MULTI-COHORT ANALYSIS OF EPSTEIN-BARR VIRUS (EBV)-POSITIVE AND NEGATIVE TUMOR SAMPLES TO IDENTIFY GENE-SIGNATURES ASSOCIATED WITH EBV ONCOGENESIS
Eden M. Maloney
Stanford, CA, United States

15:30 - 17:00
HALL 5E2-LEVEL 5

Orals Session: Kidney Access and Allocation

Chairs: Stefan Schaub, Basel, Switzerland
Naoshi Shinozaki, Tokyo, Japan

453.1 THE RELATIVE COSTS AND HEALTH BENEFITS OF AN AGE-MATCHED DECEASED DONOR ALLOCATION ALGORITHM COMPARED TO CURRENT PRACTICE
Vaishnavi Calisa
Sydney, Australia

453.2 DONOR-RECIPIENT AGE MISMATCHES: THE RELATIVE BENEFITS AND COSTS OF WAIT-LISTING, TRANSPLANTATION AND DIALYSIS
Vaishnavi Calisa
Sydney, Australia

453.3 SCOPE AND HETEROGENEITY OF OUTCOMES REPORTED IN COCHRANE SYSTEMATIC REVIEWS OF KIDNEY TRANSPLANTATION
Benedicte Sautenet
Westmead, Australia
453.4  TIMELY TRANSPLANTATION: IMPROVING ACCESS TO EARLY TRANSPLANTATION AND ACTIVE TRANSPLANTATION LISTING WITHIN SIX MONTHS OF STARTING RENAL REPLACEMENT THERAPY

**John Kanellis**
Melbourne, Australia

453.5  ROUX-EN-Y GASTRIC BYPASS AS A BRIDGE TO KIDNEY TRANSPLANTATION: EFFECTIVE BUT HOW SAFE?

**Franco H. Cabeza**
Miami, FL, United States

453.6  HEPATITIS C RNA-POSITIVE PATIENTS WHO ARE WILLING TO ACCEPT HEPATITIS C SEROPOSITIVE KIDNEYS HAVE BETTER TRANSPLANT ACCESS AND FAVORABLE WAITLIST OUTCOMES

**Junichiro Sageshima**
Sacramento, CA, United States

453.7  CHANGE IN DECEASED KIDNEY DONOR CHARACTERISTICS AND KIDNEY DONOR RISK INDEX (KDRI) IN AUSTRALIA AND NEW ZEALAND OVER TWENTY YEARS

**Samuel Shun K. Chan**
Woolloongabba, Australia

453.8  99-100% cPRA DECEASED DONOR KIDNEY TRANSPLANTS PRE AND POST NEW KIDNEY ALLOCATION SYSTEM (KAS)- A SINGLE CENTER PERSPECTIVE

**Hasan Khamash**
Phoenix, AZ, United States

453.9  A RETROSPECTIVE COHORT STUDY ON THE ASSOCIATION BETWEEN DONOR KIDNEY KDRI SCORE AND RE-HOSPITALIZATION IN TRANSPLANT RECIPIENTS

**Wilson Lin**
Bronx, NY, United States
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>454.1</td>
<td>ASSESSMENT OF IMMUNE MEDIATORS IN PLASMA FOR DETECTION OF CHRONIC REJECTION AFTER HEART TRANSPLANTATION</td>
<td>Bianca Przybylek</td>
<td>Hannover, Germany</td>
</tr>
<tr>
<td>454.2</td>
<td>AIR POLLUTION CAN SUPPORT A CHRONIC REJECTION AFTER HEART TRANSPLANTATION</td>
<td>Christoph Bara</td>
<td>Hannover, Germany</td>
</tr>
<tr>
<td>454.3</td>
<td>PRE-SENSITIZED IMMUNE CONDITION OF HOST EXAGGERATES PROLONGED COLD ISCHEMIA-MEDIATED INJURY OF CARDIAC GRAFT INVOLVING IN REGULATORY T CELLS</td>
<td>Liu Baoqing</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>454.4</td>
<td>ALTERED IMMUNOGENICITY OF PORCINE HEARTS VIA EX VIVO PERFUSION</td>
<td>William R. Critchley</td>
<td>Manchester, United Kingdom</td>
</tr>
<tr>
<td>454.5</td>
<td>C4D POSITIVE STAINING IS A POOR PROGNOSTIC INDICATOR IN CARDIAC TRANSPLANT recipinets</td>
<td>Carmela D. Tan</td>
<td>Cleveland, OH, United States</td>
</tr>
<tr>
<td>454.6</td>
<td>CALCINEURIN INHIBITOR (CNI) DELAY WITH ATG INDUCTION: TEACHING AN OLD DOG, NEW TRICKS</td>
<td>Arezu Z. Aliabadi</td>
<td>Vienna, Austria</td>
</tr>
<tr>
<td>454.7</td>
<td>CELLULAR REJECTION BEYOND 2 YEARS AFTER CARDIAC TRANSPLANTATION</td>
<td>Christian Heim</td>
<td>Erlangen, Germany</td>
</tr>
</tbody>
</table>
454.8 CARDIAC ALLOGRAFT VASCULOPATHY INVOLVING THE ARTERY TO THE ATRIOVENTRICULAR NODE: AN UNDER-RECOGNIZED IMPORTANT PATHOLOGICAL FINDING IN THE AUTOPSY (abst. P.1777 in the Transplantation Journal)
E. R. Rodriguez
Cleveland, OH, United States

454.9 ENDOCAN AND RENALASE: ARE THEY RELATED IN HEART TRANSPLANT RECIPIENTS? (abst. P.1778 in the Transplantation Journal)
Jacek S. Małyszko
Bialystok, Poland

15:30 - 17:00
THEATRE 1-LEVEL 1
Orals Session: Viruses and Cancer

Chairs: Marina Berenguer, Valencia, Spain
        Simone I. Strasser, Camperdown, Australia

455.1 SURVIVAL BENEFIT OF LIVER TRANSPLANTATION FOR HIV+ CANDIDATES
Allan Massie
Baltimore, MD, United States

455.2 TREATMENT OF HCV-RECURRENT AFTER LIVER TRANSPLANTATION WITH SOFOSBUVIR/LEDIPASVIR: THE ROLE OF RIBAVIRIN
Dennis Eurich
Berlin, Germany

455.3 INTERFERON-FREE ANTIVIRAL TREATMENT OF HCV-RECURRENT WITH SOFOSBUVIR CONTAINING REGIMEN: EVALUATION OF KIDNEY FUNCTION
Dennis Eurich
Berlin, Germany

455.4 A CLOSING CHAPTER – THERAPY OF HCV GENOTYPE III RECURRENT IN LIVER TRANSPLANTS
Eva Maria EM Teegen
Berlin, Germany
455.5 THE USE OF HEPATITIS B CORE ANTIBODY POSITIVE DONORS FOR LIVER TRANSPLANTATION DOES NOT LEAD TO INFERIOR SURVIVAL

Tiffany CL Wong
Hong Kong SAR, P.R. of China

455.6 HEPATITIS B VACCINATION IN PATIENTS RECEIVING ANTIVIRAL MONOTHERAPY AFTER LIVER TRANSPLANTATION FOR CHRONIC HEPATITIS B

Tiffany CL Wong
Hong Kong SAR, P.R. of China

455.7 CHILD-PUGH CLASSIFICATION CANNOT PREDICT SURVIVAL OF HEPATOCELLULAR CARCINOMA PATIENTS AFTER LIVER TRANSPLANTATION

Walid Elmoghazy
Doha, Qatar

455.8 HEPATIC EPITHELIOID HAEMANGIO-ENDOTHELIOMA AND ADULT LIVER TRANSPLANTATION: EXTRA-HEPATIC DISEASE IS NOT A CONTRAINDICATION TO LIVER TRANSPLANTATION. REPORT OF THE EUROPEAN LIVER TRANSPLANT REGISTRY INCLUDING 149 PATIENTS

Jan Lerut
Louvain-la-Neuve, Belgium

455.9 LIVER TRANSPLANTATION AND LIVER RESECTION FOR TREATMENT OF HEPATOBLASTOMA: 10-YEARS SINGLE-CENTER EXPERIENCE

Oleg Kotenko
Kiev, Ukraine
Orals Session: Cell Transplantation

**Chairs:** Anil Dhawan, London, United Kingdom

**456.1** CHARACTERIZATION OF HEMATOPOIETICALLY-DERIVED CNS MACROPHAGES FOLLOWING BONE MARROW TRANSPLANTATION

*Josef Kurtz*
Boston, MA, United States

**456.2** CD45RA IDENTIFIES TSER DEMETHYLATED REGULATORY T CELLS WITH A STABLE PHENOTYPE AND SUPPRESSIVE CYTOKINE PROFILE

*Rebeca C. Arroyo Hornero*
Oxford, United Kingdom

**456.3** THE EARLY BEHAVIOR OF MUSCLE-PRECURSOR CELL TRANSPLANTATION IN SKELETAL MUSCLES AND HOW THIS CONDITIONS THE OUTCOME OF THE GRAFT: A STUDY IN NON-HUMAN PRIMATES

*Daniel Skuk*
Quebec, QC, Canada

**456.4** MOBILIZED HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCs) CONTAIN HIGHER PROPORTION OF IL-10 PRODUCING B CELLS IN CD8+TCR- FACILITATING CELL POPULATION THAN NON-MOBILIZED PBMCs

*Yujie Wen*
Louisville, KY, United States

**456.5** THERAPEUTIC BENEFIT OF ADIPOSE-DERIVED STEM CELL TRANSPLANTATION IN RATS OF ACUTE-ON-CHRONIC LIVER FAILURE

*Cheng-Maw Ho*
Taipei, Taiwan

**456.6** TRACKING OF IRON NANO-PARTICLE LABELLED MESENCHYMAL STEM CELLS IN OVINE HETEROTOPIC KIDNEY TRANSPLANTATION.

*Bron D. Lett*
Adelaide, Australia
456.7 EX-VIVO EXPANSION OF HUMAN ALLOANTIGEN-REACTIVE REGULATORY T CELLS USING MONOCYTE-DERIVED DENDRITIC CELLS VERSUS CD40L-STIMULATED B CELLS
Angus W. Thomson
Pittsburgh, PA, United States

456.8 DE- AND RECELLULARIZATION OF PORCINE PANCREAS
Erik Elebring
Gothenburg, Sweden

456.9 STEM CELL THERAPY AS AN EMERGING MODALITY FOR POST-TRAUMATIC PARAPLEGIA AND FOR RENAL PARENCHYMAL DISEASES
Umang G. Thakkar
Ahmedabad, India

15:30 - 17:00
CONVENTION HALL A-LEVEL 1
Orals Session: Unraveling DC Function and Migration
Chairs: Olivier Thaunat, Lyon, France
        Martin J. Hoogduijn, Rotterdam, The Netherlands

457.1 MACROPHAGE-SPECIFIC DELETION OF mTOR INHIBITS CHRONIC ALLOGRAFT REJECTION AND INDUCES LONG-TERM HEART ALLOGRAFT SURVIVAL
Xian C. Li
Houston, TX, United States

457.2 SYSTEMIC THERAPY OF REGULATORY DENDRITIC CELLS DERIVED FORM INDUCED PLURIPOTENT STEM CELLS ALLOWS ALLOGENEIC CARDIAC GRAFTS ACCEPTANCE
Songjie Cai
Tokyo, Japan

457.3 HUMAN REGULATORY MACROPHAGES ARE CapABLE OF SUPPRESSING THE ALLOGENEIC RESPONSE IN VITRO VIA SOLUBLE MOLECULES
Yuanfei Zhao
Sydney, Australia
457.4 ANTI-A IMMUNE RESPONSE IN MICE TO ABO-BLOOD CARBOHYDRATES ANTIGEN IS T CELL DEPENDENT

Lori J. West
Edmonton, AB, Canada

457.5 ANTI-ICAM-1 TREATMENT HINDERS LYMPHATIC TRAFFICKING OF DONOR PASSENGER LEUKOCYTES AND PROLONGS MURINE KIDNEY ALLOGRAFT SURVIVAL

Lucy J. Meader
London, United Kingdom

457.6 SOLUBLE FIBRINOGEN-LIKE PROTEIN 2 REGULATES DIFFERENTIATION AND ENHANCES IMMUNOSUPPRESSIVE FUNCTION OF MYELOID-DERIVED SUPPRESSOR CELLS IN ALLOGRAFT IMMUNITY

Cheng Yang
Shanghai, People's Republic of China

457.7 REDUCTION IN CXCL9–CXCR3 SIGNALS DIMINISHES TRAIL-EXPRESSING LIVER NK CELLS IN PARTIALLY HEPATECTOMIZED MICE UNDER DEPRESSED IMMUNE STATUS

Takuya Yano
Hiroshima, Japan

457.8 NK CELLS PROMOTE KIDNEY GRAFT REJECTION THROUGH EVASION OF CYCLOSPORINE A THERAPY

Muhammad Imtiaz Ashraf
Berlin, Germany

457.9 KLOTHO DEFICIENCY AGGRAVATES TACROLIMUS-INDUCED RENAL INJURY VIA THE PI3K-AKT-FOXO PATHWAY

Jian Jin
Seoul, Korea
Orals Session: Diagnosis and Monitoring of Rejection (I)

Chairs: Maria Hernandez-Fuentes, London, United Kingdom

TBA

458.1 VDJ IMMUNE REPERTOIRE SEQUENCING PREDICTS PATIENTS AT RISK OF ALLOIMMUNE INJURY
Minnie M. Sarwal
San Francisco, CA, United States

458.2 MINING THE HUMAN PROTEOME FOR MONITORING RENAL TRANSPLANT INJURY
Minnie M. Sarwal
San Francisco, CA, United States

458.3 GUT MICROBIAL COMPOSITION PREDICTIVE OF GRAM-NEGATIVE URINARY TRACT INFECTIONS IN KIDNEY TRANSPLANT RECIPIENTS
John Lee
New York, NY, United States

458.4 HOST MICROBIOTA OF CARDIAC ALLOGRAFT RECIPIENTS IS DURABLY ALTERED BY FECAL MICROBIOTA TRANSPLANT AND THESE CHANGES CORRELATE WITH ALLOGRAFT OUTCOME
Jonathan S. Bromberg
Baltimore, MD, United States

458.5 A MOLECULAR MICROSCOPE DIAGNOSTIC SYSTEM (MMDx) FOR HEART TRANSPLANT BIOPSIES DEVELOPED FROM THE MOLECULAR PHENOTYPES OF REJECTION IN KIDNEY TRANSPLANTS
Philip F. Halloran
Edmonton, AB, Canada

458.6 BIOMARKERS OF TOLERANCE IN KIDNEY TRANSPLANTATION: IMMUNOSUPPRESSION-EFFECTS ON GENE-EXPRESSION. CAN WE REALLY DETECT TOLERANCE?
Maria Hernandez-Fuentes
London, United Kingdom
458.7 IDENTIFICATION OF NOVEL THERAPEUTICS AND TARGETS FOR CHRONIC ALLOGRAFT INJURY USING INTEGRATIVE INFORMATICS APPROACH

Li Li
New York, NY, United States

458.8 FIRST CLINICAL RESULTS OF A SALIVA TESTING FOR MONITORING AFTER RENAL TRANSPLANTATION

Dietmar K. Abendroth
Ulm, Germany

458.9 MOLECULAR AND FUNCTIONAL IMMUNE ASSAYS AS NON-INVASIVE DIAGNOSTIC TOOLS TO ASSESS THE RISK OF ACUTE SUBCLINICAL REJECTION AFTER KIDNEY TRANSPLANTATION

Josep Grinyo
Barcelona, Spain

15:30 - 17:00
CONVENTION HALL C-LEVEL 1

Orals Session:
Longterm Challenges following Paediatric Solid Organ Transplantation

Chairs: Jonathan Craig, Sydney, Australia
        Stanley H.K. Lo, Hong Kong SAR, P.R. of China

459.1 IMPACT OF EVEROLIMUS AND LOW-DOSE CICLOSPORIN ON CYTOMEGALOVIRUS REPLICATION AND DISEASE IN PEDIATRIC RENAL TRANSPLANTATION

Burkhard Tönshoff
Heidelberg, Germany

459.2 VACCINATION STATUS AND TITERS BEFORE AND AFTER PEDIATRIC RENAL TRANSPLANTATION: AN ANALYSIS OF THE CERTAIN REGISTRY

Burkhard Tönshoff
Heidelberg, Germany

459.3 PEDIATRIC KIDNEY TRANSPLANT OUTCOMES: A SINGLE-CENTER EXPERIENCE ACCORDING TO TRANSPLANT ERA

Marta L. Monteverde
Buenos Aires, Argentina
459.4 PERCEPTION, DIAGNOSIS, AND MANAGEMENT OF BK POLYOMAVIRUS REPLICATION AND DISEASE IN PAEDIATRIC KIDNEY TRANSPLANT RECIPIENTS IN EUROPE
Lars Pape
Hannover, Germany

459.5 PUBERTAL DEVELOPMENT IN PEDIATRIC KIDNEY TRANSPLANT PATIENTS RECEIVING MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS OR CONVENTIONAL IMMUNOSUPPRESSION
Lars Pape
Hannover, Germany

459.6 TRANSITIONAL CARE AND ADHERENCE OF ADOLESCENTS AFTER KTX IN GERMANY AND AUSTRIA: A BINATIONAL OBSERVATORY CENSUS WITHIN THE TRANSNEPHRO TRIAL
Lars Pape
Hannover, Germany

459.7 HEALTH AND WEALTH IN CHILDREN AND ADOLESCENTS WITH KIDNEY TRANSPLANTS (K-CAD STUDY)
Madeleine Didsbury
Westmead, Australia

459.8 INCIDENCE OF POST-TRANSPLANT MALIGNANCY (PTM) AFTER PEDIATRIC KIDNEY TRANSPLANTATION (PKTx)
Oscar K. Serrano
Minneapolis, MN, United States

459.9 INCIDENCE OF CARDIOVASCULAR DISEASE AFTER PEDIATRIC KIDNEY TRANSPLANTATION
Oscar K. Serrano
Minneapolis, MN, United States
### ISN-TTS Sister Transplantation Center Program

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 460     | PRESENTATION OF ISN-TTS SISTER TRANSPLANTATION CENTER PROGRAM | Randall Lou Meda (Guatemala, Guatemala)  
Abdullah El-Kishawi (Gaza City, Palestine) |

### Campfire Presentations: Unraveling Alloreactivity: innovative approaches (II) - Campfire Table 1

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>470.1</td>
<td>THE ROLE OF HLA CLASS II ANTIBODIES IN CHRONIC KIDNEY REJECTION</td>
<td>Gabriel Cantanhede (Newcastle-upon-Tyne, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>470.2</td>
<td>THE PROPER ISCHEMIC PRECONDITIONING ATTENUATES AGAINST RENAL ISCHEMIA-REPERFUSION INJURY BY INHIBITING TOLL-LIKE RECEPTOR 4/NF-KB SIGNALING PATHWAY IN MICE</td>
<td>Kyungjai Ko (Seoul, Korea)</td>
<td></td>
</tr>
<tr>
<td>470.3</td>
<td>RELATIONSHIP BETWEEN B CELL-RICH TERTIARY LYMPHOID ORGANS AND SYSTEMIC AS WELL AS LOCAL HUMORAL ALLORESPONSES IN A MURINE KIDNEY ALLOGRAFT MODEL</td>
<td>Anna Nowocin (London, United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>
470.4 KIDNEY TRANSPLANT RECIPIENTS AFTER SOLID ORGAN TRANSPLANTATION OTHER THAN KIDNEY SHOW LOW ALLOREACTIVITY BUT AN INCREASED RISK OF INFECTIOUS COMPLICATIONS

Thomas Schachtner
Berlin, Germany

470.5 AGING EFFECT ON IMMUNITY IMPLYING TO MINIMIZE IMMUNOSUPPRESSION IN ELDER TRANSPLANT RECIPIENTS IN A MURINE MODEL

Kun-Ming Chan
Taoyuan, Taiwan

470.6 CD3+CD8+GRANZYMEB+ CYTOTOXIC T LYMPHOCYTES PLAY ROLE IN CHRONIC ANTIBODY MEDIATED TRANSPLANT REJECTION

Brijesh Yadav
Lucknow, India

17:00 - 18:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

Campfire Presentations: Kidney II - Campfire Table 2

Chairs: Anwar Naqvi, Karachi, Pakistan
        Carrie A. Schinstock, Rochester, MN, United States

471.1 BODY MASS INDEX (BMI) IS ASSOCIATED WITH MICROALBUMINURIA IN THE LATE RENAL TRANSPLANT PERIOD

Boris Zingerman
Petach-Tikva, Israel

471.2 POSTTRANSPLANT HYPERURICEMIA AS A CARDIOVASCULAR RISK FACTOR: CORRELATION BETWEEN CARDIOVASCULAR RISK FACTORS

Turan Colak
Ankara, Turkey

471.3 DEFINITE (dBKPVN) AND PRESUMPTIVE (pBKPVN) POLYOMAVIRUS ASSOCIATED NEPHROPATHIES CANNOT BE DISTINGUISHED CLINICALLY BUT VIRAL CLEARANCE IN pBKPVN DEPENDS ON RENAL FUNCTION AT THE TIME OF THE BIOPSY

Cinthia B. Drachenberg
Baltimore, MD, United States
471.4 THE PREVENTATIVE EFFECT OF mTOR INHIBITION BY ANTI-A/B ANTIBODY LIGATION AND mTOR-INHIBITOR ON ANTI-HLA-DR ANTIBODY MEDIATED COMPLEMENT DEPENDENT CYTOTOXICITY

Takaaki Kobayashi
Nagoya, Japan

471.5 OUTCOME OF RENAL TRANSPLANTATION IN OBESE RECIPIENTS

Mahir Kirnap
Ankara, Turkey

471.6 DECREASED NUMBER OF PLASMA CELLS IN PERIPHERAL CIRCULATION IS ASSOCIATED WITH ACUTE REJECTION IN RENAL TRANSPLANTATION

Mukut Minz
Chandigarh, India

17:00 - 18:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

Campfire Presentations: Optimizing Donation - Campfire Table 3

Chairs: Richard D.M. Allen, Sydney, Australia
See Ming Simon Hou, Hong Kong SAR, P.R. of China

472.1 TOWARDS A STANDARDIZED INFORMED CONSENT PROCEDURE FOR LIVE DONOR NEPHRECTOMY: WHAT DO SURGEONS TELL POTENTIAL DONORS?

Kirsten Kortram
Rotterdam, The Netherlands

472.2 ANALYSIS OF DIALYSIS COST AND MEDIAN WAITING TIME ON RETURN ON INVESTMENT (ROI) OF THE US NATIONAL LIVING DONOR ASSISTANCE CENTER (NLDAC) PROGRAM

Robert M. Merion
Ann Arbor, MI, United States

472.3 THE INCREASING NUMBER OF UNSPECIFIED LIVING KIDNEY DONORS

Willij Zuidema
Rotterdam, The Netherlands
472.4 CHINESE ADULT PERCEPTION TOWARDS ORGAN DONATION IN HONG KONG
Wah Chun Li
Hong Kong SAR, P.R. of China

472.5 KIDNEY TRANSPLANTATION FROM DONORS WITH RHABDOMYOLYSIS AND ACUTE RENAL FAILURE: A REPORT OF 16 CASES
Xiaopeng Yuan
Guangzhou, People’s Republic of China

472.6 INCREASED CONSENTED-NOT RECOVERED (CNR) CASES AS A CONSEQUENCE OF AGGRESSIVE DONOR PURSUIT: IMPACT AND IMPLICATIONS
Jeffrey P. Orlowski
Oklahoma City, OK, United States

17:00 - 18:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

Campfire Presentations: Paediatrics - Campfire Table 4

Chairs: Burkhard Tönshoff, Heidelberg, Germany
        Diana Shellmer, Pittsburgh, PA, United States

473.1 PEDIATRIC RENAL TRANSPLANTATION IN THE SCANDIATRANSPLANT REGION 1997-2012
Lars Wennberg
Stockholm, Sweden

473.2 RESULTS OF THE FIRST KIDNEY TRANSPLANT IN PEDIATRIC PATIENTS IN ARGENTINA: PERIOD 1998-2014
Liliana Bisigniano
Buenos Aires, Argentina

473.3 ENBLOC KIDNEY TRANSPLANT IN PEDIATRIC RECIPIENTS - THE MIAMI EXPERIENCE
Linda J. Chen
Miami, FL, United States

473.4 WHEN THE VENA CAVA INFERIOR IS MISSING: KIDNEY TRANSPLANTATION IN CHILDREN WITH VENOUS DRAINAGE TO THE PORTAL VEIN
Udo Vester
Essen, Germany
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>473.5</td>
<td>Nationwide Conversion to Generic Tacrolimus in Paediatric Kidney Transplant Recipients</td>
<td>Derisha Naicker</td>
<td>Auckland, New Zealand</td>
</tr>
<tr>
<td>473.6</td>
<td>Recent Advancements in the Pediatric Liver Transplantation: A Single-Center Study of 235 Patients Over 27 Years</td>
<td>Nam-Joon Yi</td>
<td>Seoul, Korea</td>
</tr>
</tbody>
</table>

**17:00 - 18:00**  
**HALL 5FG-LEVEL 5**  
**NOT A CME SESSION**  

**Campfire Presentations:**  
**Immuno and Beyond / Patient Outcomes - Campfire Table 5**

**Chairs:** Bronwyn J. Levvey, Melbourne, Australia  
TBA

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>474.1</td>
<td>Immunosuppression at First Hospital Discharge After Transplantation May Not Accurately Predict Risk of Cancer in Solid Organ Transplant Recipients</td>
<td>Claire M. Vajdic</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>474.2</td>
<td>Longitudinal Immunosuppression Data Reduces Exposure Misclassification and Improves Outcome Prediction Among Solid Organ Transplant Recipients</td>
<td>Maarit A. Laaksonen</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>474.3</td>
<td>National Transplantation Pregnancy Registry (NTPR): 25 Years of Data Collection</td>
<td>Michael J. Moritz</td>
<td>Emmaus, PA, United States</td>
</tr>
<tr>
<td>474.4</td>
<td>Prospective Randomized Controlled Study Evaluating the Relationship Between Electronic Adherence Data and Tacrolimus Concentration Data</td>
<td>Adam S. Bodzin</td>
<td>Chicago, IL, United States</td>
</tr>
</tbody>
</table>
474.5 AUTOMATIC ISCHEMIA TIME CALCULATION IN THE INTRA-OPERATIVE NURSING RECORD
Carmen J. Sierra
Miami, FL, United States

474.6 IMPACTS OF URETERIC STENT REMOVAL TIMING ON POST RENAL TRANSPLANT MAJOR UROLOGICAL COMPLICATION. A SINGLE CENTRE EXPERIENCE
Hassan A. Aleid
Riyadh, Saudi Arabia

17:00 - 19:00
HALL 5E3-LEVEL 5
NOT A CME SESSION
Poster Sessions
Detailed list of all the posters available on page 273

18:30 - 19:30
CONVENTION HALL A-LEVEL 1
BY INVITATION ONLY - NOT A CME SESSION
International Transplantation Science Mentee-Mentor Awards Networking Event
### MORNING SESSIONS

**MORNING SESSIONS MONDAY • AUGUST 22**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Plenary: Hepatitis C Virus in Solid Organ Tx.: Have the Rules Changed? (Hall 5BC - L5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magnitude of the Problem (Solved &amp; Unsolved Issues) - Prof. Marina Berenguer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment of HCV Infection Before and/or After Organ Tx. - Prof. Greg T. Everson</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Impact of Antiviral Therapy on Hepatic &amp; Extra-Hepatic - Prof. Simone I. Strasser</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>Coffee Break and Poster Viewing (Hall 5FG - L5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMS Financial Neutrality...</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMS EMS Fostering Innovation To Avoid Extinction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMS EMS EMS Fostering Innovation To Avoid Extinction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMS EMS EMS Fostering Innovation To Avoid Extinction</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>President’s Plenary and Awards (Hall SBC - L5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coffee Break and Poster Viewing (Hall 5FG - L5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Industry Symposium - Expanding Treatment Options with ATLG (Hall S3 - L5)</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Lunch Break - Exhibition (Hall 5FG - L5)</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In addition to a special lecture by Professor Jiefu Huang on “Transplant Reform in China”, please join us in congratulating the recipients of the Young Investigators’ Scientific Awards, TTS Recognition Awards, Transplantation Best Publication Awards, Women in Transplantation Awards, and the 2016 Medawar Prize.

HALL 5BC - LEVEL 5
TTS BUSINESS MEETING

17:00–18:00

- Announcement of the TTS 2020 destination city
- Presentation of the 2016-2018 Council
- TTS 2016 Congress report

Light Refreshments will be served.

CONVENTION HALL A - LEVEL 1
TTS and the members of the Host Country Liaison Committee invite the participants of the 26th International Congress of The Transplantation Society to a unique evening under the theme 'Asian Market Place'. This will be taking place at Jumbo Kingdom Floating Restaurant, an internationally renowned tourist attraction, ornated like an ancient Chinese Palace.

JUMBO KINGDOM, Shum Wan Pier Dr., Aberdeen
Ticket Required
07:00 - 08:15
S-221-LEVEL 2

Early Morning Symposia:
Pancreatic Beta Cell Replacement Therapy: What Will We Be Doing in 2025?

Chair: Peter Stock, San Francisco, CA, United States

Supported by

500.1 SOLID PANCREAS TRANSPLANT
Raphael Meier
Geneva, Switzerland

500.2 STEM CELL DERIVED BETA CELLS
Christian Schuetz
Boston, MA, United States

500.3 XENO-ISLET TRANSPLANT
Wayne J. Hawthorne
Westmead, Australia

500.4 AUTO/ALLO ISLET TRANSPLANT
Hanne Scholz
Oslo, Norway

07:00 - 08:15
THEATRE 1-LEVEL 1

Early Morning Symposia:
Fostering Innovation To Avoid Extinction: Current Trends in Health Professions Education

Chairs: Marcelo Cantarovich, Montreal, QC, Canada
Medhat Z. Askar, Dallas, TX, United States

501.1 CORE EDUCATOR COMPETENCIES FOR CLINICIANS IN THE NEW MILLENNIUM
Wayne C. Hodgson
Clayton, Australia

501.2 CURRENT INNOVATIONS IN HEALTH PROFESSIONS EDUCATION: KEEPING UP WITH TRAINEES EXPECTATIONS
Margaret Hay
Clayton, Australia
501.3 THE ROLE OF PROFESSIONAL SOCIETIES IN ADVANCING PROFESSIONAL HEALTH EDUCATION: THE TTS EDUCATION ACADEMY MODEL

Medhat Z. Askar
Dallas, TX, United States

07:00 - 08:15 THEATRE 2-LEVEL 1

Early Morning Symposia: Assessing and Managing Cardio-Metabolic Risk in Transplantation

Chairs: Hallvard Holdaas, Oslo, Norway
Helen Pilmore, Auckland, New Zealand

502.1 NEW INSIGHTS INTO THE DIAGNOSIS OF PTDM

Trond Jenssen
Oslo, Norway

502.2 METABOLIC SYNDROME AFTER LIVER TRANSPLANTATION

Simone I. Strasser
Camperdown, Australia

502.3 CVS RISK ASSESSMENT IN 2016

Helen Pilmore
Auckland, New Zealand

07:00 - 08:15 CONVENTION HALL A-LEVEL 1

Early Morning Symposia: Financial Neutrality - but Not Financial Incentives - to Further Promote Organ Donation

Chairs: Elmi M. Muller, Cape Town, South Africa
Beatriz Dominguez-Gil, Madrid, Spain

503.1 FINANCIAL NEUTRALITY FOR THE LIVING DONOR

Dominique E. Martin
Geelong, Australia

503.2 FINANCIAL NEUTRALITY FOR DECEASED DONOR FAMILIES

Alexander M. Capron
Los Angeles, CA, United States
503.3 HEALTH INSURANCE FOR THE LIVING DONOR IN THE FINANCIAL NEUTRALITY FRAMEWORK

John S. Gill
Vancouver, BC, Canada

07:00 - 08:15
CONVENTION HALL B-LEVEL 1

Early Morning Symposia: Fibrosis - All You Ever Wanted to Know (But Were Afraid to Ask)

Chairs: Brian J. Nankivell, Westmead, Australia
        Michael Mengel, Edmonton, AB, Canada

504.1 BIOLOGY AND RESOLUTION

Dany Anglicheau
Paris, France

504.2 BIOPSY ANALYSIS

Alton “Brad” Farris III
Atlanta, GA, United States

504.3 IN VIVO IMAGING OF FIBROSIS

Faikah Gueler
Hannover, Germany

07:00 - 08:15
CONVENTION HALL C-LEVEL 1

Early Morning Symposia: Cochrane Systematic Reviews: Useful for Decision Making?

Chairs: Angela Webster, Sydney, Australia
        Jonathan Craig, Sydney, Australia

505.1 SYSTEMATIC REVIEWS IN THE CONTEXT OF HEALTHCARE, GUIDELINES AND OTHER FORMS OF RESEARCH

Colin Wilson
Newcastle-upon-Tyne, United Kingdom

505.2 WHAT IS THE DIFFERENCE BETWEEN COCHRANE REVIEWS AND NON COCHRANE REVIEWS

Philip Masson
Edinburgh, United Kingdom
08:30 - 10:00
HALL 5BC-LEVEL 5

Plenary:
Hepatitis C Virus in Solid Organ Transplantation: Have the Rules Changed?

Chairs: Chung-Mau Lo, Hong Kong SAR, P.R. in China
Nancy Ascher, San Francisco, CA, United States

510.1 MAGNITUDE OF THE PROBLEM (SOLVED & UNSOLVED ISSUES) IN SOLID ORGAN TRANSPLANTATION
Marina Berenguer
Valencia, Spain

510.2 TREATMENT OF HCV INFECTION BEFORE AND/OR AFTER ORGAN TRANSPLANTATION
Gregory T. Everson
Aurora, CO, United States

510.3 IMPACT OF ANTIVIRAL THERAPY ON HEPATIC AND EXTRA-HEPATIC MANIFESTATIONS OF CHRONIC HCV INFECTION
Simone I. Strasser
Camperdown, Australia

10:00 - 10:30
COFFEE BREAK
HALL 5FG-LEVEL 5
10:30 - 12:30  
HALL 5BC-LEVEL 5  
NOT A CME SESSION

Plenary:  
President’s Plenary and Awards

Chairs: Philip J. O’Connell, Westmead, Australia  
Nancy Ascher, San Francisco, CA, United States  
Francis L. Delmonico, Waltham, MA, United States

520  
TRANSPLANTATION REFORM IN CHINA

Jiefu Huang  
Beijing, People’s Republic of China

520  
PRESIDENTIAL ADDRESS

Philip J. O’Connell  
Westmead, Australia

MEDAWAR PRIZE LECTURE

DISTRIBUTION OF AWARDS

12:30 - 13:30  
LUNCH BREAK

12:30 - 13:30  
HALL 5E3-LEVEL 5

Industry Symposium:  
Expanding Treatment Options with Anti-T Lymphocyte Immunoglobulin (ATLG)

Organized by neovii

Please refer to page 344 for details.
13:30 - 15:00  
HALL 5BC-LEVEL 5

State-of-the-Art Session: Live Kidney Donation – Overcoming Immunological Barriers

Chairs: Chi Yuen Simon Cheung, Hong Kong SAR, P.R. of China  
Jean-Paul P. Soulillou, Nantes, France

540.1 IS THERE STILL A PLACE FOR LIVING DONOR KIDNEY TRANSPLANTS WITH A POSITIVE CROSSMATCH?

Carrie A. Schinstock  
Rochester, MN, United States

540.2 ABO INCOMPATIBLE TRANSPLANTATION, WHEN IS IT NOT SAFE?

Kazunari Tanabe  
Tokyo, Japan

540.3 KIDNEY PAIRED DONATION – PROBLEMS AND SOLUTIONS?

Paolo Ferrari  
Sydney, Australia

13:30 - 15:00  
HALL 5D-LEVEL 5

State-of-the-Art Session: When Organ Donation Becomes Routine, Can We Take Ethical Practice for Granted?

Chairs: Jenny Koo, Hong Kong SAR, P.R. of China  
Marta López Fraga, Strasbourg, France

541.1 PSYCHOSOCIAL EVALUATION OF LIVING KIDNEY DONORS: WHAT DO GUIDELINES SAY, AND WHAT ARE THE CHALLENGES?

Allison Tong  
Sydney, Australia

541.2 ROUTINE CONSIDERATION OF ORGAN DONATION: AN ETHICAL DUTY FOR THOSE PROVIDING END-OF-LIFE CARE

Beatriz Dominguez-Gil  
Madrid, Spain

541.3 ROUTINE CARE OF FOREIGN DONORS AND RECIPIENTS – IMPLEMENTING ETHICAL GUIDELINES IN THE TRANSNATIONAL SETTING

Jacqueline J. Chin  
Singapore, Singapore
13:30 - 15:00
HALL 5E1-LEVEL 5
State-of-the-Art Session:
Facing Challenges in the Developing World

Chairs: Shiro Takahara, Osaka, Japan
       Ifeoma Ulasi, Enugu, Nigeria

542.1  LATIN AMERICA…A HETEROGENEOUS ENVIRONMENT
       Rudolf A. Garcia-Gallont
       Guatemala City, Guatemala

542.2  HIV POSITIVE DONORS AND THE IMPACT OF THE SECOND VIRAL STRAIN ON RECIPIENT KIDNEYS
       Elmi M. Muller
       Cape Town, South Africa

542.3  IMPROVING TRANSPLANTATION PRACTICE IN MONGOLIA
       Byambadorj Batsuuri
       Ulaanbaatar, Mongolia

13:30 - 15:00
HALL 5E2-LEVEL 5
State-of-the-Art Session:
What’s New in VCA

Chairs: Emmanuel Morelon, Lyon, France
       Linda C. Cendales, Durham, NC, United States

543.1  OUTCOME IN VCA
       Palmina Petruzzo
       Lyon, France

543.2  HISTOPATHOLOGY IN VCA: BANFF SCORE 2015
       Linda C. Cendales
       Durham, NC, United States

543.3  IMMUNOLOGY OF VCA:
       LESSONS FROM THE MOUSE
       Wayne W. Hancock
       Philadelphia, PA, United States
13:30 - 15:00
S-221-LEVEL 2
State-of-the-Art Session: Xenotransplantation Will Provide Solutions, Not Problems

Chairs: Wayne J. Hawthorne, Westmead, Australia
        Agnes Azimzadeh, Baltimore, MD, United States

544.1 ADVANCES IN GENETIC MODIFICATION OF PIGS
       Peter Cowan
       Melbourne, Australia

544.2 ADVANCES IN SOLID ORGAN XENOTRANSPLANTATION
       Muhammad M. Mohiuddin
       Bethesda, MD, United States

544.3 ADVANCES IN PORCINE ISLET XENOTRANSPLANTATION
       Chung-Gyu Park
       Seoul, Korea

13:30 - 15:00
THEATRE 1-LEVEL 1
State-of-the-Art Session: Two Decades of Living Donor Adult Liver Transplantation: Pushing the Limits

Chairs: Mohamed Rela, Chennai, India
        See Ching Chan, Hong Kong SAR, P.R. of China

545.1 GETTING MORE HORSEPOWER FROM YOUR GRAFT: SHIFTING FROM RIGHT TO LEFT
       Chao-Long Chen
       Kaohsiung, Taiwan

545.2 HOW DOES THE LEFT STACK UP TO THE RIGHT?
       Yuji Soejima
       Fukuoka, Japan

545.3 EXTENDED CRITERIA LIVING DONORS
       Chung-Mau Lo
       Hong Kong SAR, P.R. of China
13:30 - 15:00
THEATRE 2-LEVEL 1

State-of-the-Art Session:
Post-Transplant Viral Infections

Chairs: Ban Hock Tan, Singapore, Singapore
        Kelvin Kai-Leung Ho, Hong Kong SAR, P.R. of China

546.1 NEW INSIGHTS INTO THE BIOLOGY OF PTLD

Olivia M. Martinez
Stanford, CA, United States

546.2 POST TRANSPLANT HEP B

James Fung
Hong Kong SAR, P.R. of China

546.3 POST TRANSPLANT TREATMENT OF HIV

Peter Stock
San Francisco, CA, United States

13:30 - 15:00
CONVENTION HALL A-LEVEL 1

State-of-the-Art Session:
Epitopes - The Target of HLA Antibodies

Chairs: Janette Kwok, Hong Kong SAR, P.R. of China
        Peter William Nickerson, Winnipeg, MB, Canada

547.1 OVERVIEW - DEFINITION AND TOOLS FOR IDENTIFYING HLA ANTIBODY EPITOPES

Frans H.J. Claas
Leiden, The Netherlands

547.2 IMMUNOGENICITY - ARE ALL HLA EPITOPES THE SAME?

Anat R. Tambur
Chicago, IL, United States

547.3 CLINICAL RELEVANCE OF HLA EPITOPES - WHERE DO WE STAND?

Chris J. Wiebe
Winnipeg, MB, Canada
13:30 - 15:00  
CONVENTION HALL B-LEVEL 1

State-of-the-Art Session: Moving Tolerance Into the Clinic

Chairs: Carla Baan, Rotterdam, The Netherlands  
Qizhi Tang, San Francisco, CA, United States

548.1  TRACKING THE ALLOREACTIVE T CELL REPERTOIRE: INSIGHTS INTO TOLERANCE AND REJECTION

Megan Sykes  
New York, NY, United States

548.2  CLINICAL TRIALS USING TREGS

Qizhi Tang  
San Francisco, CA, United States

548.3  CAR-TREGS

Megan Levings  
Vancouver, BC, Canada

13:30 - 15:00  
CONVENTION HALL C-LEVEL 1

State-of-the-Art Session: Cardiac Perfusion Strategies

Chairs: Peter S. MacDonald, Sydney, Australia  
Anne I. Dipchand, Toronto, ON, Canada

549.1  IN VIVO RE-ANIMATION

Simon J. Messer  
Cambridge, United Kingdom

549.2  HYPOTHERMIC PERFUSION

Franklin L. Rosenfeldt  
Melbourne, Australia

549.3  NORMOTHERMIC PERFUSION

Kumud K. Dhital  
Darlinghurst, Australia

15:00 - 15:30  
COFFEE BREAK

HALL 5FG-LEVEL 5
15:30 - 17:00
HALL 5BC-LEVEL 5

Orals Session: Complications

Chairs: Marcelo Cantarovich, Montreal, QC, Canada
Alejandro Niño-Murcia, Bogota, Colombia

550.1 PROSPECTIVE TREATMENT AND NOVEL BIOMARKERS OF BK POLYOMAVIRUS ASSOCIATED NEPHROPATHY

Minal Borkar
Calgary, AB, Canada

550.2 BK VIRUS NEPHROPATHY IN RENAL TRANSPLANTATION- A PATHOLOGIST’S PERSPECTIVE

Kamlesh S. Suthar
Ahmedabad, India

550.3 THE IMPACT OF RECURRENT GLOMERULONEPHRITIS AFTER KIDNEY TRANSPLANTATION IN THE ERA OF CONTEMPORARY MAINTENANCE IMMUNOSUPPRESSION

Penelope J. Allen
Hunters Hill, Australia

550.4 TROJAN KIDNEYS: UNEXPECTED DONOR-DERIVED VIRAL TRANSMISSION IN KIDNEY TRANSPLANT RECIPIENTS – A SYSTEMATIC REVIEW

Rashmi Shingde
Sydney, Australia

550.5 SEQUENTIAL BIOPSY FINDINGS OF POLYOMAVIRUS ASSOCIATED NEPHROPATHY

Handan Özdemir
Ankara, Turkey

550.6 POLYOMAVIRUS (PV) REPLICATION AND SMOKING ARE INDEPENDENT RISK FACTORS FOR BLADDER CANCER AFTER RENAL TRANSPLANTATION

John C. Papadimitriou
Baltimore, MD, United States
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>550.7</td>
<td>BK VIRUS-ASSOCIATED NEPHROPATHY IN SCOTLAND: EVIDENCE OF BETTER TRANSPLANT SURVIVAL BUT VARIATION IN INCIDENCE, MANAGEMENT AND OUTCOME BETWEEN RENAL UNITS</td>
<td>Michaela C. Petrie</td>
<td>Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>550.8</td>
<td>HIGH NUMBERS OF INTRAGRAFT BLOOD DENDRITIC CELL ANTIGEN-1 (BDCA-1)-POSITIVE MYELOID DENDRITIC CELLS DURING BK POLYOMAVIRUS-ASSOCIATED NEPHROPATHY</td>
<td>Jesper Kers</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>550.9</td>
<td>OUTCOME AFTER ECULIZUMAB THERAPY TO PREVENT RECURRENCE OF ATYPICAL HEMOLYTIC UREMIC SYNDROME: EXPERIENCE IN TWELVE RENAL TRANSPLANT RECIPIENTS</td>
<td>Julien Zuber</td>
<td>Paris, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>HALL 5D-LEVEL 5</td>
<td><strong>Orals Session:</strong> Pancreas/Islet Tx: Donor and Technical Aspects</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P&amp;I</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Dixon B. Kaufman, Madison, WI, United States Mitsukazu Gotoh, Osaka, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>551.1</td>
<td>INFLUENCE OF PANCREAS IMPORT AND COLD ISCHEMIA ON OUTCOMES FOLLOWING PANCREAS TRANSPLANTATION</td>
<td>Robert J. Stratta</td>
<td>Winston-Salem, NC, United States</td>
</tr>
<tr>
<td>551.2</td>
<td>WHY ARE PANCREAS TRANSPLANTS DECLINING IN THE UNITED STATES IN THE PAST DECADE?</td>
<td>Robert J. Stratta</td>
<td>Winston-Salem, NC, United States</td>
</tr>
<tr>
<td>551.3</td>
<td>EXTENDED PANCREAS DONOR PROGRAM – THE EXPAND STUDY, A PROSPECTIVE MULTICENTRE TRIAL</td>
<td>Andrea Proneth</td>
<td>Regensburg, Germany</td>
</tr>
</tbody>
</table>
551.4  PRESERVATION OF HUMAN PANCREAS WITH HYPOTHERMIC MACHINE PERFUSION

Diego Cantarovich
Nantes, France

551.5  A PROPOSAL FOR NEW DONOR CRITERIA FOR PANCREAS TRANSPLANTATION BASED ON POSTOPERATIVE INSULIN SECRETION

Taihei Ito
Aichi, Japan

551.6  TOTAL PANCREATECTOMY WITH ISLET AUTOTRANSPLANTATION IMPROVES QUALITY OF LIFE ALLOWING FOR THE RESOLUTION OF THE INTRACTABLE PAIN WITH GOOD GLUCOSE CONTROL IN PROPERLY SELECTED PATIENTS WITH CHRONIC PANCREATITIS

Julia Solomina
Chicago, IL, United States

551.7  VALIDATION OF A NEW NORTH AMERICAN ISLET DONOR SCORE FOR DONOR PANCREAS SELECTION AND SUCCESSFUL ISLET ISOLATION

Julia Solomina
Chicago, IL, United States

551.8  IS SUPERIOR MESENTERIC ARTERY SO INDISPENSABLE FOR PANCREAS TRANSPLANT?

Alexey Pinchuk
Moscow, Russian Federation

551.9  TOTAL PANCREATECTOMY WITH AUTOLOGOUS ISLET TRANSPLANTATION FOR CHRONIC PANCREATITIS: CONSIDERATIONS FOR EARLY OPERATION

Kenneth L. Brayman
Charlottesville, VA, United States
15:30 - 17:00
HALL 5E1-LEVEL 5

Orals Session:
Increasing Donation: A Global Perspective

Chairs: Susan Gunderson, Minneapolis, MN, United States
Anantharaman Vathsala, Singapore, Singapore

552.1 A NEW ERA FOR ORGAN DONATION AND TRANSPLANTATION IN CHINA

Haibo Wang
Hong Kong SAR, P.R. of China

552.2 PROGRESS IN DECEASED ORGAN DONOR TRANSPLANTATION IN INDIA

Lalitha Raghuram
Hyderabad, India

552.3 THE AFRICAN AMERICAN JOURNEY IN ORGAN DONATION AND THE METHODOLOGIES THAT RESULTED IN MOVEMENT FROM THE BOTTOM TO THE TOP

Clive O. Callender
Washington DC, United States

552.4 CENTER EFFECT ON OUTCOME OF KIDNEY TRANSPLANTATION FROM PEDIATRIC DECEASED DONOR IN CHINA

Huanxi Zhan
Guangzhou, People's Republic of China

552.5 EXPANDING THE DONOR POOL THROUGH INTENSIVE CARE TREATMENT TO FACILITATE ORGAN DONATION: RESULTS OF A SPANISH MULTICENTER STUDY

Beatriz Dominguez-Gil
Madrid, Spain

552.6 DECEASED ORGAN DONATION PERFORMANCE IN THE CHINESE COMMUNITY: AN AUDIT OF HOSPITAL MEDICAL RECORD IN HONG KONG

Chi Yuen Simon Cheung
Hong Kong SAR, P.R. of China
552.7 ALLOCATION OF EXTENDED CRITERIA DECEASED DONOR KIDNEYS BASED ON EXPLANT BIOPSY AND MODIFIED REMUZZI SCORES OPTIMIZES THEIR UTILIZATION
Anantharaman Vathsala
Singapore, Singapore

552.8 50 YEARS OF TRANSPLANTATION IN POLAND
Roman Danielewicz
Warsaw, Poland

552.9 RISKY ORGANS: TRENDS IN COMORBIDITIES AMONG POTENTIAL AND ACTUAL AUSTRALIAN ORGAN DONORS IN NEW SOUTH WALES
Imogen K. Thomson
Sydney, Australia

15:30 - 17:00
HALL 5E2-LEVEL 5

Orals Session: Living Donor Transplant
Chairs: Paul Harden, Oxford, United Kingdom
Mona Alrukhaimi, Dubai, United Arab Emirates

553.1 ADVERSE EARLY OUTCOMES FOR RIGHT-SIDED LIVING DONOR KIDNEY TRANSPLANTS
Deepak Chhabra
Sydney, Australia

553.2 GLOBAL KIDNEY EXCHANGE
Michael A. Rees
Toledo, OH, United States

553.3 CHRONIC KIDNEY DISEASE AMONG LIVING KIDNEY DONORS: A COHORT STUDY
Philip Masson
Edinburgh, United Kingdom

553.4 TECHNIQUE AND OUTCOME OF ROBOTIC KIDNEY TRANSPLANTATION IN 161 ADULT RECIPIENTS
Pranjal Modi
Ahmedabad, India
553.5 TRANSVAGINAL INSERTION OF KIDNEY AND ROBOTIC KIDNEY TRANSPLANTATION: FIRST 19 CASES

Pranjal Modi
Ahmedabad, India

553.6 PRELIMINARY RESULTS FROM A PILOT STUDY UTILIZING ERAS PROTOCOL IN LIVING DONOR NEPHRECTOMY

Debra L. Sudan
Durham, NC, United States

553.7 OBESITY IS ASSOCIATED WITH INCREASED RISK OF ESRD AMONG LIVING KIDNEY DONORS

Jayme E. Locke
Birmingham, AL, United States

553.8 WHAT DISTINGUISHES DONORS FROM NON-DONORS? ANALYSIS OF 2306 POTENTIAL LIVING KIDNEY DONORS

Hillary J. Braun
San Francisco, CA, United States

553.9 ESTABLISHING A LEARNING CURVE FOR LAPAROSCOPIC LIVING DONOR NEPHRECTOMY

Zubir Ahmed
London, United Kingdom

15:30 - 17:00
S-221-LEVEL 2

Orals Session:
Enhanced Surgical Techniques in Transplantation (Videos)

Chairs: George W. Burke, Miami, FL, United States
        Henry H.P. Pleass, Hunters Hill, Australia

554.1 ROBOTIC SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION IN OBESE RECIPIENT

Chun Chieh Yeh
Taichung, Taiwan

554.2 TIPS FOR A SUCCESSFUL NORMOTHERMIC LIVER PERFUSION

David Nasralla
Oxford, United Kingdom
554.3 CONTRAST-ENHANCED INTRAOPERATIVE ULTRASONIC CHOLANGIOGRAPHY IN LIVING DONOR HEPATECTOMY
Takeshi Urad
Kobe, Japan

554.4 TOTAL ARTIFICIAL HEART BRIDGE TO COMBINED HEART-LIVER TRANSPLANTATION FOR TRANSTHYRETIN AMYLOIDOSIS
Amit Sharma
Richmond, VA, United States

554.5 ROBOTIC ASSISTED KIDNEY TRANSPLANTATION
Selcuk Sahin
Istanbul, Turkey

554.6 RENO- AND SPLENOPORTAL ANASTOMOSIS FOR A RETRANSPANT PATIENT WITH SITUS INVERSUS
Hajime Uchida
Tokyo, Japan

554.7 A CASE OF DECEASED DONOR LIVER TRANSPLANTATION USING RENOPORTAL ANASTOMOSIS IN PATIENTS WITH DIFFUSE PORTOMESENTERIC THROMBOSIS
Tae-Seok Kim
Daegu, Korea

15:30 - 17:00
THEATRE 1-LEVEL 1
Orals Session: Tolerance - Immunological Aspects

Chairs: Alberto Sanchez-Fueyo, London, United Kingdom
Sandy Feng, San Francisco, CA, United States

555.1 PRIMARY OUTCOME OF IWITH: A 12 CENTER NORTH AMERICAN CLINICAL TRIAL OF IMMUNOSUPPRESSION WITHDRAWAL IN STABLE PEDIATRIC LIVER TRANSPLANT RECIPIENTS
Sandy Feng
San Francisco, CA, United States
555.2 AT1R ANTIBODIES AT 1-YEAR NEGATIVELY IMPACT 5-YEAR NATIVE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS
Duska Dragun
Berlin, Germany

555.3 THE IMPACT OF PREFORMED DONOR-SPECIFIC ANTIBODIES IN LIVING DONOR LIVER TRANSPLANTATION DEPENDING ON GRAFT VOLUME
Ryoichi Goto
Sapporo, Japan

555.4 THE STRATEGY FOR LIVING DONOR LIVER TRANSPLANTATION IN THE RECIPIENTS WITH PREFORMED DONOR SPECIFIC ANTIBODIES
Atsushi Yoshizawa
Kyoto, Japan

555.5 OUTCOMES OF SIROLIMUS CONVERSION FOR CALCINEURIN INHIBITOR INDUCED NEUROTOXICITY IN LIVER TRANSPLANTATION
Greg J. McKenna
Dallas, TX, United States

555.6 COMPARISON OF THE EFFECTS OF BRAND NAME VERSUS GENERIC IMMUNOSUPPRESSANTS ON LONG-TERM GRAFT FAILURE RISK AMONG U.S. LIVER TRANSPLANT RECIPIENTS: ANALYSIS OF SRTR AND MEDICARE CLAIMS DATA
Jarcy Zee
Ann Arbor, MI, United States

555.7 NORMAL LIVER ENZYMES DO NOT EXCLUDE SIGNIFICANT PATHOLOGY IN LIVER TRANSPLANT RECIPIENTS
Richard Gilroy
Fairway, KS, United States

555.8 PREFERENTIAL ACCUMULATION OF T HELPER CELLS BUT NOT CYTOTOXIC T CELLS CHARACTERIZES BENIGN SUBCLINICAL REJECTION OF HUMAN LIVER ALLOGRAFTS
Richard Taubert
Hannover, Germany

555.9 EXPERIENCE WITH mTOR INHIBITORS IN PEDIATRIC LIVER TRANSPLANTATION
Figen Ozcay
Ankara, Turkey
Orals Session: Chronic Allograft Injury

Chairs: Michael Mengel, Edmonton, AB, Canada  
Rudolf Oehler, Vienna, Austria

556.1 MODELS OF ALLOGRAFT FAILURE IN PRIMARY RENAL TRANSPLANT RECIPIENTS WITH ANTI-HLA ALLOANTIBODIES (DSA)
Matthew J. Everly  
Los Angeles, CA, United States

556.2 TUBULOINTERSTITIAL EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR IN RENAL ALLOGRAFT PROTOCOL BIOPSIES AT 3 MONTHS PREDICTS INTERSTITIAL FIBROSIS AT 5 YEARS
Thomas Vanhove  
Leuven, Belgium

556.3 EFFECT OF EPIGENETIC MODIFICATIONS IN GRAFT KIDNEYS PROGRESSING TO CHRONIC ALLOGRAFT DYSFUNCTION
Sai Vineela Bontha  
Charlottesville, VA, United States

556.4 INFLAMMATION IN SCARRING ON 1 YEAR SURVEILLANCE BIOPSIES DOES NOT CHANGE THE 5 YEAR PROGNOSTIC OF KIDNEY TRANSPLANTATION
Magali Giral  
Nantes, France

556.5 THE ONE YEAR RENAL BIOPSY INDEX (1-RBI): A CLINICAL MARKER TO SCREEN PATIENTS FOR ONE YEAR SURVEILLANCE BIOPSY INDICATION AFTER THE TRANSPLANTATION
Magali Giral  
Nantes, France

556.6 ANGIOTENSIN SYSTEM BLOCKADE REDUCE PROTEINURIA IN KIDNEY TRANSPLANT RECIPIENTS: A META-ANALYSIS
Guodong Chen  
Guangzhou, People’s Republic of China
556.7 CHEMOKINE RECEPTOR CXCR4 ANTAGONIST, A NOVEL PATHWAY TO PREVENT CHRONIC ALLOGRAFT NEPHROPATHY

Yue Xu
Beijing, People’s Republic of China

556.8 PERIPHERAL NK-CELL REPERTOIRE DISTRIBUTION IN CHRONIC ALLOGRAFT DYSFUNCTION AFTER RENAL TRANSPLANTATION

Sailaja Kesiraju
Hyderabad, India

556.9 PROGRESSIVE ALLOGRAFT DYSFUNCTION IS ASSOCIATED WITH AN EARLY (12 MONTHS) INCREASE IN LEVELS OF VEGF-C, PLGF AND FOLLISTATIN AFTER RENAL TRANSPLANTATION

Marlies Reinders
Leiden, The Netherlands

15:30 - 17:00
CONVENTION HALL A-LEVEL 1

Orals Session: Interplay Between Innate: Adaptive Immune Cells

Chairs: Dany Anglicheau, Paris, France
        Xunrong Luo, Chicago, IL, United States

557.1 QUANTIFICATION OF LYMPHATIC FLOW USING SPECT/CT LYMPHOSCINTIGRAPHY REVEALS INCREASED LYMPH FLOW DURING CHRONIC REJECTION

Wilson Wong
London, United Kingdom

557.2 RECEPTOR TYROSINE KINASE MER MEDIATES EXPANSION OF MDSCS CRITICAL FOR TRANSPLANTATION TOLERANCE

Xunrong Luo
Chicago, IL, United States
557.4 REGULATORY T CELLS WITH HLA-A*02-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CAN CONTROL STRONG ALLOGENEIC IMMUNE RESPONSES AND INDUCE OPERATIONAL TOLERANCE

Elmar Jaeckel
Hannover, Germany

557.5 miRNA-181 PROMOTES GRAFT PROLONGATION BY PLASMACYTOID DENDRITIC CELLS BY DECREASING MARGINAL ZONE B CELLS AND PLASMABLASTS

Olivia M. Martinez
Stanford, CA, United States

557.6 MOLECULAR LANDSCAPE OF ALLOGRAFT REJECTION: DEFINITIVE MAPPING OF SHARED AND SELECTIVE MOLECULES FOR T CELL-MEDIATED REJECTION AND ANTIBODY-MEDIATED REJECTION

Philip F. Halloran
Edmonton, AB, Canada

557.7 EXOSOMES RELEASED INTO THE CIRCULATION FOLLOWING LUNG AND HEART TRANSPLANTATION: COMPOSITION AND ROLE IN ALLOGRAFT REJECTION

Thalachallour Mohanakumar
Phoenix, AZ, United States

557.8 NK CELLS ARE REQUIRED IN B-CELL DEPENDENT ANTIBODY MEDIATED ISLET TRANSPLANT TOLERANCE

Christian Schuetz
Boston, MA, United States

557.9a THE ROLE OF DNA METHYLATION OF INTERFERON GAMMA AND PROGRAMMED DEATH 1 IN ALLOGRAFT REJECTION AFTER KIDNEY TRANSPLANTATION

(abst. P. 1005 in Transplantation Journal)

Carla Baan
Rotterdam, The Netherlands
**Orals Session:** Making it Work: Challenges in Immunosuppression

**Chairs:** Henri G.D. Leuvenink, Groningen, The Netherlands  
Tianshu Zhang, Baltimore, MD, United States

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.1</td>
<td>HUMAN ENDOTHELIAL-LIKE CELLS TRANSDIFFERENTIATED FROM MONOCYTES SUPPRESS ALLO-REACTIVE T CELLS</td>
<td>Yuka Tanaka</td>
<td>Hiroshima, Japan</td>
</tr>
<tr>
<td>558.2</td>
<td>INTERACTION BETWEEN MICROCHIMERISM-DERIVED EXOSOMES AND HOST DENDRITIC CELLS GENERATES SPLIT TOLERANCE</td>
<td>William J. Burlingham</td>
<td>Madison, WI, United States</td>
</tr>
<tr>
<td>558.3</td>
<td>HIGH-LEVEL CO-EXPRESSION OF CD86 IN RECIPIENT HEPATOCYTES TRANSDUCED WITH AAV-KD BREAKS TOLERANCE TO KD-BEARING SKIN GRAFTS</td>
<td>Mario L. Leong</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>558.4</td>
<td>A COMPARISON OF ANTI-CD28 (FR104) AND ANTI-B7 (BELATACEPT) IMMUNOTHERAPY IN MONKEY CARDIAC ALLOGRAFT TRANSPLANTATION</td>
<td>Tianshu Zhang</td>
<td>Baltimore, MD, United States</td>
</tr>
<tr>
<td>558.5</td>
<td>SELECTIVE BLOCKADE OF CD28 COSTIMULATION PREVENTED HUMAN ALLO-SKIN GRAFT REJECTION IN A HUMANISED MOUSE MODEL</td>
<td>Masaaki Zaitsu</td>
<td>Sapporo, Japan</td>
</tr>
<tr>
<td>558.6</td>
<td>MODULATION OF INFLUENZA-SPECIFIC HUMORAL RESPONSES BY SELECTIVE CD28 BLOCKADE</td>
<td>Agnes Azimzadeh</td>
<td>Baltimore, MD, United States</td>
</tr>
</tbody>
</table>
558.7 MODULATION OF THE IMMUNE SYSTEM BY SECRETOME-DEFICIENT MALIGNOCYMAL STEM CELLS

Franka Luk
Rotterdam, The Netherlands

558.8 UPREGULATION OF HEME OXYGENASE-1 IN IMMATURE DENDRITIC CELLS IMPROVES THEIR TOLEROGENIC CAPACITY IN ALLOTRANSPLANTATION

Gang Chen
Wuhan, People’s Republic of China

558.9 INDEFINITE SURVIVAL OF MURINE KIDNEY ALLOGRAFTS INDUCED BY DEPLETION OF DONOR PASSENGER LEUKOCYTES

Wilson Wong
London, United Kingdom

15:30 - 17:00
CONVENTION HALL C-LEVEL 1

Orals Session:
Diagnosis and Monitoring of Rejection (II)

Chairs: Menna R. Clatworthy, Cambridge, United Kingdom
Emmanuel Zorn, New York, NY, United States

559.1 IMMUNOGLOBULIN M THERAPY PREVENTS DEVELOPMENT OF TYPE 1 DIABETES BY MODULATING THE EXPRESSION OF DYSREGULATED PANCREATIC microRNAs ASSOCIATED WITH DISEASE PATHOGENESIS

Kenneth L. Brayman
Charlottesville, VA, United States

559.2 THE ROLE OF CALCINEURIN INHIBITION IN THE DENDRITIC CELL RESPONSE TO ASPERGILLUS FUMIGATUS INFECTION IN LUNG TRANSPLANT RECIPIENTS

Amit G. Adlakha
London, United Kingdom

559.3 HUMAN B CELL CYTOKINES PREDICT RENAL ALLOGRAFT REJECTION AND EARLY TRANSPLANT OUTCOMES

Aravind Cherukuri
Pittsburgh, PA, United States
559.4 TRANSITIONAL B CELL T1/T2 RATIO IS A PROGNOSTIC MARKER FOR HUMAN RENAL ALLOGRAFT DETERIORATION

David Rothstein
Pittsburgh, PA, United States

559.5 THE UNHOLY TRIAD OF INFLAMMATION, INFECTION AND IMMUNE REJECTION OF THE KIDNEY ALLOGRAFT: PARTNERS IN CRIME?

Thangamani Muthukumar
New York, NY, United States

559.6 THE HET/HOM RATIO CALCULATED FROM RNA-SEQ DATA: A UNIVERSAL AND UNBIASED QUANTITATIVE MEASURE OF IMMUNE CELL INVASION INTO HUMAN ALLOGRAFTS

Thangamani Muthukumar
New York, NY, United States

559.7 IMPORTANCE OF THE NATURE AND BINDING SPECIFICITY OF THE SECONDARY ANTIBODY USED IN LUMINEX SINGLE ANTIGEN BEAD ASSAYS FOR MONITORING CLINICALLY RELEVANT HLA IgG ANTIBODIES IN PRE- AND POST-TRANSPLANT PATIENTS

Mepur H. Ravindranath
Los Angeles, CA, United States

559.8 DE-NOVO DONOR SPECIFIC ANTIBODIES (DSA) MONITORING IN LIVING RELATED TRANSPLANTATION

Rajkumar Sharma
Lucknow, India

559.9 EVIDENCE FOR STRUCTURAL VARIANTS WITHIN AN INDIVIDUAL HLA-I MOLECULE COATED ON LUMINEX SINGLE ANTIGEN BEAD ASSAYS: IMPACT ON MONITORING HLA ANTIBODIES FOR ORGAN ALLOCATION AND DE NOVO DSA IN TRANSPLANT PATIENTS

Vadim Jucaud
Los Angeles, CA, United States
17:00 - 18:00
CONVENTION HALL A-LEVEL 1
NOT A CME SESSION

Society Meeting:
TTS Business Meeting

18:00 - 18:20
HALL 5FG-LEVEL 5 (Behind TTS booth in aisle 500)
NOT A CME SESSION

ISN-TTS Sister Transplantation Center Program

565 PRESENTATION OF ISN-TTS SISTER TRANSPLANTATION CENTER PROGRAM

Randall Lou Meda
Guatemala, Guatemala

Abdullah El-Kishawi
Gaza City, Palestine

18:00 - 19:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

Campfire Presentations:
Immunossuppression - Campfire Table 1

Chairs: Luis E. Morales-Buenrostro, Mexico City, Mexico
Maggie Kam Man Ma, Hong Kong SAR, P.R. of China

570.1 EVALUATION OF PK PROFILE AND CLINICAL OUTCOMES WITH HEXAL® VERSUS PROGRAF® IN DE NOVO RENAL TRANSPLANT RECIPIENTS: RESULTS FROM SPARTACUS - A MULTICENTRE, PROSPECTIVE RANDOMIZED STUDY

Peter Schenker
Bochum, Germany

570.2 REDUCED INCIDENCE OF CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS: A COST-EFFECTIVENESS ANALYSES

Jose Medina Pestana
Sao Paulo, Brazil
570.3 ABBREVIATED THYMoglobulin AND BASILIXIMAB INDUCTION THERAPY IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION RESULTS IN SUPERIOR GRAFT AND PATIENT SURVIVAL WITH LESS INFECTIOUS COMPLICATIONS
Vaughn E. Whittaker
Manlius, NY, United States

570.4 COMPARISON OF MYCOPHENOLIC ACID (MPA) EXPOSURE AFTER CONVERSION FROM ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) TWICE-DAILY TO ONCE-DAILY IN ADULT KIDNEY TRANSPLANT RECIPIENTS
Diego Cantarovich
Nantes, France

570.5 IMPACT OF EARLY RED BLOOD CELL TRANSFUSION AFTER KIDNEY TRANSPLANTATION ON DE NOVO HLA SENSITIZATION IN THE SETTING OF ANTITHYMOCYTE GLOBULIN INDUCTION
Lionel Rostaing
Toulouse, France

570.6 EVALUATION OF GENETIC VARIANTS IN DIABETES SUSCEPTIBILITY GENES AND DISPOSITION-RELATED GENES AS RISK FACTORS FOR THE DEVELOPMENT OF NEW-ONSET DIABETES AFTER TRANSPLANTATION IN SINGAPORE ASIAN ADULT KIDNEY TRANSPLANT RECIPIENTS
Wai-Ping Yau
Singapore, Singapore
Campfire Presentations: Complications - Campfire Table 2

**Chairs:** Man Fai Lam, Hong Kong SAR, P.R. of China
            Ignatius Kum-Po Cheng, Hong Kong SAR, P.R. of China

**571.1** MANAGEMENT OF HUMORAL REJECTION IN RENAL TRANSPLANTATION: RESULTS OF A SINGLE CENTER

*Mahir Kirnap*
Ankara, Turkey

**571.2** NEVER EVENTS AND HOSPITAL ACQUIRED CONDITIONS AFTER KIDNEY TRANSPLANT

*Linda J. Chen*
Miami, FL, United States

**571.3** CLINICAL OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION ON PATIENTS WITH CARDIAC ALLOGRAFT VASCULOPATHY

*Raymond Chi-yan Fung*
Hong Kong SAR, P.R. of China

**571.4** NKG2A+ NATURAL KILLER CELLS DOMINATE THE RESPONSE TO LATENT EPSTEIN-BARR VIRUS INFECTION

*Olivia M. Martinez*
Stanford, CA, United States

**571.5** ERYTHROPOIETIN LEVEL AND POST-TRANSPLANT ANEMIA: A COMPARISON OF LIVING RELATED KIDNEY TRANSPLANT, STANDARD DECEASED DONOR KIDNEY TRANSPLANT, AND EXPANDED CRITERIA DECEASED DONOR KIDNEY TRANSPLANT

*Kanin Thammavaranucupt*
Bangkok, Thailand

**571.6** MDR1 C3435T, C1236T AND G2677T/A POLYMORPHISMS IN RENAL TRANSPLANT PATIENTS WITH TREMOR

*Maria Outea Macias III*
A Coruña, Spain
Campfire Presentations: Infectious Diseases - Campfire Table 3

18:00 - 19:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

**Chairs:** Mirza Naqi Zafar, Karachi, Pakistan
Deborah Marriott, Sydney, Australia

572.1 THE VALUE OF INTERFERON-GAMMA RELEASING ASSAYS (IGRA) DETERMINING LATENT TUBERCULOSIS INFECTION IN RENAL TRANSPLANT CANDIDATES

Füsun Eyüboglu
Ankara, Turkey

572.3 CATHETER-ASSOCIATED URINARY TRACT INFECTION (CAUTI) IN KIDNEY TRANSPLANT RECIPIENTS IS HIGH COST BURDEN AND PROLONG HOSPITAL STAY, REPORT FROM A SINGLE CENTER IN THE NORTHEASTERN THAILAND

Ubonrat Toimamueang
Khon Kaen, Thailand

572.4 MYCOBACTERIUM TUBERCULOSIS IN SOLID ORGAN TRANSPLANTATION, IMPACT OF EXPANDED ISONIAZID PROPHYLAXIS

Hassan A. Aleid
Riyadh, Saudi Arabia

572.5 BLOODSTREAM INFECTIONS AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RISK FACTORS, ETIOLOGIC SPECTRUM AND PREDICTORS OF FATAL OUTCOME

Igor Stoma
Minsk, Belarus

572.6 THE FREQUENCY OF PRETRANSPLANT HHV-8 AND BKV IN RENAL TRANSPLANT RECIPIENTS AND DONORS AND THE EFFECT OF RENAL TRANSPLANTATION ON HHV-8 AND BKV REPLICATIONS

Aydin Turkmen
Istanbul, Turkey
Campfire Presentations
Intestine - Campfire Table 4

Chairs: Hiroto Egawa, Tokyo, Japan
Gabriel E. Gondolesi, Buenos Aires, Argentina

573.1 SERIAL TRANSVERSE ENTEROPLASTY FOR PATIENTS WITH SHORT BOWEL SYNDROME SECONDARY TO RADIATION THERAPY

Yousheng Li
Nanjing, People’s Republic of China

573.2 THE PROPHYLACTIC EFFECT OF SECRETIN FOR INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE

Yousheng Li
Nanjing, People’s Republic of China

573.3 SURGICAL CHALLENGES IN THE LONGTERM FOLLOW-UP AFTER INTESTINAL AND MULTIVISCERAL TRANSPLANTATION

Undine Gerlach
Berlin, Germany

573.4 CLINICAL PRESENTATION AND OUTCOME OF NOROVIRUS ENTERITIS IN SMALL BOWEL TRANSPLANT RECIPIENTS COMPARED TO NON-SMALL BOWEL TRANSPLANT RECIPIENTS

Diana F. Florescu
Omaha, NE, United States

573.5 CONDITIONAL LONG TERM INTESTINE PATIENT AND GRAFT SURVIVAL IS IMPROVING UNDER rATG IMMUNOSUPPRESSION IN PEDIATRIC INTESTINE TRANSPLANTATION

Neslihan Celik
Pittsburgh, PA, United States

573.6 THE EFFECT OF PROBIOTICS ON THE HEALING OF COLON ANASTOMOSIS AFTER ISCHEMIA AND REPERFUSION INJURY IN THE RAT

Necdet Ozcan
Ankara, Turkey
### 18:00 - 19:00
**HALL 5FG-LEVEL 5**
**NOT A CME SESSION**

**Campfire Presentations: Ethical Dilemmas in Donation and Transplantation - Campfire Table 5**

*Chairs: Dominique E. Martin, Geelong, Australia  
Allison Tong, Sydney, Australia*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>574.1</td>
<td>PUBLIC PROMOTION OF UNSPECIFIED LIVE KIDNEY DONATION: AN ELPAT VIEW</td>
<td>Frank J.M.F. Dor</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>574.2</td>
<td>DOES PRIVACY EXIST IN DIRECTED ORGAN DONATION</td>
<td>Alvin Wee</td>
<td>Indianapolis, ID, United States</td>
</tr>
<tr>
<td>574.3</td>
<td>TRANSPLANT VOLUME IN CHINA</td>
<td>David Matas</td>
<td>Winnipeg, MB, Canada</td>
</tr>
<tr>
<td>574.4</td>
<td>INTERNATIONAL INITIATIVE TO ENHANCE THE ORGAN DONATION AND TRANSPLANTATION SYSTEMS IN THE BLACK SEA AREA: THE BSA PROJECT</td>
<td>Marti Manyalich</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>574.5</td>
<td>THE EFFECT OF THE SYRIAN CRISIS ON ORGAN TRANSPLANTATION IN SYRIA</td>
<td>Bassam Saeed</td>
<td>Damascus, Syrian Arab Republic</td>
</tr>
<tr>
<td>574.6</td>
<td>ESTABLISHING CREDIBLE EVIDENCE OF HUMAN ORGAN TRAFFICKING. THE NEED TO EFFECTIVELY MANAGE PURPORTED ORGAN TRAFFICKING CLAIMS ORIGINATING FROM SPECIAL INTEREST GROUPS</td>
<td>Campbell Fraser</td>
<td>Brisbane, Australia</td>
</tr>
</tbody>
</table>
18:00 - 19:00
HALL 5FG-LEVEL 5
NOT A CME SESSION

Poster Sessions
Detailed list of all the posters available on page 273

19:00 - 22:00
OFFSITE: JUMBO KINGDOM
SHUM WAN PIER DR., ABERDEEN
TICKETED EVENT $

Congress Networking Evening
Please see details on page 72
Plenary: Transformational Sciences in Transplantation? (Hall 5E3 - L5)
Proteomics: Eavesdropping on Communicating Immune Cells - Dr. Felix Meissner
mTOR Pathway in Aging & Chronic Disease - Dr. Brian K. Kennedy
CRISPR/Cas9 – The Promise of Gene Editing Technologies in Transplantation - Prof. Alfred Joseph Tector

Coffee Break (Hall 5E - South Concourse)

Plenary: What Changes Will We See in TX. over the Next Five Years? (Hall 5E3 - L5)
Basic Sciences - Prof. Carla Baan / Clinical Sciences - Dr. John S. Gill

Closing Ceremony (Hall 5E3 - L5)
THANK YOU for attending!

TTS 2016
26th International Congress of the Transplantation Society
Hong Kong
August 18–23

See you in Madrid in 2018!
07:00 - 08:15
THEATRE 1-LEVEL 1
Early Morning Symposia: B Cells and Antibodies

Chairs: Shane T. Grey, Darlinghurst, Australia
       Menna R. Clatworthy, Cambridge, United Kingdom

600.1 BAFF AS A REGULATOR TREG AND BREG
Shane T. Grey
Darlinghurst, Australia

600.2 MODULATING TFH IN HUMANS
Di Yu
Clayton, Australia

600.3 WHAT DOES THE ANTIBODY SEE
Anat R. Tambur
Chicago, IL, United States

600.4 REGULATORY B/PLASMA CELLS IN TRANSPLANTATION
Menna R. Clatworthy
Cambridge, United Kingdom

07:00 - 08:15
THEATRE 2-LEVEL 1
Early Morning Symposia: New Challenges in VCA

Chairs: Fadi Issa, Oxford, United Kingdom
       Stefan Schneeberger, Innsbruck, Austria

601.1 CHRONIC REJECTION IN VCA
Olivier Thaunat
Lyon, France

601.2 NON-MYELOABLATIVE APPROACH FOR TOLERANCE INDUCTION IN VCA
Suzanne T. Ildstad
Louisville, KY, United States

601.3 EXIT STRATEGIES IN VCA
Emmanuel Morelon
Lyon, France

601.4 ONGOING EFFORTS OF UNOS TO ESTABLISH VCA GUIDELINES
Sue McDiarmid
Los Angeles, CA, United States
07:00 - 08:15
CONVENTION HALL A-LEVEL 1

Early Morning Symposia: Establishing Normothermic Organ Perfusion Systems

Chairs: Marti Manyalich, Barcelona, Spain
       Feng Huo, Guangzhou, People’s Republic of China

602.1 KIDNEY
Michael L. Nicholson
Cambridge, United Kingdom

602.2 LIVER
Constantino Fondevila
Barcelona, Spain

602.3 HEART
Peter S. MacDonald
Sydney, Australia

07:00 - 08:15:
CONVENTION HALL B-LEVEL 1

Early Morning Symposia: Understanding Immune Responses to Transplanted Beta Cells

Chairs: Dixon B. Kaufman, Madison, WI, United States
       Carole Guillonneau, Nantes, France

603.1 MONITORING AUTOIMMUNITY PRE- AND POST-TRANSPLANT
George W. Burke
Miami, FL, United States

603.2 PROLONGING ISLET ALLOGRAFT SURVIVAL: MONITORING AND PREVENTING LATE ISLET LOSS
Thierry P.S. Berney
Geneva, Switzerland

603.3 OPTIMIZING SURVIVAL OF STEM CELL DERIVED BETA CELL SURVIVAL EARLY AFTER TRANSPLANT
Qizhi Tang
San Francisco, CA, United States
07:00 - 08:15
CONVENTION HALL C-LEVEL 1
Early Morning Symposia:
International Registries - What, Why and How

Chairs: Stephen McDonald, Adelaide, Australia
       Caner Süsal, Heidelberg, Germany

604.1 CONTRIBUTIONS OF THE SCIENTIFIC COLLABORATIVE TRANSPLANT STUDY

Caner Süsal
Heidelberg, Germany

604.2 IN THE WORLD OF LEVEL 1 EVIDENCE RCT, WHAT CAN REGISTRIES ADD?

Stephen McDonald
Adelaide, Australia

604.4 TOWARDS A GLOBAL TRANSPLANT REGISTRY

José Ramón Núñez Peña
Geneva, Switzerland

08:30 - 10:00
HALL 5E3-LEVEL 5
Plenary:
Transformational Sciences in Transplantation?

Chairs: Mehmet Haberal, Ankara, Turkey
       TBA

610.1 PROTEOMICS: EAVESDROPPING ON COMMUNICATING IMMUNE CELLS

Felix Meissner
Martinsried/Munich, Germany

610.2 mTOR PATHWAY IN AGING & CHRONIC DISEASE

Brian K. Kennedy
Novato, CA, United States

610.3 CRISPR / CAS9 - THE PROMISE OF GENE EDITING TECHNOLOGIES IN TRANSPLANTATION

Alfred Joseph Tector
Birmingham, AL, United States
10:00 - 10:30
COFFEE BREAK
HALL 5E - SOUTH CONCOURSE

10:30 - 12:00
HALL 5E3-LEVEL 5

Orals Session: Complications and Immunosuppression

Chairs: Adisorn Lumpaopong, Bangkok, Thailand
         Graeme R. Russ, Adelaide, Australia

620.1 PREGNANCY OUTCOMES IN FEMALE SOLID ORGAN TRANSPLANT RECIPIENTS WITH EXPOSURE TO MYCOPHENOLIC ACID PRODUCTS

Michael J. Moritz
Emmaus, PA, United States

620.2 EVALUATION OF IMMUNOSUPPRESSIVE REGIMENS ON THE INCIDENCE OF NEW-ONSET DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION: 24-MONTH ANALYSIS OF THE ELEVATE STUDY

Steve J. Chadban
Camperdown, Australia

620.3 RAPID DISCONTINUATION OF PREDNISONE (RDP) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS: 15-YEAR OUTCOMES

Arthur Matas
Minneapolis, MN, United States

620.4 HIGH INTRAPATIENT VARIABILITY OF TACROLIMUS CONCENTRATIONS PREDICTS ACCELERATED PROGRESSION OF CHRONIC HISTOLOGIC LESIONS IN RENAL RECIPIENTS

Thomas Vanhove
Leuven, Belgium

256
26th International Congress of The Transplantation Society
620.5 EVEROLIMUS (EVR) VERSUS MYCOPHENOLATE SODIUM (MPS) FOR RECIPIENTS OF KIDNEY TRANSPLANTS FROM EXPANDED CRITERIA DONORS (ECD) RECEIVING ANTI-THYMOCYTE GLOBULIN (r-ATG) AND TACROLIMUS (TAC)

Jose Medina Pestana
Sao Paulo, Brazil

620.6 EARLY CONVERSION TO PREDNISOLONE AND EVEROLIMUS FROM A CALCINEURIN-INHIBITOR-CONTAINING TRIPLE DRUG THERAPY AS AN ALTERNATIVE WEANING REGIMEN ASSOCIATED WITH BENEFICIAL RENAL TRANSPLANT HISTOLOGY AND FUNCTION: THE RANDOMIZED-CONTROLLED MECANO TRIAL

Jesper Kers
Amsterdam, Netherlands

620.7 HIGH TACROLIMUS VARIABILITY IS ASSOCIATED WITH THE EMERGENCE OF DE-NOVO DONOR SPECIFIC ANTIBODY

Marc J. Clancy
Glasgow, United Kingdom

620.8 COMPARISON OF THE EFFECTS OF BRAND NAME VERSUS GENERIC IMMUNOSUPPRESSANTS ON LONG-TERM GRAFT FAILURE RISK AMONG U.S. KIDNEY TRANSPLANT RECIPIENTS: ANALYSIS OF SRTR AND MEDICARE CLAIMS DATA

Jarcy Zee
Ann Arbor, MI, United States

620.9 EFFICACY AND SAFETY OF A 4-MONTH POST-RENAI TRANSPANT DOSE REDUCTION OF TACROLIMUS PROLONGED-RELEASE

Philippe Gatault
Tours, France
10:30 - 12:00
HALL 5D-LEVEL 5
Orals Session
Pancreas & Islet Tx: Immunosuppression and Immunology

Chairs:  Raja Kandaswamy, Minneapolis, MN, United States
        Duck-Jong Han, Seoul, Korea

621.1  CNI VS CNI-FREE IMMUNOSUPPRESSION: IMPACT ON 1-YEAR KIDNEY PROTOCOL BIOPSY FOLLOWING SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION

Diego Cantarovich
Nantes, France

621.2  RABBIT ANTI-THYMOCYTE IN SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION: DOES DURATION MATTER?

Karen L. Hardinger
Kansas City, KS, United States

621.3  ASSOCIATION OF AUTOREACTIVE MEMORY CD4 T CELLS EXPRESSING THE CHEMOKINE RECEPTOR CXCR3 IN THE PERIPHERAL BLOOD OF PANCREAS-KIDNEY TRANSPLANT RECIPIENTS WITH TYPE 1 DIABETES RECURRENCE

George W. Burke
Miami, FL, United States

621.4  EMPIRIC DOSE REDUCTION IS A RISK FOR LATE ACUTE REJECTION DESPITE ALEMTUZUMAB INDUCTION IN STEROID-FREE SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANT RECIPIENTS

J. R. Bank
Leiden, The Netherlands

621.5  THE CLINICAL RELEVANCE OF ONE-WAY ZERO HLA MISMATCHES AMONG POST-PANCREAS TRANSPLANT ACUTE GRAFT-VERSUS HOST DISEASE POPULATION

Yoshihide Nanno
Kobe, Japan

621.6  DE-NOVO DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN ISLET CELL TRANSPLANT RECIPIENTS IN AUSTRALIA

Siu Man Hue
Hong Kong SAR, P.R. of China
<table>
<thead>
<tr>
<th>Session ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>621.7</td>
<td>APPLICATION OF TREATMENT WITH PLASMAPHERESIS AND IMMUNOGLOBULINS FOR HIGH LEVEL OF HLA DONOR SPECIFIC ANTIBODIES IN ISLET ALLOGRAFT RECIPIENTS</td>
<td>Julia Solomina</td>
<td>Chicago, IL, United States</td>
</tr>
<tr>
<td>621.8</td>
<td>TYPE ONE DIABETES DECEASED ORGAN DONOR ISOLATED HUMAN ISLET-INFILTRATING CD4+ T CELLS RECOGNIZE A DEAMIDATED PROINSULIN EPITOPE PRESENTED BY HLA-DQ8</td>
<td>Vimukti Pathiraja</td>
<td>Sunbury, Australia</td>
</tr>
<tr>
<td>621.9</td>
<td>FIBROBLAST GROWTH FACTOR-21 IN CLINICAL ISLET TRANSPANTATION</td>
<td>Raphael Meier</td>
<td>Geneva, Switzerland</td>
</tr>
</tbody>
</table>

**10:30 - 12:00**

**HALL 5E1-LEVEL 5**

Orals Session: Post Transplant Diabetes and Infectious Complications

**Chairs:** Rudolf A. Garcia-Gallont, Guatemala City, Guatemala  
Yingyos Avihingsanon, Bangkok, Thailand

<table>
<thead>
<tr>
<th>Session ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>622.1</td>
<td>OUTCOMES WITH PRE TRANSPLANT BARIATRIC SURGERY IN RENAL TRANSPLANT RECIPIENTS</td>
<td>Titte R. Srinivas</td>
<td>Charleston, SC, United States</td>
</tr>
<tr>
<td>622.2</td>
<td>POST-TRANSPLANT DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION IN JAPANESE PATIENTS: THE JAPAN ACADEMIC CONSORTIUM OF KIDNEY TRANSPLANTATION STUDY</td>
<td>Kazuya Omoto</td>
<td>Toda, Japan</td>
</tr>
<tr>
<td>622.3</td>
<td>SODIUM/GLUCOSE COTRANSPORTER 2 INHIBITOR FOR THE TREATMENT OF DIABETES IN KIDNEY TRANSPLANT PATIENTS</td>
<td>Jin M. Kong</td>
<td>Busan, Korea</td>
</tr>
</tbody>
</table>
622.4 ABNORMAL GLUCOSE METABOLISM IN DIALYSIS PATIENTS AND ITS CORRELATION WITH THE DEVELOPMENT OF NEW ONSET DIABETES AFTER RENAL TRANSPLANTATION

Manish Rathi
Chandigarh, India

622.5 EPIDEMIOLOGY AND RISK FACTORS FOR INFECTION AFTER LIVING DONOR LIVER TRANSPLANTATION

Cybele Lara R. Abad
Rochester, MN, United States

622.6 POSTOPERATIVE FUNGAL INFECTION IN LIVER TRANSPLANT RECIPIENTS: INDICATOR BUT NOT THE CAUSE OF OVERALL MORTALITY

Katharina Schmidt
Regensburg, Germany

622.7 AN INTERNATIONAL SURVEY OF INFECTIONS AFTER TOTAL ARTIFICIAL HEART TRANSPLANTATION

Heather E. Chambers
Omaha, NE, United States

622.8 RISK FACTORS FOR CLINICAL URINARY TRACT INFECTIONS IN KIDNEY TRANSPLANT RECIPIENTS WITH ASYMPTOMATIC BACTERIURIA

Azemi A. Barama
Montreal, QC, Canada

622.9 BETA CELL FUNCTION AND INSULIN RESISTANCE AFTER THE CONVERSION FROM TACROLIMUS TWICE DAILY TO EXTENDED-RELEASE TACROLIMUS ONCE DAILY IN STABLE RENAL TRANSPLANT RECIPIENTS

Prajje Ruangkanchanasetr
Bangkok, Thailand
10:30 - 12:00
HALL 5E2-LEVEL 5
Orals Session:
Antibody Mediated Injury

**Chair:** Thomas A. Nakagawa, St. Petersburg, FL, United States

623.1 RACIAL DIFFERENCES IN INCIDENT DE NOVO ANTI-HLA ALLOANTIBODIES AMONG PRIMARY RENAL TRANSPLANT RECIPIENTS

Matthew J. Everly
Los Angeles, CA, United States

623.2 IgG DILUTIONS, SUBCLASSES, C1q, AND IgM: WHAT ARE THE IMPORTANT CHARACTERISTICS OF DE NOVO DSA?

Matthew J. Everly
Los Angeles, CA, United States

623.3 MICROARRAY ASSESSMENT OF KIDNEY TRANSPLANT INDICATION BIOPSIES IN REAL TIME: FIRST RESULTS OF THE INTERCOMEX STUDY

Philip F. Halloran
Edmonton, AB, Canada

623.4 EARLY ACCELERATED REJECTION – AN EMERGING DISTINCT ENTITY IN ANTIBODY INCOMPATIBLE RENAL TRANSPLANTATION WHICH CAN BE TREATED

Anna M Adamusiak
London, United Kingdom

623.5 RAPID REMOVAL OF ANTI-HLA ANTIBODIES IN IMMUNIZED PATIENTS - TWO DOSE FINDING STUDIES OF THE IgG DEGRADING ENZYME IdeS

Tomas Lorant
Uppsala, Sweden

623.6 ULTRASTRUCTURAL CHANGES ADD VALUABLE DIAGNOSTIC AND PROGNOSTIC INFORMATION IN EVALUATION OF ANTIBODY-MEDIATED REJECTION (AMR) IN RENAL ALLOGRAFT BIOPSIES

John C. Papadimitriou
Baltimore, MD, United States
623.7 EFFECT OF COMPLEMENT INHIBITION THERAPY (ECULIZUMAB) IN PATIENTS WITH C1Q-BINDING DONOR-SPECIFIC ANTI-HLA ANTIBODIES: A MOLECULAR APPRAISAL

*Carmen Lefaucheur*
Paris, France

623.8 C1-INHIBITOR IN ACUTE ANTIBODY-MEDIATED REJECTION NON-RESPONSIVE TO CONVENTIONAL THERAPY IN KIDNEY TRANSPLANT RECIPIENTS: A PILOT STUDY

*Carmen Lefaucheur*
Paris, France

623.9 COMPOSITE SCORE TO DEFINE THE RISK OF ALLOGRAFT LOSS AFTER STANDARD-OF-CARE TREATMENT OF ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION

*Carmen Lefaucheur*
Paris, France

10:30 - 12:00

**S-221-LEVEL 2**

**Orals Session:**
**Vascularised Composite Allografts**

*Chairs: Sue McDiarmid, Los Angeles, CA, United States*
*Palmina Petruzzo, Lyon, France*

624.1 REFRACTORY VASCULAR REJECTION IN A HAND ALLOGRAFT IN THE PRESENCE OF ANTIBODIES AGAINST ANGIOTENSIN II (TYPE 1) RECEPTOR

*Karen Dwyer*
Victoria, Australia

624.2 ULTRA-HIGH RESOLUTION NON-CONTRAST IMAGING FOR CHRONIC REJECTION MONITORING AND PROCEDURAL PLANNING IN RECONSTRUCTIVE TRANSPLANTATION

*Shailesh B. Raval*
Pittsburgh, PA, United States

624.3 CHRONIC REJECTION IN VASCULARIZED COMPOSITE ALLOTRANSPLANTATION

*Emmanuel Morelon*
Lyon, France
624.4 DYNAMICS AND CORRELATES OF SKIN DENDRITIC CELLS WITH DISTINCTIVE IMMUNE RESPONSE PROFILES IN VASCULARIZED COMPOSITE ALLOGRAFTS

Wensheng Zhang
Pittsburgh, PA, United States

624.5 NOVEL APPROACHES TO ASSESSMENT OF FACIAL NERVE REGENERATION IN A SWINE HEMI-FACIAL COMPOSITE TISSUE FLAP MODEL: A PHYSIOLOGICAL AND HISTOLOGY STUDY

Marissa Suchyta
Rochester, MN, United States

624.6 THE INTERNATIONAL REGISTRY ON HAND AND COMPOSITE TISSUE ALLOTRANSPLANTATION (IRHCTT)

Palmina Petruzzo
Lyon, France

624.7 TRANSLATIONAL CONSIDERATIONS IN WHOLE EYEBALL TRANSPLANTATION - PORCINE MODEL

Vijay Gorantla
Pittsburgh, PA, United States

624.8 ANALYSIS OF ACUTE SKIN REJECTION IN NON-HUMAN PRIMATE MODELS OF FACE AND HAND ALLOTRANSPLANTATION

Zhi Yang Ng
Boston, MA, United States

624.9 INTRA-GRAFT INJECTION OF TACROLIMUS MAY MODULATE LOCAL IMMUNE RESPONSE PROMOTING LONG-TERM ACCEPTANCE OF VASCULARIZED COMPOSITE TISSUE ALLOTRANSPLANTATION

Adriano Taddeo
Bern, Switzerland
10:30 - 12:00
THEATRE 1-LEVEL 1

Orals Session:
Hepatocellular Cancer

Chairs: Yuji Soejima, Fukuoka, Japan
TBA

625.1 DYSREGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR III INDUCES TUMOR PROMOTING MACROPHAGES VIA COMPLEMENT C3A IN HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION

Wai Ho Oscar Yeung
Hong Kong SAR, P.R. of China

625.2 UP-REGULATION OF GSTA2 AT EARLY-PHASE AFTER LIVER TRANSPLANTATION INCREASES THE RISK OF LATE-PHASE HEPATOCELLULAR CARCINOMA RECURRENCE

Kevin Tak-Pan Ng
Hong Kong SAR, P.R. of China

625.3 PATIENTS WITH 18F-FDG NON-AVID HCC ON PET BEYOND UP-TO-SEVEN CRITERIA HAVE AN EXCELLENT OUTCOME FOLLOWING LIVER TRANSPLANTATION

Arno Kornberg
Munich, Germany

625.4 THE CLINICAL SIGNIFICANCE AND POTENTIAL THERAPEUTIC ROLE OF GPx3 IN TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION

Xiang Qi
Hong Kong SAR, P.R. of China

625.5 INFLUENCE OF DONOR AGE AND COLD ISCHEMIA ON RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION

Dilip Moonka
Detroit, MI, United States

625.6 LIVER TRANSPLANTATION OUTCOMES IN PATIENTS WITH PRIMARY LIVER CANCER

Douglas P. Slakey
New Orleans, LA, United States
625.7 INTEGRATIVE ANALYSES OF ACUTE PHASE LIVER GRAFT INJURY ON LATE PHASE TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION

Nikki Lee
Hong Kong SAR, P.R. of China

625.8 A NOVEL PROGNOSTIC INDEX IN PATIENTS WITH HEPATOCELLULAR CANCER WAITING FOR LIVER TRANSPLANTATION: TIME–RADIOLOGICAL-RESPONSE–ALPHA-FETO PROTEIN–INFLAMMATION (TRAIN) SCORE

Jan Lerut
Louvain-la-Neuve, Belgium

625.9 DEGREE OF TUMOR NECROSIS FROM PRE-TRANSPLANT LOCO-REGIONAL THERAPY IS ASSOCIATED WITH TUMOR FREE SURVIVAL AFTER LIVER TRANSPLANTATION

Dilip Moonka
Detroit, MI, United States

10:30 - 12:00 THEATRE 2-LEVEL 1

Orals Session: Adherence and Global Data Approaches

Chairs: Paul Robertson, Westmead, Australia
        Chun Sang Li, Hong Kong SAR, P.R. China

626.1 PROSPECTIVE RANDOMIZED CONTROLLED STUDY EVALUATING THE IMPACT OF AN ELECTRONIC FEEDBACK SYSTEM (EFS) ON MEDICATION ADHERENCE IN SOLID ORGAN TRANSPLANTATION

Adam S. Bodzin
Chicago, IL, United States

626.2 RANDOMIZED CONTROLLED STUDY EVALUATING ADHERENCE MONITORING WITH ELECTRONIC FEEDBACK ON REDUCING RENAL ALLOGRAFT REJECTION

Adam S. Bodzin
Chicago, IL, United States
626.3 IMPORTANCE OF EARLY MEDICATION ADHERENCE FOR LONG-TERM GRAFT SURVIVAL: A PROSPECTIVE, SINGLE-CENTRE COHORT STUDY

Mirjam Tielen
Rotterdam, The Netherlands

626.4 INTERDISCIPLINARY ORGAN AND TISSUE DONOR SUITABILITY ASSESSMENT SIMULATION TRAINING: “SHARING THE RESPONSIBILITY FOR SAFE ORGANS AND TISSUES FOR TRANSPLANTATION IN TRAINING AND IN PRACTICE”

Maria Stadtler
Boulder, CO, United States

626.5 THE HINT STUDY: A CROSS-SECTIONAL SURVEY OF AUSTRALIAN AND NEW ZEALAND TRANSPLANT CLINICIANS ON HEPATITIS TRANSMISSION RISK IN SOLID ORGAN TRANSPLANTATION

Karen Waller
Lindfield, Australia

626.6 VASCULAR ACCESS TYPES IN PATIENTS STARTING HEMODIALYSIS WITH FAILED KIDNEY TRANSPLANTS: A RETROSPECTIVE ANALYSIS

Hassan A. Aleid
Riyadh, Saudi Arabia

626.7 ADDITIONAL OPPORTUNITIES IN AUSTRALIA FOR TRANSPLANTING ORGANS FROM DONORS WITH BRAIN MALIGNANCIES? A RETROSPECTIVE COHORT STUDY OF THE NSW ORGAN AND TISSUE DONATION SERVICE ORGAN DONOR REGISTER

Angela Webster
Sydney, Australia

626.8 18 YEARS OF WORLDWIDE REPORTING IN ORGAN DONATION AND TRANSPLANTATION IRODaT

Maria P. Gomez
Sydney, Australia
A BIG DATA APPROACH TO PREDICTION OF THREE-YEAR GRAFT LOSS RISK IN KIDNEY TRANSPLANTS: STRUCTURED AND UNSTRUCTURED DYNAMIC PATIENT LEVEL DATA IMPROVE PREDICTIVE EFFICACY

Titte R. Srinivas
Charleston, SC, United States

10:30 - 12:00
CONVENTION HALL A-LEVEL 1

Orals Session: Regulatory Mechanisms 2

Chairs: Megan Levings, Vancouver, BC, Canada
        Fadi Issa, Oxford, United Kingdom

DNA-TYPED, MHC-INBRED CLAWN MINIATURE SWINE REPRESENT A HIGHLY-VALUABLE SPECIES FOR THE DEVELOPMENT OF PRECLINICAL TRANSLATIONAL RESEARCH IN TRANSPLANTATION AND REGENERATIVE MEDICINE

Takahiro Murokawa
Kagoshima, Japan

AN INTRONIC SNP OF SHROOM3 PROMOTES KIDNEY INFLAMMATION AND INJURY AFTER ISCHEMIA-REPERFUSION INJURY IN FEMALE MICE

Min Hu
Westmead, Australia

ROLE OF IL-7 AND IL-7/ANTI-IL-7ANTIBODY COMPLEXES IN TREG EXPANSION AND A MURINE SKIN ALLOGRAFT TOLERANCE MODEL

Min Hu
Westmead, Australia

PHOSPO-SPECIFIC FLOWCYTOMETRY UNVEILS THE INCOMPLETE BLOCKADE OF MONOCYTE ACTIVATION BY TACROLIMUS IN KIDNEY TRANSPLANT RECIPIENTS

Nynke Kannegieter
Rotterdam, The Netherlands
627.5 PLACENTA-DERIVED DECIDUAL STROMAL CELLS FOR TREATMENT OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE

Olle Ringden
Stockholm, Sweden

627.6 AGE-RELATED CHANGES IN RAT DONOR KIDNEYS AND OTHER ORGANS RELEVANT FOR ORGAN QUALITY AND FUNCTION

Miriam C. Banas
Regensburg, Germany

627.7 THE FUNCTION OF CD8+/TCR- FACILITATING CELLS AND REGULATORY T CELLS IS IMPAIRED IN FLT3-LIGAND KNOCKOUT MICE

Yujie Wen
Louisville, KY, United States

627.8 MURINE AND HUMAN CD4 T CELL MIGRATION ACROSS LYMPHATIC ENDOTHELIUM IS DIFFERENTIALLY REGULATED BY SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS

Jonathan S. Bromberg
Baltimore, MD, United States

627.9 LYMPH NODE STROMAL LAMININS AFFECT CD4+ T FUNCTIONS AND POLARIZATION

Jonathan S. Bromberg
Baltimore, MD, United States

10:30 - 12:00
CONVENTION HALL B-LEVEL 1

Orals Session:
Discoveries from Pre-Clinical Work

Chairs: Agnes Azimzadeh, Baltimore, MD, United States
       Valeria Mas, Charlottesville, VA, United States

628.1 MONITORING LEUKOCYTE TRANS-LYMPHATIC ENDOTHELIAL MIGRATION WITH AN IN VITRO MODEL

Jonathan S. Bromberg
Baltimore, MD, United States
628.2 VARIABLE EFFECTS OF DIFFERENT SEROTONIN RECEPTOR SUBTYPE ANTAGONISTS ON THE DEVELOPMENT OF TRANSPLANT VASCULOPATHY IN MURINE AORTIC ALLOGRAFTS

Christian Heim
Erlangen, Germany

628.3 VARIOUS PATHOGENIC MICROBES INDUCE CNI-RESISTANCE IN B-CELLS RESPONDING TO BLOOD GROUP ANTIGENS THROUGH TLR–MyD88 PATHWAY

Hiroshi Sakai
Hiroshima, Japan

628.4 ALLOREACTIVITY DRIVES THE REPOPULATION AND THE MAINTENANCE OF HUMAN INTESTINAL GRAFT TISSUE-RESIDENT MEMORY CELLS

Julien Zuber
Paris, France

628.5 VASCULAR SEQUESTRATION OF DONOR-SPECIFIC ANTIBODIES PROTECTS ALLOGENEIC ISLETS FROM HUMORAL REJECTION

Chien-Chia Chen
Lyon, France

628.6 DISRUPTION OF CD8-CORECEPTOR BINDING ABROGATES TOLERANCE INDUCTION VIA LIVER-DIRECTED EXPRESSION OF DONOR MHC CLASS I

Moumita Paul-Heng
Sydney, Australia

628.7 LONG-LASTING EXPANSION OF MEMORY-LIKE NATURAL KILLER CELLS IN THE LIVER AFTER INTRAPORTAL SYNGENEIC ISLET TRANSPLANTATION IN MICE

Yoshihiro Saeki
Hiroshima, Japan

628.8 BLOCKING m-TOR PATHWAY SPECIFICALLY IN MYELOID SYSTEM ABATE CHRONIC ALLOGRAFT REJECTION BY INHIBITING IMMUNE CELL ACTIVATION AND INFILTRATION

Chenglin Wu
Guangzhou, People’s Republic of China
628.9 SOLUBLE BAFF IS ASSOCIATED WITH INCREASED RISK OF GRAFT LOSS BUT NOT WITH PRE-TRANSPLANT IgM TO POST-TRANSPLANT IgG DSA CONVERSION

Matthew J. Everly
Los Angeles, CA, United States

10:30 - 12:00
CONVENTION HALL C-LEVEL 1

Orals Session:
Pig-to-Primate Models

Chairs: Peter Cowan, Melbourne, Australia
Chung-Gyu Park, Seoul, Korea

629.1 GENETICALLY MODIFIED PORCINE NEONATAL ISLET XENOGRAFTS PROVIDE LONG-TERM SURVIVAL IN BABOONS

Wayne J. Hawthorne
Westmead, Australia

629.2 MULTI-TRANSGENIC DONOR PIGS COMBINED WITH TARGETED DRUG TREATMENTS EXTEND LIFE-SUPPORTING ORGAN FUNCTION IN A XENOGENEIC LUNG TRANSPLANTATION MODEL

Lars Burdorf
Baltimore, MD, United States

629.3 KNOCK-OUT OF N-GLYCOLYNEURAMINIC ACID (Neu5Gc) IN GalTKO.hCD46 PIG LUNGS IMPROVES PULMONARY FUNCTION IN A XENOGENEIC PIG-TO-HUMAN LUNG PERFUSION MODEL

Lars Burdorf
Baltimore, MD, United States

629.4 CARBON MONOXIDE REDUCES ACUTE PULMONARY DYSFUNCTION IN GalT-KO PIG-TO-CYNOMOLGUS MONKEY ORTHOTOPIC LUNG TRANSPLANTATION

Hisashi Sahara
Kagoshima, Japan

629.5 EMPIRICAL STUDY OF GTKO PIG - TIBETAN MACAQUE SPLENIC FOSSA HETEROTOPIC AUXILIARY LIVER XENOTRANSPLANTATION

Zhaoxu Yang
Xi’an, People’s Republic of China
629.6 MARKED IMPROVEMENT IN PIG-TO-BABOON LIVER XENOGRAFT SURVIVAL: A MAJOR STEP TOWARDS CLINICAL APPLICATION

Jigesh A. Shah
Charlestown, MA, United States

629.7 USE OF MULTI-TRANSGENE EXPRESSION FOR PREVENTION OF CARDIAC XENOTRANSPLANTATION ASSOCIATED CONSUMPTIVE COAGULOPATHY

Joshua L. Chan
Bethesda, MD, United States

629.8 HUMAN ANTI THROMBOTHIC GENES DO NOT OBVIATE THE NEED FOR ANTICOAGULATION IN AIDING LONG TERM XENOGRAFT SURVIVAL

Muhammad M. Mohiuddin
Bethesda, MD, United States

629.9 THE EFFECT OF IL-6 BLOCKADE ON REVASCULARIZATION OF ISLET AFTER TRANSPLANTATION IN PIG TO NONHUMAN PRIMATE (NHP) ISLET XENOTRANSPLANTATION

Byoung-Hoon Min
Seoul, Korea

12:00 - 13:00
HALL 5E3-LEVEL 5

Plenary:
What Changes Will We See in Transplantation over the next Five Years?

Chairs:  Nancy Ascher, San Francisco, CA, United States
         José María Morales, Madrid, Spain

630.1 BASIC SCIENCES

Carla Baan
Rotterdam, The Netherlands

630.2 CLINICAL SCIENCES

John S. Gill
Vancouver, BC, Canada
13:00 - 13:30  
HALL 5E3-LEVEL 5  
NOT A CME SESSION  

Plenary:  
Closing Ceremony  

640.1 CLOSING ADDRESS  
Philip J. O’Connell  
Westmead, Australia  

640.2 CLOSING ADDRESS  
Nancy Ascher  
San Francisco, CA, United States  

640.3 PRESENTATION OF TTS 2018 CONGRESS IN MADRID, SPAIN  
José María Morales  
Madrid, Spain  

EDUCATIONAL GRANT:  

TTS gratefully acknowledges the support of Gilead Sciences, Inc. through the provision of an educational grant.
**Poster List**

**POSTER SESSIONS ARE NOT CME ACCREDITED**

Posters will be available for attendees to view during the day from August 20 at 12:30 until August 22 at 19:00 in the Exhibit Area, Hall 5FG-Level 5.

The poster presenters are required to be available for questions only during the three Poster Sessions noted below.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>17:00-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>17:00-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>18:00-19:00</td>
</tr>
</tbody>
</table>

Please note that some posters, although accepted under one track, will be presented at a different location on the floor in order to be grouped with other posters from the same presenter. These posters are listed below both in their original track (at the end of the track list) and in their display order (they have been numbered as such).

A floorplan showing where posters are located is available inside the Hall 5FG – Level 5.

Please also note that any cancellations and additions to the poster list that occurred after the printing of this program is available as an addendum sheet at the Registration Desk.

**Basic and Translational Sciences Posters**

P.1000 Solving the Structural Basis for Alloantibody Recognition of Asian HLA in Solid Organ Transplantation

Gu Yue, Singapore, Singapore

P.1001 Phenotypic patterns of B cells subsets in the peripheral blood of patients with long-term kidney allograft function

Marian Klinger, Wroclaw, Poland

P.1002 Human ABH antibody repertoire elucidated by coupled high throughput sequencing and proteomics

Liu Logen, Henyang, People’s Republic of China

P.1003 mHLA-G Expression on CD4+CD25(high) T Cell and CD16+ Natural Killer Cell Associated With Clinical Status in Renal Transplantation Patients

Bilkay Bastürk, Adana, Turkey

P.1004 Ectopic lymphoid follicles are present in type I T-cell mediated kidney transplant rejection

Carla Baan, Rotterdam, The Netherlands
**P.1006** Mechanism of FK506 Induced TNF Related Apoptosis in Jurkat T Cells  
*Sang Young Chung*, Gwangju, Korea

**P.1007** Isatis tinctoria L. combined with co-stimulatory molecules blockade inhibits accelerated rejection mediated by allo-primed CD4+ memory T cells in mice  
*Feifei Du*, Xiamen, People's Republic of China

**P.1008** A delay of bone marrow transplantation after low dose irradiation impairs engraftment  
*Suzanne T. Ildstad*, Louisville, KY, United States

**P.1009** Investigation of a novel multi-lineage human-mouse chimeric model for in vivo transplantation research  
*Fadi Issa*, Oxford, United Kingdom

**P.1010** Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats  
*Jian Jin*, Seoul, Korea

**P.1011** Clinical Features Indicating Irreversible Rejection after Uterus Allotransplantation in Cynomolgus Monkey  
*Iori Kisu*, Tokyo, Japan

**P.1012** Hepatic miR-301a: its mode of action on T-helper 17 cell-mediated rejection via targeting interleukin-6/STAT3 axis in rats  
*Chia-Yun Lai*, Kaohsiung, Taiwan

**P.1013** Combining Monoclonal Antibodies with 1,25(OH)2D3 Treatment to Prolong the Survival Time of Cardiac Allograft in Accelerated Rejection Models of Mice  
*Yaguang Li*, Xiamen, People’s Republic of China

**P.1015** Activation of Human CD4+CD25+CD127loFOXP3+Treg by IL-4 and alloantigen induces activated Treg that do not express CD45RA and express the IL-5 receptor alpha (CD125)  
*Nirupama D. Verma*, Liverpool, Australia

**P.1016** Regulatory T-cell mediated suppression of T-cell responses induced by primary human hepatocytes in vitro is cell-contact dependent  
*Florian WR Vondran*, Hannover, Germany

**P.1017** A Traditional chinese herbal medicine “Huaier” induced prolongation of fully MHC-mismatched murine cardiac allograft  
*Enzhi Yin*, Tokyo, Japan
P.1018 Transplant tolerance induced by a single infusion of extracorporeal photopheresis treated donor splenocytes prior to transplantation

Zheng Zhang, Chicago, IL, United States

P.1019 The effect of donor’s chemokines (CXCL9, CXCL10 and CCL5) and growth factor (TGFβ1) on the renal allograft dysfunction

Ayisha Abid, Karachi, Pakistan

P.1020 Negative influence of liver irradiation on liver resident NK cells

Ryosuke Nakano, Hiroshima, Japan

P.1021 Ex vivo generation of alloantigen-specific Immunomodulatory cells with co-stimulation blockade: do we need Treg purification for cell therapy?

Torbjorn Lundgren, Stockholm, Sweden

P.1022 A non-hematopoietic erythropoietin analogue, ARA 290, prolonged allogeneic islet graft survival in a mouse model

Torbjorn Lundgren, Stockholm, Sweden

P.1023 Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus

Long Jin, Seoul, Korea

P.1024 Immune Modulatory Effect of Thalidomide and Dexamethasone Co-Treatment on T cell Subsets

Eun Jee Kim, Seoul, Korea

P.1025 Effect of isolated intraperitoneal sirolimus treatment on the kidneys of C57BL/6 mice

Joon Ye Kim, Seoul, Korea

P.1026 Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines

Sukwon Suh, Seoul, Korea

P.1027 The liver-wrapping nanofiber releasing nitric oxide downregulated the cleaved Caspase-3 expression on rat hepatic ischemia-reperfusion injury

Hyung Joon Ahn, Seoul, Korea

P.1028 Remote perconditioning on rat hepatic ischemia-reperfusion injury downregulated the Bax and cleaved Caspase-3 expression

Hyung Joon Ahn, Seoul, Korea

P.1029 Supplemented Celsior and Peri-mortem Heparin Enhances Recovery of Rodent DCD Hearts

Hong Chee Chew, Kingsgrove, Australia
P.1030 Pretreatment of cilostazol attenuates hepatic ischemia/reperfusion injury in rats
Taku Fujii, Hiratsuka, Japan

P.1031 Donor pretreatment with carbon monoxide prevents ischemia/reperfusion injury following heart transplantation in rats
Noritomo Fujisaki, Nishinomiya, Japan

P.1032 Effects of Ulinastatin on liver cold ischemia/reperfusion injury and graft survival in mice
Lianyue Guan, Chang Chun, People’s Republic of China

P.1033 Effects of Ulinastatin on liver warm ischemia reperfusion injury in mice
Lianyue Guan, Chang Chun, People’s Republic of China

P.1034 Perfusion of Porcine Kidneys with Macromolecular Heparin Ameliorates Early Ischemia Reperfusion Injury
Amir Sedigh, Uppsala, Sweden

P.1035 Hydrogen sulfide prevents renal ischemia-reperfusion injury in CLAWN miniature swine
Mitsuhiro Sekijima, Kagoshima, Japan

P.1036 The effects of resveratrol on liver transplantation from non-heart-beating donors in pigs
Kenji Shimizu, Sendai, Japan

P.1037 The renoprotective effects of epigallocatechin gallate and dipeptidyl peptidase IV inhibitor gemigliptin on tacrolimus-induced nephrotoxicity in mice
Byung Chul Shin, Gwangju, Korea

P.1038 CHBP and Caspase-3 SiRNA Ameliorate Mouse Renal Ischemia Reperfusion Injury
Bin Yang, Leicester, United Kingdom

P.1039 A study of oxidative stress biomarkers in renal allograft transplant recipients
Sunil Kumar, Chandigarh, India

P.1040 Polymicrobial oro-esophageal infection presenting with dysphagia in a renal allograft transplant recipient
Sunil Kumar, Chandigarh, India

P.1041 Intra-peritoneal administration of sodium acetate improves renal function and prolongs survival in a murine model of renal allograft transplantation
Steve J. Chadban, Camperdown, Australia

P.1042 IL-17 production and inflammatory cascade is decreased by ATG
Dietmar K. Abendroth, Ulm, Germany
P.1043 Hypothermic Machine Perfusion Oxigenation. A Real Step Forward? Tissue and Perfusate mRNA Expression
Victoria Gomez Dos Santos, Madrid, Spain

P.1044 MicroRNAs Panel Validation in Kidney Graft Hypothermic Machine Perfusion Fluid as Novel Biomarkers for Graft Disfunction
Victoria Gomez Dos Santos, Madrid, Spain

P.1045 Reduced plasmalogenes and increased ceramides in the sera from acute hepatic allograft rejection
Nayoung Kim, Seoul, Korea

P.1046 A simple and precise LC/MS method to quantitate 6 beta-hydroxycortisol and cortisol in human urine: Use of the 6 beta-hydroxycortisol to cortisol ratio as an indicate of the remnant-liver function in a donor for liver transplantation
Satoshi Kishino, Kiyose/Tokyo, Japan

P.1047 Budget Impact Analysis of Quantiferon-CMV Assay for High-risk Kidney Transplant Recipients
Frank K. Kuhr, Germantown, PA, United States

P.1048 Impact of circulating exosomes on the development and recurrence of hepatocellular carcinoma in rats
Toshiaki Nakano, Kaohsiung, Taiwan

P.1049 Association of Delayed Graft Function (DGF) with Serum Level of Soluble Fibrinogen-like Protein 2 (sFGL2) in Patients with Kidney Transplantation
Hassan Nikoueinejad, Tehran, Iran (Islamic Republic of)

P.1050 CD28-positive cytomegalovirus specific cytotoxic T lymphocytes as a novel biomarker associated with cytomegalovirus viremia in kidney allorecipients
Maciej Zielinski, Gdansk, Poland

P.1051 Human Blood Cell-Free Circulating DNA (cfDNA) and miRNA as Biomarkers of Liver and Kidney Antibody Mediated Rejection (AMR) or Cellular Allograft Rejection (ACR). Pilot study
Tomasz Kozlowski, Chapel Hill, NC, United States

P.1052 Natural History of Spontaneous Porto-Systemic Shunt (PSs) and Transplant Outcomes in Liver Allograft Recipients
Tomasz Kozlowski, Chapel Hill, NC, United States

P.1053 Development of de-novo donor specific antibody (DSA) and vitamin D status after renal transplantation
Sonia Mehrotra, Lucknow, India
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1054</td>
<td>De-novo donor specific antibody (DSA) against HLA-DQ antigens by lysate based cross match on Luminex platform resulting in acute antibody mediated rejection in a renal transplant patient</td>
<td>Sonia Mehrotra, Lucknow, India</td>
<td></td>
</tr>
<tr>
<td>P.1055</td>
<td>Association Between Donor Toll-Like Receptors-4 Polymorphism and Acute Rejection After Liver Transplantation in Belarus</td>
<td>Denis Efimov, Minsk, Belarus</td>
<td></td>
</tr>
<tr>
<td>P.1056</td>
<td>Minocycline targets multiple key driver genes in a model of acute allograft rejection</td>
<td>Karen L. Keung, North Epping, Australia</td>
<td></td>
</tr>
<tr>
<td>P.1057</td>
<td>Association between Interleukin 17A and IL17RA Gene Polymorphisms and Acute Rejection following Kidney Transplantation</td>
<td>Hong joo Lee, Seoul, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1058</td>
<td>Association between Interleukin 7 receptor α gene polymorphism and chronic rejection after renal transplantation in Korean Patients</td>
<td>Hong joo Lee, Seoul, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1059</td>
<td>Biomarker Discovery of Delayed Graft Function from Perfusate Proteome</td>
<td>Somchai Chutipongtanate, Bangkok, Thailand</td>
<td></td>
</tr>
<tr>
<td>P.1064</td>
<td>Extracellular matrix extract as a therapeutic approach for ischemic liver in mice</td>
<td>Kamal Hany Hussein, Chuncheon-si, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1065</td>
<td>Optimization of a therapeutic protocol of human mesenchymal stem cells in mice heart transplant model</td>
<td>Longshan Liu, Guangzhou, People’s Republic of China</td>
<td></td>
</tr>
<tr>
<td>P.1066</td>
<td>Biliary tree as a window for repopulation of the decellularized liver scaffold</td>
<td>Satoshi Ogiso, Kyoto, Japan</td>
<td></td>
</tr>
<tr>
<td>P.1067</td>
<td>Efficacious combination of substrate and medium for feeder-free culture of naïve porcine iPS</td>
<td>Shiori Waki, Kagoshima, Japan</td>
<td></td>
</tr>
<tr>
<td>P.1068</td>
<td>Immunodepletion and hypoxia preconditioning of mouse compact bone cells as a novel protocol to isolate highly immunosuppressive Mesenchymal Stem Cells</td>
<td>Kisha Nandini Sivanathan, Adelaide, Australia</td>
<td></td>
</tr>
<tr>
<td>P.1069</td>
<td>Graft Maturation After Repopulation of Decellularized Rat Livers</td>
<td>Benjamin Struecker, Berlin, Germany</td>
<td></td>
</tr>
</tbody>
</table>
P.1070 Serum levels of stem cell factor and granulocyte colony-stimulating factor during hepatic regeneration after partial hepatectomy in humans
Laura Tariciotti, Rome, Italy

P.1071 IL-6 blockade attenuates posthepatectomy liver injury, accelerates liver regeneration and improves survival
Yinzhe Xu, Beijing, People’s Republic of China

P.1072 The Property of Modulatory T cells Generated by Mixed Lymphocyte Culture with CD154 Blockade
Kiyohiko Hotta, Boston, MA, United States

P.1073 Targeting histone deacetylase in renal tubular epithelial cells inhibits amplification of Th1 cell-mediated inflammation
Sun-woo Kang, Busan, Korea

P.1074 Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T Lymphocytes
Ho kyun Lee, Gwangju, Korea

P.1076 Anti-CD272 antibody (6B2) induced prolongation of fully MHC-mismatched murine cardiac allograft and generation of Foxp3+ regulatory T cells
Masateru Uchiyama, Tokyo, Japan

P.1077 Screening of medical supplements to prevent and ameliorate non-alcoholic steatohepatitis (NASH)
Li-Wen Hsu, Kaohsiung City, Taiwan

P.1078 Pre-clinical insight into the use of dendritic cells as cellular therapies in inducing tolerance to liver allografts
Muhammad Atif, Birmingham, United Kingdom

P.1079 High Peripheral Transitional B Cells and High Expression of B Cell Associated Genes in Peripheral Blood at 3 Months After Kidney Transplantation: Identification of Low Risk Phenotype
Petra Hruba, Prague, Czech Republic

P.1080 Heart En Bloc Thymus Transplantation Permits Long-Term, Acute Rejection-Free Cardiac Allograft Survival in Nonhuman Primates (NHPs)
Makoto Tonsho, Tokyo, Japan

P.1081 NKT cells in the liver are important for peripheral tolerance induction in mice
Zhanpeng Wang, Changchun, People’s Republic of China

P.1082 In vitro immune cell monitoring as a guide for long-term immunosuppression in adult liver transplant recipients
Eunkyoung Jwa, Seoul, Korea
P.1083 Survival outcomes of combined hepatocellular carcinoma-cholangiocarcinoma following liver resection and liver transplantation

Eunkyoung Jwa, Seoul, Korea

P.1086 Mitochondrial Damage-Associated Molecular Patterns (MTDs) Released from Hepatic Ischemia Reperfusion Induce Inflammatory Response

Ian P. Alwayn, Halifax, NS, Canada

The posters below belong to the Basic and Translational Sciences track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1106 Protective Effect of Crepidiastrum denticulatum Extract Pretreatment Against Hepatic Ischemia-Reperfusion Injury in Mice

Cheon-Soo Park, Gangneung-Si, Korea

P.1110 Bile as a diagnostic tool after liver transplantation: miRNA pattern and protein based biomarkers may predict acute cellular rejection

Rosa B. Schmuck, Berlin, Germany

Liver Posters

P.1100 Donor’s age and Body mass index are independent factors for estimation of liver weight in deceased donor liver transplantation

Gyu-seong Choi, Seoul, Korea

P.1101 Inferior Hepatic Veins are Inherited to Offsprings Dominantly- Lessons Learned from Donor Volumetry

Gyu-seong Choi, Seoul, Korea

P.1102 Aborted liver transplantation – Single center experience

Gyu-seong Choi, Seoul, Korea

P.1103 Younger donor age poses a risk for overestimation of graft weight in adult living donor liver transplantation

Toshihiro Kitajima, Kyoto, Japan

P.1104 Indocyanin green retention rate at 15 minutes of 20% or higher can be a predictive factor of living liver donor with right hepatectomy?

Cheon-Soo Park, Gangneung-Si, Korea

P.1105 Early Experiences of Adult Living Donor Liver Transplantation in Single Hospital

Cheon-Soo Park, Gangneung-Si, Korea
P.1106 Protective Effect of Crepideastrum denticulatum Extract Pretreatment Against Hepatic Ischemia-Reperfusion Injury in Mice
Cheon-Soo Park, Gangneung-Si, Korea

P.1107 Difference in donor complications by types of skin incision in LDLT
Jonghwan Lee, Seoul, Korea

P.1108 Living donor liver transplantation using a graft procured from an advanced age-donor
Atsuyoshi Mita, Matsumoto, Japan

P.1109 Single Pass Albumin Dialysis (SPAD) – Optimizing bridging therapy for liver transplantation in acute liver failure
Rosa B. Schmuck, Berlin, Germany

P.1110 Bile as a diagnostic tool after liver transplantation: miRNA pattern and protein based biomarkers may predict acute cellular rejection
Rosa B. Schmuck, Berlin, Germany

P.1111 Successful Transplantation after Normothermic Machine Perfusion of a Liver Procured from a Donor with Cold Agglutinin Formation Secondary to Mycoplasma Pneumoniae Infection – A Case Report
Maren Schulze, Essen, Germany

P.1112 Outcomes of living and deceased donor liver transplant recipients according to the MELD score
Jae Geun Lee, Seoul, Korea

P.1113 Outcome of Second Kidney Transplantation Compared to Primary Transplantation
Jae Geun Lee, Seoul, Korea

P.1114 CoCl2 Induced ER Stress Protein Mediated Cytotoxicity In FKS06 Treated Hepatoma HepG2 Cells
Soo Jin Na Choi, Gwangju, Korea

P.1115 Changes in T cells in Peripheral Blood after Adult Liver Transplantation
Jong Man Kim, Seoul, Korea

P.1116 Differences in Peripheral Blood Lymphocytes Between Brand-Name and Generic Tacrolimus Treated in Stable Liver Transplant Recipients
Jong Man Kim, Seoul, Korea

P.1117 Selection of Immunosuppression in Hepatitis C Virus Liver Transplant Recipients Prevents Biopsy-proven Acute Rejection
Jong Man Kim, Seoul, Korea
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1118</td>
<td>Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival</td>
<td>Jong Man Kim</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>P.1119</td>
<td>A modified heterotopic auxiliary liver transplantation for Wilson's disease with the graft implanted in the splenic fossa</td>
<td>Kefeng Dou</td>
<td>Xi'an, People's Republic of China</td>
</tr>
<tr>
<td>P.1120</td>
<td>Clinical Outcomes with Modified Release Tacrolimus in Liver Transplant Recipients: a single centre observational study</td>
<td>Elankumaran Krishnan</td>
<td>Chennai, India</td>
</tr>
<tr>
<td>P.1121</td>
<td>Long term observation of children after liver transplantation across ABO blood groups. A single center experience</td>
<td>Malgorzata Markiewicz-Kijewska</td>
<td>Warsaw, Poland</td>
</tr>
<tr>
<td>P.1122</td>
<td>Early conversion from twice-daily tacrolimus to prolonged-release tacrolimus in liver transplantation: a single-center experience</td>
<td>Yasuhiro Ogura</td>
<td>Nagoya, Japan</td>
</tr>
<tr>
<td>P.1123</td>
<td>Liver Transplantation in Germany – with specific focus on adult transplantation of extremely ill patients receiving “bottom-up” immunosuppression early after transplantation</td>
<td>Hans J. Schlitt</td>
<td>Regensburg, Germany</td>
</tr>
<tr>
<td>P.1124</td>
<td>ABO-incompatible liver transplantation – a single center experience</td>
<td>Mariana Mihaila</td>
<td>Bucharest, Romania</td>
</tr>
<tr>
<td>P.1126</td>
<td>Single use of Anti-platelet agent for prevention of early hepatic artery thrombosis after liver transplantation</td>
<td>Young Yeon Choi</td>
<td>Daegu, Korea</td>
</tr>
<tr>
<td>P.1127</td>
<td>Aggressive preoperative haemodialysis improves left ventricular ejection fraction in primary hyperoxaluria for combined kidney and liver transplantation</td>
<td>Ilankumaran Kaliamoorthy</td>
<td>Medavakkam, India</td>
</tr>
<tr>
<td>P.1128</td>
<td>A case of successful deceased donor liver transplantation of grand old age recipient</td>
<td>Pyoung-Jae Park</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Authors</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>P.1129</td>
<td>Postoperative Blood Glucose Level Lesser than 150 mg/dL is Associated with Decreased Cytomegalovirus Infection in Seropositive Liver Transplant Recipients</td>
<td>Jun Chul Shin, Seoul, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1130</td>
<td>Transfusion of Old Red Blood Cells Stored During Greater Than 2 Weeks is Not Associated with Liver Transplant Death</td>
<td>Jun Chul Shin, Seoul, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1131</td>
<td>The immunoexpression of HSP70, Glipican3, Glutamin synthetase and Beta-Catenin in HCC post-liver transplantation. The association between Glipican 3 and Beta-Catenin with the presence of larger nodules</td>
<td>Elaine C. Ataide, Campinas, Brazil</td>
<td></td>
</tr>
<tr>
<td>P.1132</td>
<td>The possibility of radiotherapy for downstaging before living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus</td>
<td>Jin Yong Choi, Seoul, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1133</td>
<td>Impact of autologous and homologous blood transfusion in liver transplant on outcome of patients with hepatocellular carcinoma</td>
<td>Walid Elmoghazy, Doha, Qatar</td>
<td></td>
</tr>
<tr>
<td>P.1134</td>
<td>Predictors of intra-operative red blood cell transfusion during liver transplant: A single center experience over 20 years</td>
<td>Walid Elmoghazy, Doha, Qatar</td>
<td></td>
</tr>
<tr>
<td>P.1135</td>
<td>Long term results of liver transplantation for malignances</td>
<td>Gabriel E. Gondolesi, Buenos Aires, Argentina</td>
<td></td>
</tr>
<tr>
<td>P.1136</td>
<td>Hepatocellular carcinoma is an independent predictor of recurrent hepatitis C infection following donation after cardiac death liver transplantation</td>
<td>Shiva Kumar, Abu Dhabi, United Arab Emirates</td>
<td></td>
</tr>
<tr>
<td>P.1137</td>
<td>Immunohistochemical Markers for Prognosis of Hepatocellular Carcinoma after Liver Resection and Liver Transplantation</td>
<td>Soo Ho Lee, Uijeongbu-si, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1138</td>
<td>Should Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Be Contraindicated for Living Donor Liver Transplantation?</td>
<td>Deok-Bog Moon, Seoul, Korea</td>
<td></td>
</tr>
</tbody>
</table>
P.1139 Impact of endoscopic ultrasound guided fine needle aspiration on prospective liver transplant patients with cirrhosis and hepatocellular carcinoma or pyrexia of unknown origin
Saigal Sanjiv, Gurgaon, New Delhi, India

P.1141 Technical Refinement to Prevent Hepatic Outflow Disturbance in Right Lobe Living Donor Liver Transplantation : New Simplified One-Orifice Venoplasty
Donglak Choi, Daegu, Korea

P.1142 Is Systemic Heparinization Necessary During Living Donor Hepatectomy?
Donglak Choi, Daegu, Korea

P.1143 The Best Level of Recipient’s Biliary Duct for Anastomosis to Prevent Postoperative Anastomosis Stricture
Keisuke Arai, Kobe-city, Hyogo, Japan

P.1144 Causes of mortality in patients transplanted for NASH or Cryptogenic cirrhosis: A single center experience over 23 years!
Chandra Bhati, Richmond, VA, United States

P.1145 The Correlation Between Platelet Counts and Spleen Size after Successful Liver Transplantation
Ahmet Sedat Boyacioglu, Ankara, Turkey

P.1146 Long-Term Outcomes in Pediatric Live-Donor Liver Transplantation
Neslihan Celik, Pittsburgh, PA, United States

P.1147 Durability of Initial Successful Treatment for Biliary Anastomotic Strictures in Right Lobe Living Donor Liver Transplantation
Kenneth Siu Ho Chok, Hong Kong SAR, P.R. of China

P.1148 Intrahepatic artery pseudoaneurysm-induced hemobilia caused by a plastic biliary stent after ABO-incompatible living donor liver transplantation: A Case Report
Jae Min Chun, Daegu, Korea

P.1149 Late hepatic venous outflow obstruction following inferior vena cava stenting in the patient with deceased donor liver transplantation using modified piggyback technique: A case report
Jae Min Chun, Daegu, Korea
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1150</td>
<td>Does Matching Donor–Recipient Age Impact Long-Term Survival in Liver Transplantation?</td>
<td>Cristina Dopazo</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>P.1151</td>
<td>Low Dose of Anti-human T-lymphocyte Globulin (ATG) warrant a good Glomerular Filtration Rate after Liver Transplant on recipients with pre-transplant renal dysfunction</td>
<td>Cristina Dopazo</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>P.1152</td>
<td>Evaluation of protocol biopsies after liver transplantation</td>
<td>Henrik A. Gjertsen</td>
<td>Stockholm, Sweden</td>
</tr>
<tr>
<td>P.1153</td>
<td>Liver transplantation in the presence of diffuse Portal Vein Thrombosis: A 16-year experience with Cavoportal Hemitransposition</td>
<td>Sofia Gyllenswärd</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td>P.1154</td>
<td>Technical solution to upper caval stricture after liver transplantation</td>
<td>Sofia Gyllenswärd</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td>P.1155</td>
<td>Novel technique for arterial conduits in liver and multivisceral transplantation</td>
<td>Sofia Gyllenswärd</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td>P.1156</td>
<td>Use stapling devices with caution in order to avoid cavastrictures in liver transplantation</td>
<td>Sofia Gyllenswärd</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td>P.1157</td>
<td>Incidence and outcomes of de novo malignancies after living donor liver transplantation in comparison with the Japanese general population</td>
<td>Taizo Hib</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td>P.1158</td>
<td>Management of CNI Induced Posterior Reversible encephalopathy Syndrome with Everolimus Change after Living Donor Liver Transplantation (case)</td>
<td>Geun Hong</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>P.1159</td>
<td>Treatment of Biliary Stone and Cast After Liver Transplantation Using the Percutaneous Transhepatic Cholangioscopy (PTCS); A Case Report</td>
<td>Ju Ik Moon</td>
<td>Daejeon, Korea</td>
</tr>
<tr>
<td>P.1160</td>
<td>The Impact of Recipient’s BMI at the Deceased Donor Kidney Transplantation</td>
<td>Ju Ik Moon</td>
<td>Daejeon, Korea</td>
</tr>
<tr>
<td>P.1161</td>
<td>Outcome of Deceased Donor Liver Transplantation for Alcoholic Liver Disease</td>
<td>Suk Kyun Hong</td>
<td>Seoul, Korea</td>
</tr>
</tbody>
</table>
P.1162 Graft versus Host Disease (GVHD) After Liver Transplantation (LT) focused on Deceased Donor LT (DDLT)
Suk Kyun Hong, Seoul, Korea

P.1163 Posttransplant mellitus (PTDM) after liver Transplantation: Risk factors and outcome
Byeongju Kang, Ulsan, Korea

P.1164 The influence of perioperative acute kidney injury for the prediction of decreased renal function after liver transplantation
Gun Woo Kang Jr., Daegu, Korea

P.1165 Steal Syndrome After Liver Transplantation: A Single Center Experience
Gokhan Moray, Ankara, Turkey

P.1166 Percutaneous ultrasound guided biliary interventions after pediatric liver transplantation using fine needle and 0.014 inch guide-wire
Gokhan Moray, Ankara, Turkey

P.1167 Simultaneous percutaneous large profile multiple plastic stents for biliary anastomotic strictures after liver transplantation
Gokhan Moray, Ankara, Turkey

P.1168 Successful percutaneous management of recurrent sclerosing cholangitis after liver transplantation with multiple intrahepatic plastic biliary stent placement with only one access
Gokhan Moray, Ankara, Turkey

P.1169 Extensive Indications for HCC in Living Donor Liver Transplantation
Gokhan Moray, Ankara, Turkey

P.1170 Renal cell carcinoma in transplanted kidney
Gokhan Moray, Ankara, Turkey

P.1171 Dual stent placement for suprahepatic inferior vena cava stenosis after deceased donor liver transplantation with piggy-back technique
Tae-Seok Kim, Daegu, Korea

P.1172 A case of early organizing portal vein thrombosis followed by arterio-portal shunt without hepatic dysfunction after liver transplantation
Tae-Seok Kim, Daegu, Korea
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1173</td>
<td>Immune modulation with CMV-hyperimmunoglobulin improves outcome in high-risk (MELD ≥ 30) liver transplant patients</td>
<td>Arno Kornberg</td>
<td>Munich, Germany</td>
</tr>
<tr>
<td>P.1174</td>
<td>Liver transplantation for alcoholic liver disease without pre-transplant abstinence</td>
<td>Hae Won Lee</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>P.1175</td>
<td>Surgical Results of Outflow Reconstruction in Living Donor Liver Transplantation</td>
<td>Yang Won Nah</td>
<td>Ulsan, Korea</td>
</tr>
<tr>
<td>P.1176</td>
<td>Risk factors in primary liver transplantation - a retrospective single centre analysis</td>
<td>Manuel Maglione</td>
<td>Innsbruck, Austria</td>
</tr>
<tr>
<td>P.1177</td>
<td>Successful Retransplantation of an Allograft after Early Recurrence of Focal Segmental Glomerulosclerosis in the First Recipient</td>
<td>Manuel Maglione</td>
<td>Innsbruck, Austria</td>
</tr>
<tr>
<td>P.1178</td>
<td>Acquired haemostatic disorders by orthotopic liver transplantation</td>
<td>Eviatar Nesher</td>
<td>Ein Vered, Israel</td>
</tr>
<tr>
<td>P.1179</td>
<td>Percutaneous transhepatic bililiary drainage after living donor liver transplantation resulting in acute hepatic failure: a case of hepatic compartment syndrome</td>
<td>Je Ho Ryu</td>
<td>Yangsan-si, Korea</td>
</tr>
<tr>
<td>P.1180</td>
<td>Surgical techniques and outcome of autologous portal vein interposition for anomalous right portal veins in living donor liver transplantation</td>
<td>Je Ho Ryu</td>
<td>Yangsan-si, Korea</td>
</tr>
<tr>
<td>P.1181</td>
<td>Surgical Technique for Hepatic Arterial Reconstruction in Pediatric Patients Undergoing Monosegmental Living Donor Liver Transplantation</td>
<td>Yukihiro Sanada</td>
<td>Shimotsuke, Japan</td>
</tr>
<tr>
<td>P.1182</td>
<td>Postoperative outcomes of Controlled Donation after Cardiac Death compared with Donation after Brain Death: a meta-analysis</td>
<td>Jianxin Tang</td>
<td>Guangzhou, People’s Republic of China</td>
</tr>
<tr>
<td>P.1183</td>
<td>Analysis of initial 100 cases of a new liver transplantation program: the Korea University Anam hospital experience</td>
<td>Young-Dong Yu</td>
<td>Seoul, Korea</td>
</tr>
</tbody>
</table>
POSTER LIST

P.1184 Testosterone deficiency a diagnosis to consider: In adult male post liver transplant (LTx) recipients with failure to thrive, muscle wasting or sarcopenia is observed

Ashokkumar Jain, Hershey, PA, United States

P.1185 Measurement of Creatinine clearance in immediate post Kidney transplant (KTx) period with functioning allograft

Ashokkumar Jain, Hershey, PA, United States

P.1186 Incidence and Management of Bile Stone After Liver Transplantation: Report of a Single Center

Mahir Kirnap, Ankara, Turkey

P.1187 Management of Early Hepatic Arterial Thrombosis After Liver Transplantation

Mahir Kirnap, Ankara, Turkey

P.1188 Unusual Indications for a Liver Transplant: a Single-Center Experience

Mahir Kirnap, Ankara, Turkey

P.1189 Effects of the Natural Immune System on Acute Rejection of Living donor Renal Transplantation

Mahir Kirnap, Ankara, Turkey

P.1190 Outcomes for pediatric liver re-transplantation at a single center

Akinari Fukuda, Tokyo, Japan

P.1191 Retransplantation of the liver: single center results

Sergey V. Gautier, Moscow, Russian Federation

P.1192 Poor Patient Outcome in Combined Liver-Kidney Transplant: a fifteen years experience from a single centre

Niaz Ahmad, Leeds, United Kingdom

P.1193 Pediatric living donor liver transplantation at KFSH&RC – implementation of the laparoscopic retrieval in a high volume center

Markus U. Boehnert, Riyadh, Saudi Arabia

P.1194 Right-sided diaphragmatic hernia after living donor Right hepatectomy: A rare complication after living donor

Gyu-seong Choi, Seoul, Korea

P.1195 Living donor liver transplantation in a Jehovah’s Witness- the first adult living donor liver transplantation in Korea

Gyu-seong Choi, Seoul, Korea
P.1196 Anastomosis of type 2 portal vein variation and low-lying right posterior duct anomaly in living donor liver transplantation
Kwangsik Chun, Daejeon, Korea

P.1197 More Than 16 Years Follow Up of Living Donor Liver Transplantation for Two Cases of Homozygous Familial Hypercholesterolemia from the Heterozygous Donor
Naoki Kawagishi, Sendai, Japan

P.1198 Renal function status in liver transplant patients in the first month post-transplant is associated with progressive chronic kidney disease
Naoki Kawagishi, Sendai, Japan

P.1199 Early Experience of Living Donor Liver Transplantation at Dong-A University Hospital: Initial 24 cases
Kwan Woo Kim, Busan, Korea

P.1200 Right lobe living donor liver transplantation with middle hepatic vein for treatment end stage liver diseases
Oleg Kotenko, Kiev, Ukraine

P.1201 Early Term Results of Biliary Reconstruction Using Microsurgical Outer Knotted Suture Technique in Living Donor Liver Transplantation
Shigehito Miyagi, Sendai, Japan

P.1202 Prior kidney donation does not impact the outcome of subsequent living right liver lobe donation
Amit Sharma, Richmond, VA, United States

P.1203 The study of the measurement of liver volume by methods of multi-slice spiral CT and displacement method
Chao Sun, Tianjin, People’s Republic of China

P.1204 Successful living donor liver transplantation for primary biliary cirrhosis with ABO blood type incompatibility and strongly positive donor-specific HLA antibodies
Yuki Takano, Tokyo, Japan

P.1205 Rapid preparation for ABO-incompatible living donor liver transplantation in acute liver failure with high isoagglutinin titers
Tsunghan Wu, Taoyuan, Taiwan

P.1206 ABO incompatible living donor liver transplantation in patient with fulminant hepatic failure
Sam-Youl Yoon, Seoul, Korea
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1207</td>
<td>The Czech single centre experience with split liver transplantation: 3 years of the program, 37 splits and 72 transplants</td>
<td>Jiri Fronek</td>
<td>Prague, Czech Republic</td>
</tr>
<tr>
<td>P.1208</td>
<td>Deceased donor uterus retrieval as part of uterus transplant trial – the first Czech experience</td>
<td>Jiri Fronek</td>
<td>Prague, Czech Republic</td>
</tr>
<tr>
<td>P.1209</td>
<td>ABO-Incompatible liver Transplantation, Full Size, Partial, Auxiliary - Single Centre Experience</td>
<td>Jiri Fronek</td>
<td>Prague, Czech Republic</td>
</tr>
<tr>
<td>P.1210</td>
<td>ABO Incompatible Living Donor Liver Transplantation in Patient with History of Platelet Transfusion Related Anaphylaxis</td>
<td>Jai Young Cho</td>
<td>Seongnam, Korea</td>
</tr>
<tr>
<td>P.1211</td>
<td>Liver transplantation in a small volume center; initial outcome</td>
<td>Ho Joong Choi</td>
<td>Bucheon, Korea</td>
</tr>
<tr>
<td>P.1212</td>
<td>Urgent living-donor liver transplantation in a patient with concurrent active tuberculosis: a case report</td>
<td>Bo-Hyun Jung</td>
<td>Busan, Korea</td>
</tr>
<tr>
<td>P.1213</td>
<td>Living donor liver transplantation in over 70 years old patients</td>
<td>Jae Hyun Kwon</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>P.1214</td>
<td>Embolization of an intrahepatic portal systemic shunt for the treatment of hepatic encephalopathy to defer urgent liver transplantation</td>
<td>I Ha Lao</td>
<td>Tainan, Taiwan</td>
</tr>
<tr>
<td>P.1215</td>
<td>Impact of serial change of donor specific antibodies on the graft outcomes after liver transplantation</td>
<td>Jung Jun Lee</td>
<td>Seongnam-si, Korea</td>
</tr>
<tr>
<td>P.1216</td>
<td>Living Donor Liver Transplantation in Patients Older Than 60 Years: Single center experiences</td>
<td>Byunggon Na</td>
<td>Dae-gu, Korea</td>
</tr>
<tr>
<td>P.1217</td>
<td>Survival analysis for patients with MELD score &lt; 15</td>
<td>Wong Hoi She</td>
<td>Hong Kong SAR, P.R. of China</td>
</tr>
<tr>
<td>P.1218</td>
<td>Role of Liver Transplantation in Patients of Acute Liver Failure with Hepatic Coma requiring Mechanical Ventilation: Is it justified? Single center successful experience</td>
<td>Ashok Thorat</td>
<td>Taichung, Taiwan</td>
</tr>
</tbody>
</table>
P.1219 Successful Living Donor Liver Transplantation in a Case of Pulmonary Hypertension

Youngkyoung You, Seoul, Korea

P.1220 Outcome Results of Cardiac Surgery and Cardiac Intervention After Liver Transplantation

Mitsuru Nakatsuka, Richmond, VA, United States

P.1221 Safety and Complications of Living Donor Hepatectomy

Mitsuru Nakatsuka, Richmond, VA, United States

P.1222 Current Status of Cadaveric and Living Donor Kidney Transplantation of The Last 6 Years, Compared With Previous 6 Years Experience

Mitsuru Nakatsuka, Richmond, VA, United States

P.1223 Neoplasms or cancers in HCVab-positive OLT recipients with hepatocellular carcinoma: the analysis of the outcomes

Olga M. Tsiroulnikova, Moscow, Russian Federation

P.1224 HCV treatment after liver transplantation 2006-2016: result assessment

Olga M. Tsiroulnikova, Moscow, Russian Federation

P.1225 Transforming growth factor beta 1 blood level relates with liver disease etiology and fibrosis severity in pediatric liver recipients

Olga M. Tsiroulnikova, Moscow, Russian Federation

P.1226 Pediatric living donor liver transplantation: correlation plasma level of transforming growth factor beta -1 with tacrolimus dosage but not with its concentration

Olga M. Tsiroulnikova, Moscow, Russian Federation

P.1229 Single center experience treating post-transplant Hepatitis C patients with direct acting antivirals (DAAs)

Ashish Sharma, Chandigarh, India

P.1230 Daclatasvir plus asunaprevir as interferon-free regimen for recurrent hepatitis C virus infection after liver transplantation: A preliminary study

Motofumi Tanaka, Kobe, Japan

The posters below belong to the Liver track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1052 Natural History of Spontaneous Porto-Systemic Shunt (PSs) and Transplant Outcomes in Liver Allograft Recipients

Tomasz Kozlowski, Chapel Hill, NC, United States
P.1083 Survival outcomes of combined hepatocellular carcinoma-cholangiocarcinoma following liver resection and liver transplantation
   Eunkyoung Jwa, Seoul, Korea

P.1269 ABO Incompatible Liver Transplantation using Plasma Exchange and Anti-CD20 Monoclonal Antibody
   Nam Kyu Choi, Gwangju, Korea

P.1432 The relation between the inflammatory cytokine expression with acute rejection episodes and hepatitis recurrence in liver allograft recipients
   Handan Özdemir, Ankara, Turkey

P.1574 Extracorporeal Membrane Oxygenation after Liver Transplantation in a Patient with Hepatopulmonary Syndrome and Refractory Hypoxemia
   Pınar Zeyneloğlu, Ankara, Turkey

P.1589 Epidemiology and risk factors of cholangitis after liver transplantation – single center experience
   Jolanta Gozdowska, Warsaw, Poland

P.1590 Post-transplantation lymphoproliferative disease in a patient after two liver transplant because of cirrhosis of the liver's own post-inflammatory etiology HCV and HBV
   Jolanta Gozdowska, Warsaw, Poland

Kidney Posters

P.1250 Plasmapheresis on Demand in ABO Incompatible (ABOi) Post Kidney Transplant Management
   Abdulnaser M. Alabadi, Dammam, Saudi Arabia

P.1251 Anti-HLA antibody-induced rejection in ABO-incompatible kidney transplant patients
   Joon Heon Jeong, Busan, Korea

P.1252 Role of plasmapheresis in management of ABO incompatible renal transplantation: A single centre experience
   Kamal V. Kanodia, Ahmedabad, India

P.1253 De novo focal and segmental glomerulosclerosis in renal allograft: a single center five year experience
   Kamal V. Kanodia, Ahmedabad, India

P.1254 Successful transplantation in ABO- and HLA-incompatible living kidney-transplant patients: a report on 12 cases
   Lionel Rostaing, Toulouse, France
<table>
<thead>
<tr>
<th>P.1255</th>
<th>NODAT development is associated with Tacrolimus blood level in relatively more elderly patients with pre-transplant impaired fasting glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selcuk Sahin, Istanbul, Turkey</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1256</th>
<th>Peak Panel Reactive Antibody Related States of Patients Awaiting for Deceased Kidney Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selcuk Sahin, Istanbul, Turkey</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1257</th>
<th>Rituximab induction significantly reduced acute rejection in ABO-incompatible kidney transplantation: A cohort study of 405 patients over 25 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akihito Sannomiya, Tokyo, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1258</th>
<th>Gastrointestinal perforation after renal transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Shin, Seoul, Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1259</th>
<th>Clinical outcomes of DSA positive alone in kidney transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Shin, Seoul, Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1260</th>
<th>Living donor renal transplantation in patients with antiphospholipid syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Shin, Seoul, Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1261</th>
<th>Clinical significance of ABO incompatible kidney transplantation from spousal donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chul Woo Yang, Seoul, Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1262</th>
<th>Outcomes of ABO Incompatible Kidney Transplantation Without Antibody Remove: Multicenter Experiences from China</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang Yi, Hengyang, People’s Republic of China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1263</th>
<th>Pilot Conversion Study from Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Junjji Uchida, Osaka, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1264</th>
<th>Acute Cellular Rejection in ABO-Incompatible Kidney Transplant Recipients Receiving Rituximab is Associated with Late-Onset Neutropenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Junjji Uchida, Osaka, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1265</th>
<th>Impact of low BMI on renal graft outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tahir Aziz, Karachi, Pakistan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1266</th>
<th>Dialysis vintage: A dominating factor affecting growth and final height after pediatric renal Transplantation: A single center experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tahir Aziz, Karachi, Pakistan</td>
<td></td>
</tr>
</tbody>
</table>
P.1268 The safety using intraoperative ureteric double J stent for prevention of urological complications in kidney transplant recipients
Nam Kyu Choi, Gwangju, Korea

P.1269 ABO Incompatible Liver Transplantation using Plasma Exchange and Anti-CD20 Monoclonal Antibody
Nam Kyu Choi, Gwangju, Korea

P.1270 Age-dependent impact of acute rejection on graft survival in young and old kidney transplant recipients
Tomasz Dziodzio, Berlin, Germany

P.1271 Outcomes of kidney transplantation for elderly aged more than 70 years
Akira Kurowsawa, Tochigi, Japan

P.1272 Outcomes in kidney transplantation from older donors: A single center experience
Kyung Hee Lee, Daegu, Korea

P.1273 The new Kidney Allocation System Hits the 305
Franco H. Cabeza, Miami, FL, United States

P.1275 It is Safe to Transplant Kidneys with Renal Masses
Giselle Guerra, Miami, FL, United States

P.1276 Transplantation of Kidneys from Donors with Renal Artery Aneurysm
Giselle Guerra, Miami, FL, United States

P.1277 Long-term outcomes after kidney transplantation in patients with the history of hemodialysis vascular access thromboses
Janis Jushinskis, Riga, Latvia

P.1278 Quantitative measurement of elasticity of the donor kidney using shear wave elastography to evaluate donor kidney status – pilot study
Sung Hoon Kim, Wonju, Korea

P.1279 Kidney donor profile index trend analyses
Debra L. Sudan, Durham, NC, United States

P.1280 Is Weight Gain a Barrier to Transplant Listing for Peritoneal Dialysis Patients?
Denise A. Fracchia, Melbourne, Australia

P.1281 Validation In Veracruz Mexico Of The Estimated Posttransplant Survival Score For Allocation Of Deceased Donor Kidney In The United States
Ernesto Soto-Miranda, Veracruz, Mexico
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1282</td>
<td>Validation in Veracruz Mexico of Kidney Donor Profile Index for Allocation of Deceased Donor Kidney in the United States</td>
<td>Ernesto Soto-Miranda</td>
<td>Veracruz, Mexico</td>
</tr>
<tr>
<td>P.1283</td>
<td>Successful short-term kidney transplantation outcomes after desensitization with plasmapheresis, intravenous immunoglobulin and rituximab in highly sensitized living donor kidney transplant patients: Mexican single-center experience</td>
<td>Ernesto Soto-Miranda</td>
<td>Veracruz, Mexico</td>
</tr>
<tr>
<td>P.1284</td>
<td>Thymoglobulin induction in living donor renal transplant recipients: Southern Mexican center experience</td>
<td>Ernesto Soto-Miranda</td>
<td>Veracruz, Mexico</td>
</tr>
<tr>
<td>P.1285</td>
<td>Impact of Brain Death Duration on Kidney Transplant Outcomes in Veracruz, Mexico</td>
<td>Ernesto Soto-Miranda</td>
<td>Veracruz, Mexico</td>
</tr>
<tr>
<td>P.1286</td>
<td>Relationship Between Dialysis Duration and Prevalence of Cardiovascular Diseases in Kidney Transplantation Recipients</td>
<td>Keisuke Hata</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td>P.1287</td>
<td>Development of protocol for deceased kidney transplantation recipients while waiting for kidney transplantation</td>
<td>Hyun Jung Kim</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>P.1288</td>
<td>Anti-Diuretic Hormone Response Related to Kidney Transplantation in Dialysis Patients</td>
<td>Jin Soo Kim</td>
<td>Busan, Korea</td>
</tr>
<tr>
<td>P.1289</td>
<td>Comparison of Barriers to Wait Listing for Kidney Transplantation between hemodialysis center</td>
<td>Keun-Myoung Park</td>
<td>Incheon, Korea</td>
</tr>
<tr>
<td>P.1290</td>
<td>Mean fluorescence intensity by Luminex single antigen bead and one year graft outcome in DSA positive kidney transplantation</td>
<td>Leslie A. Yap</td>
<td>San Juan, Philippines</td>
</tr>
<tr>
<td>P.1291</td>
<td>Evolution of Renal Transplantation - Experience From a Single Center</td>
<td>Viktor Denisov</td>
<td>Donetsk, Ukraine</td>
</tr>
<tr>
<td>P.1292</td>
<td>Surgical and technical aspects of re-operative (/&gt;=3) Kidney transplantation</td>
<td>Tarunjeet S. Klair</td>
<td>New York, NY, United States</td>
</tr>
</tbody>
</table>
P.1293 Renal Transplant for Patients on Long-Term Dialysis (more than 20 years) at our Center
Koichi Kozaki, Ibaraki, Japan

P.1294 Need for more than just renal replacement - Analysis of a special cohort
Mettu Srinivas Reddy, Chennai, India

P.1295 Decremental Change in Perioperative Hemoglobin Concentration is Associated with Poor Early Graft Function in Kidney Transplant Patients: a Retrospective Study
Arpa Chutipongtanate, Bangkok, Thailand

P.1296 Rate of Dysregulation of Serum Immunoglobulins is Higher in Acute Allograft Rejection in Renal Transplant Recipients
Ravi Dhital, Chandigarh, India

P.1297 Paricalcitol pretreatment attenuates apoptosis and inflammation in renal ischemia-reperfusion injury via EP4 pathway
Suk Young Kim, Daejeon, Korea

P.1298 Pretreatment with cilastatin attenuates renal ischemia-reperfusion injury
Suk Young Kim, Daejeon, Korea

P.1299 Intra-abdominal cooling system prevents ischemia-reperfusion injury during robotic-assisted renal transplantation
Raphael Meier, Geneva, Switzerland

P.1300 Increased Gene expression of BAFF-R, TACI and BCMA is associated with acute rejection in kidney transplantation
Mukut Minz, Chandigarh, India

P.1301 Plasma neutrophil gelatinase-associated lipocalin (NGAL) - biomarker in kidney injury. Is it a useful tool to predict the renal function after transplantation?
Marta Sekowska, Poznan, Poland

P.1302 When Does Delayed Graft Function not Make a Difference in Deceased Donor Kidney Transplant Outcomes?
Robert J. Stratta, Winston-Salem, NC, United States

P.1303 The role of alloimmunity in death-censored kidney allograft failure
Mohamad M. Alkadi, New York, NY, United States
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1304</td>
<td>Urine metabolomics: quinolinate, a product of tryptophan metabolism,</td>
<td>Mohamad M. Alkadi, New York, NY, United States</td>
</tr>
<tr>
<td></td>
<td>is associated with BK virus nephropathy and intragraft inflammation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in kidney transplant recipients</td>
<td></td>
</tr>
<tr>
<td>P.1305</td>
<td>Breast implants surgery in patient who had kidney transplantation</td>
<td>Marina Ratkovic, Podgorica, Montenegro</td>
</tr>
<tr>
<td>P.1306</td>
<td>Case of rapamycin induced pancreatitis and deep venous thrombosis</td>
<td>Marina Ratkovic, Podgorica, Montenegro</td>
</tr>
<tr>
<td>P.1307</td>
<td>Plasmapheresis and rituximab therapy in a second living-related</td>
<td>Marina Ratkovic, Podgorica, Montenegro</td>
</tr>
<tr>
<td></td>
<td>kidney transplant patient with recurrent focal segmental glomerulosclerosis</td>
<td></td>
</tr>
<tr>
<td>P.1308</td>
<td>Complications of kidney transplantation performed through black</td>
<td>Marina Ratkovic, Podgorica, Montenegro</td>
</tr>
<tr>
<td></td>
<td>organ markets affiliations</td>
<td></td>
</tr>
<tr>
<td>P.1309</td>
<td>Does C1q SAB assay have any value in prediction of kidney</td>
<td>Arpita Ghosh-Mitra, Kolkata, India</td>
</tr>
<tr>
<td></td>
<td>transplantation outcome in highly sensitized patients?</td>
<td></td>
</tr>
<tr>
<td>P.1310</td>
<td>Bortezomib and Antibody Mediated Rejection in Renal Allograft</td>
<td>Lorna K. Henderson, Edinburgh, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Recipients</td>
<td></td>
</tr>
<tr>
<td>P.1311</td>
<td>A flare up of de novo donor-specific antibodies following the</td>
<td>Cheol Woong Jung, Seoul, Korea</td>
</tr>
<tr>
<td></td>
<td>ruptured ectopic pregnancy after kidney transplant from spousal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>donor</td>
<td></td>
</tr>
<tr>
<td>P.1312</td>
<td>Relationship between de novo donor-specific anti-HLA-DQ antibody</td>
<td>Furusawa Miyuki, Tokyo, Japan</td>
</tr>
<tr>
<td></td>
<td>and chronic antibody-mediated rejection in kidney transplant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>recipients</td>
<td></td>
</tr>
<tr>
<td>P.1313</td>
<td>Analysis of Significance of Vascular Rejection in Kidney</td>
<td>Marek Novotny, Prague, Czech Republic</td>
</tr>
<tr>
<td></td>
<td>Transplant Biopsy Samples</td>
<td></td>
</tr>
<tr>
<td>P.1314</td>
<td>Clinical relevance of de novo donor-specific HLA antibodies (DSA)</td>
<td>Florian Sommer, Augsburg, Germany</td>
</tr>
<tr>
<td></td>
<td>in renal transplantation</td>
<td></td>
</tr>
</tbody>
</table>
P.1315  Clinical and Pathological Evaluations of Combination Therapy for Active Antibody Mediated Rejection in Renal Transplantation; a Single-Center Experience
Masayuki Tasaki, Niigata, Japan

P.1316  Eculizumab rescue from acute antibody-mediated rejection and long-term stable graft function
Rolf Weimer, Giessen, Germany

P.1317  Do anti-HLA antibodies as detected by the Luminex assay have an impact on kidney allograft survival beyond 10 years post transplant?
Angeline Goh, Singapore, Singapore

P.1318  Long term follow up glycemic status of live kidney donors
Angeline Goh, Singapore, Singapore

P.1319  Anti-HLA Antibody Reduced Graft Survival in Living-Related Transplants: Over 20 Years Experience
Kazuo Mizutani, Tokyo, Japan

P.1320  Assessment of EGFR and One-Hour Biopsy Using In-Situ-Cooling Double-Balloon Catheters in Deceased Kidney Transplants
Kazuo Mizutani, Tokyo, Japan

P.1321  Phytohemagglutinin-Induced Il2 Mrna as a Useful Marker of Kidney Transplants
Kazuo Mizutani, Tokyo, Japan

P.1322  C4D Binding Correlated with Strong HLA Antibodies in Kidney Transplantation
Kazuo Mizutani, Tokyo, Japan

P.1323  Effective monitoring of CMV infection by quantitative analysis of CMV mRNA. Case report in renal transplant
Kazuo Mizutani, Tokyo, Japan

P.1324  Donor specific HLA-antibodies are a risk factor for graft dysfunction in both presumptive BKVN and biopsy positive BKVN
Essa A. Abuheilaiqa, New York, NY, United States

P.1325  Polyomavirus Associated Nephropathy with Concurrent Recurrence of IgA Nephropathy in a post Kidney Transplant patient: A Case Report
Ramona Espera-Lobaton, Taguig City, Philippines

P.1326  Sirolimus leads to Negative Conversion of BK Virus in Renal Transplantation Patients
Sang Youb Han, Goyang, Korea
P.1327 Clinical Outcomes of BK Virus Associated Nephropathy in Kidney Transplant Recipients

**Kyubok Jin**, Daegu, Korea

P.1328 BK Polyomavirus Prophylaxis with Ciprofloxacin in Kidney Transplant Recipients: a Prospective Study

**Xiaopeng Yuan**, Guangzhou, People's Republic of China

P.1329 Implantation biopsy of cardiac death donors and its implication in predicting renal graft outcomes

**Xiaopeng Yuan**, Guangzhou, People's Republic of China

P.1330 Retrospective review on the prevalence of hyperuricaemia before and after renal transplantation and the risk factors predicting hyperuricaemia after renal transplantation in a single centre

**Siu Kim Chan**, Hong Kong SAR, P.R. of China

P.1331 Is There a Link Between Proteinuria and Increased FGF-23 Levels in Renal Transplant Patients?

**Turan Colak**, Ankara, Turkey

P.1332 Alkaline Phosphatase a New Marker for Graft Outcome and High Pulse Wave Velocity in Renal Transplant Recipients

**Turan Colak**, Ankara, Turkey

P.1333 Ambulatory blood pressure measurement as a prognostic tool in renal transplant recipients

**Turan Colak**, Ankara, Turkey

P.1334 Arteriolar Hyaline Formation caused by Hypertension and High TG Levels as well as CNI Toxicity Appeared to be a Long-Term Risk Factor of Allograft Function

**Yoshihiro Itabashi**, Tokyo, Japan

P.1335 Correlation between Resistance Index and urinary albumin excretion at early stage after renal transplantation

**Kabei Kazuya**, Osaka, Japan

P.1336 Serum cystatin C as a good predictor of chronic allograft dysfunction in renal transplant recipients

**Sirilak Leawseng**, Bangkok, Thailand

P.1339 New Risk factor of Newly Onset Diabetes Mellitus after Kidney Transplantation

**Michal P. Nowicki**, Lodz, Poland

P.1340 Impaired Fastig Glucose according to different diagnostic criteria in kidney transplanted patients

**Liliana Miriam Obregon**, La Plata, Argentina
P.1341 Serum 25-hydroxyvitamin D levels with metabolic profiles in renal transplant recipients with chronic allograft nephropathy

Bancha Satirapoj, Bangkok, Thailand

P.1342 Using analgesics including nonsteroidal anti-inflammatory drugs in patients with chronic kidney disease (CKD 1-4) and after kidney transplantation – one center experiences

Alicja Debska-Slizien, Gdańsk, Poland

P.1343 The Treatment of Hypertension in Patients after renal Transplantation - One Center Observational Study

Alicja Debska-Slizien, Gdańsk, Poland

P.1344 Achromobacter denitrificans pneumonia in a renal transplant patient– dose-dependent decrease of phagocytic activity as a potential mechanism for the everolimus pulmonary toxicity

Alicja Debska-Slizien, Gdańsk, Poland

P.1345 Preimplantation and intragraft molecular transcripts in serial biopsies of standard and extended criteria donor kidneys: effect of donor type and immunosuppressive protocols

Mario Abbud-Filho, Sao Jose do Rio Preto, Brazil

P.1346 Outcomes of Kidney Transplantation from DBD, DCD or DBCD Donors: A Single Center Experience from China

Guodong Chen, Guangzhou, People's Republic of China

P.1347 Kidney transplantation from pediatric donors of deceased organ donation

Chen Chuanbao, Guangzhou, People's Republic of China

P.1348 The analysis of discarded kidneys from donors of deceased organ donation

Chen Chuanbao, Guangzhou, People's Republic of China

P.1349 Long Term Graft and Recipient Outcome of Deceased Donor Renal Transplantation at the National Kidney and Transplant Institute

Romina A. Danguilan, Quezon, Philippines

P.1350 Clinical research of kidney transplantation from cardiac death pediatric donors

Han Feng, Xi'an, People's Republic of China

P.1351 Clinical Investigation of kidney transplantation from cardiopulmonary resuscitation of DCD

Han Feng, Xi'an, People's Republic of China
TTS 2016 Congress

P.1352 Pyeloureteric junction obstruction in renal allografts
Andrej Grajn, Brisbane, Australia

P.1353 Patient and Graft survival and graft function three years after Living-related donation and Brain-dead donation: results from a single center
Hai An Ha Phan, Hanoi, Viet Nam

P.1354 BK virus infection among kidney transplant recipients: data from Department of Kidney Diseases and Dialysis, Viet Duc hospital
Hai An Ha Phan, Hanoi, Viet Nam

P.1355 Establishing of uncontrolled donation after circulatory determination of death (UDCDD) protocol in Poland – first two cases
Marek Karczewski, Poznan, Poland

P.1356 Identifying Risk Severity Using Proposed Wuhan Chart In Deceased Donor Kidney Transplantation
Kiran J. Kunwar, Kathmandu, Nepal

P.1357 The impact of delayed graft function after kidney transplantation on long-term graft function and survival
Sukyung Kwon, Seoul, Korea

P.1358 Incidence and outcome of vascular complications in kidney transplantation after expanding acceptance criteria: Single centre experience
Mohamed Morsy, London, United Kingdom

P.1359 Incidence and outcome of Post-transplant urological complications in kidney transplantation after expanding acceptance criteria: Single centre experience
Mohamed Morsy, London, United Kingdom

P.1360 Pathological analysis of 544 cases of indicated renal allograft biopsies
Changxi Wang, Guangzhou, People's Republic of China

P.1361 En Bloc Kidney Transplantation from Infant Donors Less Than 10 kg – surgical skill, clinical management and outcome in a transplant center in China
Changxi Wang, Guangzhou, People's Republic of China

P.1362 Comparison of kidney transplantation from living and deceased donation: a consecutive data analysis since implement of donation after citizen's death in China
Changxi Wang, Guangzhou, People's Republic of China
P.1363 Conversion from mycophenolate mofetil to mizoribine and its therapeutic exposure in Chinese renal transplant recipients with leucopenia
Longshan Liu, Guangzhou, People’s Republic of China

P.1364 Hemodynamics in Transplant Renal Artery Investigated by Computational Fluid Dynamics
Changxi Wang, Guangzhou, People’s Republic of China

P.1365 Universal vascular index to predict organ quality during rewarming machine perfusion for kidney transplantation from Donation after Cardiac Death
Hiromichi Obara, Hachiouji, Tokyo, Japan

P.1366 Outcome of Kidney Transplantation from Expanded Criteria Deceased Donors
Mohammad Raslan, Kuwait, Kuwait

P.1368 Kidney Donor Profile Index as a Prognostic Factor in Transplants in Colombia
Alejandro Niño-Murcia, Bogota, Colombia

P.1369 Basiliximab Vs. rabbit antithymocyte globulin (rATG) induction in “low risk” Kidney transplantation in Colombia
Alejandro Niño-Murcia, Bogota, Colombia

P.1370 Intensive Care Unit Feedback About Organ Donation
Alejandro Niño-Murcia, Bogota, Colombia

P.1371 En Bloc Dual Kidney Transplantation: a Novel Technique
Dai Nghiem, Westminster, CA, United States

P.1372 A New Approach to the Hostile Bladder in Transplantation
Dai Nghiem, Westminster, CA, United States

P.1374 Pre-transplant deceased donor kidney biopsy is decision-making for single versus dual kidney transplantation
Kamlesh S. Suthar, Ahmedabad, India

P.1375 Excellent Long-term Outcomes of Renal Transplantation from Donation after Cardiac Death Donors: A Single Center Experience
Masashi Takenaka, Aichi, Japan

P.1376 Comparison of hypothermic and normothermic pulsatile machine perfusion in an ex-vivo porcine kidney model
Natalie Vallant, London, United Kingdom

P.1377 Extraction of green fluorescent protein labelled Mesenchymal Stem Cells to investigate their mechanisms of action on Ischemia- Reperfusion Injury in a rat kidney transplant model
Natalie Vallant, London, United Kingdom
P.1378 Kidney Transplant from Deceased Donors with Several Stages of Acute Kidney Injuries: a Comparison with Standard Donors and Expanded Criteria Donors
Punlop Wiwattanathum, Bangkok, Thailand

P.1379 Effects of Plasmapheresis and Antigen-Specific Immunoadsorption on Complement Levels in Antibody-Incompatible Live Renal Transplant
Archana Jain, Coventry, United Kingdom

P.1380 Dengue Fever in Patients with Renal Transplantation Analysis – Cases Report
Ling-Hsien Lee, Tainan City, Taiwan

P.1381 Management of highly sensitized patients in kidney transplantation: prospective single center strategy
Michel Mourad, Brussels, Belgium

P.1382 Living kidney transplantation from older donor aged 60 and older
Kiyokazu Akioka, Omihachiman, Japan

P.1383 Post-nephrectomy inflammatory syndrome: A common complication post minimal access live donor nephrectomy?
Marc J. Clancy, Glasgow, United Kingdom

P.1384 Living longer and better after kidney transplant in southern Spain
Javier de Teresa Alguacil Sr., Granada, Spain

P.1385 Identifying the main causes of kidney allograft loss: a large cohort study in Spain
Javier de Teresa Alguacil Sr., Granada, Spain

P.1386 Donors with stone-bearing kidneys are eligible for living kidney donation: a systematic review and cohort analysis
Frank JMF Dor, London, United Kingdom

P.1387 Recurrent focal segmental glomerular sclerosis after renal transplantation; prevention and treatment with Rituximab
Kenta Futamura, Nagoya, Japan

P.1388 50-year donor and recipient survival after non-twin living donor kidney transplantation
Oscar K. Serrano, Minneapolis, MN, United States

P.1389 The impact of viral replication in recipient urine, oral wash and blood before transplant on post-transplant infection
Oscar K. Serrano, Minneapolis, MN, United States

P.1390 The impact of graft thin upper pole artery ligation on living donor kidney transplantation
Takahisa Hiramitsu, Nagoya, Japan
P.1391 Efficacy and feasibility of radiotherapy for localized prostate cancer in renal transplant recipients: a single-center experience

Junpei Iizuka, Tokyo, Japan

P.1392 A Safer 2-Layer Method of Inguinal Hernia Repair for the Renal Transplant Recipient

Nobuhiro Ishido, Kobe, Japan

P.1393 Results of paired kidney exchange transplantation: initial experience of a single institution

Feza Karakayali, Ankara, Turkey

P.1394 Results of BK Virus Screening in Renal Transplant Recipients

Feza Karakayali, Ankara, Turkey

P.1395 Investigation of Body Mass Index and Cases of Living Renal Transplantation Performed in this Department

Yu Kihara, Tokyo, Japan

P.1396 Long-term renal allograft survival after sequential liver-kidney transplantation from a single living donor

Kumiko Kitajima, Tokyo, Japan

P.1397 Impact of serum creatinine levels at 1 year on 5-year graft survival

Mirza Naqi Zafar, Karachi, Pakistan

P.1398 A living donor risk model for predicting kidney allograft and patient survival in an emerging economy

Mirza Naqi Zafar, Karachi, Pakistan

P.1399 High prevalence of post transplant donor specific HLA-DQ antibody in live related renal transplantation. Is it time to extend typing to HLA-DQ in renal transplantation?

Mirza Naqi Zafar, Karachi, Pakistan

P.1403 Intra-operative fluid management for robotic kidney transplantation: an initial experience

Manisha P. Modi, Ahmedabad, India

P.1404 Preemptive kidney transplantation in Japanese patients: A propensity score-matched study

Masayoshi Okumi, Tokyo, Japan

P.1405 Who is at Risk in Living Kidney Donation?

Rajesh Sivaprakasam, London, United Kingdom

P.1406 Effect of Tacrolimus trough-level variability on New-Onset Diabetes After Transplantation in Renal Transplantation

Rajesh Sivaprakasam, London, United Kingdom
P.1407 What Component of the Cold Ischemia Time is Important?
Rajesh Sivaprakasam, London, United Kingdom

P.1410 Renal transplantation after laparoscopic radical nephrectomy due to neoplastic disease - case report
Marek Ostrowski, Szczecin, Poland

P.1411 Obstacles facing Living Related Donor Kidney Transplant Program at an urban non-transplanting Center, U.K
Husham Rasheed, Birmingham, United Kingdom

P.1412 Successful direct-acting antiviral therapy for renal transplant recipients with hepatitis C virus infection
Tamotsu Tojimbara, Atami-City, Japan

P.1413 Right-sided laparoscopic live-donor nephrectomy: results and technical aspects
Pablo Troncoso, Santiago, Chile

P.1414 Laparoscopic right donor nephrectomy: Analysis of different technique
Anant Kumar, Saket, India

P.1415 Renal Transplant in patients with abnormal bladder: Is the outcome same in developing country?
Anant Kumar, Saket, India

P.1416 TRANSFORM: Everolimus with reduced calcineurin inhibitors vs mycophenolate with standard calcineurin inhibitors in de novo kidney transplant recipients - baseline data according to donor type
Yoshihiko Watarai, Nagoya, Japan

P.1417 Comparison of Live Donor Pretransplant Renal Volume and Posttransplant Recipient Renal Volume
Masaaki Yanishi, Hirakata, Japan

P.1418 Clinical Outcomes in Recipients of Living Donor Kidney Transplants from Elderly Donors
Takayoshi Yokoyama, Tokyo, Japan

P.1421 When to Abort a Liver Donor Laparoscopic Nephrectomy?
Linda J. Chen, Miami, FL, United States

P.1422 New application of powered vascular stapler for laparoscopic live kidney donor nephrectomy
Linda J. Chen, Miami, FL, United States

P.1423 Successful use of a collateral vein in renal transplantation - First case report in an ADULT recipient
Linda J. Chen, Miami, FL, United States
Using kidneys with a congenital anomalies for transplantation: A judgement call

Linda J. Chen, Miami, FL, United States

Clinical utility of surveillance kidney transplant biopsies at one year post-transplantation: a long-term survival comparison among renal transplant recipients

Magali Giral, Nantes, France

Borderline changes on dysfunctional renal allograft biopsies: Clinical relevance in a live related renal transplant setting

M. Mubarak Nuhari, Karachi, Pakistan

Renal allograft biopsy findings in 475 pediatric live related renal transplant patients from a single center

M. Mubarak Nuhari, Karachi, Pakistan

Renal Allograft with Calcium Oxalate Deposition: its Association with Urinary Tract Infection and Development of Interstitial Fibrosis

Handan Özdemir, Ankara, Turkey

Ultrastructural findings and capillary HLA-DR expression in renal allografts with humoral, vascular and tubulointerstitial rejection: Correlation with development of transplant glomerulopathy

Handan Özdemir, Ankara, Turkey

What is the Role of Cytomegalovirus on Interstitial Fibrosis and Graft Survival?

Handan Özdemir, Ankara, Turkey

Comparison of light and electron microscope renal biopsy findings with proteinuria levels of candidate living kidney donors

Handan Özdemir, Ankara, Turkey

The relation between the inflammatory cytokine expression with acute rejection episodes and hepatitis recurrence in liver allograft recipients

Handan Özdemir, Ankara, Turkey

Prevention of Vascular Stricture by Using an Expanded Polytetrafluoroethylene (ePTFE) Graft in a Porcine Model: Preliminary Study

Handan Özdemir, Ankara, Turkey

Bridging technique of bile duct anastomosis using an expanded polytetrafluoroethylene (ePTFE) graft in a porcine model

Handan Özdemir, Ankara, Turkey
P.1435 Clinical and Pathological Analyses of Interstitial Fibrosis and Tubular Atrophy (IF/TA) Cases After Kidney Transplantation
Tomokazu Shimizu, Tokyo, Japan

P.1436 The Oxford Classification as a predictor of outcome in patients with IgA nephropathy in the renal allograft
Sansanee Thotsiri, Bangkok, Thailand

P.1437 Treatment and outcomes of recurrent focal segmental glomerulosclerosis post kidney transplantation in children
Anna Francis, Nundah, Australia

P.1438 Tonsillectomy and steroid pulse therapy for recurrence of IgA nephropathy after kidney transplantation
Kengo Horia, Gifu City, Japan

P.1439 Successful Approach to Kidney Transplantation in Patients with Secondary Hyperoxaluria
Joke I. Roodnat, Rotterdam, Netherlands

P.1440 Biopsy correlation of recurrent FSGS
Shafi Malik, Leicester, United Kingdom

P.1441 Urinary Tract Infections in Kidney Transplant Recipients
Shafi Malik, Leicester, United Kingdom

P.1442 Good patient and graft survival in recipients of kidney transplantation due to diabetic nephropathy
Amgad El-Agroudy, Manama, Bahrain

P.1443 Mycophenolate Mofetil dose reduction are associated with the risk of acute rejection and graft failure after renal transplantation
Amgad El-Agroudy, Manama, Bahrain

P.1444 Kidney Transplantation Tourism: High risk and bad outcome for the recipients
Amgad El-Agroudy, Manama, Bahrain

P.1446 Single center experience of pediatric renal transplantation at PKI, SIH
Saeed Akhter, Islamabad, Pakistan

P.1447 Single center experience of open versus hand assisted live donor nephrectomies
Saeed Akhter, Islamabad, Pakistan

P.1448 Hand Assisted Laparoscopic Donor Nephrectomy initial experience of junior surgeons at PKI, SIH
Saeed Akhter, Islamabad, Pakistan
The posters below belong to the Kidney track, but have been placed under another track in order to be grouped with other posters from the same presenter.

**P.1113** Outcomes of Second Kidney Transplantation Compared to Primary Transplantation  
*Jae Geun Lee*, Seoul, Korea

**P.1160** The Impact of Recipient’s BMI at the Deceased Donor Kidney Transplantation  
*Ju Ik Moon*, Daejeon, Korea

**P.1177** Successful Retransplantation of an Allograft after Early Recurrence of Focal Segmental Glomerulosclerosis in the First Recipient  
*Manuel Maglione*, Innsbruck, Austria

**P.1185** Measurement of Creatinine clearance in immediate post Kidney transplant (KTx) period with functioning allograft  
*Ashokkumar Jain*, Hershey, PA, United States

**P.1222** Current Status of Cadaveric and Living Donor Kidney Transplantation of The Last 6 Years, Compared With Previous 6 Years Experience  
*Mitsuru Nakatsuka*, Richmond, VA, United States

**P.1653** Decreased resistive index (RI) in renal transplant recipients—a treatable imaging finding  
*Rehan Mohsin*, Karachi, Pakistan

**P.1657** Psychosocial long-term impact of donation on donation on kidney living donors- a comparative study of two major europea transplant centres  
*Ana T. Menjivar*, Barcelona, Spain

**P.1668** The effects of Normal saline solution versus Hartmann’s solution on the acid–base and electrolytes status and renal function after kidney transplantation  
*Won-Hyun Cho*, Daegu, Korea

**P.1708** NODAT in Africans: Is it higher than in other ethnic groups?  
*Ihab A. M. Ahmed*, Khartoum, Sudan

**P.1752** Pre transplant at1r antibodies and the risk of recurrent focal segmental glomerulosclerosis (FSGS)  
*Hatem Amer*, Rochester, MN, United States
P.1811 Comparison of Baseline Proteinuria and Outcomes and Baseline Comorbidities and New Onset Proteinuria in Live Kidney Donors - UK Cohort Study  
**Nithya Krishnan**, Coventry, United Kingdom

P.1892 The effects of MyD88 inhibitor local infusion in ischemia-reperfusion kidney injury  
**Hong R. Cho**, Ulsan, Korea

### Kidney Immunosuppression Posters

P.1475 Effect of conversion from cyclosporine to tacrolimus on cardiovascular risk profile in renal transplant recipients  
**Minjung Kim**, Daegu, Korea

P.1476 Variation of Induced Tolerance Practices and Outcomes across Countries: A Scoping Review  
**Jathurong Kittrakulrat**, Bangkok, Thailand

P.1477 Study of Serum BKV Load in Patients prior to Renal Transplantation  
**William Chi-Shing Tai**, Hong Kong SAR, P.R. of China

P.1478 Longitudinal Study of Serum BKV load in Patients before and after Renal Transplantation  
**William Chi-Shing Tai**, Hong Kong SAR, P.R. of China

P.1479 A Comparison of Early Postoperative Results of Living-Donor Kidney Transplantations Using Calcineurin Inhibitors (Tacrolimus Extended-Release Formulation vs. Cyclosporine)  
**Osamu Konno**, Tokyo, Japan

P.1480 Cost of kidney transplant in Colombia  
**Eyner Lozano**, Bogota, Colombia

P.1483 Outcomes of patients on non-standard immunosuppression after renal transplantation  
**Asha M. Zimmerman**, Cranston, RI, United States

P.1484 Impact of conversion from original MMF to generic MMF in kidney transplant recipients: a single-center experience  
**Hajime Hirano**, Takatsuki, Japan

P.1485 What has changed in Renal transplantation in some small islands in Japan? Strategy of our center  
**Hajime Hirano**, Takatsuki, Japan
P.1486 Excellent antirejection prophylaxis and low incidence of infections after kidney transplant with low dose rabbit antithymocyte globulin induction therapy in high immunologic risk patients
Pedro W. Baron, Redlands, CA, United States

P.1487 Outcome of Deceased Donor Renal Transplantation Patients who Underwent Induction Therapy with Basiliximab and Rabbit Anti-Thymocyte Globulin at National Kidney and Transplant Institute from January 2007 to December 2011
Joel B. Benavidez, Quezon City, Philippines

P.1488 Non Induction Therapy In Low Risk Living Related Kidney Transplantation In India
Kshitija G. Gadekar, Aurangabad, India

P.1489 After Alemtuzumab Induction, Tac+MMF is Superior to CsA+MMF in Pediatric Kidney Transplantation
Michael M. Kaabak, Moscow, Russian Federation

P.1490 Antibody Induction Therapy for Kidney Transplant before the Introduction of Thai Transplant Care
Krit Pongpirul, Bangkok, Thailand

P.1491 Antithymocyte globulin induction prescription heterogeneity. Results of an observational study on the French DIVAT kidney transplant network
Chapal Marion, La Roche sur Yon, France

P.1492 Efficacy of administration of rabbit anti thymocyte globulin as induction therapy in living-donor kidney transplant sensitized patients
Toru Murakami, Tokyo, Japan

P.1493 Experience of 120 cases using Antithymocyte globulin as an induction immunosuppressant in Kidney transplantation in Korea
Kyungjai Ko, Seoul, Korea

P.1494 Lymphocyte Subset Test as a Determinant of Cytomegalovirus Prophylaxis in Renal Transplant Recipients with Antithyctocyte Globulin Induction Therapy: A Pilot Study
Yungjai Ko, Seoul, Korea

P.1495 Efficacy and Safety of Rabbit Antithymocyte Globulin or Interleukin-2 Receptor Antagonist for Induction Therapy in Chinese Living Donor Renal Transplantation Recipients: a Retrospective Study
Jiang Qiu, Guangzhou, People's Republic of China
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1496</td>
<td>Mica Positive Status and Immunosuppression</td>
<td>Vijaya Rajakumari, New Delhi, India</td>
<td></td>
</tr>
<tr>
<td>P.1497</td>
<td>Optimal Dose of Thymoglobulin for Induction Therapy in High Risk Kidney Transplant Recipients</td>
<td>Seungyeup Han, Daegu, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1498</td>
<td>A Case of Coexistence of Intracranial and Intramedullary Tuberculomas in Kidney Transplantation Recipient</td>
<td>Seungyeup Han, Daegu, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1499</td>
<td>Cost-effectiveness of Single Daily-dose of Sirolimus and Tacrolimus-XR for Kidney Transplantation</td>
<td>Yingyos Avihingsanon, Bangkok, Thailand</td>
<td></td>
</tr>
<tr>
<td>P.1500</td>
<td>Therapeutically Equivalent Results to Caucasians in Black Kidney Transplant Recipients Using Astagraf XL Despite a Higher Degree of HLA Mismatch: A Post-Hoc Analysis of Phase III Data from over 2000 Patients</td>
<td>Jason J. Schwartz, Northbrook, IL, United States</td>
<td></td>
</tr>
<tr>
<td>P.1501</td>
<td>Comparative performance of apparent oral midazolam clearance and plasma 4β-hydroxycholesterol to predict tacrolimus disposition in renal recipients</td>
<td>Thomas Vanhove, Leuven, Belgium</td>
<td></td>
</tr>
<tr>
<td>P.1502</td>
<td>The P-glycoprotein probe fexofenadine does not predict tacrolimus disposition in renal recipients</td>
<td>Thomas Vanhove, Leuven, Belgium</td>
<td></td>
</tr>
<tr>
<td>P.1503</td>
<td>Evaluation and inter-laboratory comparison of a real-time PCR-based DNA demethylation assay to assess the frequency of naturally occurring regulatory T cells (nTregs) in peripheral blood</td>
<td>Eberhard Wieland, Stuttgart, Germany</td>
<td></td>
</tr>
<tr>
<td>P.1504</td>
<td>Influence of CYP3A4<em>22 and CYP3A5</em>3 genetic polymorphisms on tacrolimus pharmacokinetics in adult renal transplant patients</td>
<td>Pilar Salvador, A Coruña, Spain</td>
<td></td>
</tr>
<tr>
<td>P.1505</td>
<td>Effect of MDR1 C3435T, C1236T and G2677T/A polymorphisms on 5-year tacrolimus pharmacokinetics and renal function in renal transplant recipients</td>
<td>Pilar Salvador, A Coruña, Spain</td>
<td></td>
</tr>
<tr>
<td>P.1506</td>
<td>Influence of CYP3A5 polymorphisms on 5-year tacrolimus pharmacokinetics and renal function in renal transplant recipients</td>
<td>Pilar Salvador, A Coruña, Spain</td>
<td></td>
</tr>
</tbody>
</table>
P.1507 Influence of CYP3A4*1 and MDR1 C3435T, C1236T and G2677T/A genetic polymorphisms on itraconazole-tacrolimus interaction in adult renal transplant patients

Maria Outeda Macias III, A Coruña Spain

P.1508 Levetiracetam treatment of epileptic seizures in transplant patients

Maria Outeda Macias III, A Coruña Spain

P.1509 The association between trough blood level and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation

Sayamon Sukkha, Bangkok, Thailand

P.1510 Pharmacokinetics Study of Once Daily Immunosuppression in Kidney Transplantation

Natavudh Townamchai, Bangkok, Thailand

P.1511 Comparison of the Pharmacokinetics and Pathology for Low-Dose Once-Daily and Twice-Daily Tacrolimus following Living Kidney Transplantation: Five-Year Results from a Prospective Trial

Kohei Unagami, Tokyo, Japan

P.1513 Increased starting dose of Everolimus did not affect early renal function after renal transplantation

Mary Eng, Louisville, KY, United States

P.1515 Adherence to immunosuppression after conversion of twice-daily Tacrolimus to once-daily Tacrolimus in stable kidney transplant patients in Thailand: A prospective study

Sopon Jirasiritham, Pathumtanee, Thailand

P.1516 A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-Daily Prolonged Release Tacrolimus

Soo Kyoung Kang, Pusan, Korea

P.1517 The prevalence of renal transplant recipients with low exposure to mycophenolic acid taking mofetil mycophenolate or enteric-coat sodium mycophenolate and possible influence factors

Elizete Keitel, Porto Alegre, Brazil

P.1518 Effect of Everolimus Conversion in Hepatitis C Viremia in Adult Kidney Recipients

Elizete Keitel, Porto Alegre, Brazil
P.1519  Association of Tacrolimus Trough Levels with Incidence of New Onset of Diabetes after Transplantation and the Graft Function Assessed by Concentration and Dose Ratio
Sailaja Kesiraju, Hyderabad, India

P.1520  Conversion to once-daily tacrolimus extended-release formulation (TAC XL) in renal transplantation: A multicenter experience in Argentina
Rafael A. Maldonado, Cordoba, Argentina

P.1521  Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in Chinese Living-Donor Kidney Transplant Recipients: A Multicenter Prospective Cohort Study
Chunbai Mo Sr., Tianjin, People’s Republic of China

P.1522  Impact of preoperative donor-specific anti-HLA antibody in adult living donor kidney transplantation
Young M. Song, Seoul, Korea

P.1523  Optimal Initial Everolimus Dose in Renal Transplant Recipients Administered Tacrolimus
Hironori Takeuchi, Hachioji, Tokyo, Japan

P.1524  Survival of HLA Class Two Positive Recipients Compared to Standard Risk Recipients After Renal Transplantation at the National Kidney and Transplant Institute from January 1, 2009 to December 31, 2013
Jonathan John F. Tamin, Quezon City, Philippines

P.1525  Successful early additional mTORi therapy with a low-dose calcineurin inhibitor in renal transplant patients: a single-center pilot study
Yuki Nakamura, Hachioji, Tokyo, Japan

P.1526  The examination of the breaking point of expanded criteria deceased donor in Japan
Yuki Nakamura, Hachioji, Tokyo, Japan

P.1527  5 Year Follow-Up Results of the HERAKLES Study: Superior Renal Function after Early Conversion to an Everolimus-Based Calcineurin Inhibitor Free Regimen
Wolfgang Arns, Cologne, Germany

P.1528  Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: 5 Year Follow-Up Results of The HERAKLES Trial
Klemens Budde, Berlin, Germany

P.1529  Baseline characteristics of Asian and non-Asian renal transplant recipients: Findings from the TRANSFORM trial
Po-Chang Lee, Tainan, Taiwan
### POSTER LIST

The posters below belong to the Kidney Immunosuppression track, but have been placed under another track in order to be grouped with other posters from the same presenter.

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Presenter(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1189</td>
<td>Effects of Natural Immune System on Acute Rejection of Living Donor Renal Transplantation</td>
<td>Mahir Kirnap, Ankara, Turkey</td>
<td></td>
</tr>
<tr>
<td>P.1284</td>
<td>Thymoglobulin induction in living donor renal transplant recipients: Southern Mexican center experience</td>
<td>Ernesto Soto-Miranda, Veracruz, Mexico</td>
<td></td>
</tr>
<tr>
<td>P.1321</td>
<td>Phytohemagglutinin-Induced II2 Mrna As A Useful Marker Of Kidney Transplants</td>
<td>Kazuo Mizutani, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>P.1344</td>
<td>Achromobacter denitrificans pneumonia in a renal transplant patient-- dose-dependent decrease of phagocytic activity as a potential mechanism for the everolimus pulmonary toxicity</td>
<td>Alicja Debska-Sliuzen, Gdańsk, Poland</td>
<td></td>
</tr>
<tr>
<td>P.1363</td>
<td>Conversion from mycophenolate mofetil to mizoribine and its therapeutic exposure in Chinese renal transplant recipients with leucopenia</td>
<td>Longshan Liu, Guangzhou, People’s Republic of China</td>
<td></td>
</tr>
<tr>
<td>P.1369</td>
<td>Basiliximab Vs. rabbit antithymocyte globulin (rATG) induction in “low risk” Kidney transplantation in Colombia</td>
<td>Alejandro Niño-Murcia, Bogota, Colombia</td>
<td></td>
</tr>
<tr>
<td>P.1406</td>
<td>Effect of Tacrolimus trough-level variability on New-Onset Diabetes After Transplantation in Renal Transplantation</td>
<td>Rajesh Sivaparakasam, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P.1443</td>
<td>Mycophenolate Mofetil dose reduction are associated with the risk of acute rejection and graft failure after renal transplantation</td>
<td>Amgad El-Agroudy, Manama, Bahrain</td>
<td></td>
</tr>
<tr>
<td>P.1731</td>
<td>Factors affecting medication non-adherence among kidney transplant recipients</td>
<td>Ninoslav Ivanovski, Skopje, The Former Yugoslav Republic of Macedonia</td>
<td></td>
</tr>
<tr>
<td>P.1861</td>
<td>Variable Hernia Rates Following Transplantation: The Role that Transplant Type, Incision and Immunosuppression Play</td>
<td>Wayne J. Hawthorne, Westmead, Australia</td>
<td></td>
</tr>
</tbody>
</table>
P.1550 Intracranial Hemorrhage After Liver Transplantation; A Case
Seong-Hwan Chang, Seoul, Korea

P.1551 Serum Osteoprotegerin is an Independent Marker of Peripheral Arterial Disease in Kidney Transplantation Patients
Bang-Gee Hsu, Hualien, Taiwan

P.1552 Positive Correlation of Serum Adipocyte Fatty Acid Binding Protein Levels with Metabolic Syndrome in Kidney Transplantation Patients
Bang-Gee Hsu, Hualien, Taiwan

P.1553 Patient and graft outcomes among kidney transplant recipients who underwent pre-transplant coronary angiography
Jason Paul T. Medina, Quezon City, Philippines

P.1554 Mineral metabolism and vascular calcification before and at one year of the kidney transplantation
Eduardo Chuluyan, Buenos Aires, Argentina

P.1556 Prevalence of Transfusion-transmitted Virus infection and its association with renal post-transplant complications
Eghlim Nemati, Tehran, Iran (Islamic Republic of)

P.1557 Recalcitrant warts in solid organ transplantation
Hugo S. Petrone, Buenos Aires, Argentina

P.1558 Endovascular treatment of arteriovenous fistulas secondary to renal graft biopsy. Presentation of 3 cases
Hugo S. Petrone, Buenos Aires, Argentina

P.1559 Post-transplantation lymphoproliferative disorder (PTLD) intestinal after renal transplantation: a case report and review of the literature
Hugo S. Petrone, Buenos Aires, Argentina

P.1560 Surgical complications of ureteric anastomosis following renal transplantation - a study in techniques
Abheesh Prasad, Coventry, United Kingdom

P.1561 Cancer incidence after kidney transplantation in Saudi Arabia
Hassan A. Aleid, Riyadh, Saudi Arabia

P.1562 Predictive model for new onset diabetes in renal transplant recipients
Hassan A. Aleid, Riyadh, Saudi Arabia

P.1563 Urological Cancers after Renal Transplantation
Wael A. Alshomali Sr., Kuwait City, Kuwait
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1564</td>
<td>Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis</td>
<td>Antonia Cronin</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>P.1565</td>
<td>Complete molecular response of de novo chronic myelogenic leukemia with dasatinib therapy in renal transplant recipient</td>
<td>Heungman Jun</td>
<td>Seoul, Korea</td>
</tr>
<tr>
<td>P.1566</td>
<td>High incidence of urothelial carcinoma in Thai renal transplant recipients, 24 years experience</td>
<td>Wisit Liwlompaisan</td>
<td>Bangkok, Thailand</td>
</tr>
<tr>
<td>P.1568</td>
<td>Immortal Time Bias Correction: Comparing the Cancer Risk Between Patients who had Undergone Kidney Transplantation and those Waiting for the Procedure</td>
<td>Shih-Feng Weng</td>
<td>Kaohsiung, Taiwan</td>
</tr>
<tr>
<td>P.1569</td>
<td>First case of spindle cell lipoma in an end-stage renal allograft</td>
<td>Zitong Zhao</td>
<td>Singapore, Singapore</td>
</tr>
<tr>
<td>P.1570</td>
<td>Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation</td>
<td>Pinar Zeyneloglu</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>P.1571</td>
<td>Acute respiratory distress syndrome in solid organ transplant recipients</td>
<td>Pinar Zeyneloglu</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>P.1572</td>
<td>Venoarterial Extracorporeal Membrane Oxygenation Support as a Bridge to Heart Transplantation: Report of three cases</td>
<td>Pinar Zeyneloglu</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>P.1573</td>
<td>Left Ventricular Assist Device as the Bridge to Heart Transplantation: Five-Case Series</td>
<td>Pinar Zeyneloglu</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>P.1574</td>
<td>Extracorporeal Membrane Oxygenation after Liver Transplantation in a Patient with Hepatopulmonary Syndrome and Refractory Hypoxemia</td>
<td>Pinar Zeyneloglu</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>P.1575</td>
<td>Calcineurin-inhibitor induced pain syndrome (CIPS): A review of 4 cases in Renal Retransplantation</td>
<td>Fabio Ruben Acosta</td>
<td>Rosario, Argentina</td>
</tr>
<tr>
<td>P.1576</td>
<td>Adherence to Bone-Mineral Metabolism Guidelines among Kidney Transplant Candidates</td>
<td>Fabio Ruben Acosta</td>
<td>Rosario, Argentina</td>
</tr>
</tbody>
</table>
P.1577 Histopathological Complications in the New Onset Diabetes Mellitus after Kidney Transplantation
Bernadett Borda, Szeged, Hungary

P.1578 Computed tomography measures of nutrition deficits in patients with liver and intestine failure
Jason Davis, Indianapolis, IN, United States

P.1579 Use of Cinacalcet in the treatment of post-renal transplantation hyperparathyroidism. Experience from an Argentinean site
Carlos H. Diaz, Buenos Aires, Argentina

P.1580 A prospective study of renal transplant recipients: the inter-relationship between insulin secretion and sensitivity underpins dysglycemia post following renal transplantation
Karen Dwyer, Victoria, Australia

P.1581 Balloon Kyphoplasty is a Safe and Effective Option for the Treatment of Vertebral Compression Fractures in Solid Organ Transplant Recipients
Mehmet Haberal, Ankara, Turkey

P.1582 Diabetic Nephropathy in Patients with new Onset Diabetes after Kidney Transplantation
Hyeon Jo Jeong, Seoul, Korea

P.1585 Obesity and overweight as a potential risk factors of graft function loss and death in renal transplant recipients
Przemyslaw Miarka, Krakow, Poland

P.1586 Change of bone densitometry after kidney transplantation
Yeon Ho Park, Incheon, Korea

P.1588 Comparison of metabolic syndrome rates in living-donor and deceased-donor kidney recipients – a three-year follow-up
Jolanta Gozdowska, Warsaw, Poland

P.1589 Epidemiology and risk factors of cholangitis after liver transplantation – single center experience
Jolanta Gozdowska, Warsaw, Poland

P.1590 Post-transplantation lymphoproliferative disease in a patient after two liver transplant because of cirrhosis of the liver’s own post-inflammatory etiology HCV and HBV
Jolanta Gozdowska, Warsaw, Poland

P.1591 Adherence to Treatment Among Renal Post-Transplant Patients
Jolanta Gozdowska, Warsaw, Poland
P.1592 Characteristics of alert pathogens isolated from inpatients of a Department of Transplantation and Nephrology at one of Warsaw hospitals in 2014

Jolanta Gozdowska, Warsaw, Poland

The posters below belong to the Complications track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1170 Renal cell carcinoma in transplanted kidney

Gokhan Moray, Ankara, Turkey

P.1364 Hemodynamics in Transplant Renal Artery Investigated by Computational Fluid Dynamics

Changxi Wang, Guangzhou, People's Republic of China

P.1442 Good patient and graft survival in recipients of kidney transplantation due to diabetic nephropathy

Amgad El-Agroudy, Manama, Bahrain

P.1494 Lymphocyte Subset Test as a Determinant of Cytomegalovirus Prophylaxis in Renal Transplant Recipients with Antithyocyte Globulin Induction Therapy: A Pilot Study

Kyungjai Ko, Seoul, Korea

P.1508 Levetiracetam treatment of epileptic seizures in transplant patients

Maria Outeda Macias III, A Coruña Spain

P.1780 Underrecognition and underestimation of disturbances In calcium-phosphate balance in kidney transplant recipients

Jacek S. Malyszko, Bialystok, Poland

Infectious Diseases Posters

P.1601 Urinary tract infections in renal transplant recipients

Hande Arslan, Ankara, Turkey

P.1602 Late-Onset BK Viruria in Renal Transplant Recipients

Mediha Boran, Ankara, Turkey

P.1603 Disseminated Cryptococcosis Initially Presenting as Lower Limb Cellulitis in a Renal Transplant Recipient

Katrina Chakradeo, Mackay, Australia

P.1604 Parvovirus B19 Associated Pure Red Cell Aplasia After Renal Transplantation

Takashi Fujita, Nagoya, Japan
P.1605  Spectrum of Pneumonia in Renal Transplant Recipients in a Tertiary Care Centre

Krishan L. Gupta, Chandigarh, India

P.1606  Efficacy of Valganciclovir for Prevention of Cytomegalovirus in High–Risk Renal Transplantation

Taiji Hayashi, Osaka, Japan

P.1607  Usefulness of valacyclovir prophylaxis for preventing cytomegalovirus infection after anti-thymocyte globulin treatment as antirejection therapy

Eun Jeong Ko, Seoul, Korea

P.1608  Non-tuberculous mycobacterial infections in transplant patients in Singapore – an emerging cause for concern

Lionel H. Lum, Singapore, Singapore

P.1610  A predictive pharmacokinetic model of ribavirin plasma concentration in lung transplant recipients with active respiratory syncytial virus or human metapneumovirus infection

Eliza JT Milliken, Sydney, Australia

P.1611  Antibiotic prophylaxis for ureteral stent removal after kidney transplantation: to use, or not to use, that’s the question

Thangamani Muthukumar, New York, NY, United States

P.1612  Furunculosis and its complications: a cause of morbidity in renal transplant recipients?

Asma Nasim, Karachi, Pakistan

P.1613  Cryptococcal Meningitis after Kidney Transplantation: Two Cases Report

Hien Trong Nguyen, Ho Chi Minh, Viet Nam

P.1614  The Effect of Direct Acting Antiviral Medications in Kidney Transplant Recipients with Hepatitis C Virus: A Case Report

Sho Nishida, Kumamoto, Japan

P.1615  Chikungunya infection in a kidney transplant recipient: a case report.

Ligia C. Pierrotti, São Paulo, Brazil

P.1616  Pre-emptive Screening and Management of BK Polyoma virus in Renal Transplant Recipients

Joyce Popoola, London, United Kingdom

P.1617  Profile of infections in renal transplant recipients in a tertiary care hospital from India

Sriram Sriperumbuduri, Visakhapatnam, India
P.1618 Urinary tract infection in kidney transplant recipients in King Chulalongkorn Memorial Hospital

Sarita Thawanaphong, Bangkok, Thailand

P.1619 Tuberculosis before and after the Modern Era of Kidney Transplantation

Sirion Watcharananan, Bangkok, Thailand

P.1620 An insight into the predisposing risk factors of pneumonia in renal transplant patients

Nikhil Vijaykumar Mahajan, Chandigarh, India

P.1621 A novel single port retroperitoneal approach of donor nephrectomy using non muscle cutting lombotomy incision

Nikhil Vijaykumar Mahajan, Chandigarh, India

P.1622 The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg) positive donor and/or recipients: A center experience

Berna Yelken, Istanbul, Turkey

P.1623 The Effect of C1q Test Done Before Kidney Transplantation on Acute Rejections: Center Experience

Berna Yelken, Istanbul, Turkey

The posters below belong to the Infectious Diseases track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1040 Polymicrobial oroesophageal infection presenting with dysphagia in a renal allograft transplant recipient

Sunil Kumar, Chandigarh, India

P.1323 Effective monitoring of CMV infection by quantitative analysis of CMV mRNA. Case report in renal transplant

Kazuo Mizutani, Tokyo, Japan

P.1389 The impact of viral replication in recipient urine, oral wash and blood before transplant on post-transplant infection

Oscar K. Serrano, Minneapolis, MN, United States

P.1441 Urinary Tract Infections in Kidney Transplant Recipients

Shafi Malik, Leicester, United Kingdom

P.1498 A Case of Coexistence of Intracranial and Intramedullary Tuberculomas in Kidney Transplantation Recipient

Seungyeup Han, Daegu, Korea
P.1592 Characteristics of alert pathogens isolated from inpatients of a Department of Transplantation and Nephrology at one of Warsaw hospitals in 2014

Jolanta Gozdowska, Warsaw, Poland

P.1663 To identify the risk factors for Pneumocystis jiroveci Pneumonia (PcP) in Renal Transplant Recipients

Navdeep Singh, Chandigarh, India

Donation and Procurement Posters

P.1625 Implementing a collaborative request model for organ donation in an Australian ICU - the art of change management

Bettina R. Clark, Eltham, Australia

P.1626 The organ preservation and enhancement of donation success ratio effect of Extracorporeal Membrane Oxygenation in circulatory unstable brain death donor

Xiaoli Fan, Wuhan, People’s Republic of China

P.1627 Hypothermic machine perfusion attenuate liver warm ischemia injury on a novel venous bypass supported pig liver auto-transplantation model

Xiaoli Fan, Wuhan, People’s Republic of China

P.1628 Tissue Recovery Activity from 2012 to 2014 in Eastern Japan and Tokyo Area: More struggle than Organ Donation and Much to Learn from the United States

Yumi Akashi, Tokyo, Japan

P.1629 The interaction between health care personnel and parents approached for organ and/or tissue donation and their adjustment to loss

Tamar Ashkenazi, Tel Aviv, Israel

P.1630 The effect of Family Accommodation on the organ donation process in Israel

Tamar Ashkenazi, Tel Aviv, Israel

P.1631 Comparative analysis of the last 5 edition of the Master degree in Donation and Transplantation of organs, tissues and cells of the University of Barcelona

Gloria Páez, Barcelona, Spain

P.1632 European Mediterranean Postgraduate Program on Organ Donation and Transplantation (EMPODAT)

Gloria Páez, Barcelona, Spain

P.1634 Closing the Flamingo Highway: heroin deaths in Florida

Jean Davis, Tampa, FL, United States
P.1635  Deciding to discuss organ donation with parents: An in-depth interview study with Chinese young adults  
**Timothy K. F. Fung**, Hong Kong SAR, P.R. of China

P.1636  Main Factors Affecting Loss of The Potential Deceased Donors for Kidney Transplantation  
**Luis García Covarrubias**, México City, Mexico

P.1637  Correlation in a year Of Monitoring Kidney Donors Glomerular Filtration Rate Between DTPA Renal Scan Vs Renal Creatinine Clearance in 24 Hrs Urine, MDRD-4, CKD-EPI and Cockcroft – Gault  
**Luis García Covarrubias**, México City, Mexico

P.1638  Impact of the Network of Clinicians and School Teachers on Awareness and Attitudes of Adolescents Toward Organ Donation and Transplantation  
**Hee Jung Jeon**, Seoul, Korea

P.1639  The experience of donation coordinator  
**Anes Kim**, Seoul, Korea

P.1640  Measures to improve family discussion for deceased organ donation  
**Taehyun Lee**, Seoul, Korea

P.1641  Deceased Organ Donation in Hong Kong (1995-2014): An Age-Period-Cohort Analysis  
**Maggie Kam Man Ma**, Hong Kong SAR, P.R. of China

P.1642  Organ and tissue donation in Emergency Clinical Hospital of Oradea Romania  
**Carmen Pantis**, Oradea, Romania

P.1643  Unexpected Donors after Circulatory Death: Coagulation Profiles after Prolonged Cardiac Arrest in a Porcine Model  
**Alvaro Rojas-Pena**, Ann Arbor, MI, United States

P.1644  Vascularized Composite Allografts: Prolonged (24hr) Ex situ Perfusion of Human Limbs  
**Alvaro Rojas-Pena**, Ann Arbor, MI, United States

P.1645  The Effectives of an Organ Donation Process in Chiangrai Prachanukroh Hospital  
**Thanypat Phongwiwat**, Chiang Rai, Thailand

P.1646  Is the Kidney Donor Risk Index (KDRI) applicable to all populations? The Puerto Rican experience  
**Rafael G. Ramos**, Pittsburgh, PA, United States

P.1647  Demographic and patient profiles in an area of low organ donation rate  
**Ming-Hui Shih**, Hualien, Taiwan
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doubts and questions – Differences in the attitude of healthcare staff and lay people towards organ donation</td>
<td>Aniko Smudla</td>
<td>Budapest, Hungary</td>
</tr>
<tr>
<td>Deceased organ donation in a public hospital - A model programme</td>
<td>Sujatha Suriyamoorthi</td>
<td>Chennai, India</td>
</tr>
<tr>
<td>Barriers to Early Post-Operative Discharge in Living Liver Donors</td>
<td>Hillary J. Braun</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td>Endourological management of live donors with urolithiasis at the time of donor nephrectomy: a single centre experience</td>
<td>Sandeep Guleria</td>
<td>New Delhi, India</td>
</tr>
<tr>
<td>Laparoscopic live donor nephrectomy: a single centre experience</td>
<td>Rehan Mohsin</td>
<td>Karachi, Pakistan</td>
</tr>
<tr>
<td>Decreased resistive index (RI) in renal transplant recipients—a treatable imaging finding</td>
<td>Rehan Mohsin</td>
<td>Karachi, Pakistan</td>
</tr>
<tr>
<td>Donor Comprehension of Provided Information During Informed Consent Process in Live Donor Nephrectomy; Does It Matter What We Tell Donors? A Pilot study</td>
<td>Kirsten Kortram</td>
<td>Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>Quality of life and socio-psychological issues in donors after kidney donation</td>
<td>Anwar Naqvi</td>
<td>Karachi, Pakistan</td>
</tr>
<tr>
<td>Living organ donation high quality practices: LIDOBS network recommendations</td>
<td>Ana T. Menjivar</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>Psychosocial long-term impact of donation on donation on kidney living donors- a comparative study of two major europea transplant centres</td>
<td>Ana T. Menjivar</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>Long term outcome of post living kidney donation monitored by the international foundation for organ transplant incorporated</td>
<td>Rose Marie Rosete-Liquete</td>
<td>Quezon City, Philippines</td>
</tr>
<tr>
<td>Robotic-assisted versus laparoscopic hand-assisted live donor nephrectomy</td>
<td>Pamela Sun</td>
<td>Genève, Switzerland</td>
</tr>
</tbody>
</table>
P.1660 Ultrasonography versus CT-scanning as imaging modality for long term follow up after kidney donation
Khe Tran, Rotterdam, The Netherlands

P.1661 Retroperitoneal Single Port Donor Nephrectomy through Lumbotomy incision - A novel approach
Navdeep Singh, Chandigarh, India

P.1662 Hybrid Laparo-endoscopic single-site (LESS) donor nephrectomy with homemade port; An initial experience
Navdeep Singh, Chandigarh, India

P.1663 To identify the risk factors for Pneumocystis jiroveci Pneumonia (PcP) in Renal Transplant Recipients
Navdeep Singh, Chandigarh, India

P.1664 Risky organs: using organs from donors with blood-borne viruses in New South Wales (NSW), Australia, 2010-2015
Karen Waller, Lindfield, Australia

P.1666 Long period follow-up of renal function of living renal donor
Kazunari Yoshida, Sagamihara, Kanagawa, Japan

P.1667 Promotional Effects of Organ Donation on Online Communities
Won-Hyun Cho, Daegu, Korea

P.1668 The effects of Normal saline solution versus Hartmann's solution on the acid–base and electrolytes status and renal function after kidney transplantation
Won-Hyun Cho, Daegu, Korea

P.1669 A report of deceased donor organ preservation with histidine-tryptophan-ketoglutarate solution (HTK) at a single, large volume U.S. center over 12 years’ time
Richard S. Mangus, Indianapolis, IN, United States

P.1670 Effects of Purification Perfusate during Subnormothermic Machine Perfusion for Porcine Liver Donation after Cardiac Death
Noriyuki Morito, Hachioji, Japan

P.1671 Amino acid metabolism as viability assessment of liver grafts in a porcine model during ex vivo normothermic machine perfusion
Noriki Okada, Tochigi-ken shimotsuke-shi, Japan

P.1672 Impact of Machine Perfusion on Long-Term Kidney Transplant Outcomes
Shaifali Sandal, Montreal, QC, Canada
Non-standardized preservation techniques may lead to freezing of the donor kidney during storage and may preclude transplantation

Imeshi U. Wijetunga, Leeds, United Kingdom

Demands of overseas organ transplant recipients’ family caregivers: comparing gender and Chinese family relationships

Hong-Mei Chen, Taipei, Taiwan

The posters below belong to the Donation and Procurement track, but have been placed under another track in order to be grouped with other posters from the same presenter.

Deceased donor uterus retrieval as part of uterus transplant trial – the first Czech experience

Jiri Fronek, Prague, Czech Republic

Impact of Brain Death Duration on Kidney Transplant Outcomes in Veracruz, Mexico

Ernesto Soto-Miranda, Veracruz, Mexico

Long term follow up glycemic status of live kidney donors

Angeline Goh, Singapore, Singapore

Intensive Care Unit Feedback About Organ Donation

Alejandro Niño-Murcia, Bogota, Colombia

What Component of the Cold Ischemia Time is Important?

Rajesh Sivaprakasam, London, United Kingdom

The examination of the breaking point of expanded criteria deceased donor in Japan

Yuki Nakagawa, Niigata City, Japan

Waiting time of children in list for renal transplantation: one center experience

Esra Baskin, Ankara, Turkey

The use information technology to develop organ fundraising education courses in Taiwan

Ming-Hsin Hsieh, Taipei, Taiwan

How to Build a Liver Transplant Unit in India: Rajasthan's Success

Christopher Taylor Barry, Jaipur, India
POSTER LIST

P.1702 International collaborative program as a way of development of adult-to-adult living-donor liver transplantation program in National Scientific Medical Research Center
Marlen Doskali, Astana, Kazakhstan

P.1704 Recurrent Nephrotic Syndrome After Renal Transplantation in Syrian Children: Does it Compare with the International Experience?
Bassam Saeed, Damascus, Syrian Arab Republic

P.1705 The Impact of Living-Unrelated Transplant on Establishing Deceased Donor Liver Program in Syria
Bassam Saeed, Damascus, Syrian Arab Republic

P.1706 Novel Hepatitis C Treatment increases access to Kidney Transplantation
Pankaj R. Shah, Ahmedabad, India

P.1707 Long Term Outcome of Living and Deceased Donor Renal Transplantation in ADPKD
Pankaj R. Shah, Ahmedabad, India

P.1708 NODAT in Africans: Is it higher than in other ethnic groups?
Ihab A. M. Ahmed, Khartoum, Sudan

P.1709 A new renal transplant centre: Experience and challenges
Ihab A. M. Ahmed, Khartoum, Sudan

P.1710 Kidney transplantation From the United States to Sub-Saharan Africa: Establishing a kidney transplant center in a resource limited country, Ethiopia
Mekdim Taddese Siyoum, Addis Ababa, Ethiopia

P.1711 Medical Students’ Knowledge About Brain Death: A South African Contribution
Sanju Sobnach, Cape Town, South Africa

P.1712 Comparison of cost and quality of life outcomes (qol) in hemodialysis patients and renal transplant recipients
Ayub Ali Chowdhury, Dhaka, Bangladesh
(abst. 374.5 in the Transplantation Journal)

The posters below belong to the Transplantation in Developing Countries track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1415 Renal Transplant in patients with abnormal bladder: Is the outcome same in developing country?
Anant Kumar, Saket, India
P.1444 Kidney Transplantation Tourism: High risk and bad outcome for the recipients
Amgad El-Agroudy, Manama, Bahrain

P.1485 What has changed in Renal transplantation in some small islands in Japan? Strategy of our center
Hajime Hirano, Takatsuki, Japan

Ethics, Community and Economics & Declaration of Istanbul Posters

P.1725 A model for provision of liver transplantation services on a nation-wide basis – a novel approach by the Omani health care system
Mettu Srinivas Reddy, Chennai, India

P.1726 A Google Advanced Search for illegal and immoral activities related to organ transplantation in twenty-five developed and developing countries
Ruhul H. Kuddus, Orem, UT, United States

P.1728 Organ donation: viewpoint analysis of Lithuanian doctors and future physicians in accordance with opinion influencing factors
Valdone Kolaityte, Kaunas, Lithuania

P.1729 The transplantation of organs from deceased donors due to irreversible cardiac arrest in Poland in 2013 and 2014
Edyta Agata Skwirczynska, Szczecin, Poland

P.1730 The sad story of kidney buyers on the Balkans
Ninoslav Ivanovski, Skopje, The Former Yugoslav Republic of Macedonia

P.1731 Factors affecting medication non-adherence among kidney transplant recipients
Ninoslav Ivanovski, Skopje, The Former Yugoslav Republic of Macedonia

P.1732 Risk Factors Associated With Early Readmission After Renal Transplantation: Effects on Cost and Graft Survival
Deanne Leonard, Jacksonville, FL, United States

P.1733 Kidney Transplantation Outcomes in Patients with a History of Renal Cancer: a National Perspective
Douglas P. Slakey, New Orleans, LA, United States

P.1734 Balneotherapy - an intriguing option of rehabilitation after kidney transplantation
Barbara Grandtnerova, Banska Bystrica, Slovakia
P.1735 Health-Related Quality of Life and its Influencing Factors in Chinese Renal Transplant Recipients

Hongxia Liu, Beijing, People’s Republic of China

P.1736 The Impact of Transplant Nephrectomy for Patient Survival over the Last 15 Years - A Single Centre Study

Masaki Muramatsu, Tokyo, Japan

P.1737 Health-Related Quality of Life is Improved After Liver Transplantation and is Related to Disease Acceptance, Helplessness and Perceived Disease Benefits

Louis G. Onghena, Ghent, Belgium

The posters below belong to the Ethics, Community and Economics / Declaration of Istanbul tracks, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1308 Complications of kidney transplantation performed through black organ markets affiliations

Marina Ratkovic, Podgorica, Montenegro

P.1591 Adherence to Treatment Among Renal Post-Transplant Patients

Jolanta Gozdowska, Warsaw, Poland

Composite Tissues Posters

P.1750 Skin as a Harbinger of Rejection of Underlying Structures In VCA: Concordance or Discordance?

Linda C. Cendales, Durham, NC, United States

P.1751 A Clinical Hand Transplant Program Five Years On: Lessons Learned and Future Direction

Hatem Amer, Rochester, MN, United States

P.1752 Pre transplant at1r antibodies and the risk of recurrent focal segmental glomerulosclerosis (FSGS)

Hatem Amer, Rochester, MN, United States

P.1753 On-demand drug delivery system with self-assembled hydrogel in vascularized composite allotransplantation

Dzhuliya V. Dzhonova, Bern, Switzerland

P.1754 Bilateral arm allotransplantation: a case report in Mexico

Raul M. Favela, Chihuahua, Mexico

P.1755 Comic for the promotion of donation of vascularized composite allografts in Mexico

Raul M. Favela, Chihuahua, Mexico
<table>
<thead>
<tr>
<th>P.1756</th>
<th>Rat skin morphology by reflectance confocal microscopy: a reference study for experimental vascularized composite allograft rejection studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Huseyin Karagoz</strong>, Istanbul, Turkey</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1757</th>
<th>The Effect of Donor/Recipient Chimeric Cells on Donor-Specific Chimerism and Composite Tissue Allograft Survival in Face Transplantation Model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Fatih Zor</strong>, Ankara, Turkey</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1758</th>
<th>Composite Eye and Periorbital Allotransplantation Flap: From rat model to cadaveric study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Fatih Zor</strong>, Ankara, Turkey</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1759</th>
<th>Composite Tissue Xenopreservation: A New Living Tissue Bank</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Fatih Zor</strong>, Ankara, Turkey</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1760</th>
<th>A Novel Murine Orthotopic Forelimb Transplantation Model that Allows for Reliable Assessment of Functional Recovery Resulting from Nerve Regeneration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Barbara Kern</strong>, Innsbruck, Austria</td>
</tr>
</tbody>
</table>

| P.1761 | Vascularized composite allotransplantation in orthotopic porcine hind limb model                                                |
|        | **Chen Hsiang Kuan**, Taipei, Taiwan                                                                                           |

<table>
<thead>
<tr>
<th>P.1762</th>
<th>Our experience with immunosuppression protocols for composite tissue transplant (bilateral hand transplantation)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>George Kurian</strong>, Ernakulam, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P.1763</th>
<th>AMD3100 (Plerixafor) As A Clinically Relevant Stem Cell Mobilizing Agent In Vascularized Composite Tissue Allograft (VCA) Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>David W. Mathes</strong>, Aurora, CO, United States</td>
</tr>
</tbody>
</table>

The poster below belongs to the Composite Tissue track, but have been placed under another track in order to be grouped with other posters from the same presenter.

<table>
<thead>
<tr>
<th>P.1644</th>
<th>Vascularized Composite Allografts: Prolonged (24hr) Ex situ Perfusion of Human Limbs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Alvaro Rojas-Pena</strong>, Ann Arbor, MI, United States</td>
</tr>
</tbody>
</table>
Heart and Lung Posters

P.1775 The natural course of renal function with Everolimus after heart transplantation
Tsao Chuan-I, Taipei, Taiwan

P.1776 Life's a Beach - Spending Holidays after LVAD Implantation
Christian Heim, Erlangen, Germany

P.1779 Vitamin D status in heart and kidney transplant recipients
Jacek S. Malyszko, Białystok, Poland

P.1780 Underrecognition and underestimation of disturbances in calcium-phosphate balance in kidney transplant recipients
Jacek S. Malyszko, Białystok, Poland

P.1782 Influence of CYP3A5 Polymorphism on Pharmacokinetic Interaction of Fluconazole and Tacrolimus, and Effect of Fluconazole on Everolimus Pharmacokinetics in Heart Transplant Recipient
Yuka Terada, Suita, Japan

P.1783 Initial experience of lung transplantation with a national organ procurement organization effort to use lungs from brain and cardiac death donors or cardiac death donors in a single Chinese center
Jingyu Chen, Wuxi, People's Republic of China

P.1784 The Early Outcome of Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction After Lung Transplantation: Experience in Korean Single Center
Jin Gu Lee, Seoul, Korea

P.1785 Optimum serum level of mycophenolate mofetil in chronic phase after lung transplantation
Yasushi Matsuda, Sendai, Japan

P.1786 Pediatric lung transplantation in patients with chemoradiation associated pulmonary fibrosis: limited medium term survival compared to age-matched controls
Ernestina Melicoff, Houston, TX, United States

P.1787 Journey of Lung Transplant Program in Saudi Arabia
Imran Nizami, Riyadh, Saudi Arabia

P.1788 Mycobacterium Tuberculosis Infection After Lung Transplantation, Saudi Arabia Experience
Imran Nizami, Riyadh, Saudi Arabia
The prevalence, possible risk factors and the outcome of swallowing abnormalities in post lung transplant patients

Imran Nizami, Riyadh, Saudi Arabia

The posters below belong to the Heart /Lung tracks, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1572 Venoarterial Extracorporeal Membrane Oxygenation Support as a Bridge to Heart Transplantation: Report of three cases

Pinar Zeyneloglu, Ankara, Turkey

P.1573 Left Ventricular Assist Device as the Bridge to Heart Transplantation: Five-Case Series

Pinar Zeyneloglu, Ankara, Turkey

P.1831 Lung Transplantation in Argentina: Results after Changes in the Clinical Emergency Setting

Liliana Bisigniano, Buenos Aires, Argentina

Histocompatibility Posters

P.1800 Pre-transplant immunological risk assessment : CDC cross-match supplemented by Luminex antibody Screen (Qualitative) -more sensitive approach to prevent early antibody mediated rejection

Feroz Aziz, Calicut, India

P.1802 The Frequency and the Reactivity Patterns of HLA Class I Donor-Specific Epitope Antibodies Identified in Korean Patients

Soo-Kyung Kim, Seoul, Korea

P.1803 Positive Rates of Preliminary T and B Cell Flow Cytometry Crossmatches Among Transplant Candidates in the Korean Network for Organ Sharing

Myoung Hee Park, Seoul, Korea

P.1804 An inventory of the presence of pretransplant Donor-Specific HLA Antibodies as tested with Luminex Single Antigen tests of Lifecodes and One Lambda and their complement variants

Dave Roelen, Leiden, The Netherlands

P.1805 Effect of Recipient Age (<3 years) During Liver Transplantation on the Prevalence of Post-Transplant Class II Anti-Human Leukocyte Antigen Antibody

Kazuaki Tokodai, Sendai, Japan
POSTER LIST

P.1806 Transplantation of highly sensitized patients with circulating preformed donor specific antibodies: how safe is it?
Angeliki G. Vittoraki, Athens, Greece

P.1807 Antibodies against Angiotensin II type 1 receptor and HLA donor specific antibodies in renal allograft rejection
Angeliki G. Vittoraki, Athens, Greece

P.1808 Presence of Day-14 Post Transplantation Donor Specific IgM Antibody Predicts Poor Graft Survival in HLA-incompatible Renal Transplantation
Nithya Krishnan, Coventry, United Kingdom

P.1809 Clinical Relevance of Pre-formed IgM HLA- Donor Specific Antibodies (DSA) in HLA-Incompatible Kidney Transplantation
Nithya Krishnan, Coventry, United Kingdom

P.1810 Removal of Unacceptable Antigens to Increase the Likelihood of a Patient Receiving Aa Renal Transplant: A Cross-Sectional Study
Nithya Krishnan, Coventry, United Kingdom

P.1811 Comparison of Baseline Proteinuria and Outcomes and Baseline Comorbidities and New Onset Proteinuria in Live Kidney Donors - UK Cohort Study
Nithya Krishnan, Coventry, United Kingdom

P.1812 Glass cliff effect in transplantation – Myth or Reality?
Nithya Krishnan, Coventry, United Kingdom

P.1813 Non-HLA and HLA antibodies in lung transplantation (LTx): Results from a prospective study
Duncan C. Walton, West Melbourne, Australia

P.1814 Reducing cold ischemia time of organs by increasing the speed of laboratory testing for deceased donor workups - better methodologies, better outcomes
Prakash Rao, New Providence, NJ, United States

The posters below belong to the Histocompatibility track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1054 De-novo donor specific antibody (DSA) against HLA-DQ antigens by lysate based cross match on Luminex platform resulting in acute antibody mediated rejection in a renal transplant patient
Sonia Mehrotra, Lucknow, India
P.1322 C4d Binding Correlated with Strong Hla Antibodies in Kidney Transplantation
Kazuo Mizutani, Tokyo, Japan

P.1399 High prevalence of post transplant donor specific HLA-DQ antibody in live related renal transplantation. Is it time to extend typing to HLA-DQ in renal transplantation?
Mirza Naqi Zafar, Karachi, Pakistan

Paediatrics Posters

P.1825 Perspectives of the Development of Renal Transplantation in Children in Kazakhstan
Dinara Galiyeva, Edinburgh, United Kingdom

P.1826 A Ten-Year Review on the Surgical Outcomes of Paediatric Renal Transplantation: A Hong Kong Experience
Alan Lo, Hong Kong SAR, P.R. of China

P.1827 Predictive value of early period doppler ultrasonography on early and long-term allograft function
Esra Baskin, Ankara, Turkey

P.1828 Effects of renal transplant age on the graft functions in pediatric transplant patients
Esra Baskin, Ankara, Turkey

P.1829 Waiting time of children in list for renal transplantation: one center experience
Esra Baskin, Ankara, Turkey

Liliana Bisigniano, Buenos Aires, Argentina

P.1831 Lung Transplantation in Argentina: Results after Changes in the Clinical Emergency Setting
Liliana Bisigniano, Buenos Aires, Argentina

P.1832 Postoperative mortality in infants following liver transplantation; impact of large for size graft and preoperative portal vein size
Chan Woo Cho, Seoul, Korea

P.1833 Experience with Two Cases of Living Donor Liver Transplantation for Neonatal Hemochromatosis Developed in Siblings
Takumi Katano, Tochigi, Japan

P.1834 Coordinating Living Donor Liver Transplantation for Neonatal Fulminant Hepatic Failure
Erika Onuma, Simotuke, Japan
### POSTER LIST

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1835</td>
<td>Liver Transplantation in a Pediatric Patient After Treatment for Yolk Sac Tumor</td>
<td>Taiichi Wakiya, Hirosaki, Japan</td>
<td></td>
</tr>
<tr>
<td>P.1836</td>
<td>Acquired Diaphragmatic Hernia following Pediatrics Living Donor Liver Transplantation</td>
<td>Kai Wang, Tianjin, People’s Republic of China</td>
<td></td>
</tr>
<tr>
<td>P.1837</td>
<td>Back to School and Normality after Lung Transplantation in Childhood and the Need for Psychosocial Interventions</td>
<td>Andrea Caby, Hamburg, Germany</td>
<td></td>
</tr>
</tbody>
</table>

The posters below belong to the Paediatrics track, but have been placed under another track in order to be grouped with other posters from the same presenter.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1225</td>
<td>Transforming growth factor beta 1 blood level relates with liver disease etiology and fibrosis severity in pediatric liver recipients</td>
<td>Olga M. Tsiroulnikova, Moscow, Russian Federation</td>
<td></td>
</tr>
<tr>
<td>P.1226</td>
<td>Pediatric living donor liver transplantation: correlation plasma level of transforming growth factor beta -1 with tacrolimus dosage but not with its concentration</td>
<td>Olga M. Tsiroulnikova, Moscow, Russian Federation</td>
<td></td>
</tr>
<tr>
<td>P.1266</td>
<td>Dialysis vintage: A dominating factor affecting growth and final height after pediatric renal Transplantation: A single center experience</td>
<td>Tahir Aziz, Karachi, Pakistan</td>
<td></td>
</tr>
<tr>
<td>P.1704</td>
<td>Recurrent Nephrotic Syndrome After Renal Transplantation in Syrian Children: Does it Compare with the International Experience?</td>
<td>Bassam Saeed, Damascus, Syrian Arab Republic</td>
<td></td>
</tr>
</tbody>
</table>

### Pancreas and Islet Posters

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1850</td>
<td>Effect off different glutathione-related compounds on survival of hypoxic human islets</td>
<td>Heide Brandhorst, Oxford, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P.1851</td>
<td>Mesenchymal stem cell-preconditioned medium increases survival of hypoxic human islets</td>
<td>Heide Brandhorst, Oxford, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P.1852</td>
<td>Different effects of neutral proteases on human islet viability</td>
<td>Heide Brandhorst, Oxford, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
### POSTER LIST

<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.1853</td>
<td>Tetrahydrocurcumin Enhances Islet Cell Function and Attenuates Apoptosis in Mouse Islets</td>
<td><strong>Hyuk Jai Jang</strong>, Gangneung, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1854</td>
<td>How About Heparin-Pegylated Islets in Allo-Islet Transplantation in Cynomolgus Monkeys</td>
<td><strong>Kyo Won Lee</strong>, Seoul, Korea</td>
<td></td>
</tr>
<tr>
<td>P.1855</td>
<td>Australia’s first successful remote centre paediatric islet auto-transplant after pancreatectomy in a 7 year old for hereditary pancreatitis</td>
<td><strong>Toni M. Radford</strong>, Adelaide, Australia</td>
<td></td>
</tr>
<tr>
<td>P.1856</td>
<td>Evaluation of donor characteristics including histological analysis of pancreases allocated for islet isolations</td>
<td><strong>Frantisek Saudek</strong>, Praha, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>P.1857</td>
<td>Evaluation of a newly developed pancreas preservation solution, F6H8S5, for clinical islet isolation and transplantation</td>
<td><strong>Hanna Schierbeck</strong>, Uppsala, Sweden</td>
<td></td>
</tr>
<tr>
<td>P.1858</td>
<td>The investigation on target matrix of collagenase G for achieving tailor-made islet isolation</td>
<td><strong>Satoru Yoshida</strong>, Sendai, Japan</td>
<td></td>
</tr>
<tr>
<td>P.1859</td>
<td>The availability of marmoset diabetes modeling as a transplantation model</td>
<td><strong>Wenji Yuan</strong>, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>P.1860</td>
<td>Factors Effecting Islet Isolation Outcomes Over the Past 15 Years for the Westmead Islet Transplant Program</td>
<td><strong>Wayne J. Hawthorne</strong>, Westmead, Australia</td>
<td></td>
</tr>
<tr>
<td>P.1861</td>
<td>Variable Hernia Rates Following Transplantation: The Role that Transplant Type, Incision and Immunosuppression Play</td>
<td><strong>Wayne J. Hawthorne</strong>, Westmead, Australia</td>
<td></td>
</tr>
<tr>
<td>P.1865</td>
<td>Pancreas rejection with graft necrosis presenting with episodic massive intestinal bleeding</td>
<td><strong>Shih-Chin Chen</strong>, Taipei, Taiwan</td>
<td></td>
</tr>
<tr>
<td>P.1866</td>
<td>ATG induction markedly reduced acute rejection and improved graft survival in pancreas transplantation</td>
<td><strong>Kazuhiro Iwadoh</strong>, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>P.1867</td>
<td>Exocrine drainage in pancreas transplantation: medium-term results of enteric conversion and significance of bladder drainage</td>
<td><strong>Ichiro Koyama</strong>, Tokyo, Japan</td>
<td></td>
</tr>
</tbody>
</table>
P.1868 Hybrid laparoscopic distal pancreatectomy of living donor using Shuriken shaped umbilicoplasty
   Yoshinobu Sato, Yokohama City, Japan

P.1869 Pancreas Transplant at Taipei Veterans General Hospital
   Yi-Ming Shyr, Taipei, Taiwan

P.1870 Hepatic Veno-Occlusive Disease Related to Tacrolimus after Pancreas Transplantation
   Yi-Ming Shyr, Taipei, Taiwan

P.1871 Severe transplantation-mediated alloimmune thrombocytopenia in two recipients of organs from the same donor
   Isabella Sönnerborg, Stockholm, Sweden

P.1872 Successfull Simultaneous Pancreas Kidney Transplantation in a patient with Congenital Partial Lipodystrophy
   Pablo D. Uva, Buenos Aires, Argentina

The poster below belongs to the Pancreas and Islet track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1022 A non-hematopoietic erythropoietin analogue, ARA 290, prolonged allogeneic islet graft survival in a mouse model
   Torbjorn Lundgren, Stockholm, Sweden

Cell Transplant & Xenotransplantation Posters

P.1875 Optimization of procedures for short-time hepatocyte preservation prior to transplantation
   Kengo Fukuoka, Sendai, Miyagi, Japan

P.1876 New strategies for cell banking for regulatory T cell (Treg)-based therapy in order to overcome compromise of cell viability and Treg altered phenotype during cryopreservation
   Karolina Golab, Chicago, IL, United States

P.1877 A parallel comparison of suppressive capacity in immune responses: regulatory T cells versus regulatory macrophages
   Fei Guo, Changsha, People's Republic of China

P.1878 Comparison of three transplantation techniques in a mouse model of hepatocyte transplantation
   Bo Goran Ericzon, Stockholm, Sweden
P.1880 Coming home: Hepatocyte transplantation to the liver via the splenic artery in a juvenile large animal model
Nathanael Raschzok, Berlin, Germany

P.1881 Humoral Diagnosis of Acute Rejection in Myogenic Cell Allotransplantation in Skeletal Muscles: a Study in Nonhuman Primates
Daniel Skuk, Quebec, QC, Canada

Xiaoqian Ma, Changsha, People’s Republic of China

P.1883 Necroptosis plays a central role in hypoxia-induced islets cell death
Xiaoqian Ma, Changsha, People’s Republic of China

P.1884 Induced pluripotent stem cells play an immunomodulatory role in skin allograft acceptance
Charles Yuen Yung Loh, Taoyuan Hsien, Taiwan

P.1885 Generation of novel Cag-Luc-EGFP transgene-expressing murine embryonic stem cell derived hepatoblasts as a transplantable cell source
Olivia M. Martinez, Stanford, CA, United States

P.1886 Intravascular transplantation of CD34+ stem cells inhibit intimal hyperplasia after vascular injury
Piotr Religa, Stockholm, Sweden

P.1888 Relevance of Immunomodulatory factors: HLA-G, Treg Cells and Cytokine Levels in Hematopoietic Stem Cell Transplantation
Uma Kangla, New Delhi, India

P.1889 HLA-G Molecules: Possible Predictor of GvHD
Manish Kumar Mourya, Delhi, India

P.1890 Development of an anti-HLA antibody-producing humanized mouse model
Senichiro Yanagawa, Hiroshima, Japan

P.1891 The transforming chronic GVHD toward acute GVHD by deletion of host CD137 signaling
Hong R. Cho, Ulsan, Korea

P.1892 The effects of MyD88 inhibitor local infusion in ischemia-reperfusion kidney injury
Hong R. Cho, Ulsan, Korea

P.1896 Preformed IgM antibody target in non-human primate received α-GTKO pig heart and artery
Yun Shin Chung, Seoul, Korea
P.1897 Histological and ultra-structure characterization of human immune cells against neonatal porcine islet xenograft

Wenlong Huang, Edmonton, AB, Canada

P.1899 Student Opinions in Xenotransplantation

Kyeonghee Jang, Abilene, TX, United States

P.1900 No PERV infection in pig islets recipients after 15 years of xenotransplantation

Xiaofeng Jiang, Guangzhou, People's Republic of China

P.1901 Levels of anti-Gal IgG2 negatively correlate with the survival of porcine islet graft in non-human primates under immunosuppression of anti-CD154

Hee Jung Kang, Anyang-si, Korea

P.1902 Janus kinase 3 inhibitor, Tofacitinib prolonged pig-to-mouse xenogeneic islet transplantation

Seong-jun Sung Kang, Seoul, Korea

P.1904 Enhancement of CRISPR-mediated homology-directed repair using small molecule in porcine fibroblasts.

Young June Kim, Pyeong Chang, Korea

P.1905 The analysis of C5 inhibitor efficacy in antibody mediated xenogeneic immune responses modulation using a microfluidic system

Eun Mi Lee, Seoul, Korea

P.1906 The analysis of αGal antigen in tree shrew

Yanping Li, Xiamen, People's Republic of China

P.1907 Induction of diabetes in cynomolgus monkey with one injection of streptozotocin

Zhengzhao Liu, Shenzhen, People's Republic of China

P.1908 Gene editing techniques in Cardio-xenotransplantation

Meisam Naeimi Kararoudi, Perugia, Italy

P.1909 Comparison of Islet Isolation Yields from Three Different Wild Type Adult Pig Breeds

Jun-Seop Shin, Seoul, Korea

P.1910 Immunosuppressive Effect of Arsenic Trioxide (A2O3) on Xeno-Islet Transplantation

Bin Zhao, Xiamen, People's Republic of China

P.1911 Acute Rejection Patterns of Outbred Rats to Heterotopic Heart Xenotransplantation

Necdet Ozcay, Ankara, Turkey

P.1912 Surgical technique of harvesting two kidneys from a mouse for xenotransplantation studies

Necdet Ozcay, Ankara, Turkey
The poster below belongs to the Xenotransplantation track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1759 Composite Tissue Xenopreservation: A New Living Tissue Bank.

Fatih Zor, Ankara, Turkey

Surgical Techniques Posters

P.1925 Temperature change in the kidney graft during laparoscopic kidney transplant

Bulang He, Perth, Australia

P.1926 Laparoscopic kidney transplant by extra peritoneal approach: Two years follow up

Bulang He, Perth, Australia

P.1927 Real-time intraoperative fluorescent lymphography – a new technique for lymphatic sparing surgery

Giuseppe Ietto, Varese, Italy

P.1928 Our Experience with Modified Lich-Gregoir Technique in the Prevention of Urological Complications Post Kidney Transplant

Zi Qin Ng, Perth, Australia

P.1929 "Artery first, Vein Second” Approach for Vascular Anastomosis in Kidney Transplantation

Zi Qin Ng, Perth, Australia

P.1930 3D surgical planning in complex renal artery aneurysms: mid term results

Gabriele Soldini, Varese, Italy

P.1931 Minimal Invasive Access in Kidney Transplantation - Self Experience

Marek Ostrowski, Szczecin, Poland

P.1932 End-to-side versus end-to-end uretero-ureteral anastomosis in kidney transplant recipients with disused atrophic bladder

Volkan Turunç, Istanbul, Turkey

P.1933 Vena Cava Resection without Venous Bypass for Liver Transplant (LT) Does Not Increase Morbidity But Does Decrease Operative Time

Juan Francisco Guerra, Santiago, Chile
The posters below belong to the Surgical Techniques track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1130 Transfusion of Old Red Blood Cells Stored During Greater Than 2 Weeks is Not Associated with Liver Transplant Death
   Jun Chul Shin, Seoul, Korea

P.1423 Successful use of a collateral vein in renal transplantation - First case report in an ADULT recipient
   Linda J. Chen, Miami, FL United States

P.1424 Using kidneys with a congenital anomalies for Transplantation: A judgement call
   Linda J. Chen, Miami, FL, United States

P.1433 Prevention of Vascular Stricture by Using an Expanded Polytetrafluoroethylene (ePTFE) Graft in a Porcine Model: Preliminary Study
   Handan Özdemir, Ankara, Turkey

P.1434 Bridging technique of bile duct anastomosis using an expanded polytetrafluoroethylene (ePTFE) graft in a porcine model
   Handan Özdemir, Ankara, Turkey

P.1621 A novel single port retroperitoneal approach of donor nephrectomy using non muscle cutting lombotomy incision
   Nikhil Vijaykumar Mahajan, Chandigarh, India

P.1912 Surgical technique of harvesting two kidneys from a mouse for xenotransplantation studies
   Necdet Ozcay, Ankara, Turkey

Registries & Transplantation Nursing Posters

P.1950 HLA Haplotype Frequencies of Hong Kong
   Jenny C.Y. Ho, Pokfulam, People’s Republic of China

P.1951 Survey of questionnaire for transplant and dialysis patients on preparation for disaster
   Masae Ikeda, Sagamihara, Japan

P.1952 An analysis of waiting period of deceased donor kidney transplant - Korean single center analysis
   Sarome Lee, Seoul, Korea
P.1953  The acquiring skill of the adolescents and young adults to get along with the difficulties in their social activities after transplantations

Yasuko Suzuki, Matsumoto, Japan

P.1954  Analyses of Relationship Between Obstetric Complications and Preterm Delivery in Japanese Recipients Received Kidney Transplant

Yuki Yoshikawa, Hirakata City, Osaka, Japan

P.1955  “Preventing”: A New Application for Smartphones to Assess and Improve Immunosuppressant’s Adherence in Renal Transplant Recipients

Jorge Morales-Barría, Santiago, Chile

Gender in Transplantation Posters

The posters below belong to the Gender in Transplantation track, but have been placed under another track in order to be grouped with other posters from the same presenter.

P.1677  Demands of overseas organ transplant recipients’ family caregivers: comparing gender and Chinese family relationships

Hong-Mei Chen, Taipei, Taiwan

P.1812  Glass cliff effect in transplantation – Myth or Reality?

Nithya Krishnan, Coventry, United Kingdom
Industry Organized Sessions

Light meals will be served inside the Hall at the beginning of the sessions for attendees attending the session ONLY. Please note that only a LIMITED NUMBER of meals have been ordered by our sponsors, and those will be distributed on a first-come first-serve basis. No attendees will be allowed to leave the room with a meal, all food items to be consumed in the session room.

SATURDAY, AUGUST 20, 2016, 12:30-13:30
HALL 5E3 - LEVEL 5
Optimizing Immunosuppression: A Key for Improving Long-term Outcomes

WELCOME NOTE AND OPENING
Wai-Leung Chak
Hong Kong SAR, P.R. of China

Simone I. Strasser
Sydney, Australia

NATURAL HISTORY OF THE ORGAN TRANSPLANT: OPPORTUNITIES TO OPTIMIZE IMMUNOSUPPRESSION
Philip F. Halloran
Edmonton, AB, Canada

THE IMMUNOSUPPRESSIVE MANAGEMENT FOR LONG-TERM OUTCOME
Jong Man Kim
Seoul, Korea

PANEL DISCUSSIONS
SATURDAY, AUGUST 20, 2016, 17:30-19:00
HALL 5E3 - LEVEL 5
Donoe Specific Antibody Monitoring

ORGANIZED BY
ONE LAMBDA
A Thermo Fisher Scientific Brand

STRATEGIES TO IMPROVE LONG-TERM GRAFT OUTCOMES: BEGIN AT THE BEGINNING
Peter William Nickerson
Winnipeg, MB, Canada

LONG TERM GRAFT SURVIVAL: THE NEXT FRONTIER
John J. Friedewald
Chicago, IL, United States

SUNDAY, AUGUST 21, 2016, 12:30-13:30
HALL 5E3 - LEVEL 5
Modern Approaches of Immunosuppressive Therapies for Renal Transplant Patients

ORGANIZED BY
NOVARTIS PHARMACEUTICALS

mTORI PROTOCOL TO OVERCOME KEY CHALLENGES IN KIDNEY TRANSPLANT PATIENTS: A LONG TERM CLINICAL EXPERIENCE
Josep M. Campistol
Barcelona, Spain

A REVIEW OF CLINICAL EXPERIENCE WITH THE USE OF MPA IN RENAL TRANSPLANTATION
Wai Lim
Perth, Australia

AN ART OF IMMUNOSUPPRESSANT REGIMEN ADJUSTMENT IN CHINA TO MEET NEW ERA OF TRANSPLANTATION
Tao Lin
Chengdu, People's Republic of China
Expanding Treatment Options with Anti-T Lymphocyte Immunoglobulin (ATLG)

ATLG IN LIVER TRANSPLANTATION
Jan Lerut
Louvain-la-Neuve, Belgium

COMPARISON OF TWO DOSE REGIMENS OF ATLG IN KIDNEY TRANSPLANTATION
Xiaodong Zhang
Beijing, People’s Republic of China

ATLG IN LIVE DONOR KIDNEY TRANSPLANT
Mumtaz Yilmaz
Izmir, Turkey
A future powered by experience

neovii is proud to sponsor the TTS congress, 2016
Visit our symposium on Monday 22nd August at 12.30 on Expanding treatment options with ATLG

CellCept®
myophenolate mofetil
Trust what you know

KEEP IN UPRIGHT POSITION
HUMAN ORGAN FOR TRANSPLANT
HANDLE WITH CARE

EVEN IN TRANSPLANTATION:
CERTAIN THINGS SHOULDN'T BE REPLACED
Exhibit Opening Hours

The Exhibit Area is located in Hall 5FG, on Level 5 of the HKCEC. Access to the Exhibit Area is open to all registered participants and guests of the TTS 2016 Congress. Please note that you must wear your badge to access the Exhibit Area.

Coffee and tea will be served within the Exhibit Area during the coffee breaks every day from August 20 to 22, 2016.
EXHIBIT AREA (HALL 5FG - LEVEL 5)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, Aug 19</td>
<td>18:30-20:00</td>
</tr>
<tr>
<td>Saturday, Aug 20</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>09:30-18:30</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>09:30-19:00</td>
</tr>
</tbody>
</table>
Come by our booth located centrally in the Exhibit Area and celebrate The Transplantation Society’s 50th anniversary. Our official journal, *Transplantation*, as well as *Transplantation Direct* will have their own interactive station, and a corner designated for our Historical Project. Why not come and get your picture taken at our photo booth to commemorate this moment! Please visit us for information on membership, our sections, and our Alternate Year Program of meetings. And lastly, we will feature the beautiful city of Madrid as our next destination for the Congress in 2018!

Over the last 50 years, The Transplantation Society has grown exponentially and has become the largest international transplant community. Established in 1966, it serves as the principle international forum for the advancement of both basic and clinical transplantation science throughout the world. The Transplantation Society is a Non-Governmental Organization (NGO) and is comprised of over 6,700 professionals including but not limited to, physicians, surgeons, and scientists in over 105 countries. The Transplantation Society’s mission is to provide the focus for global leadership in transplantation through the development of the science and clinical practice, scientific communication, continuing education, and the guidance on ethical practices.

TTS is also proud to have a distinguished group of sections: Cell Transplant and Regenerative Medicine Society (CTRMS), International Pancreas & Islet Transplant Association (IPITA), International Society for Organ Donation and Procurement (ISODP), International Xenotransplantation Association (IXA), Transplant Infectious Disease (TID), Intestinal Rehabilitation & Transplant Association (IRTA), International Society of Vascularized Composite Allotransplantation (ISVCA), and the International Pediatric Transplant Association (IPTA).

**International Headquarters**

505 René-Lévesque Blvd. West, Suite 1401
Montreal, QC H2Z 1Y7 Canada

Phone +1 514.874.1717  
Fax +1 514.874.1716

www.tts.org  
membership@tts.org
The ISN-TTS Sister Transplant Center Program is a new joint partnership between the International Society of Nephrology (ISN) and The Transplantation Society (TTS) to create new kidney transplant centers and develop existing kidney transplant programs in emerging countries. This initiative encourages transplant centers to work together to increase opportunities for kidney transplant patients in developing countries. An experienced transplant center in the developed world lends its support to an emerging transplant center to facilitate vital multidisciplinary training and encourage both centers to exchange their knowledge and expertise.

POSTER PRESENTATIONS:
During the congress, posters will be presented by two centers: a center from Guatemala that teamed up with UCLA in California, USA, and a center from Gaza, Palestine that teamed up with the Royal Liverpool University Hospital in the UK.

Location: Hall 5FG, behind the TTS Booth in Aisle 500

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Aug 20</td>
<td>17:00-17:20</td>
</tr>
<tr>
<td>Sunday, Aug 21</td>
<td>17:00-17:20</td>
</tr>
<tr>
<td>Monday, Aug 22</td>
<td>18:00-18:20</td>
</tr>
</tbody>
</table>
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com

F. Hoffmann-La Roche Ltd

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche's transplant treatments are designed to support the long-term survival of transplanted organs.

www.roche.com
Neovii Pharmaceutical

SPONSOR

Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. Neovii was founded in 2013 by the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals. Neovii’s global headquarters are located in Rapperswil, Switzerland.

www.neovii.com

Novartis Pharmaceutical

SPONSOR

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas.

www.novartis.com
One Lambda, Inc., a Thermo Fisher Scientific Brand, is a global leader in transplant diagnostics offering a full range of HLA Typing and antibody monitoring products to support clinicians and laboratories in the management of transplant patients. Visit www.onelambda.com to discover how we can help you improve patient outcomes.

DFKC is an independent, family-owned business with representations on all five continents. DFKC has been an establishment for over 55 years, providing products in the field of electrolytes, contrast media, antidotes, anesthetic pharmaceuticals as well as organ protective and cardioplegic solutions. These latter products in particular have made DFKC a committed partner of cardiac and transplant surgery worldwide.

www.koehler-chemie.de
JDRF International

CONTRIBUTOR

www.jdrf.org

Shire

CONTRIBUTOR

Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions that are often misunderstood, undiagnosed and life-threatening.

www.shire.com
EXHIBITORS

Alexion Pharmaceuticals  Booth #106

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion’s goal is to deliver medical breakthroughs where none currently exist.

Alexion was established in 1992 and is headquartered in New Haven, Connecticut with approximately 3,000 employees around the world serving patients in 50 countries.

www.alexion.com

Baskent University  Booth #804

Baskent University was founded in 1993, as one of the foundation universities of Turkey. The founder and honorary president, Prof. Dr. Mehmet Haberal, performed the first successful transplantation surgery in Turkey (1975) and is renowned worldwide in the medical community. Baskent University has a broad spectrum of faculties in all branches of science including medicine, dentistry, engineering, administration, social and political financial sciences and law.

www.baskent.edu.tr
Bridge to Life supplies organ preservation solutions under the Belzer UW® trademark and high flow tubing and cannulas. We now supply our products to 35 countries in 5 continents. Please stop by to ask us more about exciting future developments.

www.bridgetolife.com

The Congress of the Asian Society of Transplantation (CAST) is the region’s largest and longest running gathering of transplant physicians, surgeons and other health professionals involved in transplantation held every two years in participating countries in Asia. The 15th CAST will be hosted by the Transplantation Society of the Philippines and is to be held in Cebu, Philippines on November 27-30, 2017.
**Epoch Group Limited**

Epoch Times is an independent voice in print (8 languages) and on the web (in 21 languages). We report news responsibly and truthfully so that readers can improve their own lives and increase their understanding and respect for their neighbors next door and around the globe. In our approach and in our content, we uphold universal human values, rights, and freedoms. We are a business that puts our readers' interests first, in all that we do.

[www.epochtimes.com](http://www.epochtimes.com)

---

**European Society for Organ Transplantation (ESOT)**

ESOT is Europe’s main umbrella transplantation body, under which all transplant activities are organized. ESOT’s mandate is to represent the goals and needs of transplantation surgery, with members including physicians, surgeons, scientists and transplant professionals. ESOT works with organizations to structure and streamline activities, give advice, promote strong educational programs and scientific networking and pursues scientific knowledge and best clinical practices professionals.

[www.esot.org](http://www.esot.org)
Gift of Life Institute is an international training center for donation professionals offering comprehensive, interdisciplinary resources for skills-based learning, continuing education, collaborative research, and consulting services.

www.giftoflifeinstitute.org

Glycorex Transplantation AB (publ) is a world-leader in ABO-incompatible technologies. As a medical technology company, we are involved in the development, production and sales in the fields of organ transplantation and other closely related disciplines. Our main product has been used clinically for more than 15 years and is currently being used in 24 countries on 4 continents.

www.glycorex.se
**Hong Kong Kidney Foundation**

Hong Kong Kidney Foundation (HKKF) is a non-profit voluntary organization incorporated on July 10th, 1979. The HKKF Board of Governors is responsible for the governance of HKKF. The Board members are medical professionals, society leaders and interested members of the general public, who serve as volunteers for HKKF. Our major services include the following:

1. Provide assistance, treatment and services to persons suffering from kidney failure.
2. Promote kidney health and awareness of kidney disease through general public activities and education programs.
3. Promote organ donation.
5. Support training for medical and nursing staff.

[www.hkkf.org.hk](http://www.hkkf.org.hk)

**The Hong Kong Liver Foundation**

The Hong Kong Liver Foundation is a charitable organization established in August 1992 by a group of concerned members of the community with the support of doctors specialising in liver diseases.

[www.liverfound.org.hk](http://www.liverfound.org.hk)
The Hong Kong Liver Transplant Patients' Association is a patient support group chartered 18 years ago in 1998 through the assistance of Professor Fan Sheung Tat and Professor Lo Ching Mau. As a charitable non-profit organization, we have been proactively advocating the vision and mission "to celebrate rebirth through self-offering to help the needy". Our goal is to encourage mutual support care for liver patients and their families and care takers; and promoting the organ transplant scheme; educating secondary schools' student and communities on the importance of prevention of liver diseases.

www.livertpa.org

The Hong Kong Society of Transplantation was incorporated in March 1995:

- To promote for the public benefit the interests in and a better understanding of the advancement of science and knowledge in the transplantation and harvesting of organs and tissues
- To promote organ donation
- To promote research, education, training, and appreciation in the science and technology of transplantation, and to make available to the community up-to-date information on new developments in transplantation and organ/tissue harvesting for public benefit
- To promote academic and social exchange among local and overseas transplant community, and to organize activities/conferences in this respect

www.hkst.org
The Hong Kong Transplant Sports Association (HKTSA) was incorporated in March 2008, and is formed by organ transplant recipients, organ donors (and their families) and health care workers related to transplantation. Its mission is to develop, promote and organize sports activities for organ transplant recipients, provide a chance for them to demonstrate their potential, and to help them build up confidence, be positive and optimistic towards life. The association also promotes organ donation and helps promulgate the knowledge on organ transplantation to the public.

www.hktsa.org

The International Society of Nephrology (ISN) is dedicated to advancing the diagnosis, treatment, and prevention of kidney diseases in the world. The Society represents a wide international network and provides an efficient platform for timely scientific exchange, debate and dissemination between healthcare professionals around the world. ISN has over 9,000 professional members from more than 126 countries. In addition, ISN closely collaborates with over 70 national and regional nephrology societies around the world, representing about 20,000 professionals.

www.theisn.org
Kidney Disease: Improving Global Outcomes (KDIGO) is an independent foundation incorporated in Belgium accountable to the public and the patients it serves. Its mission is to improve the care and outcomes of kidney disease patients worldwide through the development and implementation of global clinical practice guidelines.

www.kdigo.org

Supporting over 218 transplant programs in 32 countries, Organ Recovery Systems is the global market-leading provider of organ preservation products and services. We are committed to advancing organ preservation for transplantation by developing innovative medical technologies and systems to preserve and protect donor organs, helping clinicians transform outcomes post transplantation.

www.organ-recovery.com
OrganOx® Limited is a medical device company with a mission to increase the quality and supply of organs for transplantation. OrganOx’s normothermic machine perfusion technology allows the preservation of donor livers for up to 24 hours using physiological flows, pressures and temperature.

www.organox.com

Otsuka Pharmaceutical (H.K.) Ltd. was founded in 1997, and operates as a subsidiary of Otsuka Pharmaceutical Co., Ltd. We are committed to a holistic approach to health and well-being of people and are striving to create innovative, thoroughly-original pharmaceutical and nutraceutical products based on our corporate philosophy “Otsuka-people creating new products for better health worldwide”.

www.otsuka.hkg
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

www.pfizer.com.hk

QIAGEN is the leading global provider of Sample to Insight solutions, enabling our customers to gain valuable molecular insights from their samples. Our technologies isolate DNA, RNA and proteins from blood and tissue samples. Our diagnostic assays make these biomolecules available for analysis. Finally, our bioinformatics and automation solutions combine for cost-effective workflows, providing relevant, actionable insights for transplantation teams.

www.qiagen.com
QRS International
Booth #207

We believe that every patient deserves the best possible care. For this reason we only want to supply products which meet the highest quality standards! Products which perform at the highest possible level like you expect they will do at the most crucial moments. To enable us providing the highest quality of services to our customers, we constantly search the world markets for new and even better solutions for the patients and the car which is provided to them.

www.qrsinternational.nl

Swoop Films
Booth #805

SWOOP FILMS is an American film production company based in New York that creates engaging documentaries and feature films for worldwide theatrical distribution.

www.swoopfilms.com

Taiwan Association for International Care of Organ Transplants
Booth #206

Since Taiwan Association for International Care of Organ Transplants (TAICOT) was established in 2006, the organization has been dedicated to raising public awareness of organ donation and promoting medical ethics of organ transplantation. Our objective is to ensure patients’ fundamental rights to decent medical care. We also endeavor to stop any existing transplant malpractice.

www.organcare.org.tw
The Thai Transplantation Society is a center for the information about the transplantation in Thailand. Thailand has long been providing organ transplantation services to Thai patients with almost all types of organ failure. Organ Transplantation in Thailand is considered to have World-class academic excellence. Thailand’s organ transplant profession is well developed, and has contributed to advancement of both solid organs and bone marrow / stem cell transplantation services.

www.transplantthai.org

Thompson Surgical celebrates 50 years as a leader in exposure and the original manufacturer of the table-mounted retractor. We understand the value of exposure in surgery and are dedicated to providing innovative, high quality systems that deliver safe, versatile, and low-profile retraction. From pediatric to obesity, simple to complex exposures, we offer unlimited customization and safe, independent, retraction. The Thompson Retractor allows surgeons in multiple specialties to achieve Uncompromised Exposure.

www.thompsonsurgical.com
TPM-DTI Foundation is an international non-profit organization committed since 1991 to raise organ donation by providing counseling and support to international entities, and to the public and private health sector in the creation, development and strengthening of networks, programs and services related to the donation and transplantation of organs, tissues and human cells.

www.tpm-dti.com

The World Transplant Games Federation promotes the power of the gift of life through the staging of the world’s largest event for the success of transplantation – the Summer World Transplant Games. For nearly 40 years the Federation has been staging international multi-class sports competitions for solid organ and bone marrow recipients. The games unite more than 60 countries in the celebration of the gift of life and cast a spotlight on the need for more organ donors. Core to the purpose of the Federation is the necessity to promote the full rehabilitation and wellbeing of transplant athletes through healthy lifestyle achieved through exercise and sport. The Federation has produced a Fit for Life programme to help all recipients’ live life to the fullest.

www.wtgf.org
Agency for Volunteer Service (AVS) founded in 1970, is a non-profit organization mainly financed by funds from the Government of the Hong Kong Special Administrative Region, The Community Chest of Hong Kong, The Hong Kong Jockey Club Charities Trust and public and private donations. With the vision to build a civil society and caring community, AVS is dedicated to playing a proactive and pivotal role in the promotion and development of sustainable volunteerism, and to develop partnership with all sectors of the community to provide value-added and quality volunteer service.


The Hong Kong Tourism Board established Meetings and Exhibitions Hong Kong (MEHK) to continue strengthening the city’s position as the number one destination for meetings, incentive trips, conventions and exhibitions in Asia-Pacific. MEHK offers extensive support services that make world-leading MICE events simple to set up and smooth to execute. Together with the city’s network of highly qualified professionals, and a “can do” attitude that’s famously Hong Kong, the MEHK team is dedicated to helping before, during and after your event to achieve success at every stage.

For more information, please visit [www.mehongkong.com/eng](http://www.mehongkong.com/eng)
2017 MEETINGS CALENDAR

To view the complete calendar and to learn more about our up-coming meetings, including Milestones and Program Themes, please visit www.tts.org
Discover Hong Kong

A few weeks, days or just hours are enough to get you hooked on the incredible city that is Hong Kong! Whether you’re a first timer, or already have a love-affair with our great city, this series of guides has something new for you: it’s a compilation of stories, recommendations and tips on Hong Kong from people in the know. Pick a topic that interests you—from incredible Chinese superstitions in “Traditions and Spirituality”, to funky art galleries in “Industrial Revolution”—and you’ll discover real, up-to-the-minute local advice to guide you through many exciting experiences and adventures. We also put the spotlight on particular districts, providing detailed itineraries, so you can do more and see more—and yet still go home wanting more.

For further information, please visit www.discoverhongkong.com.

You can also visit our Congress Services Desk at Hall 5E South Concourse, Level 5 for personalized assistance.

Participating Hotel Info

ICC, TTS’ Official Housing Bureau will be available on-site throughout the TTS 2016 congress to assist participants with their hotel booking. Their representative will have a counter at the Delegate Services Area, located on Hall 5E South Concourse.

Please see the full city map with hotel locations found on the inside back cover fold out of this program:

**Grand Hyatt Hong Kong – Headquarter Hotel**
1 Harbour Road, Wanchai, Hong Kong

**Renaissance Harbour View Hotel – Headquarter Hotel**
1 Harbour Road, Wanchai, Hong Kong

**Empire Hotel Hong Kong – Wanchai**
8 Wing Hing Street, Causeway Bay, Hong Kong

**Gloucester Luk Kwok Hong Kong**
72 Gloucester Road, Wanchai, Hong Kong

**Novotel Century Hong Kong**
238 Jaffe Road, Wanchai, Hong Kong

**The Excelsior Hong Kong**
281 Gloucester Road, Causeway Bay, Hong Kong

**The Harbourview**
4 Harbour Road, Wanchai, Hong Kong

**The Wharney Guang Dong Hotel Hong Kong**
57-73 Lockhart Road, Wanchai, Hong Kong
Transportation

GETTING TO HKCEC

From Hong Kong International Airport

- 24 minutes to Hong Kong Island by Airport Express (Hong Kong station then transfer to headquarter hotels with free shuttle bus).
- 45 minutes by taxi – You must take a red taxi, and payments are cash-only in Hong Kong dollars. (only red taxis operate on Hong Kong Island; blue and green taxis operate on other islands).
- 40 minutes by MTR (Hong Kong station then transfer to Wanchai station)
- 80 minutes by Bus (Route A11 or E11 to Wanchai then transfer to route 40M)

Visit www.discoverhongkong.com for more information.

From Hung Hom Railway Station

- 20 minutes by Bus (Route 104 or 101 to Wanchai)
- 30 minutes by taxi

The HKCEC is located only a short walking distance from Wanchai Station (MTR) and from Wanchai ferry terminal.

GETTING AROUND HONG KONG

MTR (Mass Transit Railway) – Day passes available for unlimited travel to experience Hong Kong.

Taxis – Can typically be hailed on the street, with the exception of certain restricted areas, or summoned by phone. Taxis are relatively cheap in Hong Kong and are equipped with a meter as well as air conditioning. Red taxis operate throughout most of Hong Kong, green taxis only serve the New Territories and blue taxis operate on Lantau Island.

Buses – Bus routes cover almost all of Hong Kong and are a very comfortable way to travel. Popular among tourists are the ‘double-decker’ buses which offer a great view of the city. Exact change is required if paying by cash, otherwise you can purchase an Octopus Card (see below).

Ferries – The legendary Star Ferry has been offering scenic transfers between Hong Kong Island and Kowloon since 1888.

Outlying Island Services – Other ferry services provide transfers to Outlying Islands of Peng Chau, Cheung Chau, Lamma and Lantau. You can either opt for standard ferries, or faster slightly more expensive ferries.
TRAVELER Information

Trams – Another way to visit the Island is by taking a step back in time with the historic tram system which has been travelling the city since 1904. Exact change is required if paying by cash, otherwise you can purchase an Octopus Card (see below).

Peak Tram – Known as the steepest funicular railway in the world, the Peak Tram is by far the easiest way to get the most spectacular view of the city. Exact change is required if paying by cash, otherwise you can purchase an Octopus Card (see below).

Visit www.discoverhongkong.com for more information.

Octopus Card – This handy rechargeable chip card can be used across the entire MTR system, buses, ferries, coaches and trams, as well as in various convenience and department stores, supermarkets, bakeries, fast food chains, cafés, cinemas, skating rinks, theme parks, etc.


Currency Exchange

The official currency is the Hong Kong Dollar (HKD). One ($) USD will give you approx. 7.76 HKD.

Major banks open from 09:00 to 16:30 on weekdays and 09:00 to 12:30 on Saturdays. You can exchange your currency for Hong Kong dollars at any authorised money exchanger. For extra peace of mind, look for a money exchanger that is accredited by the Quality Tourism Services (QTS) Scheme. ATMs are widespread and operate 24 hours. Exchange rates fluctuate daily depending on currency markets.

Traveller’s Cheques and Credit Cards

Traveller’s cheques are accepted by most leading banks and hotels. International credit cards such as American Express, VISA, Diners Club and MasterCard are also welcome at many hotels, retail shops and restaurants. Such premises usually display stickers showing the credit cards they accept at their entrances.

Taxes

There are no goods and services tax (GST), harmonized sales tax, value added tax (VAT) or any other sales tax in Hong Kong.
Tipping and Means of Payments

International credit cards are welcome everywhere in Hong Kong, although most local smaller restaurants prefer cash payments, and taxis only take cash.

A 10 to 15% tip is usually left on the table or at the cash register. However, some tea cafes do not impose service charges. Please check with the waiter about the charges before being seated.

ATM

ATMs can be found almost everywhere. Many take international cards and some HSBC 'Electronic Money' machines provide 24-hour cash withdrawal (HK$) facilities for Visa and MasterCard holders.
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abuab, Y.</td>
<td>622.5</td>
</tr>
<tr>
<td>Abbas, Khawar</td>
<td>320.12</td>
</tr>
<tr>
<td>Abbud-Filho, Mario</td>
<td>P1345</td>
</tr>
<tr>
<td>Abe, Toyofumi</td>
<td>426.11</td>
</tr>
<tr>
<td>Abd-Endroth, Dietmar K.</td>
<td>458.8, P1042</td>
</tr>
<tr>
<td>Abid, Ayisha</td>
<td>427.12, P1019</td>
</tr>
<tr>
<td>Abis, Daniel Oscar</td>
<td>354.1</td>
</tr>
<tr>
<td>Abuhelaiaia, Essa A</td>
<td>P1324</td>
</tr>
<tr>
<td>Acosta, Fabio Ruben</td>
<td>P1575</td>
</tr>
<tr>
<td>Adamusiak, Anna M</td>
<td>623.4</td>
</tr>
<tr>
<td>Adlakha, Amit G</td>
<td>559.2</td>
</tr>
<tr>
<td>Ahmad, Niaz</td>
<td>P1192</td>
</tr>
<tr>
<td>Ahmed, Ihab A. M.</td>
<td>P1708, P1709</td>
</tr>
<tr>
<td>Ahmed, Zubir</td>
<td>320.7, 553.9</td>
</tr>
<tr>
<td>Ahn, Hyung Joon</td>
<td>P1027, P1028</td>
</tr>
<tr>
<td>Aida, Naohiro</td>
<td>321.8</td>
</tr>
<tr>
<td>Aitken, Emma L</td>
<td>423.8</td>
</tr>
<tr>
<td>Akamatsu, Nobuhisa</td>
<td>325.1</td>
</tr>
<tr>
<td>Akashi, Yumi</td>
<td>P1628</td>
</tr>
<tr>
<td>Alketer, Saeed</td>
<td>P1446, P1447, P1448</td>
</tr>
<tr>
<td>Alkhi, Rachid</td>
<td>421.11</td>
</tr>
<tr>
<td>Aljoki, Kiyokazu</td>
<td>P1382</td>
</tr>
<tr>
<td>Akutsu, Naotake</td>
<td>327.12</td>
</tr>
<tr>
<td>Al-Housani-Blakely, Roberta J</td>
<td>232.2, 348.2</td>
</tr>
<tr>
<td>Alabadi, Abdulnaser M.</td>
<td>422.12, P1250</td>
</tr>
<tr>
<td>Alami Laroussi, Nassiba</td>
<td>359.7</td>
</tr>
<tr>
<td>Albert, Mathew</td>
<td>310.2</td>
</tr>
<tr>
<td>Aleid, Hassan A</td>
<td>424.5, 474.6, 572.4, 626.6, P1561, P1562</td>
</tr>
<tr>
<td>Aliaabadi, Arezu Z</td>
<td>454.6</td>
</tr>
<tr>
<td>Alkadi, Mohamad M</td>
<td>P1303, P1304</td>
</tr>
<tr>
<td>Allen, Penelope J</td>
<td>550.3</td>
</tr>
<tr>
<td>Alotaibe, Fahad</td>
<td>P1576</td>
</tr>
<tr>
<td>Alrakhahim, Mona</td>
<td>444.2</td>
</tr>
<tr>
<td>Alshomali, Sr., Wael A.</td>
<td>P1563</td>
</tr>
<tr>
<td>Althwaif, Ian P</td>
<td>P1086</td>
</tr>
<tr>
<td>Ambagtsheer, Frederike</td>
<td>326.8, 326.9, 326.10</td>
</tr>
<tr>
<td>Amer, Hatem</td>
<td>P1751, P1752</td>
</tr>
<tr>
<td>Anglicheau, Dany</td>
<td>504.1</td>
</tr>
<tr>
<td>Anis, Sabiba</td>
<td>424.12</td>
</tr>
<tr>
<td>Appakaiakai, Balamurungan N.</td>
<td>351.9</td>
</tr>
<tr>
<td>Arai, Katsuko</td>
<td>P1143</td>
</tr>
<tr>
<td>Arinyoshi, Yulchi</td>
<td>354.4</td>
</tr>
<tr>
<td>Arnol, Miha</td>
<td>426.4</td>
</tr>
<tr>
<td>Arns, Wolfgang</td>
<td>P1528</td>
</tr>
<tr>
<td>Arreola, Jose Manuel</td>
<td>323.2</td>
</tr>
<tr>
<td>Arroyo Horrucci, Rebeca C</td>
<td>456.2</td>
</tr>
<tr>
<td>Arslan, Hande</td>
<td>424.6, P1601</td>
</tr>
<tr>
<td>Ascher, Nancy</td>
<td>300.4, 640.2</td>
</tr>
<tr>
<td>Ashkenazi, Tamir</td>
<td>P1629, P1630</td>
</tr>
<tr>
<td>Ashraf, Muhammad Imlaz</td>
<td>457.8</td>
</tr>
<tr>
<td>Askar, Medhat Z</td>
<td>501.3</td>
</tr>
<tr>
<td>Assounga, Alain G.</td>
<td>427.13</td>
</tr>
<tr>
<td>Ataide, Elaine C</td>
<td>P1131</td>
</tr>
<tr>
<td>Atif, Muhammad</td>
<td>P1078</td>
</tr>
<tr>
<td>Avlinsanju, Yingyos</td>
<td>P1049</td>
</tr>
<tr>
<td>Azimzadeh, Agnes</td>
<td>443.1, 558.6</td>
</tr>
<tr>
<td>Aziz, Feroz</td>
<td>P1300</td>
</tr>
<tr>
<td>Aziz, Tahir</td>
<td>374.5a, P1265, P1266</td>
</tr>
<tr>
<td>Baan, Carla</td>
<td>224.3, 404.2, 557.9a, 610.1, P1004</td>
</tr>
<tr>
<td>Baglietto, Aranzazu Quiralte</td>
<td>352.8</td>
</tr>
<tr>
<td>Banas, Miriam C</td>
<td>627.6</td>
</tr>
<tr>
<td>Bank, J., R. T</td>
<td>353.3, 621.4</td>
</tr>
<tr>
<td>Baqing, Liu</td>
<td>454.3</td>
</tr>
<tr>
<td>Bara, Christoph</td>
<td>454.2</td>
</tr>
<tr>
<td>Barama, Azem A.</td>
<td>622.8</td>
</tr>
</tbody>
</table>
PRESENTER INDEX

Chapman, Jeremy R. ........................................................................................................................................ 404.1
Chau, Ka Foon .......................................................................................................................................... 233.4
Chen, Chao-Long ......................................................................................................................................... 545.1
Chen, Chien-Chia ......................................................................................................................................... 628.5
Chen, Gang ................................................................................................................................................. 558.8
Chen, Guodong ........................................................................................................................................... 352.9, 556.6, P.1346
Chen, Hong-Mei ......................................................................................................................................... P.1677
Chen, Jingyu .............................................................................................................................................. 120.7, P.1783
Chen, Linda J .............................................................................................................................................. 426.7, 473.3, 571.2, P.1421, P.1422, P.1423, P.1424
Chen, Sharon ............................................................................................................................................. 347.2
Chen, Shih-Chin ......................................................................................................................................... P.1805
Cheng, Elaine Y......................................................................................................................................... 329.4
Cherukuri, Aravind .................................................................................................................................. 358.2, 559.3
Cheung, Chi Yuen Simon ....................................................................................................................... 552.6
Chew, Hong Che ....................................................................................................................................... 324.10, 428.4, P.1029
Cihabra, Deepak ....................................................................................................................................... 553.1
Chien, Chia-Shen ..................................................................................................................................... 370.4
Chin, Jacqueline J. .................................................................................................................................... 541.3
Cho, Chan Woo .......................................................................................................................................... P.1832
Cho, Hong R .............................................................................................................................................. P.1891, P.1892
Cho, Jai Young ......................................................................................................................................... P.18210
Cho, Min-ji .................................................................................................................................................. 350.7, 420.4, 420.5
Cho, Won-Hyun ....................................................................................................................................... P.1667, P.1668
Choi, Donglak ............................................................................................................................................ P.1141, P.1142
Choi, Gyu-seong ...................................................................................................................................... P.1100, P.1101, P.1102, P.1194, P.1195
Choi, Ho Joong ......................................................................................................................................... P.1211
Choi, Jin Yong ........................................................................................................................................... P.1132
Choi, Nam Kyu ................................................................ ............................................................................ P.1268, P.1269
Choi, Seo Jin Na ....................................................................................................................................... P.1114
Choi, Young Yeon .................................................................................................................................... P.1126
Choi, YoungRok ....................................................................................................................................... 329.10
ChoK, Kenneth Siu Ho ........................................................................................................................... P.1147
Chow, Kevin .............................................................................................................................................. 427.11
Chowdhury, Ayub Ali .......................................................................................................................... P.1712
Chuan-I, Tsoa ........................................................................................................................................... P.1775
Chuanbao, Chen ....................................................................................................................................... P.1347, P.1348
Chuluyan, Eduardo ............................................................................................................................... 373.5, P.1554
Chun, Jae Min ......................................................................................................................................... P.1148, P.1149
Chun, Kwansik ......................................................................................................................................... P.1196
Chung, Sang Young ................................................................................................................................ P.1006
Chung, Yun Shin ....................................................................................................................................... P.1896
Chutipongtatane, Arpa ........................................................................................................................... P.1295
Chutipongtatane, Somchai ..................................................................................................................... P.1059
Ciaas, Frans H.J. ....................................................................................................................................... 547.1
Clancy, Marc J. .......................................................................................................................................... 620.7, P.1383
Clark, Bettina R. ..................................................................................................................................... P.1625
Claxworthy, Menna R .......................................................................................................................... 122.3, 600.4
Colak, Turan ............................................................................................................................................ 421.13, 471.2, P.1331, P.1332, P.1333
Constantinescu, Serban ..................................................................................................................... 426.2
Coughlan, Timothy E. ........................................................................................................................... 354.8
Cowan, Peter ............................................................................................................................................. 357.9, 428.9, 429.1, 544.1
Craig, Jonathan ......................................................................................................................................... 222.3
Crichtley, William R. .............................................................................................................................. 328.6, 454.4
Croin, Antonia .......................................................................................................................................... 403.1, P.1564
Crossthwaite, Amy A ............................................................................................................................ 452.8
Dai, Zhenhua ........................................................................................................................................... 121.4
Dangullan, Romina A ............................................................................................................................ P.1349
Daniel, Dolly ........................................................................................................................................... 303.2
Danilewicz, Roman ................................................................................................................................ 552.8
David, Paolo Miguel A .......................................................................................................................... 420.11
Davis, Jason ............................................................................................................................................... 329.8, P.1578
Davis, Jean ................................................................................................................................................ P.1634
de Graaf, Gretchen N .............................................................................................................................. 427.6
de Rinaldis, Emanuele ........................................................................................................................... 202
de Teresa Alguacil St., Javier ................................................................................................................... P.1384, P.1385

380
26th International Congress of The Transplantation Society
PRESENTER INDEX

Franco, Antonio ............................................................................................................................. 452.3
Fraser, Campbell ............................................................................................................................. 574.6
Freire, Maristela Pinheiro .............................................................................................................. 424.2
Fronka, Jiří ..................................................................................................................................... P1207, P1208, P1209
Fu, Jianing .................................................................................................................................... 451.5
Fujii, Taku ....................................................................................................................................... P1030
Fujisaki, Noritomo ......................................................................................................................... P1031
Fujita, Takashi ............................................................................................................................... P1604
Fukuda, Akinari .............................................................................................................................. P1190
Fukuoka, Kengo ............................................................................................................................. P1875
Fung, James .................................................................................................................................... 546.2
Fung, John J .................................................................................................................................... 328.5, 425.9, 428.10
Fung, Raymond Chi-yan ................................................................................................................ 571.3
Fung, Timothy K. F. ...................................................................................................................... P1635
Futamura, Kenta ............................................................................................................................ P1387
Gadekar, Kshitita G ....................................................................................................................... P1488
Galiyeva, Dinara ............................................................................................................................ P1825
Gandhi, Manish ............................................................................................................................. 358.8
Garcia Covarrubias, Luis ............................................................................................................... P1636, P1637
Garcia Gallont, Rudolf A. .............................................................................................................. 542.7
Gatault, Philippe ............................................................................................................................ 620.9
Gautier, Sergey V ............................................................................................................................ P1191
Geissler, Edward K ......................................................................................................................... 343.2
Gentry, Sommer E ........................................................................................................................... 444.1
Gerbase-De Lima, Maria ............................................................................................................... 373.2, 428.11
Gerlach, Ursunde ........................................................................................................................... 573.3
Ghita, Ryan ..................................................................................................................................... 353.9
Ghosh-Mitra, Arpita ....................................................................................................................... P1309
Gilbo, Nicholas ............................................................................................................................... 325.9, 329.1, 425.7
Gill, John S ..................................................................................................................................... 123.2, 222.1, 503.3, 630.2
Gilroy, Richard .............................................................................................................................. 555.7
Giral, Magali ................................................................................................................................... 323.12, 556.4, 556.5, P1425
Gjertsen, Henrik K. ....................................................................................................................... P1152
Glanville, Allan R ............................................................................................................................ 448.2
Globoke, Brigitta K.M .................................................................................................................... 425.4
Goh, Angelina .................................................................................................................................. P1317, P1318
Goh, Su Kah .................................................................................................................................. 328.10
Golab, Karolina .............................................................................................................................. P1876
Gomez, Maria P .............................................................................................................................. 626.8
Gomez Dos Santos, Victoria .......................................................................................................... P1043, P1044
Gongolesi, Gabriel E ...................................................................................................................... P1135
Gorantla, Vijay ............................................................................................................................... 624.7
Goto, Ryoichi ................................................................................................................................... 555.3
Gozdowska, Jolanta ....................................................................................................................... P1588, P1589, P1590, P1591, P1592
Graj, Andrej ................................................................................................................................... P1352
Grandnerova, Barbara ................................................................................................................... P1734
Grey, Shane T ................................................................................................................................... 122.2, 600.1
Grimm, Paul C .................................................................................................................................. 220.2
Grinyo, Josep ................................................................................................................................... 458.9
Guan, Lianyue .................................................................................................................................. P1032, P1033
Gueler, Faikah .................................................................................................................................. 504.3
Guerra, Giselle .................................................................................................................................. 350.2, 425.10, P1275, P1276
Guerra, Juan Francisco .................................................................................................................... P1933
Guleria, Sandeep ............................................................................................................................ P1651
Gultekin, Bahadir ............................................................................................................................ 324.11
Gunderson, Susan ......................................................................................................................... 213.3
Guo, Fei ........................................................................................................................................... 429.4, P1877
Guo, Yanhong .................................................................................................................................. 133.1
Gupta, Krishan I .............................................................................................................................. P1605
Guzman Vinasco, Luis F ................................................................................................................... 424.8
Gyllenswärd, Sofia .......................................................................................................................... P1153, P1154, P1155, P1156
Ha, Jongwon .................................................................................................................................... 213.4
Ha Phan, Hai An .............................................................................................................................. P1353, P1354
Haberal, Mehmet ........................................................................................................................... P1581
Haberal, Murat .................................................................................................................................. 325.10
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hall, Bruce M.</td>
<td>356.6</td>
<td></td>
</tr>
<tr>
<td>Halleck, Fabian</td>
<td>421.2</td>
<td></td>
</tr>
<tr>
<td>Halloran, Philip F.</td>
<td>121.2, 458.5, 557.6, 623.3</td>
<td></td>
</tr>
<tr>
<td>Hameed, Ahmer</td>
<td>322.7</td>
<td></td>
</tr>
<tr>
<td>Hammad, Ebah A.</td>
<td>320.1</td>
<td></td>
</tr>
<tr>
<td>Han, Duck-Jong</td>
<td>440.2</td>
<td></td>
</tr>
<tr>
<td>Han, Sang Youb</td>
<td>P1326</td>
<td></td>
</tr>
<tr>
<td>Han, Seungyeup</td>
<td>P1497, P1498</td>
<td></td>
</tr>
<tr>
<td>Hancock, Wayne W.</td>
<td>543.3</td>
<td></td>
</tr>
<tr>
<td>Hanif, Farine</td>
<td>421.7</td>
<td></td>
</tr>
<tr>
<td>Hanson, Camilla S.</td>
<td>422.5</td>
<td></td>
</tr>
<tr>
<td>Hara, Hitotaka</td>
<td>327.9, 429.7</td>
<td></td>
</tr>
<tr>
<td>Harden, Paul</td>
<td>233.2, 356.7</td>
<td></td>
</tr>
<tr>
<td>Hardinger, Karen L.</td>
<td>621.2</td>
<td></td>
</tr>
<tr>
<td>Harimoto, Norifumi</td>
<td>371.6</td>
<td></td>
</tr>
<tr>
<td>Harper, Claudia L.</td>
<td>326.12</td>
<td></td>
</tr>
<tr>
<td>Hata, Ketsuke</td>
<td>P1286</td>
<td></td>
</tr>
<tr>
<td>Hata, Koichiro</td>
<td>329.3</td>
<td></td>
</tr>
<tr>
<td>Hawthorne, Wayne J</td>
<td>500.3, 629.1, P1160, P1161</td>
<td></td>
</tr>
<tr>
<td>Hay, Margaret</td>
<td>501.2</td>
<td></td>
</tr>
<tr>
<td>Hayashi, Taiji</td>
<td>P11064</td>
<td></td>
</tr>
<tr>
<td>Hayashida, Shintaro</td>
<td>329.12</td>
<td></td>
</tr>
<tr>
<td>He, Bulong</td>
<td>P1925, P1926</td>
<td></td>
</tr>
<tr>
<td>He, Xiaoshun</td>
<td>133.3</td>
<td></td>
</tr>
<tr>
<td>Heim, Christian</td>
<td>324.12, 454.7, 628.2, P1776</td>
<td></td>
</tr>
<tr>
<td>Henderson, Lorna K</td>
<td>P1310</td>
<td></td>
</tr>
<tr>
<td>Hernandez-Fuentes, Maria</td>
<td>458.6</td>
<td></td>
</tr>
<tr>
<td>Hesselink, Dennis</td>
<td>450.3</td>
<td></td>
</tr>
<tr>
<td>Hibi, Taizo</td>
<td>P1157</td>
<td></td>
</tr>
<tr>
<td>Hirai, Toshihito</td>
<td>328.4, 356.8</td>
<td></td>
</tr>
<tr>
<td>Hiramitsu, Takahisa</td>
<td>P1390</td>
<td></td>
</tr>
<tr>
<td>Hirano, Hajime</td>
<td>P1484, P1485</td>
<td></td>
</tr>
<tr>
<td>Hirose, Takayuki</td>
<td>320.4</td>
<td></td>
</tr>
<tr>
<td>Ho, Cheng-Maw</td>
<td>456.5</td>
<td></td>
</tr>
<tr>
<td>Ho, Jenny CY</td>
<td>P1950</td>
<td></td>
</tr>
<tr>
<td>Hodgson, Wayne C.</td>
<td>501.1</td>
<td></td>
</tr>
<tr>
<td>Hodgkinson, Suzanne J.</td>
<td>328.3</td>
<td></td>
</tr>
<tr>
<td>Holdaas, Hallvard</td>
<td>210.3, 440.3</td>
<td></td>
</tr>
<tr>
<td>Hong, Geun</td>
<td>P1158</td>
<td></td>
</tr>
<tr>
<td>Hong, Suk Kyun</td>
<td>P1161, P1162</td>
<td></td>
</tr>
<tr>
<td>Hoogduijn, Martin J</td>
<td>447.2</td>
<td></td>
</tr>
<tr>
<td>Horia, Kengo</td>
<td>P1438</td>
<td></td>
</tr>
<tr>
<td>Hotta, Kiyohiko</td>
<td>356.4, 356.5, P1072</td>
<td></td>
</tr>
<tr>
<td>Howard, Kirsten</td>
<td>403.2</td>
<td></td>
</tr>
<tr>
<td>Howell, Martin</td>
<td>326.4, 420.6</td>
<td></td>
</tr>
<tr>
<td>Hoy, Dieter</td>
<td>322.9</td>
<td></td>
</tr>
<tr>
<td>Hrubas, Petra</td>
<td>P1079</td>
<td></td>
</tr>
<tr>
<td>Hsieh, Ming- Hsin</td>
<td>P1700</td>
<td></td>
</tr>
<tr>
<td>Hsu, Bang-Gee</td>
<td>P1551, P1552</td>
<td></td>
</tr>
<tr>
<td>Hsu, Li-Wen</td>
<td>P1077</td>
<td></td>
</tr>
<tr>
<td>Hu, Min</td>
<td>429.11, 627.2, 627.3</td>
<td></td>
</tr>
<tr>
<td>Huang, Dandan</td>
<td>429.2</td>
<td></td>
</tr>
<tr>
<td>Huang, Gang</td>
<td>424.10</td>
<td></td>
</tr>
<tr>
<td>Huang, Jiefe</td>
<td>120.2, 520</td>
<td></td>
</tr>
<tr>
<td>Huang, Yuoh</td>
<td>322.5</td>
<td></td>
</tr>
<tr>
<td>Huang, Wenlong</td>
<td>P1397</td>
<td></td>
</tr>
<tr>
<td>Hue, Siu Man</td>
<td>621.6</td>
<td></td>
</tr>
<tr>
<td>Hussein, Kamal Hany</td>
<td>328.7, P1064</td>
<td></td>
</tr>
<tr>
<td>Ichikawa, Hirohito</td>
<td>351.4, 423.1, 426.13</td>
<td></td>
</tr>
<tr>
<td>Ijetto, Giuseppe</td>
<td>P1927</td>
<td></td>
</tr>
<tr>
<td>Iizuka, Junpei</td>
<td>P1391</td>
<td></td>
</tr>
<tr>
<td>Ikeda, Masae</td>
<td>P1951</td>
<td></td>
</tr>
<tr>
<td>Ildstad, Suzanne T.</td>
<td>450.1, 601.2, P1008</td>
<td></td>
</tr>
<tr>
<td>Ishido, Nobuhiko</td>
<td>P1392</td>
<td></td>
</tr>
<tr>
<td>Issa, Fadi</td>
<td>P1009</td>
<td></td>
</tr>
</tbody>
</table>
PRESENTER INDEX

Itabashi, Yoshihiro ................................................................. P.1334
Ito, Taihei ........................................................................... 551.5
Ivanovski, Ninoslav .......................................................... 420.9, P.1730, P.1731
Iwadoh, Kazuhiro ............................................................... P.1866
Jackson-Spence, Francesca ............................................ 421.9, 421.10, 452.6
Jaecel, Elmar ...................................................................... 557.4
Jain, Archana ..................................................................... P.1379
Jain, Ashokkumar .............................................................. P.1184, P.1185
Jang, Hyuk Jai .................................................................... P.1853
Jang, Kyeonghee ............................................................... P.1899
Jenssen, Trond .................................................................... 502.1
Jeon, Hee Jung .................................................................... P.1638
Jeong, Hyeon Joo .............................................................. P.1582
Jeong, Joon Heon .............................................................. P.1251
Jiang, Xiaofeng ................................................................... P.1900
Jin, Jian ............................................................................. 459.7, P.1010
Jin, Kyubok ......................................................................... P.1327
Jin, Long ............................................................................. P.1023
Jiniritham, Sopon ............................................................... P.1515
Johannesen, Justin H ....................................................... 324.13, 325.2
Johnsen, Paul R. V. ............................................................ 305.2
Jucaud, Vadim .................................................................... 559.9
Jun, Heungman ................................................................... P.1565
Jung, B. Hyun .................................................................... P.1212
Jung, Cheol Woong .......................................................... P.1311
Juchinskis, Janis ................................................................ P.1277
Jwa, Eunkyung ................................................................... P.1082, P.1083
Kaabak, Michael M .......................................................... 353.5, P.1489
Kable, Kathy ..................................................................... 232.1
Kakizaki, Yuta .................................................................... 371.4
Kaliamoorthy, Ilankumaran ............................................. P.1127
Kandaswamy, Raja ............................................................ 305.1, 422.7
Kanelis, John .................................................................... 453.4
Kang, Byeongju ................................................................. P.1163
Kang, Gun Woo ................................................................. P.1164
Kang, Hee Jung ................................................................ P.1901
Kang, Seong-jun Sung ....................................................... P.1902, P.1903
Kang, Soo Kyoung ........................................................... P.1516
Kang, Sun-woo ................................................................... P.1073
Kanga, Uma .................................................................... P.1888
Kannegieter, Nynke .......................................................... 627.4
Kanodia, Kamal V ............................................................. P.1252, P.1253
Kao, John W. .................................................................... 200.2
Kara, Tonya ........................................................................ 359.5
Karagoz, Huseyin ............................................................ P.1756
Karabayali, Feraz ................................................................ P.1393, P.1394
Karczewski, Marek .......................................................... P.1355
Kasiske, Bertram L ............................................................ 340.2, 400.1
Katan, Takumi ................................................................... P.1833
Kaufman, Dixon B. ........................................................... 341.1
Kawagishi, Naoki ............................................................. P.1197, P.1198
Kazuya, Kaber ................................................................. P.1335
Keitel, Eizette ................................................................. P.1517, P.1518
Kemochi, Takaishi ........................................................... 321.7
Kennedy, Brian K ............................................................. 610.2
Kern, Barbara .................................................................... P.1393, P.1760
Kers, Jesper ......................................................................... 550.8, 620.6
Kesraju, Sailaja ................................................................. 556.8, P.1519
Keung, Karen L ................................................................. P.1056
Khazhov, Dmytro ............................................................. 353.6
Khamash, Hasan .............................................................. 453.8
Kheradmand, Taba ........................................................... 358.3
Kho, Marcia M.L .............................................................. 424.3, 424.4
Kihara, Yu ......................................................................... P.1395
Kim, Anes ........................................................................ P.1639
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim, Eun Jee</td>
<td>P1024</td>
</tr>
<tr>
<td>Kim, Hyun Jung</td>
<td>P1287</td>
</tr>
<tr>
<td>Kim, Jim</td>
<td>321.1</td>
</tr>
<tr>
<td>Kim, Jin Soo</td>
<td>P1288</td>
</tr>
<tr>
<td>Kim, Jong Hae</td>
<td>325.3</td>
</tr>
<tr>
<td>Kim, Jong Man</td>
<td>325.12, P1115, P1116, P1117, P1118</td>
</tr>
<tr>
<td>Kim, Joon Ye</td>
<td>P1025</td>
</tr>
<tr>
<td>Kim, Kwan Woo</td>
<td>P1199</td>
</tr>
<tr>
<td>Kim, Kyung Sik</td>
<td>425.8</td>
</tr>
<tr>
<td>Kim, Minjung</td>
<td>P1475</td>
</tr>
<tr>
<td>Kim, Nayoung</td>
<td>P1045</td>
</tr>
<tr>
<td>Kim, Seoung Hyun</td>
<td>325.5</td>
</tr>
<tr>
<td>Kim, Soo-Kyung</td>
<td>P1802</td>
</tr>
<tr>
<td>Kim, Suk Young</td>
<td>P1297, P1298</td>
</tr>
<tr>
<td>Kim, Sung Hoon</td>
<td>P1278</td>
</tr>
<tr>
<td>Kim, Tae-Seok</td>
<td>534.7, P1171, P1172</td>
</tr>
<tr>
<td>Kim, Young June</td>
<td>P1904</td>
</tr>
<tr>
<td>Kim,ap, Mahar</td>
<td>471.5, 571.1, P1186, P1187, P1188, P1189</td>
</tr>
<tr>
<td>Kishino, Satoshi</td>
<td>P1046</td>
</tr>
<tr>
<td>Kisui, Iori</td>
<td>P1011</td>
</tr>
<tr>
<td>Kitajima, Kumihiro</td>
<td>P1136</td>
</tr>
<tr>
<td>Kitajima, Toshihiro</td>
<td>P1103</td>
</tr>
<tr>
<td>Kittrakulrat, Jathurong</td>
<td>P1476</td>
</tr>
<tr>
<td>Kjøsen, Gisle</td>
<td>321.2</td>
</tr>
<tr>
<td>Klar, Tarunjeet S</td>
<td>P1292</td>
</tr>
<tr>
<td>Klinger, Marian</td>
<td>P1001</td>
</tr>
<tr>
<td>Knight, Richard J</td>
<td>321.13</td>
</tr>
<tr>
<td>Knoll, Gregory Alan</td>
<td>400.3</td>
</tr>
<tr>
<td>Ko, Eun Jeong</td>
<td>P1607</td>
</tr>
<tr>
<td>Ko, Kyungil</td>
<td>370.1, 470.2, P1493, P1494</td>
</tr>
<tr>
<td>Ko, Wing-Man</td>
<td>240.2</td>
</tr>
<tr>
<td>Kobayashi, Takaaki</td>
<td>471.4</td>
</tr>
<tr>
<td>Kolaityte, Voldone</td>
<td>P1728</td>
</tr>
<tr>
<td>Kong, Jin M</td>
<td>622.3</td>
</tr>
<tr>
<td>Konno, Osamu</td>
<td>P1479</td>
</tr>
<tr>
<td>Koo, Jenny</td>
<td>304.1</td>
</tr>
<tr>
<td>Kornberg, Arno</td>
<td>425.13, 625.3, P1173</td>
</tr>
<tr>
<td>Kortram, Kirsten</td>
<td>422.6, 472.1, P1654</td>
</tr>
<tr>
<td>Kotenko, Oleg</td>
<td>455.9, P1200</td>
</tr>
<tr>
<td>Koulimanda, Maria</td>
<td>446.3</td>
</tr>
<tr>
<td>Koyama, Ichiro</td>
<td>P1867</td>
</tr>
<tr>
<td>Kozaki, Koichi</td>
<td>P1293</td>
</tr>
<tr>
<td>Kozlowski, Tomasz</td>
<td>P1051, P1052</td>
</tr>
<tr>
<td>Krums, Sheri</td>
<td>356.9, 359.1, 452.1</td>
</tr>
<tr>
<td>Kreisel, Daniel</td>
<td>101.1</td>
</tr>
<tr>
<td>Krishnan, Elankumaran</td>
<td>P1120</td>
</tr>
<tr>
<td>Krishnan, Nithya</td>
<td>320.2, 320.3, 370.5, 401.1, P1808, P1809, P1810, P1811, P1812</td>
</tr>
<tr>
<td>Krüger, Bernd</td>
<td>452.7</td>
</tr>
<tr>
<td>Kuan, Chen Hsiang</td>
<td>P1761</td>
</tr>
<tr>
<td>Kuddus, Ruhul H</td>
<td>P1726</td>
</tr>
<tr>
<td>Ruhr, Frank K</td>
<td>P1047</td>
</tr>
<tr>
<td>Kumano, Kenjiro</td>
<td>327.4</td>
</tr>
<tr>
<td>Kumar, Anant</td>
<td>P1414, P1415</td>
</tr>
<tr>
<td>Kumar, Dhiren</td>
<td>350.4</td>
</tr>
<tr>
<td>Kumar, Shiva</td>
<td>371.2, 371.3, P1136</td>
</tr>
<tr>
<td>KUMAR, SUNIL</td>
<td>P1039, P1040</td>
</tr>
<tr>
<td>Kumwar, Kiran J</td>
<td>P1356</td>
</tr>
<tr>
<td>Kuramitsu, Kaoi</td>
<td>325.7</td>
</tr>
<tr>
<td>Kurian, George</td>
<td>P1762</td>
</tr>
<tr>
<td>Kuroasawa, Akira</td>
<td>P1271</td>
</tr>
<tr>
<td>Kurtz, Josef</td>
<td>456.1</td>
</tr>
<tr>
<td>Kute, Vivek</td>
<td>422.10, 422.11</td>
</tr>
<tr>
<td>Kuypers, Dirk</td>
<td>110.4, 123.3</td>
</tr>
<tr>
<td>Kwok, Janette</td>
<td>100.1, 423.5, 423.6</td>
</tr>
<tr>
<td>Kwon, Jae Hyun</td>
<td>371.5, P1213</td>
</tr>
</tbody>
</table>
Kwon, Sukyung .............................................................. 425.12, P1357
Kryiazis, Periklis P .......................................................... 327.8
Laaksonen, Maarit A .......................................................... 474.2
Lai, Chia-Yun ................................................................. P1012
Laird, Christopher T ......................................................... 429.6
Lakey, Jonathan .............................................................. 327.5
Lam, Yin Fan Lynn .......................................................... 452.4
Lam, Yiu Chung .............................................................. 426.8
Langley, Vernon L .......................................................... 352.7
Lao, I Ha ................................................................. P1214
Lau, Yew Weng Perry .................................................. 359.8
Leavsekong, Sirilak ........................................................ 1336
Lee, Eun Mi ................................................................. P1905
Lee, Hae-Won ............................................................... P1774
Lee, Ho Kyun ............................................................... P1074
Lee, Hong joo ............................................................... P1657, P1658
Lee, Jacqueline I ........................................................... 324.1, 451.9
Lee, Jae Geun ............................................................... 371.1, P1112, P1113
Lee, Jin Gu ............................................................... P1784
Lee, John ................................................................. 458.3
Lee, Jonghwan ............................................................. P1017
Lee, Jung Jun ............................................................ P1215
Lee, Kye Woo ............................................................. P1854
Lee, Kyung Hee LKH ................................................... P1272
Lee, Ling-Hsien ............................................................ P1380
Lee, Nikki ................................................................. 625.7
Lee, Po-Chang ............................................................ P1530
Lee, Sarome ............................................................... P1952
Lee, Soo Ho ............................................................... P1137
Lee, Taehyun ............................................................... P1640
Lefaucheur, Carmen .................................................. 623.7, 623.8, 623.9
Legendre, Christophe Michel ........................................ 110.1, 301.2, 410.3
Leichtman, Alan B ....................................................... 420.2
Leonard, Deanne ........................................................ P1732
Leong, Mario L .......................................................... 558.3
Lerut, Jan ................................................................. 455.8, 625.8
Lett, Bron D ............................................................... 456.6
Levings, Megan .......................................................... 548.3
Levvey, Bromwyn J .................................................... 232.3, 348.1
Li, Li ................................................................. 458.7
Li, Wah Chun ............................................................ 472.4
Li, Wenjun ............................................................... 354.2, 354.3
Li, Xian C ............................................................... 111.3, 457.1
Li, Yaguang ............................................................... P1013
Li, Yanping ............................................................. P1906
Li, Yousheng ........................................................... 573.1, 573.2
Li, Chang Xian .......................................................... 357.6
Lian, Qichou ............................................................. 201.3
Lim, Wal ................................................................. 450.9
Lin, Wilson ............................................................... 453.9
Lin, Yi-Chang ............................................................ 324.9
Linkermann, Andreas ................................................. 101.3
Liu, Chun-Jen ........................................................... 210.1
Liu, Hongxia ........................................................... 425.5, P1735
Liu, Hui ................................................................. 328.11
Liu, Jianguo ............................................................. 357.8
Liu, Longshan ........................................................... P1065, P1363
Liu, Qiang ............................................................... 322.1
Liu, Xiaobelg ........................................................... 428.6
Liu, Zhengzhao ........................................................ P1907
Liwompaisan, Witsit ................................................... P1566
Lo, Alan ................................................................. P1826
Lo, Chung-Mau ....................................................... 210.4, 545.3
Locke, Jayme E ........................................................ 423.7, 553.7
Logen, Liu ............................................................... P1002
Loh, Charles Yuen Yung.................................................................P.1884
López Fraga, Marta ......................................................................349.1
Lorant, Tomas .............................................................................623.5
Lou Meda, Randall.......................................................................360, 460, 565
Loupy, Alexandre........................................................................221.2, 323.9, 323.10
Lozano, Eyner ..............................................................................P.1480
Lu, David Bo................................................................................357.7
Luk, Chor Kwan Amanda ............................................................372.3
Luk, Franka ..................................................................................558.7
Lum, Lionel H................................................................................P.1608
Lundgren, Torbjorn.....................................................................P.1021, P.1022
Luo, Xunrong ..............................................................................429.3, 557.2
Ma, Maggie Kam Man ...............................................................P.1641
Ma, Xiaojian ...............................................................................P.1882, P.1883
Ma, Yuen Yuen ...........................................................................328.6
MacDonald, Peter S ....................................................................602.3
Machado, Clarisse ......................................................................347.3
Macias III, Maria Outeda ............................................................571.6, P.1507, P.1508
Maeda, Akira ..............................................................................429.13
Maglione, Manuel .......................................................................P.1176, P.1177
Mahajan, Nikhil Vijaykumar ......................................................P.1620, P.1621
Mahillo, Beatriz B .......................................................................344.2
Maldonado, Rafael A ....................................................................P.1520
Malheiros, Jorge .........................................................................323.4, 423.3
Malik, Shaif ..................................................................................P.1440, P.1441
Maloney, Eden M ........................................................................452.9
Maluf, Daniel G ............................................................................329.5, 355.4
Małyszko, Jacek S .........................................................................454.9, P.1779, P.1780
Mangus, Richard S .....................................................................322.2, P.1669
Manyalich, Marti .........................................................................223.4, 342.3, 354.4
Marada, Tomas ..........................................................................320.11, 370.2
Marion, Chapal ............................................................................P.1491
Markiewicz-Kijewska, Małgorzata ............................................P.1121
Martin, Dominique E ..................................................................326.1, 503.1
Martinez, Olivia M .......................................................................452.2, 546.1, 557.5, 571.4, P.1885
Martinez de la Maza, Lilia ...........................................................321.11
Martina, Tereza ..........................................................................448.1
Mas, Valeria .................................................................................211.1, 221.3
Massie, Allan ..............................................................................422.2, 455.1
Masson, Philip .............................................................................505.2, 553.3
Matas, Arthur ..............................................................................620.3
Matas, David ................................................................................574.3
Mathes, David W .........................................................................P.1763
Matsuda, Yasushi ........................................................................P.1785
Matsuno, Naoto ...........................................................................355.8, 355.9
Mazarioglos, George V ................................................................220.4, 441.1
McAdams-DeMarco, Mara A .....................................................421.3
McClarey, Andrew WJ ...............................................................424.11
McDermid, Sue ..........................................................................601.4
McDonald, Stephen ....................................................................604.2
McKenna, Greg J .........................................................................535.5
Meader, Lucy J ............................................................................457.5
Medina, Jason Paul T ..................................................................P.1553
Medina Pestana, Jose ..................................................................570.2, 620.5
Meheotra, Sonia ..........................................................................P.1053, P.1054
Meier, Raphael ............................................................................351.7, 500.1, 621.9, P.1299
Meissner, Felix ...........................................................................610.1
Melicoff, Ernestina .....................................................................P.1786
Menahem, Solomon ..................................................................354.7
Mengel, Michael .........................................................................121.1, 211.2
Menjivar, Anat ...........................................................................P.1480
Mengel, Michael .........................................................................623.5
Melo, Danilo ...............................................................................509.5
Merion, Robert M .......................................................................427.2
Messer, Simon J ..........................................................................549.1
Mierka, Przemyslaw .....................................................................P.1585
Mihaila, Mariana .........................................................................P.1124
Milliken, Eliza J. ................................................................. P.1610
Min, Byoung-Hoon .......................................................... 629.9
Minnee, Robert ................................................................. 426.9
Minz, Mukut ............................................. 471.6, P.1300
Mita, Atsuyoshi ............................................................... P.1088
Mitra, Palash ................................................................. 374.1
Miura, Kohei ................................................................. 325.13
Myagi, Shigejiro ............................................................... P.1201
Miyazaki, Yuki ................................................................. 327.3
Miyuki, Furusawa ............................................................... P.1312
Mizuta, Koichi ................................................................. 359.2
Mizutani, Kazuo ............................................................... P.1319, P.1320, P.1321, P.1322, P.1323
Mo Sr., Chumbal ............................................................. P.1521
Moawad, Mamdoh ........................................................... 373.1
Modi, Manisha P. .............................................................. P.1403
Modi, Pranjal ................................................................. 533.4, 553.5
Mohankumar, Thalachalour ........................................... 597.7
Mohiuddin, Muhammad M. ........................................... 429.12, 544.2, 629.8
Mohsin, Rehan ............................................................... P.1652, P.1653
Mone, Thomas D ............................................................ 326.2
Montenovo, Martin ........................................................ 425.3, 451.7
Monteverde, Marta I ....................................................... 459.3
Montgomery, Robert A ................................................... 1003.1, 443.2
Moon, Deek-Bog ............................................................ P.1138
Moon, Ju Ik ................................................................. P.1159, P.1160
Moonka, Dilip .............................................................. 625.5, 625.9
Moore, Hunter B ............................................................ 355.6
Morales, Jose Maria ....................................................... 421.8, 640.3
Morales-Barria, Jorge ...................................................... P.1955
Moray, Gokhan ........................................................... P.1165, P.1166, P.1167, P.1168, P.1169, P.1170
Morelli, Adrian E ........................................................... 111.1
Morelon, Emmanuel ....................................................... 321.3, 601.3, 624.3
Morito, Noriyuki ........................................................... P.1670
Moritz, Michael J. .......................................................... 474.3, 620.1
Morris, Michele I ........................................................... 300.5
Morris, Randall E ......................................................... 123.4, 132.4
Morsy, Mohamed ......................................................... P.1358, P.1359
Mourad, Michel ........................................................... P.1381
Mourya, Manish Kumar ................................................ P.1889
Moussa, Omar ............................................................. 358.9
Mudge, David W .......................................................... 505.3
Muller, Elmi M .............................................................. 203.3, 349.2, 542.2
Murakami, Toru ............................................................ P.1492
Muramatsu, Masaki ...................................................... P.1736
Murakawa, Takahiro ...................................................... 627.1
Muthukumar, Thangamani ............................................... 421.12, 559.5, 559.6, P.1611
Na, Byunggon ............................................................. P.1216
Naeimi Karauroudi, Meisam ........................................ P.1908
Nah, Yang Won ........................................................... P.1175
Naicker, Derisha .......................................................... 473.5
Nakagawa, Yuki ........................................................... P.1527
Nakamura, Yuki ........................................................... P.1526
Nakano, Ryosuke ........................................................ P.1020
Nakano, Toshiaki ........................................................ P.1048
Nakatsu, Mitsuhiro ......................................................... P.1220, P.1221, P.1222
Nankivell, Brian J ......................................................... 121.3, 301.3, 340.1
Nanno, Yoshinori ........................................................ P.621.5
Naqvi, Anwar ............................................................. 231.7, 424.7, P.1655
Narm, Kyung Shik ........................................................ P.354.5
Nasim, Asma ............................................................... P.1612
Nascalla, David ............................................................ 322.3, 355.1, 554.2
Nathan, Howard M ....................................................... 213.3, 352.2, 372.1
Natsuda, Koji .............................................................. 325.11
Navarro, Aurora .......................................................... 213.6
Nemati, Eghlim ............................................................ P.1556
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peng, Qi</td>
<td>357.5</td>
</tr>
<tr>
<td>Pathiraja, Vimukti</td>
<td>621.8</td>
</tr>
<tr>
<td>Park, YeonHo</td>
<td>P.1586</td>
</tr>
<tr>
<td>Park, Chung-gyu</td>
<td>544.3</td>
</tr>
<tr>
<td>Pareek, Shishir</td>
<td>329.7</td>
</tr>
<tr>
<td>Papadimitriou, John</td>
<td>550.6, 623.6</td>
</tr>
<tr>
<td>Pantis, Carmen</td>
<td>374.6, P.1631, P.1632</td>
</tr>
<tr>
<td>Núñez Peña, José Ramón</td>
<td>133.5, 223.5, 604.4</td>
</tr>
<tr>
<td>O'Connell, Philip J.</td>
<td>120.1, 240.1, 350.6, 520, 640.1</td>
</tr>
<tr>
<td>O'Neill, Natalie A.</td>
<td>328.9</td>
</tr>
<tr>
<td>Oberhuber, Rupert</td>
<td>428.5</td>
</tr>
<tr>
<td>Oregón, Liliana Miriam</td>
<td>P.1340</td>
</tr>
<tr>
<td>Oehler, Rudolf</td>
<td>442.1</td>
</tr>
<tr>
<td>Ogiso, Satoshi</td>
<td>P.1066</td>
</tr>
<tr>
<td>Ogura, Yasuhiro</td>
<td>P.1122</td>
</tr>
<tr>
<td>Okada, Manabu</td>
<td>323.5</td>
</tr>
<tr>
<td>Okada, Noriko</td>
<td>P.1671</td>
</tr>
<tr>
<td>Okumura, Yusuke</td>
<td>451.3</td>
</tr>
<tr>
<td>Okumi, Masayoshi</td>
<td>P.1404</td>
</tr>
<tr>
<td>Moto, Kazuya</td>
<td>622.2</td>
</tr>
<tr>
<td>Onghena, Louis G.</td>
<td>326.13, P.1737</td>
</tr>
<tr>
<td>Ono, Minoru</td>
<td>324.8</td>
</tr>
<tr>
<td>Onuma, Erika</td>
<td>P.1834</td>
</tr>
<tr>
<td>Orlando, Giuseppe</td>
<td>130.3, 353.7, 423.12, 447.1</td>
</tr>
<tr>
<td>Orlofsky, Jeffrey P.</td>
<td>352.3, 472.6</td>
</tr>
<tr>
<td>Ostrouwski, Marek</td>
<td>P.1410, P.1931</td>
</tr>
<tr>
<td>Ozcay, Figen</td>
<td>555.9</td>
</tr>
<tr>
<td>Ozcay, Necdet</td>
<td>573.6, P.1911, P.1912</td>
</tr>
<tr>
<td>Özdemir, Handan</td>
<td>320.13, 550.5, P.1428, P.1429, P.1430, P.1431, P.1432, P.1433, P.1434</td>
</tr>
<tr>
<td>Padilla, Benita</td>
<td>231.1</td>
</tr>
<tr>
<td>Pérez, Gloria</td>
<td>374.6, P.1631, P.1632</td>
</tr>
<tr>
<td>Pantis, Carmen</td>
<td>P.1642</td>
</tr>
<tr>
<td>Papadimitriou, John C.</td>
<td>550.6, 623.6</td>
</tr>
<tr>
<td>Pape, Lars</td>
<td>230.1, 449.3, 459.4, 459.5, 459.6</td>
</tr>
<tr>
<td>Pareek, Shishir</td>
<td>329.7</td>
</tr>
<tr>
<td>Park, Cheon-Soo</td>
<td>P.1104, P.1105, P.1106</td>
</tr>
<tr>
<td>Park, Chung-Gyu</td>
<td>504.3</td>
</tr>
<tr>
<td>Park, Keun-Myoung</td>
<td>P.1289</td>
</tr>
<tr>
<td>Park, Myoung Hee</td>
<td>303.3, P.1803</td>
</tr>
<tr>
<td>Park, Pyoung-Jae</td>
<td>P.1128</td>
</tr>
<tr>
<td>Park, Yeon Ho</td>
<td>P.1586</td>
</tr>
<tr>
<td>Pathiraja, Vimukti</td>
<td>621.8</td>
</tr>
<tr>
<td>Pattou, François</td>
<td>305.3</td>
</tr>
<tr>
<td>Paul-Heng, Mousmita</td>
<td>628.6</td>
</tr>
<tr>
<td>Pavlovic, Julie</td>
<td>348.3</td>
</tr>
<tr>
<td>Peng, Qi</td>
<td>357.5</td>
</tr>
<tr>
<td>Pera, Martin F.</td>
<td>446.2</td>
</tr>
</tbody>
</table>
PRESENTER INDEX

Petrie, Michaela C.............................................................................................................550.7
Petrone, Hugo S...........................................................................................................P.1557, P.1558, P.1559
Petrusso, Palmina........................................................................................................353.4, 543.1, 624.6
Phongvitwat, Thanypapat........................................................................................P.1645
Pierotti, Ligia C.............................................................................................................P.1615
Pilmore, Helen..............................................................................................................502.3
Pinchuk, Alexey............................................................................................................551.8
Pongpirul, Krit..............................................................................................................P.1490
Pongskul, Jongruk......................................................................................................372.4
Popoola, Joyce.............................................................................................................P.1616
Posgay-Barbe, Klara M............................................................................................449.1
Posselt, Andrew.........................................................................................................443.4
Prakash, Swanyaman..................................................................................................358.4
Prasad, Abheesha.......................................................................................................P.1560
Prasad, Narayan...........................................................................................................426.1, 427.8
Proneeth, Andrea........................................................................................................591.3
Proneeth, Bettina.........................................................................................................428.1
Przybylek, Blanca.......................................................................................................454.1
Qi, Xiang......................................................................................................................625.4
Qu, Jiang......................................................................................................................P.1495
Quante, Markus..........................................................................................................427.7
Quin, Nicolas................................................................................................................374.2
Radford, Toni M........................................................................................................P.1855
Raghuram, Lalitha.....................................................................................................552.2
Rahman, Mir M..........................................................................................................231.5
Rajakumari, Vijaya....................................................................................................P.1496
Ramos, Rafael G.........................................................................................................P.1646
Rao, Prakash..............................................................................................................P.1814
Raschzok, Nathanael...............................................................................................P.1880
Rasheed, Husham......................................................................................................P.1411
Raslan, Mohammad..................................................................................................P.1366
Rathi, Manish.............................................................................................................622.4
Ratkovic, Marina........................................................................................................374.4, P.1305, P.1306, P.1307, P.1308
Raval, Shalesh B.......................................................................................................624.2
Ravindranath, Meupur H.........................................................................................559.7
Reddy, Mettu Srinivas..............................................................................................325.8, 329.2, P.1294, P.1725
Reed, Elaine F............................................................................................................100.4, 448.3
Rees, Michael A..........................................................................................................326.11, 553.2
Reinders, Marlies.......................................................................................................556.9
Reinke, Petra...............................................................................................................443.3
Rela, Mohamed..........................................................................................................345.2
Religa, Piotr................................................................................................................P.1886
Ringden, Olle.............................................................................................................627.5
Ritschl, Paul Viktor..................................................................................................322.10, 357.2
Rivinmus, Rasmus.....................................................................................................324.2
Rizvi, Adibul Hasan..................................................................................................320.6, 440.1
Roberson, Paul...........................................................................................................223.1
Rocha, Eduardo..........................................................................................................223.3
Rodrigues Silva, Josue.............................................................................................351.3
Rodriguez, E. R.........................................................................................................454.8
Roelens, Dave............................................................................................................P.1804
Rojas-Canales, Darling.............................................................................................327.11
Rojas-Pena, Alvaro..................................................................................................P.1643, P.1644
Ronaghi, Martin.........................................................................................................423.10
Roodnat, Joke I..........................................................................................................P.1439
Rosenfeldt, Franklin L..............................................................................................549.2
Rosete-Liquete, Rose Marie.....................................................................................P.1658
Rostaing, Lionel........................................................................................................320.10, 323.1, 570.5, P.1254
Rothenstein, David..................................................................................................131.2, 559.4
Ruangkanchanasate, Prajej......................................................................................622.9
Rudensky, Alexander..............................................................................................310.1
Ryu, Je Ho................................................................................................................P.1179, P.1180
Saeed, Bassam..........................................................................................................574.5, P.1704, P.1705
Saeki, Yoshio............................................................................................................628.7
Sageshima, Junichiro..............................................................................................453.6
PRESENTER INDEX

Siyoun, Mekdim Tadese.................................................. P.1710
Skuk, Daniel................................................................. .456.3, P.1881
Skvircynska, Edyta Agata.............................................. P.1729
Slakey, Douglas P........................................................ 625.6, P.1733
Slatinska, Janka............................................................... 323.7
Smudla, Aniko................................................................. P.1648
Sobnach, Sanju............................................................... P.1711
Soejima, Yuji........................................................................ 545.2
Soldini, Gabriele............................................................... P.1930
Solomina, Julia................................................................... 351.2, 551.6, 551.7, 621.7
Sommer, Florian............................................................... P.1314
Song, Young M................................................................. P.1523
Song, Zhuolun..................................................................... 355.5
Sonnerborg, Isabella......................................................... P.1871
Soto-Miranda, Ernesto..................................................... P.1281, P.1282, P.1283, P.1284, P.1285
Srinivas, Titte R................................................................. 622.1, 626.9
Srirumudumbi, Srim......................................................... P.1617
Stadler, Maria..................................................................... 626.4
Stead, Sebastian O............................................................ 428.8
Stock, Peter..................................................................... 350.3, 352, 546.3
Stoma, Igor........................................................................ 572.5
Stott, John P..................................................................... 322.13
Strasser, Simon I............................................................... 502.2, 510.3
Stratta, Robert J................................................................. 551.1, 551.2, P.1302
Strober, Samuel............................................................... 320.9
Struecker, Benjamin......................................................... P.1069
Suchyta, Marissa................................................................ 624.5
Sudan, Deba L................................................................... 553.6, P.1279
Suh, Kyung-Suk.................................................................. 345.3
Suh, Sukwon..................................................................... P.1026
Sukha, Sayamon............................................................... P.1509
Sumethkul, Vasant......................................................... 240.5, 342.2
Sun, Chao ........................................................................... P.1203
Sun, Pamela...................................................................... P.1659
Sun, Xuyong...................................................................... 133.4
Suryamoorthi, Sujatha..................................................... 326.6, P.1649
Süsai, Caner...................................................................... 442.3, 604.1
Suthar, Kamlesh S............................................................ 550.2, P.1374
Suzuki, Yasuko.................................................................... P.1953
Swe, Htar Kyi...................................................................... 231.4
Sykes, Megan.................................................................... 548.1
Taddeo, Adriano.................................................................. 624.9
Taguchi, Kazuhiro............................................................. 451.2
Tai, William Chi-Shing.................................................... P.1477, P.1478
Takano, Yuki..................................................................... P.1204
Takanaka, Masasahi......................................................... 421.4, P.1375
Takuchi, Hironori.............................................................. P.1524
Tam, Ngai Lei..................................................................... 374.3
Tambur, Anat R............................................................... 402.1, 547.2, 600.3
Tamin, Jonathan John F.................................................. P.1525
Tan, Ban Hock.................................................................... 210.2, 347.1
Tan, Carmela D.............................................................. 454.5
Tanabe, Kazunari............................................................. 710.3, 540.2
Tanaka, Asuka.................................................................... 320.8
Tanaka, Motofumi.............................................................. P.1230
Tanaka, Yuka..................................................................... 558.1
Tanemura, Masahiro....................................................... 351.1
Tang, Jianxin...................................................................... P.1182
Tang, Qizhi....................................................................... 131.1, 542.8, 603.3
Tannenbaum, Cara......................................................... 401.2
Taricottti, Laura.............................................................. P.1070
Tasaki, Masayuki............................................................. 427.3, P.1315
Taubert, Richard............................................................. 555.8
Techawathanawanna, North.......................................... 372.6
Tector, Alfred Joseph...................................................... 610.3
Teegen, Eva Maria EM ................................................................. 455.4
Terada, Yuka ............................................................................. P.1782
Thakkar, Umang G. ................................................................. 456.9
Thammaranaruek, Kanin ....................................................... 571.5
Thaunat, Olivier .................................................................. 122.1, 601.1
Thavanaphong, Sarita .......................................................... P.1618
Thomas, Chris ........................................................................ 233.1
Thomson, Angus W. ............................................................... 456.7
Thomson, Imogen K ................................................................. 552.9
Thorat, Ashok ........................................................................ P.1218
Thotsiri, Sansanee ................................................................. P.1436
Tiehen, Mirjam ........................................................................ 302.2, 626.3
Tinkham, Kathryn .................................................................. 100.2, 402.2, 444.3
Toimamueang, Ubonrat ..................................................... 572.3
Tojimbara, Tamotsu ............................................................... P.1412
Tokat, Yaman ........................................................................ 345.1
Tokodi, Kazuaki ................................................................. P.1805
Tomita, Koichi ...................................................................... 370.6
Tong, Allison ......................................................................... 541.1
Tonsho, Makoto ...................................................................... P.1080
Törnhoff, Burkhard ............................................................... 220.1, 230.4, 359.6, 459.1, 459.2
Townnamchaisak, Natavudh ............................................... 323.13, P.1510
Tran, Thé ................................................................................. 422.9, P.1660
Trappe, Ralf Ulrich ...................................................... 452.5, P.1413
Tromposch, Pablo ............................................................. P.1016
Tse, Hung Fat ......................................................................... 130.1, 447.3
Tsoulounikouva, Olga M. .................................................... P.1223, P.1224, P.1225, P.1226
Tullius, Stefan G. .................................................................. 404.3, 427.4, 427.5
Turkmen, Aydin ...................................................................... 572.6
Turunç, Volkan ................................................................. P.1932
Uchida, Hajime ...................................................................... 554.6
Uchida, Junji ........................................................................ P.1263, P.1264
Uchijiyama, Masateru ........................................................ P.1076
Uematsu, Satoru Suzuki ..................................................... 351.5
Ulu Ozturk, Funda .................................................................. 421.6
Unagami, Kohel .................................................................... P.1511
Urade, Takeshi ...................................................................... 554.3
Uva, Pablo D. ........................................................................ P.1872
Vajdic, Dilara ........................................................................ 474.1
Vallant, Natalie .................................................................... P.1376, P.1377
Van Delden, Christian ....................................................... 352.4
van den Brink, Marcel R.M. ............................................... 130.2
Van Gelder, Teun .................................................................. 110.2, 420.7
Vanhove, Thomas ............................................................. 420.13, 556.2, 620.4, P.1501, P.1502
Vanikar, Aruna ...................................................................... 450.5, 450.6
Vathsalal, Anantharaman .................................................. 352.7
Verma, Nirupama D. .......................................................... P.1015
Vester, Udo ................................................................. P.1913
Vincenti, Flavio ...................................................................... 473.4
Vittoraki, Angeliki G. ........................................................ P.1806, P.1807
Vondran, Florian WR ........................................................ P.1016
Vrakas, Georgios .................................................................. 451.6
Wadei, Hani .......................................................................... 324.4
Waki, Shiori ........................................................................... P.1067
Wakiya, Taiichi ............................................................... P.1835
Wallen, Karen ........................................................................ 626.5, P.1664
Walters, Stacey N. ............................................................... 351.6
Walton, Duncan C ............................................................. P.1813
Wan, Susan S. ........................................................................ 323.11
Wang, Changxi ............................................................... P.1360, P.1361, P.1362, P.1364
Wang, Haibo ......................................................................... 120.3, 552.1
Wang, Kai ................................................................................ P.1836
Wang, Zhengpeng ............................................................... P.1081
 Warner, Susan S Y ............................................................ 451.8
Watanabe, Hironosuke ....................................................... 354.6
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Watanabe, Takuya</td>
<td>324.5</td>
</tr>
<tr>
<td>Watarai, Yoshihiko</td>
<td>P.1416</td>
</tr>
<tr>
<td>Watcharananan, Sirion</td>
<td>424.9, P.1619</td>
</tr>
<tr>
<td>Webster, Angela</td>
<td>222.2, 302.1, 321.5, 626.7</td>
</tr>
<tr>
<td>Wedel, Johannes</td>
<td>427.2</td>
</tr>
<tr>
<td>Wei, Alvin</td>
<td>574.2</td>
</tr>
<tr>
<td>Weimar, Willem</td>
<td>326.5a</td>
</tr>
<tr>
<td>Weimer, Rolf</td>
<td>P.1316</td>
</tr>
<tr>
<td>Wen, Yujie</td>
<td>456.4, 627.7</td>
</tr>
<tr>
<td>Weng, Shih-Feng</td>
<td>P.1568</td>
</tr>
<tr>
<td>Wennberg, Lars</td>
<td>473.1</td>
</tr>
<tr>
<td>West, Lori J</td>
<td>328.2, 457.4</td>
</tr>
<tr>
<td>Whittaker, Vaughn E</td>
<td>570.3</td>
</tr>
<tr>
<td>Wiebe, Chris J</td>
<td>547.3</td>
</tr>
<tr>
<td>Wieland, Eberhard</td>
<td>P.1593</td>
</tr>
<tr>
<td>Wijetunga, Imeshi U</td>
<td>322.8, 352.5, P.1673</td>
</tr>
<tr>
<td>Wilson, Colin</td>
<td>505.1</td>
</tr>
<tr>
<td>Wisel, Steven A</td>
<td>321.6, 373.4</td>
</tr>
<tr>
<td>Witkowski, Piotr</td>
<td>224.2</td>
</tr>
<tr>
<td>Wijesvannathum, Punlop</td>
<td>P.1376</td>
</tr>
<tr>
<td>Wolf, Michael</td>
<td>302.3</td>
</tr>
<tr>
<td>Womer, Karl L</td>
<td>350.1</td>
</tr>
<tr>
<td>Wong, Germaine</td>
<td>132.3, 203.4, 344.3</td>
</tr>
<tr>
<td>Wong, Tiffany C</td>
<td>455.5, 455.6</td>
</tr>
<tr>
<td>Wong, Wilson</td>
<td>557.1, 558.9</td>
</tr>
<tr>
<td>Wood, Kathryn J</td>
<td>343.1</td>
</tr>
<tr>
<td>Woodside, Kenneth J</td>
<td>426.6</td>
</tr>
<tr>
<td>Woodward, Kyle</td>
<td>327.1, 327.2</td>
</tr>
<tr>
<td>Wu, Chenglin</td>
<td>628.8</td>
</tr>
<tr>
<td>Wu, Huiling</td>
<td>428.13</td>
</tr>
<tr>
<td>Wu, Tsunghan</td>
<td>P.1205</td>
</tr>
<tr>
<td>Wuthrich, Rudolf P</td>
<td>426.5</td>
</tr>
<tr>
<td>Wynter, Lucinda</td>
<td>422.4</td>
</tr>
<tr>
<td>Xia, Junjie</td>
<td>328.1</td>
</tr>
<tr>
<td>Xu, Aimin</td>
<td>200.1</td>
</tr>
<tr>
<td>Xu, Yinzhe</td>
<td>P.1071</td>
</tr>
<tr>
<td>Xu, Yue</td>
<td>556.7</td>
</tr>
<tr>
<td>Yadav, Kunal</td>
<td>420.8</td>
</tr>
<tr>
<td>Yadav, Brijesh</td>
<td>427.1, 470.6</td>
</tr>
<tr>
<td>Yamada, Kazuhiako</td>
<td>356.1</td>
</tr>
<tr>
<td>Yamanaka, Kazuaki</td>
<td>420.12</td>
</tr>
<tr>
<td>Yamashita, Kenichiro</td>
<td>445.3</td>
</tr>
<tr>
<td>Yanagawa, Senichiro</td>
<td>P.1890</td>
</tr>
<tr>
<td>Yang, Bin</td>
<td>359.2, P.1038</td>
</tr>
<tr>
<td>Yang, Chul Woo</td>
<td>428.2, 428.3, 457.6</td>
</tr>
<tr>
<td>Yang, Chul-Woo</td>
<td>P.1261</td>
</tr>
<tr>
<td>Yang, Zhaorui</td>
<td>629.5</td>
</tr>
<tr>
<td>Yanishi, Masaaki</td>
<td>P.1417</td>
</tr>
<tr>
<td>Yano, Takuya</td>
<td>457.7</td>
</tr>
<tr>
<td>Yap M.D., Leslie A</td>
<td>P.1290</td>
</tr>
<tr>
<td>Yao, Kai-Ping</td>
<td>420.3a, 570.6</td>
</tr>
<tr>
<td>Ye, Qifa</td>
<td>133.2</td>
</tr>
<tr>
<td>Yeh, Chun Chieh</td>
<td>554.1</td>
</tr>
<tr>
<td>Yeikin, Berna</td>
<td>P.1622, P.1623</td>
</tr>
<tr>
<td>Yeung, Wai Ho Oscar</td>
<td>625.1</td>
</tr>
<tr>
<td>Yi, Nam-Joon</td>
<td>329.6, 457.3</td>
</tr>
<tr>
<td>Yi, Wang</td>
<td>P.1262</td>
</tr>
<tr>
<td>Yin, Enzhi</td>
<td>P.1017</td>
</tr>
<tr>
<td>Yokoyama, Takayoshi</td>
<td>P.1418</td>
</tr>
<tr>
<td>Yoon, Sam-Youl</td>
<td>P.1206</td>
</tr>
<tr>
<td>Yoshida, Kazunari</td>
<td>P.1666</td>
</tr>
<tr>
<td>Yoshida, Satoru</td>
<td>P.1858</td>
</tr>
<tr>
<td>Yoshikawa, Yuki</td>
<td>P.1954</td>
</tr>
<tr>
<td>Yoshizawa, Atsushi</td>
<td>555.4</td>
</tr>
<tr>
<td>You, Youngkyoung</td>
<td>P.1219</td>
</tr>
</tbody>
</table>
Young, Kimberly .................................................................................................................213.2
Yu, Di .................................................................................................................................600.2
Yu, Young-Dong ..............................................................................................................355.7, P.1183
Yuan, Wenji ......................................................................................................................P.1859
Yuan, Xiaopeng ..............................................................................................................322.4, 472.5, P.1328, P.1329
Yue, Gu .............................................................................................................................P.1000
Zafar, Mirza Naqi ..............................................................................................................213.5, 231.6, 303.1, P.1397, P.1398, P.1399
Zaitou, Masaaki ................................................................................................................558.5
Zarrinpard, Ali ....................................................................................................................357.3, 357.4, 428.7
Zavazava, Nicolas ..............................................................................................................201.4
Zee, Jarcy ............................................................................................................................555.6, 620.8
Zeng, Song ..........................................................................................................................428.12
Zeyneloglu, Pinar ..............................................................................................................324.3, P.1570, P.1571, P.1572, P.1573, P.1574
Zhai, Yuan ..........................................................................................................................101.2
Zhang, Huanxi ...................................................................................................................552.4
Zhang, Qi’an ......................................................................................................................421.5
Zhang, Tianshu ...................................................................................................................558.4
Zhang, Wensheng ..............................................................................................................624.4
Zhang, Zheng .....................................................................................................................P.1018
Zhao, Bin .............................................................................................................................P.1910
Zhao, Yuanfei ....................................................................................................................457.3
Zhao, Zitong .......................................................................................................................P.1569
Zheng, Shusen ...................................................................................................................120.4
Zheng, Zhe ..........................................................................................................................120.6
Zhu, Lan ...............................................................................................................................359.3
Zielinski, Maciej .................................................................................................................P.1050
Zimmerman, Asha M .........................................................................................................P.1483
Zingerman, Boris ..............................................................................................................471.1
Zor, Fatih ...........................................................................................................................P.1757, P.1758, P.1759
Zorn, Emmanuel ..............................................................................................................410.2
Zuber, Julien .......................................................................................................................550.9, 628.4
Zuidema, Willij ..................................................................................................................472.3
Nearest MTR Stations / District

- **Wan Chai**
  - H1 Grand Hyatt Hong Kong
  - H2 Renaissance Harbour View Hotel
  - H4 Gloucester Luk Kwok Hong Kong

- **Admiralty**
  - H3 Empire Hotel Hong Kong - Wanchai

- **Causeway Bay**
  - H5 Novotel Century Hong Kong
  - H6 The Excelsior Hong Kong
  - H7 The Harbourview
  - H8 The Wharney Guang Dong Hotel Hong Kong
Join TTS TODAY!
...and become part of a growing organization focused on the entire global transplant community.

BENEFITS INCLUDE:

- Free Online Access to *Transplantation* Journal
- Reduced Registration Fees for TTS 2018 Madrid
- Substantial discounts for TTS Section Members and those from Emerging Economies
- Entitlement for travel grants for Young Investigator Awards
- Access to Webinars & Multimedia Library with over 5000 Presentations and Growing

... and much more

Come and visit our booth in the Exhibit Area, Level 5 for your free give away!

By joining TTS there is no BETTER way to invest in YOUR CAREER

and in one of the most dynamic professions in medical science TODAY

www.tts.org
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

**Astellas Lunch Symposium**

**Optimizing immunosuppression: A key for improving long-term outcomes**

12:15-13:30  •  Saturday, 20 August 2016  
Hall 5E3, Level 5, Hong Kong Convention and Exhibition Centre

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15-12:30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:30-12:55</td>
<td>Welcome note and opening</td>
<td>Wai-Leung Chak, Hong Kong             Simone Strasser, Australia</td>
</tr>
<tr>
<td>12:55-13:15</td>
<td>The immunosuppressive management for long-term outcome</td>
<td>Kim Jong Man, Korea</td>
</tr>
<tr>
<td>13:15-13:30</td>
<td>Panel discussion</td>
<td>All</td>
</tr>
</tbody>
</table>

Seats and lunchboxes will be available on a first-come, first-served basis.
27th International Congress of The Transplantation Society

MADRID • SPAIN

AUGUST 18–23

SAVE the DATE!

www.tts2018.org